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Abstract	  
Rationale:	   Current	   therapies	   require	   daily	   injections	   of	   GCSF	   to	   treat	   patients	  with	   neutropenia	   and	   response	   to	   treatment	   is	   often	   unpredictable	   as	   GCSF	   is	  rapidly	  cleared.	  A	  number	  of	  approaches	  to	  reducing	  GCSF	  clearance	  have	  been	  tried	  mainly	  through	  conjugation	  with	  another	  moiety.	  The	  technologies	  already	  being	   employed,	   include	   PEGylation,	   immunoglobulins	   or	   albumin	   to	   increase	  the	   half‐ life	   of	   GCSF.	   However,	   although	   these	   approaches	   have	   reduced	  clearance	  the	  pharmacokinetic	  profile	  of	  GCSF	  has	  remained	  unpredictable.	  	  
Aim	   and	   Hypothesis:	   a	   glycosylated	   linker	   between	   two	   ligands	   could	   delay	  clearance	  with	  out	  blocking	  bioactivity.	  	  
Methodology:	  GCSF	   tandem	  molecules	  with	   linkers	  containing	  between	  2-­‐8	  N-­‐linked	  glycosylation	  sites	  (NAT	  motif)	  and	  their	  respective	  controls	  (Q	  replaces	  N	  in	   the	   sequence	   motif	   NAT	   so	   there	   is	   no	   glycosylation)	   were	   cloned,	   and	  sequenced.	  Following	  expression	  in	  CHO	  cells,	  expressed	  protein	  was	  quantified	  by	  ELISA	  and	  analysed	  by	  western	  blot	  to	  confirm	  molecular	  weights	  and	  protein	  integrity.	   In	  vitro	   bioactivity	  was	   tested	   using	   an	   AML-­‐193	   proliferation	   assay.	  IMAC	  was	  used	  to	  purify	  the	  protein.	  Pharmacokinetic	  and	  pharmacodynamic	  of	  GCSF	  tandems	  were	  measured	  in	  Sprague	  Dawley	  rats.	  
Results:	   Purified	   glycosylated	   tandem	  molecules	   showed	   increased	   molecular	  weight	   according	   to	   the	   number	   glycosylation	   of	   their	   sites	  when	   analysed	   by	  SDS-­‐PAGE.	  All	  GCSF	  tandems	  showed	  increased	  in	  vitro	  bioactivity	  in	  comparison	  to	   rhGCSF.	   GCSF2NAT,	   GCSF4NAT	   and	   GCSF8NAT	   containing	   2,	   4	   &	   8	  glycosylation	  sites	  respectively	  and	  GCSF8QAT	  displayed	  a	  three-­‐fold	   increased	  terminal	   half-­‐life	   compared	   to	   that	   published	   for	   GCSF,	   however	   there	  was	   no	  difference	   in	   serum	   half-­‐life	   according	   to	   the	   level	   of	   glycosylation.	   Both	  GCSF2NAT	   and	   GCSF4NAT	   showed	   a	   higher	   increase	   in	   the	   percentage	   of	  neutrophils	   over	   controls	   at	   12	  hrs	   post	   injection	   only.	   In	   contrast,	   GCSF8NAT	  exhibited	  a	  higher	  increase	  in	  neutrophil	  levels	  over	  controls	  at	  48	  hrs.	  
Conclusion:	   Using	   glycosylated	   linkers	   in	   GCSF	   tandems	   results	   in	   molecules	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with	  increased	  molecular	  weight	  according	  to	  the	  number	  of	  glycosylation	  sites.	  Tandems	   of	   GCSF	   have	   increased	   in	   vitro	  bioactivity	   compared	   to	   monomeric	  GCSF.	  Tandems	  with	  and	  without	  glycosylation	  had	  three-­‐fold	  greater	  half-­‐lives	  than	  rhGCSF.	  There	  was	  evidence	  that	  GCSF8NAT	  was	  biologically	  active	  in	  vivo.	  	  The	  results	  confirm	  the	  hypothesis	  that	  it	  is	  possible	  to	  predictably	  increase	  the	  molecular	  weight	  of	  GCSF	  tandems	  and	  retain	  biological	  activity	  but	  this	  was	  not	  associated	   with	   a	   predictable	   prolongation	   of	   the	   serum	   half-­‐life.
1	  
 Introduction	   	  1.
 History	  of	  Granulocyte	  Colony	  Stimulating	  Factor	  	  1.1Prior	  to	  the	  1960s,	  several	  studies	  on	  animal	  models	  had	  been	  performed	  to	  find	  the	   answer	   to	  how	  white	  blood	   cell	   (WBC)	  homeostasis	   can	  be	   regulated	   in	   the	  circulation.	   The	   specific	   regulator	   remained	   unknown	   until	   1966,	   when	   two	  groups	   simultaneously	   performed	   a	  method	   for	   growing	   colonies	   of	   monocytes	  and	  granulocytes	  from	  spleen	  cells,	  and	  bone	  marrow	  (BM)	  in	  semi	  sold	  cultures	  
in	  vitro	  (Bradley	  and	  Metcalf,	  1966,	  Ichikawa	  et	  al.,	  1966).	  However,	  the	  growth	  of	  these	   colonies	   was	   dependent	   on	   the	   presence	   of	   unknown	   proteins	   that	   were	  given	   the	   name	   of	   colony	   stimulating	   factors	   (CSFs).	   	   Since	   the	   middle	   of	   the	  1980s,	  efforts	  have	  been	  made	  by	  several	  laboratories	  to	  identify	  and	  purify	  these	  CSF	  proteins.	  These	  efforts	  revealed	  that	  there	  are	  four	  CSF	  proteins	  with	  different	  activities.	   They	   were	   named	   dependent	   on	   the	   type	   of	   colony	   of	   cells	   they	  stimulated:	   M-­‐CSF	   stimulated	   macrophage	   colonies;	   GM-­‐CSF	   stimulated	   both	  granulocyte	   and	   macrophage	   colonies;	   G-­‐CSF	   stimulated	   granulocyte	   colony	  formation	   and	   multi-­‐CSF	   (known	   as	   interleukin	   3,	   IL3)	   stimulated	   multiple	   of	  hematopoietic	  cell	  colonies	  (Metcalf,	  2010).	  In	  1983,	  Murine	  GCSF	  was	  first	  purified	  from	  mouse	  lung-­‐conditioned	  medium	  by	  Nicola	  and	  colleagues	   in	  Melbourne,	  Australia	  (Nicola	  et	  al.,	  1983),	  while	  Human	  GCSF	  (hGCSF)	  was	  first	  purified	  from	  the	  human	  bladder	  carcinoma	  cell	  line	  5637	  in	   1984	   (Welte	   et	   al.,	   1985).	   The	   molecular	   cloning	   of	   complementary	  deoxyribonucleic	  acid	  (cDNA)	  for	  GCSF	  and	  the	  first	  expression	  from	  E.	  coli	  were	  attained	  by	  Souza	  and	  Boone	  in	  1986	  (Souza	  et	  al.,	  1986).	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Figure	  1-­‐1:	  Human	  GCSF	  structure	  The	  molecular	  structure	  of	  hGCSF	  contains	  four	  antiparallel,	  left-­‐handed	  α-­‐helical	  bundles	  in	  a	  form	  that	  two	  helices	  A	  (Red)	  &	  B	  (Orange)	  extend	  up	  and	  two	  helices	  C	   (White)	   &	   D	   (Cyne)	   extending	   down.	   C=	   carboxyl-­‐terminus	   and	   N=	   amine-­‐terminus	  (Using	  PyMOL	  molecular	  graphics	  system).	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 GCSF	  Expression	  and	  Action	  1.3Human	  GCSF	  is	  a	  glycoprotein	  that	  regulates	  the	  proliferation,	  differentiation	  and	  functional	   activation	   of	   granulopoiesis	   (Cox	   et	   al.,	   2014)	   since	   proved	   by	   the	  significant	   decrease	   of	   neutrophils	   in	   both	   GCSF	   and	   GCSF-­‐R	   deficient	   mice	  (Lieschke	  et	  al.,	  1994,	  Liu	  et	  al.,	  1996).	  In	  response	  to	  several	  inflammatory	  factors	  such	   as,	   interleukin	   β	   (IL-­‐1β)	   necrosis	   factor	   alpha	   (TNF-­‐α)	   and	  lipopolysaccharide	   (LPS),	   GCSF	   can	   be	   produced	   by	   a	   variety	   of	   cells,	   including	  endothelial	  cells,	  fibroblasts,	  macrophages,	  monocytes,	  and	  bone	  marrow	  stromal	  cells.	  GCSF	  has	  recently	  been	  shown	  to	  be	  highly	  expressed	  on	  a	  number	  of	  cancer	  cell	  types	  including	  human	  gastric	  and	  colon	  cancers	  (Gascon,	  2012,	  Morris	  et	  al.,	  2014),	   as	   well	   as	   acute	   myeloid	   leukemia	   (AML)	   and	   other	   carcinoma	   cells	  (Beekman	  et	  al.,	  2012).	  	  In	   healthy	   individuals,	   GCSF	   is	   present	   at	   low	   levels	   and	   is	   rapidly	   increased	   in	  severe	  cases	  such	  as,	  infection	  (20	  times	  increase)	  (Cheers	  et	  al.,	  1988,	  Kawakami	  et	  al.,	  1990).	  Therefore,	   the	  physiological	  role	  of	  GCSF	  in	  the	  body	  is	  to	  maintain	  the	   production	   of	   neutrophils	   during	   steady	   state	   situations	   and	   increase	  neutrophil	   production	   during	   severe	   inflammatory	   conditions	   such	   as,	   infection	  (Hartung	  et	  al.,	  1999).	  	  	  Several	  mechanisms	  showed	  that	  GCSF	  can	  enhance	  and	  regulate	  the	  production	  of	   neutrophils	   from	   the	   bone	   marrow	   to	   the	   blood	   circulation.	   It	   enhances	   the	  proliferation	  of	  all	  granulocytic	  lineages	  from	  myloblast	  (stem	  cell)	  to	  mylocyte.	  It	  also	   drives	   neutrophil	   differentiation	   and	   accelerates	   the	   maturation	   of	  metamyelocytes.	  As	  results	  of	  these	  functions,	  GCSF	  shows	  rapid	  and	  continuous	  elevation	  in	  the	  number	  of	  neutrophils	  (Lord	  et	  al.,	  1991,	  Basu	  et	  al.,	  2002).	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 Regulation	  of	  GCSF	  Expression	  1.4During	   infection,	   several	   inflammatory	   factors	   in	   the	   extracellular	  microenvironment	  are	  elevated,	  such	  as	  IL-­‐1β,	  TNF-­‐α	  and	  LPS	  and	  thereafter	  act	  on	   target	   cells	   to	   stimulate	   GCSF	   expression	   by	   intracellular	   signaling	  transcriptional	   factors,	   such	   as	   NF-­‐κB	   and	   C/EBP	   β.	   The	   GCSF	   promoter	   region	  contains	   binding	   sites	   for	   these	   factors,	   which	   in	   turn	   stimulate	   the	   GCSF	  production	   (Figure	   1.2	   right).	   	   The	   circulatory	   levels	   of	   GCSF	   enhance	   the	  production	   and	  mobilization	   of	   neutrophils	   from	   the	   bone	  marrow	   to	   the	   blood	  circulation	  (Panopoulos	  and	  Watowich,	  2008).	  	  In	  addition	  to	  this	  pathway,	  recent	  studies	  show	  that	  IL-­‐23	  produced	  by	  dendritic	  cells	  and	  macrophages,	  induces	  T	  helper	  17	  (Th17)	  to	  synthesis	  IL-­‐17.	  IL-­‐17	  then	  drives	   the	   production	   of	   GCSF	   from	   cells	   contained	   in	   the	   stroma,	   such	   as	  endothelial	   cells,	   epithelial	   and	   fibroblasts	   through	   the	   IL-­‐17	   receptor	   (IL-­‐17R)	  (Fossiez	  et	   al.,	   1996,	  Langrish	  et	   al.,	   2005).	   	   In	   response	   to	  bacterial	  pneumonia	  infection,	   deficiency	   of	   IL-­‐17R	   resulted	   in	   decreased	   levels	   of	   GCSF	   and	  delayed	  neutrophils	   production,	   indicating	   the	   important	   role	   of	   IL-­‐17-­‐induced	  granulopoiesis	   in	   vivo	   (Figure	   1.2	   left)	   (Ye	   et	   al.,	   2001,	   Nguyen-­‐Jackson	   et	   al.,	  2010).	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Figure	   1-­‐2:	   Regulation	   pathways	   of	   GCSF	   expression	   and	   production	   of	  
neutrophils	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 GCSF-­‐Receptor	  1.5
 Discovery,	  Expression	  and	  Cloning	  	  1.5.1The	   biological	   action	   of	   GCSF	   is	   mediated	   by	   binding	   to	   its	   receptor	   (GCSF-­‐R).	  Thus,	  the	  regulation,	  proliferation	  and	  differentiation	  of	  neutrophilic	  granulocytes	  are	  highly	  dependent	  on	  this	  binding	  (Gascon,	  2012).	  GCSF-­‐R	  was	  discovered	  as	  a	  membrane	   protein	   expressed	   in	   all	   granulocytic	   lineage	   cells,	   including	  neutrophils	  and	  their	  precursors,	  and	  myeloid	  leukemia	  cells	  (Nicola	  and	  Metcalf,	  1984).	   Later,	   GCSF-­‐R	   was	   detected	   on	   normal	   B	   &	   T	   lymphocytes,	   monocytes	  (Boneberg	   et	   al.,	   2000,	   Morikawa	   et	   al.,	   2002)	   and	   non-­‐	   hematopoietic	   tissues,	  such	   as,	   cardiomyocytes	   (Harada	   et	   al.,	   2005),	   vascular	   endothelial	   cells	  (Bussolino	   et	   al.,	   1989),	   neural	   stem	   cells	   (Schneider	   et	   al.,	   2005),	   placenta	  (McCracken	   et	   al.,	   1996),	  many	  non-­‐haematopoietic	   tumours	   cell	   lines	   (Roberts,	  2005)	  and	  has	  recently	  been	  shown	  to	  be	  highly	  expressed	  on	  human	  gastric	  and	  colon	  cancers	  (Morris	  et	  al.,	  2014).	  However,	  GCSF-­‐R	  is	  predominantly	  expressed	  on	  stem	  cells,	  common	  myeloid	  progenitors	  (CMP)	  and	  mature	  neutrophils,	  where	  by	  the	  expression	  of	  this	  receptor	  increases	  during	  maturation	  (Manz	  et	  al.,	  2002).	  In	  1990,	  granulocyte	  colony	  stimulating	  factor	  receptor	  (GCSF-­‐R)	  was	  first	  cloned	  from	  mouse	  myeloid	  leukemia	  cell	  line	  (NFS-­‐60)	  and	  shown	  to	  form	  homo-­‐dimers	  upon	   binding	   to	   its	   ligand	   (GCSF),	   resulting	   in	   a	   complex	   2:2	   ligand	   receptor	  subunit	  (Fukunaga	  et	  al.,	  1990a).	  
 Structure	  and	  Function	  of	  GCSF-­‐R	  1.5.2The	  human	  GCSF	  receptor	  is	  a	  120kDa	  cell	  surface	  receptor,	  which	  belongs	  to	  the	  hematopoietic	   cytokine	   receptor	   super-­‐family,	   HCR.	   The	   GCSF-­‐R	   is	   836	   amino	  acids	   in	   length	   and	   consists	   of	   an	   extracellular	   region	   with	   604	   amino	   acids,	  transmembrane	   region	   with	   26	   amino	   acids	   and	   a	   cytoplasmic	   (intracellular)	  region	  with	   183	   amino	   acids.	   The	   extracellular	   domains	   consist	   of	   the	   cytokine	  receptor	   homology	   (CRH)	  domain,	  N-­‐terminal	   immunoglobulin	   (Ig)-­‐like	   domain,	  and	  a	  Trp-­‐Ser-­‐X-­‐Trp-­‐Ser	  (WSXWS)	  motif	  required	  for	  ligand	  binding,	  and	  the	  rest	  of	   the	   extracellular	   region	   is	   formed	   by	   3	   fibronectin	   type	   III	   (FNIII)	   domains	  (Molineux	  et	  al.,	  2012).	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The	  intracellular	  region	  contains	  2	  conserved	  sub-­‐domains	  termed	  Box	  1	  and	  Box	  2,	  and	  a	  membrane-­‐distal	  domain	  that	   includes	  Box	  3	  (less	  conserved	  sequence)	  (Fukunaga	   et	   al.,	   1990b).	   The	   intracellular	   region	   of	   GCSF-­‐R	  has	   also	   4	   tyrosine	  residues	  at	  locations	  704,	  729,	  744	  and	  764	  of	  the	  human	  receptor	  (corresponding	  to	  Y703,	  Y728,	  Y743,	  and	  Y763	  in	  the	  murine	  receptor);	  these	  conserved	  residues	  play	   an	   important	   role	   in	   the	   induction	   of	   GCSF	   cell	   survival,	   proliferation	   and	  differentiation	  (Figure	  1.3)	  (Molineux	  et	  al.,	  2012).	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Figure	  1-­‐3:	  Structure	  and	  downstream	  signal	  pathways	  of	  GCSF-­‐R	  The	   GCSF-­‐R	   contains	   of	   extracellular	   region	   and	   intracellular	   region.	   The	  extracellular	   region	   of	   the	   GCSF-­‐R	   includes	   3	   fibronectin	   type	   III	   (FNIII)-­‐like	  domains,	   WSXWS	   motif,	   a	   cytokine	   receptor	   homologous	   (CRH)	   domain,	   and	  immunoglobulin	   (Ig)-­‐like	   domain.	   Conserved	   Box	   1,	   Box	   2,	   and	   Box	   3	   and	   4	  tyrosines	  (Y703,	  Y728,	  Y743	  and	  Y763)	  mediate	  downstream	  signal	  transduction	  in	   the	   intracellular	   region.	   Binding	   of	   GCSF	   to	   its	   receptor	   induces	  phosphorylation	  of	   JAKs,	   resulting	   in	  phosphorylation	  of	   the	  4	   tyrosine	   residues	  located	   on	   the	   cytoplasmic	   region.	   Once	   these	   tyrosine	   residues	   are	  phosphorylated,	  they	  serve	  as	  docking	  sites	  for	  numerous	  proteins	  characterized	  by	   Src	  Homology	   2	   (SH2)	   domains	   resulting	   in	   activation	   of	   many	   signaling	  pathways	  that	  regulate	  different	  cell	  processes.	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The	  binding	  of	  GCSF	  to	  its	  receptor	  forms	  homo-­‐dimers,	  resulting	  in	  a	  complex	  of	  two	  GCSF	  molecules	   and	   two	  GCSF-­‐R	  molecules	   (Larsen	   et	   al.,	   1990).	   Each	  GCSF	  interacts	  with	  the	  immunoglobulin	  (Ig)-­‐like	  domain	  of	  one	  GCSF-­‐R	  subunit	  and	  the	  CRH	  domain	  of	  the	  second	  GCSF-­‐R	  subunit,	  resulting	  in	  a	  crossover	  configuration	  of	  the	  receptor	  subunits	  (Figure	  1.4.B)	  (Tamada	  et	  al.,	  2006).	  	  The	   binding	   of	   GCSF	   to	   its	   receptor	   activates	   the	   Janus	   kinase	   (Jak)/signal	  transducer	  and	  activator	  of	  transcription	  (STAT)	  signalling	  pathways.	   	   	  Molecules	  that	   get	   activated	   as	   part	   of	   the	   pathway	   include	   Jak1,	   Jak2,	   STAT1,	   STAT3,	   and	  STAT5.	  It	  has	  been	  reported	  that	  tryptophan	  residues	  localized	  between	  Box	  1	  and	  Box	   2	   in	   the	   intracellular	   region	   of	   GCSF-­‐R	   serves	   as	   a	   docking	   site	   for	   Jaks.	  Because	   GCSF-­‐R	   lacks	   intrinsic	   kinase	   activity;	   thus,	   it	  mostly	   relies	   on	   different	  non-­‐receptor	  kinases,	  for	  instance,	  activation	  of	  JAK	  family,	  mainly	  through	  JAK	  1	  and	   2	   (Meshkibaf,	   2015).	   Upon	   activation,	   the	   GCSF-­‐R	   dimerizes	   and	   brings	   the	  Jaks	   together	   into	   proximity,	   resulting	   in	   their	   trans-­‐phosphorylation	   of	   one	  another	  which	  in	  turn	  phosphorylate	  tyrosine	  (Y)	  resides	  (Y703,	  Y728,	  Y743,	  and	  Y763)	   located	   in	   the	   cytoplasmic	   region.	   Once	   these	   tyrosine	   residues	   are	  phosphorylated,	  they	  serve	  as	  docking	  sites	  for	  STAT’s.	  STAT’s	  are	  transcriptional	  factors	  found	  in	  the	  intracellular	  region	  (cytoplasmic	  region),	  and	  can	  interact	  with	  phosphotyrosine	  residues	  of	   the	  GCSF-­‐R	  via	  their	  Src	  Homology	  2	  (SH2)	  domains	  (the	  function	  of	  this	  domain	  is	  to	  identify	  the	  phosphorylated	  state	  of	  tyrosine	  (Y)	  residues).	  STAT’s	  get	  phosphorylated	  then	  form	  dimers	  and	  migrate	  to	  the	  nucleus,	  where	  they	  bind	  DNA	  and	  activate	  transcription.	  Although	  there	  are	  seven	  family	  members	   of	   STATs,	   activation	  of	   low	   level	   of	  GCSF	   results	   in	   phosphorylation	  of	  Y703	  and	  Y743,	  resulting	  in	  strong	  stimulation	  of	  STAT3	  with	  slight	  stimulation	  of	  STAT1	  and	  STAT5	  (Figure	  1.4).	  In	  vitro,	  STAT3	  activation	  seems	  to	  push	  neutrophil	  differentiation	  mediated	   by	   activation	   of	   neutrophil	   marker	   genes.	   Activation	   of	  GCSF-­‐R	   is	   also	   appeared	   to	   activate	   STAT1	   and	   STAT5,	   resulting	   in	   cell	  proliferation.	   	   In	   addition,	   it	   has	   been	   reported	   that	   Y728	   is	   a	   docking	   site	   for	  Suppressor	  of	  cytokine	  signalling	  3	  (SOCS3),	  which	  is	  a	  critical	  feedback	  inhibitor	  of	  GCSF-­‐R	  signalling	  pathway	  (Molineux	  et	  al.,	  2012).	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Figure	  1-­‐4:	  Pathway	  upon	  activation	  of	  Jak-­‐STAT	  signals	  [A]	  In	  the	  absence	  of	  the	  ligand,	  G-­‐CSFR	  is	  associated	  with	  Janus	  kinases	  (Jaks).	  [B]	  The	  binding	  of	   the	   ligand	  to	   the	  receptor	  occurs	  at	  a	  2:2	   ligand:receptor	  subunit	  stoichiometry,	  forming	  a	  cross-­‐over	  configuration	  between	  the	  receptor	  subunits	  bring	   the	   Jaks	   into	   proximity	   and	   enables	   their	   trans-­‐phosphorylation	   and	  stimulation.	   [C]	  The	   intracellular	  4-­‐tyrosine	  residues	  of	   the	  GCSF-­‐R	  (represented	  by	  stars)	  are	  phosphorylated	  by	  Jaks.	  [D]	  STAT	  interacts	  with	  the	  phosphotyrosine	  residues	   through	   their	   Src	  Homology	   2	   (SH2)	   domains	   and	   become	  phosphorylated	  by	   the	   Jak.	  Phospho-­‐dimers	  of	   STATs	  accumulate	   in	   the	  nucleus	  and	   activate	   transcription	   factors	   that	   drive	   the	   neutrophils	   from	   the	   bone	  marrow	  to	  the	  blood	  circulation.	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Although	  that	  GCSF-­‐R	  is	  widely	  accepted	  to	  activate	  Jak/STAT	  pathways,	  it	  has	  also	  been	  reported	  that	  GCSF-­‐R	  is	  linked	  to	  numerous	  components	  of	  Mitogen-­‐activated	  protein	  (MAP)	  kinase	  and	  phosphoinostide-­‐3-­‐kinase-­‐protein	  kinase	  B	  (PI-­‐3K-­‐PKB)	  and	   pathways	   resulting	   in	   activation	   of	   transcription	   factors	   and	   regulation.	   For	  instance,	   Y764	   serves	   as	   docking	   site	   for	   Growth	   factor	   receptor-­‐bound	   protein	  2(Grb2)	   and	   has	   been	   linked	   to	   activation	   of	   p21	   Ras	   pathway.	   	   A	   significant	  reduction	  of	  p21	  Ras	   activation	  and	  neutrophil	   proliferation	  was	  noticed	   in	  vitro	  when	  Y764	  was	  absent	  (Hermans	  et	  al.,	  2003).	  Extracellular	  signal-­‐regulated	  1/2	  (Erk	   1/2)	  MAP	   kinases	   are	   considered	   the	  main	   downstream	   effectors	   from	   the	  p21	  Ras	  pathway	  resulting	  in	  signaling	  proliferation	  of	  myeloid	  progenitor	  cells.	  In	  neural	  cells,	  it	  is	  also	  reported	  that	  Erk1/2	  is	  strongly	  activated	  upon	  exposure	  to	  GCSF	  (Hamilton,	  2008,	  Panopoulos	  and	  Watowich,	  2008,	  Touw	  and	  van	  de	  Geijn,	  2007).	   In	  Swan	  71	  cells,	  binding	  of	  GCSF	  to	   its	  receptor	   leads	  to	  the	  activation	  of	  both	   PI3K/Akt	   and	   Erk1/2	   pathways	   leads	   to	   the	   migration	   of	   NF-­‐kB	   to	   the	  nucleus,	   stimulating	   an	   increase	   of	  matrix	  metalloproteinase-­‐2	   (MMP-­‐2)	   activity	  and	  Vascular	  endothelial	  growth	  factor	  (VEGF)	  secretion	  (Furmento	  et	  al.,	  2014).	  It	  is	  also	  reported	  that	   the	  activation	  of	  GCSF-­‐R	  triggers	  PI-­‐3K-­‐PKB	  pathway	  that	   is	  important	  for	  the	  stimulation	  of	  cell	  survival	  by	  inhibiting	  the	  apoptotic	  cascades	  (Figure	   1.3)	   (Hunter	   &	   Avalos,	   2000;	   Touw	   &	   van	   de	   Geijn,	   2007).	   Another	  pathway	   that	   are	   induced	   by	   GCSF	   is	   the	   Tyrosine-­‐protein	   kinase	  (Lyn),	   play	   a	  crucial	   role	   in	   GCSF	   mediated	   cell	   proliferation,	   in	   addition	   to	   the	   activation	   of	  GCSF	   primed	   pro-­‐inflammatory	   responses	   in	   neutrophils	   (Sampson	   et	   al.,	   2007,	  Sivakumar	  et	  al.,	  2015).	  
 Mobilization	  of	  Neutrophils	  1.5.2.1Previously,	  it	  was	  reported	  that	  STAT3	  is	  the	  major	  transcription	  factor	  activated	  upon	  binding	  of	  GCSF	   to	   its	   receptor	  but	   the	  role	  of	  STAT3	   in	   the	  mechanism	  of	  neutrophils	  mobilization	  was	  not	  clear	  (Panopoulos	  et	  al.,	  2002).	  The	  chemokines,	  macrophage	   inflammatory	   protein-­‐2	   (MIP-­‐2,	   known	   as	   Cxcl2)	   and	   keratinocyte	  derived	   chemokine	   (KC,	   Cxcl1)	   and	   their	   shared	   receptor	   CXCR2	   induce	   the	  mobilization	   of	   neutrophils	   from	   the	  BM	   to	   the	   circulating	   blood.	   In	   contrast	   to	  this	   the	  stromal	  cell–derived	  factor	  1	  (SDF-­‐1,	  CXCL12)	  which	   is	  expressed	   in	  the	  BM	   and	   its	   chemokine	   receptor	   4	   (CXCR4),	   expressed	   on	   the	   surface	   of	  neutrophils,	   contribute	   to	   the	   retention	   of	   neutrophils	   in	   the	   BM	   and	   requiring	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dawn-­‐regulation	   to	   induce	   the	   releasing	   of	   neutrophils.	   	   Nguyen-­‐Jackson	   et	   al.	  (2010)	  demonstrated	  that	  STAT3	  controls	  the	  neutrophils	  migration	  from	  the	  BM	  to	   the	   circulating	   blood	   in	   response	   to	   GCSF	   treatment	   by	   binding	   to	   the	  chemokines	  MIP-­‐2	  and	  KC	  and	  increasing	  the	  production	  of	  these	  chemokines	  and	  reducing	   bone	   marrow	   SDF-­‐1	   expression	   in	   WT	   mice	   (Figure	   1.5)	   (Nguyen-­‐Jackson	   et	   al.,	   2010,	  Nguyen-­‐Jackson	   et	   al.,	   2012).	   In	   summary,	   because	  GCSF	   is	  itself	  not	  chemotactic,	  this	  concept	  is	  supported	  by	  the	  observation	  that	  GCSF	  fails	  to	   induce	   circulating	   neutrophil	   amounts	   in	   CXCR2-­‐knockout	  mice	   (Pelus	   et	   al.,	  2002).	   Inhibiting	   the	   SDF-­‐1/CXCR4	   interaction	   is	   sufficient	   to	   enable	   neutrophil	  release,	   as	   shown	   by	   use	   of	   the	   CXCR4	   antagonist	   AMD3100	   (Plerixafor)	  (Broxmeyer	  et	  al.,	  2005).	  	  
	  
Figure	  1-­‐5:	  Scheme	  of	  the	  proposed	  model	  How	  STAT3	  induces	  the	  mobilization	  of	  neutrophils.	  Neutrophils	  are	  reserved	  in	  the	  BM	  in	  part	  throughout	  their	  CXCR4	  expression,	  which	  binds	  to	  SDF-­‐1	  (stromal	  cells	   express	   SDF-­‐1).	   Administration	   of	   GCSF	   leads	   to	   down-­‐regulation	   and	  decreases	  of	  SDF-­‐1	  with	   its	  receptor	  CXCR4;	  suppression	  of	  SDF-­‐1	  needs	  STAT3.	  Intake	  of	  GCSF	  also	   stimulate	   the	  neutrophil	   chemo-­‐attractants	  MIP-­‐2	  and	  KC	   in	  the	   BM	   together	   with	   up-­‐regulation	   of	   their	   shared	   CXCR2	   on	   the	   neutrophils	  surface,	   STAT3	   is	   required	   in	   the	   stimulation	  of	  MIP-­‐2,	  KC	  and	  CXCR2.	  Modified	  from	  (Nguyen-­‐Jackson	  et	  al.,	  2010,	  Nguyen-­‐Jackson	  et	  al.,	  2012).	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 The	  Major	  Clinical	  Use	  of	  GCSF	  1.6
 Febrile	  Neutropenia	  Prophylaxis	  1.6.1Febrile	  neutropenia	  (FN)	  complications	  (defined	  as	  development	  of	  fever	  >38.5OC	  with	  absolute	  neutrophil	  counts	  <	  1.0x106/L)	  are	  the	  main	  symptoms	  observed	  in	  patients	   treated	   with	   systemic	   cancer	   chemotherapy.	   Administration	   of	   GCSF	  shows	  benefits	  in	  reducing	  the	  risk	  of	  FN	  and	  accelerates	  the	  neutrophils	  number	  (Shah	  and	  Welsh,	  2014).	  	  
 Mobilization	  of	  Stem	  Cells	  	  1.6.2Administration	   of	   rhGCSF	   promotes	   and	   accelerates	   hematopoietic	   stem	   cell	  (HSC)	   secretion	   into	   peripheral	   blood	   in	   order	   to	   facilitate	   collection	   of	   large	  numbers	  of	  stem	  cells	  from	  the	  peripheral	  blood.	  Thus,	  GCSF	  is	  given	  to	  patients	  following	  chemotherapies	   in	   two	  processes	  either	  autologous	  or	  allogeneic	  stem	  cell	   transplantation.	   Autologous	   stem	   cell	   transplantation	   is	   a	   process	   that	  depends	  on	  the	  collection	  of	  a	  patient's	  own	  stem	  cells,	  administration	  of	  GCSF	  is	  mainly	   alone	   or	   in	   combination	  with	   chemotherapeutic	   drugs	   (Bensinger	   et	   al.,	  1995,	   Martino	   et	   al.,	   2014).	   The	   combination	   of	   GCSF	   with	   chemotherapeutic	  drugs	   showed	   higher	   numbers	   of	   CD34+	   cells	   and	   lower	   levels	   of	   apheresis	  sessions	  in	  comparison	  to	  administration	  of	  GCSF	  alone	  (Pusic	  and	  DiPersio,	  2008,	  Tanhehco	   et	   al.,	   2010).	   In	   contrast,	   allogeneic	   stem	   cell	   transplantation	   is	   a	  process	   in	  which	   the	   patient	   receives	   stem	   cells	   from	   a	   healthy	   individual	  who	  have	  been	   injected	  with	  GCSF	   for	   the	  purpose	  of	  donation.	  This	  process	   is	  more	  effective	  and	  safe	  than	  autologous	  stem	  cell	  transplantation	  (Hölig,	  2013).	  
 Controlling	  of	  SCN	  and	  AML	  1.6.3Administration	  of	   rhGCSF	   therapy	  has	  been	   shown	   to	   improve	   the	   conditions	  of	  patients	  with	  acute	  myeloid	  leukemia	  (AML)	  prior	  to	  chemotherapy	  in	  two	  ways;	  increasing	  both	  the	  neutrophil	  counts	  in	  the	  first	  24	  hours	  and	  the	  susceptibility	  of	  myeloid	   leukemia	  blast	  cells	  to	  chemotherapy	  (Löwenberg	  et	  al.,	  2003,	  Beekman	  and	   Touw,	   2010).	   Also,	   it	   has	   shown	   to	   directly	   reduce	   the	   risk	   of	   several	  leukemia’s.	   For	   instance,	   lymphoblastic	   AML	   patients	   achieved	   complete	  remission	  when	  treated	  with	  GCSF	  alone	  (Nimubona	  et	  al.,	  2002).	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Although	   GCSF	   can	   increase	   the	   number	   of	   neutrophils	   in	   patients	   with	   severe	  congenital	   anaemia	   (SCN)	   and	   thereafter	   minimize	   this	   risk	   of	   recurrent	  infections,	  GCSF-­‐R	  mutations	  have	  been	  reported	  in	  a	  patient	  with	  SCN	  who	  may	  developed	   secondary	   AML	   and	   myelodysplastic	   syndrome (MDS)	   due	   to	  administration	   of	   GCSF	   (Ancliff	   et	   al.,	   2003,	   Beekman	   et	   al.,	   2012).	  More	   details	  about	   the	   adverse	   effects	   of	   GCSF	   administrations	  will	   be	   discussed	   in	   the	   next	  section.	  	  




Figure	  1-­‐6:	  Comparison	  of	  carboxyl-­‐terminal	  region	  of	  the	  GCSF-­‐R	  in	  patients	  
with	  AML	  Class	   IV	   isoform	   has	   no	   differences	   in	   their	   juxta-­‐membrane	   and	   extracellular	  domains,	   but	   differing	   in	   their	   cytoplasmic	   domains.	   The	   isoform	  maintains	   the	  membrane	  proximal	   sequence	   that	   required	   for	  proliferative	   signaling	  and	   loses	  at	  position	  725	   the	   carboxy-­‐terminal	  87	  amino	  acids,	  which	  are	   replaced	  with	  a	  unique	  34	  amino	  acid	  sequence.	  As	  a	  result,	  the	  4-­‐tyrosine	  residues	  (Y704,	  Y729,	  Y744	  and	  Y764)	  in	  the	  full-­‐length	  form	  class1	  (wild	  type)	  truncated	  and	  only	  Y704	  is	   conserved	   among	   this	   isoform	   (Class	   IV).	   Modified	   from	   (Liongue	   and	  Ward,	  2014).	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Table	  1-­‐1:	  The	  main	  side	  effects	  reported	  for	  patients	  treated	  with	  GCSF	  
Side	  effect	   Organ	   Possible	  mechanism	   References	  Osteopenia	  &	  osteoporosis	   Bone	   Administration	  of	  G-­‐CSF	  increases	  bone	  resorption	  via	  increasing	  the	  activity	  of	  osteoclasts	  leading	  to	  significant	  bone	  loss.	   (D'Souza	  et	  al.,	  2008)	  
Joint	  pain	  &	  generalized	  weakness	  	  
Bone	   1)	  Expansion	  of	  bone	  marrow,	  	  2)	  Enhancing	  of	  GCSF-­‐R	  on	  afferent	  nerve	  fibers	  lead	  to	  generate	  peripheral	  nociceptor	  sensitization,	  	  3)	  Stimulation	  of	  inflammatory	  cells,	  such	  as,	  macrophages	  and	  monocytes	  that	  contributes	  to	  nerve	  remodeling,	  	  4)	  Osteoblast	  and	  osteoclast	  activation.	  
(Lambertini	  et	  al.,	  2014)	  
Erythematous	  rash,	  urticarial	  and	  Sweet	  syndrome	   Skin	   Infiltration	  of	  neutrophils	  into	  dermis	  and	  epidermis.	   (Nomiyama	  et	  al.,	  1994,	  Prendiville	  et	  al.,	  2001,	  Llamas-­‐Velasco	  et	  al.,	  2013)	  Splenomegaly	  &	  extramedullary	  hematopoiesis	  	  
Spleen	   Stimulation	  of	  myelopoisis.	   (Litam	  et	  al.,	  1993,	  O'Malley	  et	  al.,	  2003,	  Dagdas	  et	  al.,	  2006)	  
Lung	  cancer	  and	  acute	  respiratory	  distress	  syndrome	  	  
Lung	   Accumulation	  of	  neutrophils	  due	  to	  releasing	  of	  chemoattractant	  molecules.	  As	  a	  result,	  these	  cells	  release	  a	  number	  of	  substances	  injurious,	  for	  instance,	  platelet,	  leukotrienes,	  proteases	  and,	  oxidants	  that	  cause	  damage	  in	  the	  alveolar	  endothelium	  and	  epithelium.	  
(Asano	  et	  al.,	  1977,	  Wada	  et	  al.,	  2011,	  Yamaguchi	  et	  al.,	  2012,	  Inokuchi	  et	  al.,	  2015)	  
Reversible	  renal	  impairments	   Kidney	   Stimulation	  of	  leukocytosis	  in	  the	  kidneys.	   (Hirokawa	  et	  al.,	  1996)	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 Available	  Commercial	  GCSF	  Preparations	  and	  Their	  Limitations	  1.8Human	   GCSF	   has	   been	   cloned	   and	   is	   currently	   available	   as	   two	   recombinant	  human	  GCSF	  (rhGCSF)	  preparations	  for	  HPC	  mobilization:	  	  
 Filgrastim	  (NEUPOGEN®)	  	  1.8.1Filgrastim	   is	   a	   non-­‐glycosylated	   form	   (18.8kD),	   obtained	   from	   E.	   coli	   and	   has	   a	  methionine	   group	   at	   its	   N-­‐terminal	   end.	   In	   1991,	   Filgrastim	   was	   licensed	   and	  marketed	   as	   a	   treatment	   for	   patients	   with	   neutropenia	   following	  chemotherapeutic	  drugs.	  Since	  its	  launch,	  clinicians	  have	  recommended	  the	  use	  of	  Filgrastim	   in	   bone	   marrow	   transplantation	   procedures,	   aplastic	   anaemia,	   sever	  congenital	   neutropenia,	   and	   to	   support	   patients	  with	   AIDS	   and	  myelodysplastic	  syndromes	  (Molineux,	  2004).	  However,	  it	  was	  reported	  that	  Filgrastim	  has	  a	  short	  half-­‐life	   in	   the	   serum	   of	   3.5	   hours	   when	   injected	   in	   to	   healthy	   volunteers	   and	  patients	  with	  malignancies	   because	   E.	   coli	   derived	   Filgrastim	   lacks	   the	  O-­‐linked	  glycosylation	  (Cooper	  et	  al.,	  2011,	  Hoggatt	  and	  Pelus,	  2014).	  
 Lenograstim	  (Granocyte®)	  1.8.2Lenograstim	  is	  an	  O-­‐glycosylated	  form	  at	  Thr-­‐133	  position	  obtained	  from	  Chinese	  hamster	   ovarian	   (CHO)	   cells	   (Nagata	   et	   al.,	   1986).	   It	   has	   a	   short	   half-­‐life	   in	   the	  serum	  of	  between3–4	  hours	  and	  O-­‐linked	  was	  shown	  to	  have	  an	  important	  role	  in	  providing	   greater	   stability	   to	   the	   GCSF	   by	   protecting	   the	   cysteine-­‐17	   sulfhydryl	  group	   from	   oxidation	   by	   free	   radicals	   (Hasegawa,	   1993,	   Cooper	   et	   al.,	   2011).	   It	  was	  believed	  that	  the	  O-­‐linked	  glycosylation	  might	  show	  clinical	  advantages	  over	  the	  non-­‐glycosylated	   form	  (Filgrastim),	  however	   the	   in	  vivo	   comparative	   studies	  showed	   that	   no	   differences	   between	   them	   in	   all	   aspects	   (Ataergin	   et	   al.,	   2008).	  Besides,	   leukemic	   patients	   need	   daily	   injections	   to	   maintain	   its	   activity	   in	   the	  circulation,	  which	  are	  inconvenient,	  expensive	  and	  painful	  especially	  for	  children.	  As	  Lenograstim	  is	  similar	  to	  the	  natural	  GCSF,	  studies	  shifted	  to	  focus	  on	  this	  form.	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  Strategies	  Used	  to	  Delay	  the	  Clearance	  of	  GCSF	  1.9Since	   the	  main	   limitations	  of	   the	  previous	   forms	  of	   rhGCSF	   (1st	   generation)	   are	  short	  circulating	  half-­‐life	  and	  daily	  injection,	  two	  strategies	  have	  been	  developed	  to	  overcome	  these	  issues.	  The	  first	  strategy	  is	  to	  increase	  the	  molecular	  weight	  of	  the	   therapeutic	   proteins	   (hydrodynamic	   radius)	   above	   the	   renal	   filtration	  threshold.	   Predominantly,	   this	   increase	   in	  molecular	   weight	   can	   be	   attained	   by	  conjugation	   with	   another	   moiety	   such	   as,	   PEGylation.	   The	   second	   strategy	   to	  extend	  the	  half-­‐life	  of	  the	  therapeutic	  proteins	  offers	  the	  benefits	  of	  the	  neonatal	  Fc	  receptor	  (FcRn)	  recycling	  mechanism	  by	  forming	  fusion	  proteins	  with	  both	  Fc	  portion	   of	   immunoglobulin	   and	   albumin	   (Natalello	   et	   al.,	   2012,	   Cox	   et	   al.,	   2014,	  Chung	  et	  al.,	  2011).	  Additional	  new	  approaches	  using	  Asterion	  profuse	  technology	  will	  also	  be	  discussed.	  	  	  
 Extension	  of	  Half-­‐life	  by	  Increasing	  the	  Molecular	  Weight	  1.9.1
 PEGylation	  	   	  1.9.1.1The	  short	  circulating	  half-­‐life	  of	  many	  recombinant	  proteins	  can	  be	  increased	  via	  conjugation	   with	   poly	   ethylene	   glycol	   (PEG),	   in	   a	   process	   termed	   PEGylation	  (Natalello	   et	   al.,	   2012).	   In	   the	   1970’s,	   It	  was	   first	   described	  by	  Abuchowski	   and	  Davis	  who	  found	  that	  PEG	  may	  improve	  the	  immunological	  properties	  and	  serum	  half-­‐life	  of	  proteins	  such	  as	  bovine	  liver	  catalase	  and	  albumin	  (Abuchowski	  et	  al.,	  1977).	  Since	  then,	  widespread	  research	  has	  been	  carried	  out	  into	  PEG	  technology	  resulting	   in	   highly	   variable	   PEGs	  with	   several	  molecular	  weights	   (Jain	   and	   Jain,	  2008).	   A	   range	   of	   Pegylated	   proteins	   are	   now	   clinically	   available,	   such	   as,	  Pegvisomant	  (Pegylated	  growth	  hormone	  antagonist,	  licensed	  for	  the	  treatment	  of	  acromegaly	  in	  2003	  (Trainer	  et	  al.,	  2000,	  Hamidi	  et	  al.,	  2006).	  To	  generate	  a	  new	  2nd	  generation	  product,	  a	  20	  kDa	  PEG	  molecule	  was	  attached	  covalently	  to	  recombinant	  methionyl	  (r-­‐met)	  human	  GCSF	  Neupogen	  (Filgrastim).	  This	   new	   molecule	   was	   marketed	   as	   Neulasta	   (Pegfilgrastim).	   In	   Pegfilgrastim,	  each	  ethylene	  oxide	  unit	  of	  PEG	  binds	  to	  three	  water	  molecules	  which	  increases	  its	  water	  solubility	  and	  also	  hydrodynamic	  radius	  (molecule’s	  diameter)	  resulting	  in	  increased	  size	  of	  the	  molecule	  to	  ~38.8kDa,	  thus	  reducing	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renal	   clearance.	   PEGylation	   also	   creates	   a	   hydrophilic	   shield	   that	   protects	   the	  protein	   from	   proteolysis	   and	   immunologic	   recognition	   (Bailon	   and	  Won,	   2009,	  Milla	   et	   al.,	   2012).	  The	  key	  behind	   the	   successful	   progress	   of	   Pegfilgrastim	  over	  Filgrastim	  was	  an	  understanding	  of	  the	  GCSF	  clearance	  processes	  in	  the	  body.	  In	  humans,	   GCSF	   has	   two	   clearance	   mechanisms:	   renal	   clearance	   and	   neutrophil-­‐mediated	  clearance	  (Yowell	  and	  Blackwell,	  2002).	  The	  presence	  of	  the	  PEG	  moiety	  decreases	  the	  renal	  clearance	  of	  Pegfilgrastim	  and	  as	  a	  result	  it	  is	  mainly	  cleared	  via	  a	  self–regulating	  neutrophil-­‐mediated	  mechanism,	  which	  is	  dependent	  on	  the	  number	  of	  neutrophils.	  Following	  administration	  of	  Pegfilgrastim,	  concentrations	  remain	   high	   in	   patient	   serums	   during	   neutropenia,	   but	   are	   reduced	   when	   the	  numbers	  of	  neutrophils	  increase.	  Therefore,	  a	  single	  injection	  of	  Pegfilgrastim	  per	  chemotherapy	   cycle	   is	   as	   efficient	   as	   the	   daily	   administration	   of	   Filgrastim	  (Curran	  and	  Goa,	  2002).	  The	  PEGylation	  of	  a	  protein	  used	   to	  be	  one	  of	   the	  major	   limitations	  because	   the	  whole	  PEG	  is	  often	  processed	  for	  excretion	  in	  the	  human	  body	  without	  undergoing	  an	  initial	  biodegradation	  which	  could	  be	  toxic	  to	  the	  body	  (Patel	  et	  al.,	  2014).	  This	  possible	   toxicity	   was	   supported	   by	   the	   detection	   of	   PEG	   in	   bile	   (Caliceti	   and	  Veronese,	  2003).	  Vacuole	  formation	  has	  also	  been	  observed	  in	  renal	  tubules	  upon	  administration	   of	   PEG	   thereby	   affecting	   the	   tissue	   distribution	   and	   in	   turn	  clearance	  (Zhang	  et	  al.,	  2014).	  Modification	  of	  GCSF	  with	  PEGylation	  reduced	   in	  vitro	  biological	  activity	  of	  GCSF	  (2	  to	  3	  fold),	  as	  the	  conjugation	  of	  PEG	  to	  the	  GCSF	  could	  induce	  structural	  change	  in	   the	  molecule	   that	   attenuates	   the	   potency	   (Kinstler	   et	   al.,	   1996,	   Gaertner	   and	  Offord,	  1996).	  The	   increased	  cost	  of	  PEGylation	   is	  considered	  to	  be	  one	  of	   the	  main	   limitations	  because	   Pegfilgrastim	   requires	   a	   post-­‐expression	   chemical	   modification	   and	  purification	   processes	   (Pisal	   et	   al.,	   2010).	   The	   table	   below	   summarizes	   the	  advantages	   and	   limitations	   of	   PEGylation	   and	   other	   different	   strategies	   used	   to	  generate	  long	  acting	  GCSF	  (Table	  1.2).	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Table	   1-­‐2:	   Summary	   of	   pros	   and	   cons	   of	   PEGylation	   and	   other	   different	  
strategies	  used	  to	  generate	  a	  long	  acting	  GCSF	  












++LR9fusion+(Asterion)+3rd++++++++generation+ ++Increased+half9life+of+GH,+reduced+immunogenicity+and+toxicity.+Naturally+occurring+sequences+ ++ ++(Wilkinson+et+al.,+2007,+Ferrandis+et+al.,+2010)+
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 Extension	  of	  Half-­‐life	  Using	  the	  FcRn-­‐Mediated	  Recycling	  1.9.2




Figure	   1-­‐7:	   Model	   of	   the	   pH-­‐dependent	   recycling	   mechanism	   of	  
albumin	  via	  the	  FcRn	  receptor	  in	  serum	  	  The	   three	   domains	   of	   albumin	   are	   marked	   in	   green	   (domain	   I),	   blue	  (domain	   II)	   and	   red	   (domain	   III).	   Domain	   III	   albumin	   is	   binding	   FcRn	  receptor	   at	   acidic	   pH	   6.0	   to	   protect	   from	   lysosomal	   degradation	   and	  recycling	   again	   to	   the	   circulation	   where	   exposure	   to	   physiological	   pH	   7.2	  causes	  the	  release	  of	  albumin.	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  Fusion	  of	  GCSF	  to	  Albumin	  1.9.2.1Human	   serum	   albumin	   (HSA)	   is	   produced	   in	   liver	   and	   has	   numerous	  physiological	   roles	   including	   transportation	  of	   fatty	  acid	  and	  metal	   ions	  as	  well	  as	  maintenance	  of	  plasma	  pH	  and	  colloid	  blood	  pressure.	  As	  albumin	  is	  a	   large	  protein	  (67kDa),	   it	   can	  be	   fused	   to	  recombinant	  proteins	   to	  extend	  their	   half-­‐life.	   As	   a	   result,	   fused	   proteins	   will	   automatically	   attain	   a	  molecular	  weight	   too	   large	   to	   be	   filtered	   through	   the	   kidney	   and	   increase	  plasma	  protein	   residency	   time	   (Dennis	   et	   al.,	   2002,	  Andersen	   and	   Sandlie,	  2009)	  	  The	   advantage	   of	   carboxy	   terminal	   domain	   III	   HAS	   (3DHAS)	   has	   been	  considered	  widely	  and	  later	  3DHAS	  was	  genetically	  fused	  to	  the	  N-­‐terminal	  of	  GCSF.	  The	  pharmacokinetic/	  pharmacodynamics	  (PK/PD)	  studies	  showed	  increased	   half-­‐life	   and	   increased	   WBC	   counts	   of	   neutropenia	   model	   mice	  compared	  to	  native	  GCSF	  (Zhao	  et	  al.,	  2013).	  	  
 	  Fusion	  of	  GCSF	  to	  IgG-­‐Fc	  	  1.9.2.2In	  humans,	  the	  circulating	  half-­‐life	  of	  IgG1	  and	  IgG4	  immunoglobulins	  is	  23	  days,	   and	   that	   IgG1	   and	   IgG4	   immunolglobulins	   have	   been	   used	   to	   form	  several	   long-­‐acting	   fusion	   proteins	   (Gaberc-­‐Porekar	   et	   al.,	   2008).	   Thus,	  immunoglobulins	  selected	  as	  the	  choice	  antibody	  for	  Fc	  fusion	  proteins.	  Structurally,	   immunoglobulins	   are	   composed	   of	   two	   identical	   light	   and	  heavy	   chains	   connected	   by	   disulphide	   bonds.	   	   Both	   chains	   contain	   two	  regions:	   	   the	   fragment	   of	   antigen	   binding	   (Fab)	   (the	   head	   region	   of	   an	  antibody)	   responsible	   for	   immunogenic	   detection	   and	   the	   crystallisable	  fragment	  (Fc)	  (the	  tail	  region	  of	  an	  antibody	  that	  interacts	  with	  cell	  surface	  receptor)	   responsible	   for	   maintenance	   of	   IgG	   in	   the	   blood	   circulation	  (Gaberc-­‐Porekar	  et	  al.,	  2008).	  	  The	  IgG	  immunoglobulin	  has	  two	  fragments:	  CH	  (CH1-­‐Hinge-­‐CH2-­‐CH3)	  and	  Fc	  (Hinge-­‐CH2-­‐	  CH3)	  domains.	  The	  Hinge	  domain	  is	  responsible	  for	  linking	  Fab	  and	  Fc	  regions	  and	  provides	  more	  flexibility.	  Many	  therapeutic	  proteins	  have	  been	  reported	  to	  joined	  via	  the	  amino-­‐termini	  of	  CH	  (CH1-­‐Hinge-­‐CH2-­‐
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CH3)	   and	   Fc	   (Hinge-­‐CH2-­‐	   CH3)	   domains	   of	   human	   IgGs	   through	   their	  carboxy-­‐termini	  (Cox	  et	  al.,	  2004).	  	  In	  mammalian	  cells,	  IgG	  fusion	  proteins	  are	   frequently	   expressed	   and	   secreted	   as	   disulfide-­‐linked	   homodimers	  because	   of	   inter-­‐chain	   disulfide	   bonds	   that	   are	   created	   between	   cysteine	  residues	   sited	   in	   the	   hinge	   region	   of	   the	   IgGs.	   The	   effective	   size	   and	  circulating	   half-­‐life’s	   of	   IgG	   fusion	   proteins	   are	   further	   increased	   by	   the	  dimeric	  structure	  of	  IgG	  fusions.	  	  Chimeric	   genes	   have	   been	   produced	   encoding	   human	  GCSF	   that	   are	   fused	  through	   a	   7-­‐amino	   acid	   flexible	   linker	   (Ser-­‐Gly-­‐Gly-­‐Ser-­‐Gly-­‐Gly-­‐Ser)	   to	   the	  N-­‐termini	   of	   the	   CH	   (CH1-­‐Hinge-­‐CH2-­‐CH3)	   and	   Fc	   (Hinge-­‐CH2-­‐	   CH3)	  domains	  of	  human	  IgG4	  and	  IgG1	  immunoglobulins	  (Figure	  1.8).	  Fusions	  of	  GCSF	   to	   human	   IgG	   domains	   were	   shown	   to	   form	   homodimers	   with	   high	  molecular	  weight,	   prolonged	   circulating	   half-­‐lives	   (5	   to	   8-­‐fold	   longer	   than	  GCSF)	  and	  accelerate	  number	  of	  neutrophils	  in	  vivo,	  without	  any	  significant	  effect	  on	  GCSF	  biological	  activity	  in	  vitro	  (Cox	  et	  al.,	  2004,	  Cox	  et	  al.,	  2014).	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Figure	  1-­‐8:	  The	  schematic	  diagram	  shows	  (A)	  G-­‐CSF/IgG-­‐Fc	  protein	  and	  
(B)	  G-­‐CSF/IgG-­‐CH	  fusion	  The	  GCSF	  carboxy-­‐terminus	   is	   linked	  through	  a	  7	  amino	  acid	   fixable	   linker	  (L)	   to	  the	  amino	  termini	  of	   the	  IgG-­‐Fc	  and	  IgG-­‐CH	  domains.	  The	  CH1,	  CH2,	  and	   CH3	   regions	   and	   hinge	   (H)	   of	   the	   IgG	   domains	   are	   also	   showed.	   The	  dimeric	   of	   fusion	   proteins	   located	   in	   the	   IgG	   hinge	   region	   is	   due	   to	   the	  presence	   of	   disulfide	   bonds	   (SS)	   that	   form	   between	   cysteine	   residues.	  Modified	  from	  (Cox	  et	  al.,	  2004,	  Cox	  et	  al.,	  2014).	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 New	  Approach	  by	  Asterion	  1.9.3
Asterion	   is	   a	   Sheffield	   University	   spin	   out	   company	   formed	   in	   2001.	   Prof	  Richard	  Ross	   is	  one	  of	   the	   founding	  directors.	  Their	   strategy	   is	   to	  develop	  long	  acting	  biological	  using	  novel	  platform	   technologies,	  which	  utilises	   the	  fusion	   of	   ligand	   with	   soluble	   extracellular	   receptor,	   termed	   Profuse™	  technology.	  
Over	  the	  last	  fifteen-­‐years,	  plans	  have	  been	  developed	  by	  Asterion	  to	  focus	  on	   the	   utility	   of	   Profuse™	   technology	   to	   produce	   long	   acting	  biopharmaceutical	   products.	   The	   current	   therapeutics	   regime	   for	   protein	  replacement	   requires	   daily	   injections,	   which	   are	   expensive	   and	  inconvenient.	  Thus,	  there	  is	  a	  need	  for	  a	  3rd	  generation	  of	  protein	  therapies	  that	   are	   easy	   to	   administrator,	   acceptable	   and	   convenient	   to	   patients	   and	  also	   minimizes	   manufacturing	   costs.	   Thus,	   two	   approaches	   have	   been	  created	  by	  Asterion	  technology: 
 Ligand/Receptor	  Fusion	  1.9.3.1Using	   flexible	   linker	   (Gly4Ser)n	   technology,	   Wilkinson	   et	   al.	   (2007)	  demonstrated	   that	   a	   fusion	   of	   Growth	   Hormone	   (GH)	   to	   its	   extracellular	  receptor	  (GH	  binding	  protein:	  GHBP)	  creates	  an	  effective	  long	  acting	  agonist	  with	   exceptional	   delayed	   clearance	  properties.	   PK	   analysis	   in	   rats	   showed	  that	   ligand-­‐receptor	   growth	   hormone	   fusion	   molecule	   (LR-­‐fusion)	   had	   a	  resulting	   300-­‐times	   reduced	   clearance	   rate	   when	   compared	   to	   native	   GH	  (Wilkinson	  et	  al.,	  2007).	  	  In	   addition,	   preclinical	   work	   on	   a	   various	   number	   of	   long	   acting	   GCSF	  molecules	  has	  been	  performed	  and	   the	  preliminary	  data	   for	  one	   construct	  (4A1)	  showed	  that	  it	  is	  possible	  to	  design,	  clone	  and	  purify	  a	  GCSF	  linked	  to	  its	  extracellular	  receptor.	  It	  was	  also	  shown	  to	  reduce	  the	  rate	  of	  clearance	  following	   subcutaneous	   injections	   (up	   to	  60	  hours)	   in	   rats	   consistent	  with	  an	  increase	  of	  15-­‐fold	  over	  that	  recorded	  for	  the	  native	  GCSF	  and	  2-­‐fold	  over	  that	  reported	  for	  Pegfilgrastim.	   	  
28	  
 	  Glycosylation	  1.9.3.2In	   medicine,	   any	   protein	   used	   for	   therapeutic	   purposes	   is	   not	   only	   a	  sequence	  of	  amino	  acids	  determined	  by	  a	  particular	  gene,	  but	  it	  still	  requires	  editing,	   altering	   of	   the	   amino	   acids	   or	   addition	   of	   carbohydrates.	   These	  modifications	  following	  the	  preliminary	  translation	  of	  the	  protein	  are	  called	  post-­‐translational	  processes	  (Li	  and	  d'Anjou,	  2009).	  	  Glycosylation	  refers	  to	  the	  post-­‐translational	  process	  that	  attaches	  oligosaccharide	  to	  polypeptides.	  It	   is	  one	  of	  the	  most	  common	  protein	  modifications	  and	  more	  than	  50%	  of	  proteins	  are	  glycosylated	  in	  the	  body,	  which	  are	  mainly	  secreted	  or	  part	  of	  cell	  membrane	  components	  (Sola	  et	  al.,	  2007).	  	  Glycosylation	   play	   a	   fundamental	   role	   in	   forming	   or	   maintaining	  glycoprotein	   integrity.	   Generally,	   it	   can	   increase	   the	   molecular	   weight	   of	  proteins,	   provide	   a	   high	   degree	   of	   protection	   against	   proteolytic	  degradation	   and	   enhance	   thermal	   stability	   by	   decreasing	   immunogenicity	  due	   to	   the	   presence	   of	   terminal	   sialic	   acid	   that	   creates	   negative	   charge	  around	  the	  glycoprotein	  resulting	  in	  delay	  clearance.	  Given	  these	  important	  functions,	   it	   is	   now	   believed	   that	   glycosylations	   contribute	   to	   regulating	  protein-­‐protein	   interactions,	   which	   is	   highly	   important	   in	   optimizing	   and	  developing	   glycoprotein	   drugs.	   In	   addition,	   an	   understanding	   of	   the	  association	  of	  the	  carbohydrate	  moieties	  to	  receptor	  binding	  can	  be	  used	  to	  enhance	  treatment	  efficacy	  (Li	  and	  d'Anjou,	  2009).	  Therefore,	  efforts	  have	  been	  made	  to	  improve	  a	  strategy	  to	  delay	  clearance	  of	   GCSF	   by	   the	   addition	   of	   natural	   carbohydrates	   (e.g.	   glycosylation)	   and	  avoiding	   limitations	   that	   were	   observed	   in	   section	   1.8.	   For	   example,	   PEG	  molecule	   is	   often	   processed	   for	   excretion	   in	   the	   human	   body	   without	  undergoing	  an	  initial	  biodegradation	  which	  could	  be	  toxic	  to	  the	  body	  (Patel	  et	   al.,	   2014).	  Whereas,	  modifying	   proteins	  with	   glycosylation	   can	   undergo	  degradation	  within	  the	  human	  body	  with	  no	  potential	  toxicity	  of	  PEGylation	  was	  supported	  by	  the	  detection	  of	  PEG	  in	  bile	  (Caliceti	  and	  Veronese,	  2003).	  For	   the	   safe	   conjugation	   of	   glycosylation	   to	   GCSF,	   it	   is	   important	   first	   to	  understand	   the	   forms	   and	   functions	   of	   glycosylation	   and	   also	   the	   best	  conjugation	  method	  to	  the	  protein.	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Normally,	   the	   majority	   of	   proteins	   synthesized	   begin	   in	   the	   endoplasmic	  reticulum	   (ER)	   undergo	   glycosylation	   and	   are	   completed	   in	   the	   Golgi	  apparatus.	   Five	   classes	   of	   glycosylation	   are	   produced;	   N-­‐linked	  glycosylation,	   O-­‐linked	   glycosylation,	   Phospho-­‐serine	   glycosylation,	   C-­‐mannosylation	  and	  formation	  of	  GPI	  anchors.	  However,	  the	  two	  major	  forms	  are	  O-­‐linked	  and	  N-­‐linked	  glycosylation	  (Saint-­‐Jore-­‐Dupas	  et	  al.,	  2007).	  	  
O-­‐linked	  Glycosylation	  O-­‐linked	  glycosylations	  are	  attached	  to	  the	  hydroxyl	  groups	  (-­‐OH)	  of	  serine	  or	   threonine	   residues	   within	   a	   protein	   (Wongtrakul-­‐Kish	   et	   al.,	   2012).	  However,	  no	  particular	  consensus	  sequences	  have	  been	  recognized	  for	  this	  reaction	   and	   it	   is	   still	   ambiguous	   why	   certain	   Ser/Thr	   residues	   are	  glycosylated	   as	   opposed	   to	   others.	   One	   theory	   is	   that	   it	   could	   be	   down	   to	  alternative	   structural	   properties	   of	   the	   protein	   that	  may	   contribute	   to	   the	  availability	  of	  the	  glycosylation	  site	  (Sinclair	  and	  Elliott,	  2005).	  	  In	   human	   GCSF,	   O-­‐linked	   glycosylation	   is	   located	   at	   Thr-­‐133	   and	   is	  necessary	   for	   the	   increased	   stability	   of	   the	   GCSF	   molecule.	   The	   actual	  molecular	  mechanism	  of	  the	  glycosylated	  forms	  increased	  stability	  remains	  to	   be	   established,	   but	   a	   study	   carried	   out	   by	   Hasegawa	   (1993)	   suggested	  that	   O-­‐linked	   glycosylation	   might	   be	   involved	   in	   the	   protection	   of	   the	  cysteine-­‐17	   sulfhydryl	   group	   by	   preventing	   oxidation	   by	   free	   radicals	  (Hasegawa,	  1993).	  	  
N-­‐linked	  Glycosylation	  N-­‐linked	  glycosylation	  is	  attached	  to	  the	  amide	  nitrogen	  of	  asparagine	  (Asn)	  residues	   within	   the	   common	   consensus	   sequence	   Asn-­‐X-­‐Ser/Thr	   where	   X	  can	  be	  any	  amino	  acid	  except	  proline	  (Pro)	  (Kornfeld	  and	  Kornfeld,	  1985).	  In	   nature,	  N-­‐linked	   is	   the	  most	   common	   form	  of	   glycosylation	   and	   is	   thus	  preferentially	   used	   in	   many	   technologies	   of	   protein	   modification	   (Spiro,	  2002).	  Therefore,	  it	  is	  the	  focus	  of	  further	  discussion.	  	  	  Glycosylation	   biosynthetic	   pathways	   start	   in	   ER	   (Figure	   1.9).	   At	   this	   early	  stage,	   a	   9-­‐Mannose	   glycan	   is	   added	   to	   the	   peptide	   of	   an	   N-­‐linked	   glycan	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(known	   as	   a	   high	   mannose	   type).	   The	   addition	   of	   these	   glycans	   is	  fundamental	  to	  the	  control	  of	  the	  folding	  of	  the	  newly	  synthesized	  proteins.	  Upon	   successful	   folding	   of	   the	   protein,	   the	   glycoprotein	  migrates	   into	   the	  Golgi	  apparatus	  where	  mannosidases	  facilitate	  the	  removal	  of	  the	  mannose	  groups.	  This	   is	   then	   followed	  by	  the	  addition	  of	  different	  monosaccharides	  to	   the	   growing	   glycan	   chain	   by	   particular	   glycosyltransferases	   (This	   is	  known	   as	   a	   hybrid	   type	   which	   contains	   both	   high	   mannose	   and	   complex	  type).	  	  At	   this	   late	   stage	   the	   biosynthetic	   process	   is	   completed	   in	   the	   Golgi	  apparatus	  with	  a	  fully	  sialylated	  glycan	  complex,	  which	  contains	  six	  sugars:	  N-­‐acetylglucosamine	  (GlcNAc),	  mannose	  (Man),	  fucose	  (Fuc),	  galactose	  (Gal)	  and	   sialic	   acid	   	   (NeuAc),	   which	   are	   linked	   by	   different	   α-­‐	   or	   β	   glycosidic	  linkages	  (Kim	  et	  al.,	  2009,	  Butler	  and	  Spearman,	  2014).	  	  Sialic	  acid	  (NeuAc)	  occupies	  the	  terminal	  site	  of	  the	  N-­‐linked	  glycan	  and	  has	  been	   found	   to	   be	   critical	   in	   maintaining	   the	   circulating	   half-­‐life	   of	  glycoproteins	   (Sola	   and	   Griebenow,	   2009,	   Kim	   et	   al.,	   2009).	   	   It	   contains	   a	  large	  group	  of	  nine	  carbon-­‐containing	  carbohydrates	  the	  most	  predominant	  of	  which	  is	  N-­‐	  acetylneuraminic	  acid	  (Neu5Ac).	  Byrne	  et	  al.,	  (2007)	  showed	  that	  many	  properties	  conferred	  onto	  proteins	  are	  due	  to	  the	  presence	  of	  the	  negative	  charge	  on	  C1	  of	  sialic	  acid.	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Figure	  1-­‐9:	  Glycan	  structure	  Initial	   input	   glycan	   (9-­‐Mannose	   glycan)	   starts	   biosynthetic	   pathway	   in	   ER	  (Top),	   the	  glycoprotein	  migrates	   into	  Golgi	  where	  the	  removal	  of	  mannose	  group	   and	   the	   addition	   of	   different	   monosaccharides	   in	   a	   process	   called	  hybrid	  type	  (mid).	  The	  biosynthetic	  processed	  then	  is	  completed	  in	  the	  Golgi	  as	   fully	   sialylated	  glycan	   complex	   (bottom).	  Man:	  mannose;	  Gal:	   galactose;	  GlcNAc:	  N-­‐acetylglucosamine;	  Fuc:	  fucose;	  NeuAc:	  sialic	  acid.	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Glycan	  and	  sialic	  acid	  function	  In	   naturally-­‐glycosylated	   proteins,	   oligosaccharides	   (glycans)	   and	   their	  terminal	  sialic	  acids	  fulfil	  a	  number	  of	  functions:	  	  1.	   Overexpression	   charge	   repulsion	   between	   glomerular	   filtration	   barrier	  and	  glycoprotein	  reducing	  renal	  clearance	  The	   presence	   of	   sialic	   acid	   on	   cell	   membrane	   surface	   proteins	   within	   the	  glomerular	   basement	   membrane	   creates	   over-­‐expression	   of	   a	   negative	  charge	   barrier	   alongside	   the	   glomerular	   filtration	   barrier	   preventing	   the	  passage	   of	   glycoproteins	   through	   charge	   repulsion.	   This	   is	   applicable	   to	  therapeutic	  glycoproteins	  as	  a	  possible	  method	  to	  increase	  circulatory	  half-­‐life	  (Varki,	  2008).	  2.	  Prevention	  of	  proteoylatic	  degradation	  	  Sialic	   acid	   occupies	   a	   comparatively	   large	   volume	   in	   glycosylation,	   which	  protects	   the	   underlying	   peptides	   from	   protease	   detection	   and	   cleavage	  within	   the	   circulation	   (e.g.	   papain)	   (Sola	   and	   Griebenow,	   2009).	   	   A	   study	  carried	   out	   by	   Raju	   and	   Scallon	   (2007)	   demonstrated	   that	   removal	   of	  terminal	   sugars	   from	   Fc	   antibody	   fragments	   (Antibodies	   are	   naturally	  glycosylated	  in	  the	  CH2	  of	  the	  Fc	  fragment)	  resulted	  in	  increased	  sensitivity	  to	  papain.	  3.	  Reduced	  receptor	  binding	  affinity	  	  Elliott	  et	  al.	  (2004)	  showed	  that	  non-­‐glycosylated	  erythropoietin	  (EPO)	  has	  seven	   times	   greater	   receptor	   binding	   affinity	   than	   native	   EPO	   (highly	  glycosylated).	  This	  is	  due	  to	  the	  presence	  of	  the	  negative	  charge	  created	  by	  sialic	  acid,	  which	  reduces	  binding	  affinity	  via	  charge	  repulsion.	  Also,	  in	  vivo	  activity	   of	   non-­‐glycosylated	   analogue	   was	   significantly	   decreased	   due	   to	  increased	  receptor	  binding	  affinity	  resulting	  in	  increased	  internalization	  and	  protein	  degradation	  (Elliott	  et	  al.,	  2004).	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4.	  Stabilization	  of	  the	  protein	  	  Glycosylations	   offer	   stability	   for	   therapeutic	   proteins	   from	   two	   points	   of	  view:	  Glycosylation	  may	  help	  decrease	  the	  immunogenicity	  of	  polypeptides	  in	  two	  ways:	  Walesh	  and	  Jefferis	  (2006)	  reported	  that	  one	  potential	  mechanism	  is	  via	   increased	   solubility	   of	   polypeptides	   due	   to	   interaction	   with	   H2O	   and	  shielding	   of	   hydrophobic	   residues	   reducing	   the	   possibility	   of	   aggregate	  formation	  that	  could	  form	  a	  stationary	  precipitate	  for	  antibody	  recognition.	  	  Another	  possible	  mechanism	   is	  via	  shielding	   the	  polypeptide,	   reducing	   the	  accessible	   surface	   area	   exposed	   for	   antibody	   recognition,	   resulting	   in	   a	  masking	  effect	  provided	  by	  sialic	  acid.	  This	  is	  shown	  with	  Darbepoetin	  alpha	  (a	   rhEPO	   analogue	   composed	   of	   two	   additional	   N-­‐linked	   glycosylations	  sequences)	  whereby	   ELISA	   tests	  were	   unable	   to	   detect	   the	   protein	   in	   the	  circulation	   from	   different	   patients	   (Sinclair	   and	   Elliott,	   2005,	   Byrne	   et	   al.,	  2007).	  	  	  	  From	   a	   manufacturing	   point	   of	   view,	   glycosylations	   offer	   stability	   for	  therapeutic	   proteins	   against	   chemical	   denaturation	   and	   pH	   by	   increasing	  the	  potency	  of	  internal	  forces	  and	  this	  is	  essential	  in	  maintaining	  therapeutic	  protein	  conformation.	  It	  is	  also	  important	  to	  increase	  the	  protein	  structural	  compactness,	   resulting	   in	  a	  decreased	  available	   surface	  area	   to	  denaturing	  pH	  or	  chemicals	  (Sola	  and	  Griebenow,	  2009).	  	  	  From	   the	   previous	   discussion,	   it	   can	   be	   shown	   that	   N-­‐linked	   is	   the	   most	  common	   form	   of	   glycosylation	   and	   is	   thus	   preferentially	   used	   in	   many	  technologies	   of	   protein	  modification	   (Spiro,	   2002).	  N-­‐linked	   strategies	   can	  be	  divided	  in	  two	  classes:	  
1-­‐	  Hyperglycosylation	  via	  Site	  Direct	  Mutagenesis	  Hyperglycosylation	  is	  defined	  as	  the	  process	  of	  increasing	  glycosylation	  on	  a	  protein	   to	   alter	   its	   pharmacokinetic	   and	   biological	   activity	   (Sola	   and	  Griebenow,	   2010).	   DNA	   mutagenesis	   is	   one	   of	   the	   main	   strategies	   to	  increase	   glycosylation.	   In	   vivo,	   mutagenesis	   of	   the	   DNA	   can	   incorporate	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additional	   glycosylation	   sites.	   This	   process	   can	   be	   achieved	   by	   identifying	  Thr/Ser	  residues	  occupying	  the	  third	  position	   in	  the	  sequence	  of	  a	  protein	  and	  mutating	   the	   first	  amino	  acid	   in	   the	  sequence	   to	  Asn	  or	  by	   identifying	  Asn	  residues	  within	  the	  sequence	  of	  a	  protein	  and	  mutating	  the	  third	  amino	  acid	   to	   Thr/Ser.	   For	   example,	   Elliott	   et	   al	   (2003)	   used	   site	   directed	   DNA	  mutagenesis	  in	  the	  development	  of	  Darbepoetin	  alpha.	  The	  process	  started	  by	  mutating	  Ala-­‐30,	  His-­‐32	  to	  Asn-­‐30,	  Thr-­‐32,	  and	  Pro-­‐87,	  Trp-­‐88,	  Pro-­‐90	  to	  Val-­‐87,	  Asn-­‐88,	  Thr-­‐90.	  All	  mutations	  were	  shown	  to	  be	  glycosylated	  with	  an	  increase	   in	  molecular	  weight	   from	   35kDa	   to	   approximately	   43kDa,	   whilst	  maintaining	  biological	  activity.	  	  Site	  direct	  mutagenesis	  has	  also	  been	  performed	  on	  GCSF.	  Hee	  et	  al.	  (2011)	  produced	  an	  N-­‐linked	  glycosylation	  site	  on	  rhGCSF	  by	  mutating	  Phe140	   to	  Asn140producing	   a	   novel	   form	   of	   human	   GCSF	   mutant.	   The	   new	   mutant	  rhGCSF	  was	  shown	  to	  be	  glycosylated	  and	  more	  effective	  than	  native	  GCSF	  for	  stimulating	  differentiation	  and	  proliferation	  of	  hematopoietic	  cells.	  	  
2-­‐	  Glycosylated	  Linkers	  The	   uses	   of	   glycosylated	   linkers	   are	   another	   glycan	   strategy	   that	   can	   be	  utilised	   to	   extend	   the	   half-­‐life	   of	   therapeutic	   proteins.	   The	   glycosylated	  linkers	  can	  be	  inserted	  between	  subunits	  of	  the	  same	  ligand	  as	  observed	  in	  recombinant	  human	  Follicle-­‐Stimulating	  Hormone	   (rhFSH)	  between	   the	  α-­‐	  and	  β-­‐	   subunits	   in	  which	   either	  N-­‐	   linked	   or	  O-­‐linked	   glycosylated	   linkers	  were	  used.	  The	  effect	  of	  the	  glycosylated	  linker	  was	  to	  increase	  the	  half-­‐life	  of	   the	  molecules	   by	   as	  much	   as	   2-­‐fold	   compared	   to	   rhFSH	   (Weenen	   et	   al.,	  2004).	  
 This	  method	   can	   also	   be	   used	   to	   insert	   glycosylated	   linkers	   between	   two	  ligands	  (tandem	  molecules).	  The	  insertions	  of	  glycosylated	  linkers	  between	  tandem	  molecules	  are	  preferable	  as	   they	  alleviate	  potential	  problems	  with	  direct	   glycosylation	   of	   the	   ligand	   itself,	   which	  may	   inhibit	   bioactivity	   and	  potentially	  introduce	  immunogenic	  sites.	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The	  Ross	  group	  (UoS)	  have	  used	  the	  advantages	  of	  both	  glycosylated	  linker	  design	   and	   tandem	  molecules	   to	   create	   a	   long	   acting	   GH	  molecules.	   They	  created	  a	  tandem	  of	  two	  GH	  molecules	  joined	  by	  a	  flexible	  (Gly4Ser)n	  	  linker	  containing	   variable	   glycosylation	   motifs.	   The	   results	   successfully	   showed	  that	  the	  use	  of	  glycosylated	  linkers	  between	  two	  GH	  ligands	  results	  in	  their	  glycosylation	  and	  increased	  molecular	  weight	  whilst	  maintaining	  biological	  activity	   and	  delaying	   clearance	   in	   a	   rat	  model.	   This	  methodology	   could	  be	  applied	  to	  other	  cytokine	  hormones	  such	  as	  GCSF.	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 Aim	  and	  Hypothesis	  1.10The	  role	  of	  recombinant	  human	  rhGCSF	  has	  been	  successful	  in	  the	  treatment	  of	  patients	  with	  neutropenia	  and	  stem	  cell	  mobilization	  in	  the	  circumstance	  of	   bone	  marrow	   transplantation,	  making	   it	   a	  multi-­‐million	   pound	  market.	  The	   fast	   growing	  market	   size	  will	   increase	   appetite	   for	   generating	   similar	  rhGCSF.	   	   Therefore,	   it	   is	   essential	   to	   produce	   new	   GCSF	   compounds	   with	  improved	  properties	  over	  other	  products.	  	  
 The	   aim	   of	   this	   project	   is	   to	   create	   a	   long	   acting	   GCSF	  with	   a	   predictable	  pharmacokinetic	   profile	   to	   provide	   a	   more	   effective	   treatment	   for	  generating	  HSCs	  for	  transplantation	  purposes.	  	  	  We	   hypothesized	   that	   the	   incorporation	   of	   variable	   glycosylation	   motifs	  (2NAT,	   4NAT	   and	   8NAT)	   within	   a	   flexible	   linker	   (Gly4Ser)n	   between	   two	  GCSF	  ligands	  will	  Increase	  the	  molecular	  weight	  (MW)	  of	  GCSF	  according	  to	  the	   number	   of	   glycosylation	   motifs	   with	   protection	   from	   proteolysis	  resulting	  in	  reduced	  clearance	  with	  out	  blocking	  bioactivity	  (Figure	  1.10	  and	  Table	   1.3).	   This	   approach	   also	   alleviates	   potential	   problems	   with	   direct	  glycosylation	   of	   the	   ligand,	   which	   may	   reduce	   bioactivity	   and	   potentially	  introduce	  immunogenic	  sites.	  	  	  
Main	  Objectives	  
1-­‐ Design,	  cloning	  and	  expression	  of	  GCSF	  tandems.	  
2-­‐ Purification	  of	  GCSF	  tandems	  from	  a	  mammalian	  cell	  line.	  
3-­‐ Analyse	   and	   compare	   the	   biological	   activity	   of	   GCSF	   tandems	   with	  rhGCSF	  using	  an	  in	  vitro	  proliferation	  assay.	  	  





Figure	  1-­‐10:	  	  An	  example	  of	  2NAT	  glycosylation	  motifs	  and	  its	  control	  
2QAT	  within	  a	  flexible	  linker	  (Gly4Ser)n	  between	  two	  GCSF	  ligands	  (A)	   The	   glycosylation	   motif	   2NAT	   inserted	   to	   the	   linker	   (glycosylated	  linker).	  (B)	  Non-­‐glycosylation	  motif	  2QAT	  control.	  	  	  
Table	  1-­‐3:	  List	  of	  GCSF	  tandems	  GCSF	  tandems	  linked	  via	  a	  flexible	  linker	  incorporating	  increasing	  numbers	  of	   the	   glycosylation	   motif	   NAT	   (glycosylated	   molecules)	   or	   control	   motif	  QAT	  (non-­‐glycosylated	  molecules).	  	  
Molecule	  name	   Number	  of	  NAT/QAT	  motifs	   Size	  of	  linker	  GCSF8NAT_Hist	   8	  x	  NAT	   282bp	  GCSF8QAT_Hist	   8	  x	  QAT	   282bp	  GCSF4NAT_Hist	   4	  x	  NAT	   147bp	  GCSF4QAT_Hist	   4	  x	  QAT	   147bp	  GCSF2NAT_Hist	   2	  x	  NAT	   147bp	  GCSF2QAT_Hist	   2	  x	  QAT	   147bp	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 Materials	  	  2.
 	  Cell	  Culture	  2.1Easy	  filtered	  flasks	  75cm2	   Nalgen	  Nunc	  intl	  Easy	  filtered	  flasks	  25cm2	   Nalgen	  Nunc	  intl	  100mm	  tissue	  culture	  dishes	   Iwaki	  SLS	  6	  well	  Cell	  Culture	  plates	   Costar	  24	  well	  Cell	  Culture	  plates	   Costar	  CHO	  Flp-­‐In	  cell	  lines	   (Invitrogen	  Corp)	  Gibco	  Cryogenic	  vials	   Nalgen	  Nunc	  intl	  Dimethylsulfoxide	  (DMSO)	   Sigma-­‐Aldrich	  Dulbecco’s	  Modified	  Eagles	  Medium	  (DMEM)/F-­‐12	  	   Sigma-­‐Aldrich	  	  Fugene-­‐6	   Roche	  Diagnostics	  Foetal	  Calf	  serum	  (FCS)	   Labtech	  HyClone	  SFM4CHO	  Cell	  Culture	  Media	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Thermo	  Scientific	  Hygromycin	  B	  Antibiotic	  (50mg/ml)	   (Invitrogen	  Corp)	  Gibco	  Ham’s	  F12	   (Invitrogen	  Corp)	  Gibco	  Labtech	  chambers	  coverglass	   Nalgen	  Nunc	  intl	  L-­‐Glutamine	   (Invitrogen	  Corp)	  Gibco	  Phosphate	  Buffer	  10X	   (Invitrogen	  Corp)	  Gibco	  Penicillin-­‐Streptomycin	  (100µg/ml)	   (Invitrogen	  Corp)	  Gibco	  pOG44	  	  	  	   (Invitrogen	  Corp)	  Gibco	  Trypsin-­‐EDTA	   (Invitrogen	  Corp)	  Gibco	  Zeocin	  Antibiotic	  (100mg/ml)	  	   (Invitrogen	  Corp)	  Gibco	  Counting	  chamber	  	   Hawksley	  Trypan	  blue	  	   Sigma	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 DNA	  Manipulation	  2.21	  kb	  ladder	   (Biolabs)	  New	  England	  100	  bp	  ladder	  	   (Biolabs)	  New	  England	  Agar	   Sigma-­‐Aldrich	  Agarose	   Sigma-­‐Aldrich	  CaCl2	   	   Sigma-­‐Aldrich	  Dithiothreitol	  (DTT)	   Sigma-­‐Aldrich	  dNTPs	  	   Upjohn	  and	  Pharmacia	  DNA	  loading	  dye	  (6X)	   Promega	  EDTA	   BD	  Biosciences	  Expand	  high	  fidelity	  PCR	  system	   Roche	  Diagnostics	  Ethidium	  bromide	  (0.5μg/ml)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Sigma-­‐Aldrich	  Gen	  EluteTM	  Gel	  Extraction	  Kit	   Sigma-­‐Aldrich	  Glycerol	   BD	  Biosciences	  KCl	   BD	  Biosciences	  MgCl2	   Sigma-­‐Aldrich	  NaCl	   	   BD	  Biosciences	  QIAGENprep	  Spin	  Miniprep	  Kit	   QIAGEN	  QIAGENquick	  PCR	  Purification	  Kit	   QIAGEN	  QIAGENquick	  Gel	  Extraction	  Kit	   QIAGEN	  Restriction	  enzymes	   Promega	  Synthesised	  DNA	  primers	   MWG	  Biotech	  T4	  DNA	  ligase	   Promega	  Taq	  polymerase	   Promega	  Tryptone	   Melford	  Tris	  –base	   Sigma-­‐Aldrich	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
40	  
 Restriction	  Endonucleases	  2.2.1
 Enzyme	  2.2.1.1Age1	   New	  England	  Biolabs	  BamH1	   Promega	  Nhe1	  	  	  	   Promega	  Xho1	   Promega	  	  
 Bacterial	  Cell	  Culture	  2.2.2
 Antibiotics	  2.2.2.1The	  table	  shows	  the	  antibiotics	  used	  and	  their	  final	  concentrations:	  Antibiotics	   Final	  concentration	  of	  antibiotic	  Carbenicillin	   100μg/ml	  	  Kanamycin	   10μg/ml	  SURE	  cells	   Genotype;	  e14-­‐(McrA-­‐)	  Δ(mcrCB-­‐hsdSMR-­‐mrr)171	  endA1	  gyrA96	  thi-­‐1	  supE44	  relA1	  lac	  recB	  recJ	  sbcC	  umuC::Tn5	  (Kanr)	  uvrC	  [F	  ́	  proAB	  lacIqZΔM15	  Tn10)	  	  
 Media	  2.2.2.2The	  table	  explains	  the	  different	  bacterial	  growth	  media	  used	  in	  this	  project:	  Media	   Formula	   Supplier	  
SOC	  medium	  
0.5%	  (w/v)	  yeast	  extract	  2.5mM	  KCl	  1mM	  MgSO4·7H2O	  1mM	  MgCl2·6H2O	  10mM	  NaCl	  2mM	  glucose	  2%	  (w/v)	  tryptone	  
	  	  	  Invitrogen	  
Luria-­‐	  Bertani	  (LB)	  medium	   1%	  sodium	  chloride,	  	  1%	  tryptone	  and	  	  0.5%	  yeast	   	  In-­‐house	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 Protein	  Analysis	  	  2.3Acetic	  acid	   Fisher	  chemical	  	  Ammonium	  persulfate	   Merck	  	  	  	  	  	  	  Ammonium	  Sulphate	   Sigma-­‐Aldrish	  Avidin-­‐HRP	   Biolegend	  30	  %	  Acrylamide/Bis	  solution	  (Geneflow)	   National	  diagnostic	  Benzamidine	   Sigma-­‐Aldrish	  	  	  Roller	  bottle	  (2L)	   Greiner	  Bio-­‐one	  Bovine	  gamma-­‐globulin	   Sigma	  Bovine	  Serum	  Albumin	  (BSA)	   Sigma	  Bradford	  reagent	   	   Bio-­‐Rad	  [BVD13-­‐3A5]	  Purified	  anti-­‐human	  GCSF	   Biolegend	  [BVD11-­‐37G10]	  Biotin	  anti-­‐human	  GCSF	   Biolegend	  Coomassie	  Blue	  reagent	   Sigma-­‐Aldrich	  Chemiluminescence	  Blotting	  substrate	   Roche	  Cuvettes	  (polystyrol/polystyrene	   SARSTEDT	  EDTA	   BDH	  Ethanol	   Fisher	  Scientific	  	  	  ECL	  western	  blotting	  detection	  system	   Amersham-­‐Pharmacia	  Imidazole	  	  	   Sigma	  2X	  Laemmli	  sample	  buffer	   	   	   Bio-­‐Rad	  Fuji	  Medical	  X-­‐ray	  Film	   Fuji	  Glacial	  acetic	  acid	   Fisher	  Glycine	   Sigma-­‐Aldrich	  Glycerol	   Fisher	  Scientific	  Vortex	  mixer	   Stuart	  Traceable	  Nano	  Timer	   Fisher	  Scientific	  Methanol	   Merck	  Minispin	  centrifuge	   Eppendorf	  Mixing	  Table	   Biotek	  instrument	  Inc	  NaHCO3	  	  	   Sigma	  NaN3	  [AnalR]	   BDH	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Nickel	  Chloride	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Sigma	  PBS	  	  	  Tablets	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  OXOID	  Plate	  Reader	  (450nm/630nm)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Yellowline	  OS10	  Basic	  Polyvinylidene	  diflouride	  membranes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Amersham-­‐Pharmacia	  96	  well	  ELISA	  plates	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Costar	  Rat	  Serum	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Sigma	  Recombinant	  human	  GCSF	  @	  200μg/ml	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Biolegend	  Sodium	  acetate	  (anhydrous)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Fisher	  Scientific	  Sodium	  hydroxide	   BDH	  Sodium	  Lauryl	  Sulfate	  (SDS)	   Sigma-­‐Aldrich	  Sodium	  phosphate	  monobasic	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  BDH	  Sodium	  phosphate	  dibasic	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  BDH	  Spectrophotometer	   Unicam	  Sprague	  male	  Dawley	  Strain	  rats	  (~300	  gram)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Royan	   Institute	  (Esfahan)	  	  	  	  	  	  	  	  	  	  	  	  	  Sulphuric	  Acid	   	  Tetramethylethylenediamine	  (TEMED)	   Merck	  BDH	  TMB	  Solution	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Sigma	  TRIS	  	  Base	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Sigma	  Tris-­‐Hcl	   Sigma-­‐Aldrich	  Tween	  20	   Sigma-­‐Aldrich	  Vivaflow	  200	  concentrator	   Sartorius	  Stedin	  	  	  	  	  1ml	  Blue	  Sepharose	  column	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  PIERCE1ml	  IMAC	  HP	  column	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  GE	  Healthcare	  3510	  pH	  Meter	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  JENWAY	  	  	  	  	  	  	   	   	   	  	  	   	  	  	  	   	  
43	  
 	  Proliferation	  Assay	  2.3.1AML-­‐193	  cell	  line	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (ATCC;	  Cat.	  #:	  CRL-­‐9589;	  Lot	  #:	  3475266)	  Iscove’s	  Modified	  Dubellco	  Media	  (IMDM)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Gibco	  L-­‐glutamine	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Gibco	  Penicillin/Streptomycin	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Gibco	  Foetal	  Calf	  Serum	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Labtech	  Transferrin	   Sigma	  Insulin	   Sigma	  GMCSF	  (5ng/ml)	   Biosource	  CellTitre	  96	  AQueous	  Proliferation	  Assay	  Reagent	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Promega	  96-­‐well	  Cell	  Culture	  Plate	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Costar	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 General	  Methods	  3.
 Preparation	  of	  Luria-­‐Bertani	  (LB)	  Media	  3.1LB	  media	  comprised	  of	  1%	  (w/v)	  sodium	  chloride,	  1%	  (w/v)	  tryptone	  and	  0.5%	   (w/v)	   yeast	   dissolved	   in	   MilliQ	   water	   and	   then	   autoclaved	   to	   fully	  dissolve	  these	  components	  as	  well	  as	  sterilize	  the	  media.	  	  
 	  Preparation	  of	  Agar	  Plates	  3.2Agar	   plates	   were	   made	   up	   by	   adding	   granulated	   agar	   to	   LB	   media	   at	   a	  concentration	   of	   1.4%	   (w/v)	   and	   autoclaved.	   	   Appropriate	   antibiotics	  (carbencillin	   at	   100μg/ml)	  were	   added	   to	   the	   agar	   plates	  when	   cooled	   to	  approximately	  60°C.	  Agar	  plates	  were	  allowed	  to	  set	  and	  dry.	  
 	  Preparation	  of	  Chemically	  Competent	  Cells	  3.3Replicating	   eukaryotic	   DNA	   in	   E.	   coli	   can	   be	   difficult	   because	   eukaryotic	  genes	  might	   incorporate	   inverted	  repeats	  or	  secondary	  structures,	   such	  as	  Z-­‐DNA,	  that	  can	  be	  deleted	  or	  rearranged	  by	  conventional	  E.	  coli.	  The	  SURE	  (Stop	   Unwanted	   Rearrangement	   Events)	   cell	   is	   particular	   strain	   of	   E.	   coli	  and	  has	  a	  unique	  advantage	  over	  conventional	  E.	  coli	  commonly	  used,	  as	  it	  is	  void	   of	   essential	   components	   of	   the	   pathways	   that	   hinders	   cloning	   of	  eukaryotic	   DNA	   in	   conventional	   E.	   coli	   (largely	   due	   to	   induction	   of	   DNA	  rearrangement	  and	  deletion	  of	  nonstandard	  DNA	  fragments).	  	  It	  was	  used	  in	  this	  study	  to	  allow	  for	  cloning	  of	  multiple	  repeat	  DNA	  sequences.	  To	  produce	  competent	  E.	  coli	  cells	  with	  the	  ability	  to	  accept	  foreign	  DNA,	  the	  E.	   coli	   SURE	   cells	   were	   plated	   out	   on	   agar	   plate	   containing	   selective	  antibiotic	   (Kanamycin	   at	   10μg/ml)	   and	   incubated	   overnight	   at	   37°C.	   The	  next	   day,	   a	   single	   isolated	   colony	   was	   selected	   and	   grown	   in	   LB	   media	  containing	  Kanamycin	  10μg/ml	  during	  the	  day	  in	  an	  orbital	  shaker	  at	  37°C.	  A	  dilution	  of	  1/1000	  was	  seeded	  into	  50ml	  LB	  media	  and	  grown	  continued	  overnight	  (37°C)	  at	  200rpm	  in	  an	  orbital	  shake.	  The	  following	  day,	  50ml	  of	  overnight	  culture	  was	   transferred	   into	  500ml	  warmed	  LB	  and	  grown	  until	  an	  optical	  density	  (measured	  at	  600nm)	  of	  approximately	  0.9	  was	  reached.	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Cells	  were	  centrifuged	  at	  2397	  x	  g	  for	  30	  minutes	  at	  4°C	  in	  a	  Beckman	  Avanti	  J201centrifuge.	   The	   supernatant	  was	   discarded	   and	   pellet	   resuspended	   in	  200ml	   ice	   cold	   sterile	   0.1M	   MgCl2	   and	   centrifuged	   again	   using	   previous	  parameters.	   Following	   removal	   of	   supernatant,	   the	   cell	   pellet	   was	  resuspended	   in	   10ml	   ice	   cold	   sterile	   0.1M	   CaCl2	   followed	   by	   a	   further	  addition	  of	  90ml	  0.1M	  CaCl2	  lower	  case	  and	  left	  on	  ice	  for	  1	  hour	  (hr)	  ,	  then	  centrifuged	  as	  before.	  The	  supernatant	  was	  discarded	  and	  cells	  resuspended	  by	  gentle	  swirling	  or	  pipetting	  in	  25ml	  sterile	  15%	  glycerol/85mM	  ice	  cold	  CaCl2.	  Finally,	  cells	  were	  aliquoted	  into	  1.5ml	  pre-­‐chilled	  sterile	  eppendorfs	  on	  ice	  and	  immediately	  flash	  frozen	  in	  liquid	  nitrogen	  then	  stored	  at	  80°C.	  
 DNA	  Cloning	  of	  GCSF	  Tandems	  for	  Expression	  3.4
 Polymerase	  Chain	  Reaction	  (PCR)	  3.4.1In	   this	   project,	   the	   PCR	   was	   used	   for	   DNA	   fragment	   amplification	   and	   to	  introduce	  restriction	  enzymes	  sites	   into	   the	  expression	  constructs	   for	  ease	  of	   cloning.	   The	   GCSF	   molecule	   was	   PCRed	   from	   pGCSFSecTag4A1	   (GCSF	  fusion	  protein	  construct	  containing	  full	  length	  GCSF	  and	  its	  signal	  sequence	  which	  was	  available	  in	  the	  laboratory)	  using	  a	  forward	  primer	  and	  reverse	  primer	  giving	  a	  final	  amplicon	  of	  ~600bp	  (all	  primers	  used	  in	  this	  study	  are	  listed	   in	   Appendix	   A.1).	   The	   PCR	   reactions	   were	   set	   up	   as	   a	   single	   step	  reaction	   utilizing	   two-­‐master	   mixes	   as	   highlighted	   in	   the	   Table	   3.1.	   A	  negative	  control	   reaction	   that	  contained	  primers	  but	  no	   template	  was	  also	  included.	  Two	  GCSF	  molecules	  were	  PCRed	   in	   this	  project,	  GCSF	  and	  GCSF	  with	  signal	  sequence.	  	   	  
46	  
Table	  3-­‐1:	  PCR	  reaction	  utilizing	  two-­‐master	  mixes	  
	  	  	  	  Master	  Mix	  1	   	  	  Volume	   	  	  	  	  	  	  	  	  Master	  Mix	  2	   Volume	  Template	   DNA	  (plasmid)	   1μl	  (100ng)	   10x	   polymerase	   buffer	   +	  MgCl2	  (1.5mM)	   5μl	  Primer	   1	   (10pmol/µl	  =	  10µM)	   1μl	   Sterile	  water	   19.15μl	  Primer	   2	   (10pmol/µl	  =	  10µM)	   1μl	   Expand	  Polymerase	   0.85μl	  dNTPs	  (10mM)	   1.25μl	  Sterile	  water	   20.75μl	  	  	  Using	   the	   TC-­‐312	   PCR	   thermocycler,	   master	   mix	   one	   and	   two	   were	  combined	  and	  cycled	  as	  follows:	  	  	  
	  
Table	  3-­‐2:	  PCR	  stages	  	  
	  Thereafter,	  the	  PCR	  reactions	  were	  loaded	  on	  1%	  (w/v)	  TAE	  agarose	  gel.	  A	  1	  Kb	  DNA	  ladder	  runs	  alongside	  the	  samples	  during	  electrophoresis	  at	  100	  V	  for	  30	  minutes	  using	  Bio-­‐Rad	  PowerPac™	  HC	  and	  gel	   isolated	   (see	   section	  3.1.5.2)	  Gene	  Snap	  software	  from	  SYGENE	  was	  used	  for	  the	  gel	  Imaging.	  	   	  
Stage	   Time	   Temperature	  Denaturation	   2	  min	   94°C	  25	  cycles	  @	   30s	   94°C	  
	  
30s	   54°C	  
	  
30s	   72°C	  
Extension	   10min	   72°C	  
47	  
 DNA	  Isolation	  from	  Agarose	  Gel	  Electrophoresis	  	  3.4.2A	  1%	   (w/v)	   agarose	   gel	  was	  prepared	  by	  dissolving	  powdered	   agarose	   in	  TAE	   buffer	   (1mM	   EDTA,	   20mM	   acetic	   acid	   and	   40mM	   Tris	   base,	   pH	   8.5)	  upon	  heating	   for	  1	  minute	  will	   not	  dissolve	  otherwise.	   0.5μg/ml	  Ethidium	  bromide	  was	  used	  as	  staining	  agent.	  1kb	  DNA	  ladder	  (0.5μg/μl)	  was	  run	  on	  each	   gel	   as	   standard.	   The	   agarose	   gel	  was	   run	   at	   100V	   using	   the	   Bio-­‐Rad	  Power	  PC.	  To	  prevent	  damage	   to	   the	  amplified	  DNA	   for	   the	  purification	   step,	  10%	  of	  the	   samples	   (PCR	   reaction)	  were	   loaded	   in	   an	   inner	  well	   for	   visualization	  with	  ultraviolet	  (UV)	  light	  using	  the	  Gene	  Snap	  software	  from	  SYGENE,	  while	  the	  remaining	  samples	  were	   loaded	   in	  a	  peripheral	   lane.	  This	  was	  done	   to	  prevent	   potential	   damage	   to	   the	   remaining	   90%	   DNA	   samples	   (in	   the	  peripheral	  lane)	  by	  UV	  light	  during	  visualization.	  The	  peripheral	  lane	  of	  the	  gel	  was	  separated	  from	  the	  rest	  of	  the	  gel	  using	  a	  clean	  razor	  blade	  prior	  to	  UV	   exposure.	   After	   visualization	   and	   excision	   of	   the	   DNA	   fragment	   of	  interest	   in	   the	  main	   gel,	   the	   corresponding	   region	   on	   the	   peripheral	   lane	  was	  then	  cut	  out	  from	  the	  agarose	  gel,	  which	  was	  thereafter	  extracted	  using	  GenElute	  extraction	  kit	  as	  per	  manufacture’s	  protocols	  in	  order	  to	  get	  rid	  of	  the	  PCR	  contaminates.	  DNA	  samples	  were	  eluted	  by	  the	  addition	  of	  50μl	  of	  buffer	  EB	  (10mM	  Tris-­‐HCl,	  pH	  8.5)	  and	  quantified	  at	  a	  wavelength	  of	  260nm	  using	   the	   Nanodrop	   spectrometer	   ND100V.	   Samples	   were	   then	   ready	   for	  ligation	  into	  plasmid	  or	  stored	  at	  -­‐20°C	  to	  preserve	  DNA.	  
 Single	  and	  Double	  Restriction	  Enzyme	  Digests	  3.4.3Restriction	  enzymes	  are	  routinely	  used	  during	  cloning	  to	  transfer	  a	  gene	  of	  interest	  into	  a	  vector	  plasmid.	  Often,	  both	  the	  vector	  plasmid	  and	  the	  target	  gene	   are	   digested	   with	   the	   same	   restriction	   enzymes	   to	   generate	   similar	  overhangs.	   The	   target	   gene	   to	   be	   expressed,	   often	   referred	   to	   as	   insert,	   is	  thereafter	  ligated	  to	  the	  vector	  plasmid	  using	  DNA	  ligase	  and	  polymerase.	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Restriction	  Digestion	  of	  Insert	  and	  Vector	  DNA	  	  In	  this	  project,	  single	  or	  double	  restriction	  digestions	  (involving	  use	  of	  one	  or	   two	   restriction	   enzymes	   respectively)	   were	   set	   up	   for	   both	   the	   insert	  (PCR	  product	  of	  target	  DNA)	  and	  the	  vector	  DNA	  (i.e.	  the	  expression	  plasmid	  DNA)	  as	  stated	  below	  in	  Table	  3.3	  and	  3.4	  respectively.	  	  1-­‐	  Digestion	  of	  insert	  For	   the	   digestion,	   the	   volume	   of	   DNA	   used	  was	   dependent	   on	   the	   sample	  concentration.	  The	  volume	  was	  made	  up	   to	  50μl	  with	   sterile	  MilliQ	  water.	  The	  reaction	  mixture	  was	  incubated	  for	  2	  hrs	  in	  a	  thermostatic	  water	  bath	  at	  37°C	   (all	   restriction	   enzymes	   and	   restriction	   enzyme	   buffers	   used	   in	   this	  study	  are	  given	  in	  Appendix	  A.2).	  	  
Table	  3-­‐3:	  Single	  step	  double	  digestion	  of	  Insert	  Undigested	  DNA	  (PCR	  fragment)	   500ng	  10x	  restriction	  Buffer	  	   5μl	  Restriction	  enzyme	  1	  	  (10units	  per	  0.5-­‐1μg	  of	  DNA)	   1μl	  Restriction	  enzyme	  2	  (10units	  per	  0.5-­‐1μg	  of	  DNA)	   1μl	  ac	  BSA	  (1mg/ml)	   5μl	  Sterile	  MiliQ	  water	   Xμl	  Total	  volume	   50μl	  
	  
 After	   incubation,	   samples	  were	   centrifuged	   at	   11,337	   x	   g	   for	   5	   seconds	   to	  remove	   condensation	   and	   then	   analyzed	   using	   1%	   agarose	   gel	  electrophoresis	   Reaction	   products	   were	   purified	   from	   agarose	   gel	   using	  QIAquick	   PCR	   purification	   kit	   as	   per	   manufacture’s	   protocol.	   Purified	  elutions	   were	   quantified	   using	   the	   Nanodrop	   spectrometer	   ND	   100	   at	  260nm.	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2-­‐	  Digestion	  of	  plasmid	  DNA	  The	  plasmid	  DNA	  was	  digested	   in	  a	   two-­‐step	  double	  digestion.	  The	  double	  digestion	  was	  carried	  out	  by	  setting	  up	  single	  restriction	  digestions	  as	  stated	  below	   and	   incubated	   for	   2	   hrs	   in	   a	   thermostatic	   water	   bath	   at	   37°C.	   The	  volume	  was	  made	  up	  to	  10μl	  with	  sterile	  MilliQ	  water.	  
Table	  3-­‐4:	  Two-­‐step	  double	  digestion	  of	  Plasmid	  DNA	  
Single	   digest	   with	  
enzyme	  1	  
Single	   digest	   with	  
enzyme	  2	  Plasmid	   1μl	  (500ng)	   1μl	  (500ng)	  10x	  restriction	  Buffer	   1μl	   1μl	  Restriction	   enzyme	   1	  	  (10units	  per	  0.5-­‐1μg	  of	  DNA)	   1μl	   -­‐	  Restriction	  enzyme	  2	   -­‐	   1μl	  ac	  BSA	  (1mg/ml)	   1μl	   1μl	  Sterile	  MiliQ	  water	   6μl	   6μl	  Total	  volume	   10μl	   10μl	  
  
 	  After	   incubation,	   2.5μl	   aliquots	   from	   each	   single	   digest	   were	   taken	   for	  further	  analysis	  to	  assess	  the	  integrity	  of	  the	  restriction	  enzymes	  used.	  The	  remainder	   volumes	   in	   the	   single	   digests	   (7.5μl)	  were	  pooled	   together	   and	  the	   following	   reagents	  were	   added	   (2μl	   acBSA,	   2μl	   10x	   restriction	   Buffer,	  1μl	  Restriction	  enzyme	  1,	  1μl	  Restriction	  enzyme	  2	  and	  14μl	  Sterile	  MilliQ	  water)	  to	  give	  a	  final	  total	  volume	  of	  35μl.	  The	  reaction	  mixture	  containing	  both	  restriction	  enzymes	  was	   then	   incubated	   for	  1-­‐2	  hrs	   in	  a	   thermostatic	  water	  bath	  at	  37°C.	  1%	  agarose	  gel	  electrophoresis	  was	  used	  to	  analyse	  samples	  from	  the	  single	  and	   double	   digestions	   as	   described	   previously	   in	   section	   3.4.2.	   When	  required,	   reaction	  products	  were	  purified	  from	  agarose	  gel	  using	  QIAquick	  PCR	  purification	  kit	  as	  per	  manufacture’s	  protocol.	  Elutions	  were	  quantified	  using	  the	  Nanodrop	  spectrometer	  ND	  100	  at	  260nm.	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  General	  DNA	  Ligation	  	  3.4.4Fragments	   and	   linkers	   were	   ligated	   into	   the	   pSecTag	   plasmid	   to	   create	  mammalian	  expression	  vectors.	  Two	  different	  controls	   (one	  without	   insert	  and,	  another	  without	   insert	  and	  DNA	  ligase)	  were	  used	   in	  each	  reaction	  to	  ascertain	  the	  success	  of	  DNA	  ligation.	  For	  each	  ligation,	  the	  amount	  of	  insert	  (I)	  used	  was	  calculated	  using	  the	  formula	  below	  from	  the	  Promega	  website.	  A	  molar	  ratio	  of	  insert	  to	  plasmid	  (P)	  of	  3:1	  was	  used.	  	  	  ng	  of	  insert	  (I)	  	  =	  	   (ng	  of	  P	  x	  Kb	  size	  of	  I)	  x	  molar	  ratio	  of	  I:P	  (3/1)	  	  	  	  	  	  	  	  	  	  Kb	  size	  of	  P	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  The	   volume	  of	  MilliQ	  water	  was	   added	   to	   compensate	   for	   the	   variation	   in	  volume	  of	  fragment	  (insert)	  to	  achieve	  a	  total	  reaction	  volume	  of	  10μl.	  The	  Plasmid	  (P)	  typically	  used	  in	  this	  method	  was	  around	  50ng.	  Ligation	   reactions	   were	   set	   up	   as	   shown	   in	   the	   table	   below	   and	   left	  overnight	  at	  room	  temperature.	  	  
Table	  3-­‐5:	  Preparation	  of	  ligation	  reactions	  	  	   (Experimental	  ligation)	   Control	  1	   Control	  2	  PCR	   fragment	   (insert)	  or	  linkers	   Variable	   -­‐	   -­‐	  Plasmid	  vector	   X	  (~50ng)	   Xμl	   Xμl	  10x	  ligase	  buffer	   1μl	   1.5μl	   1.5μl	  MilliQ	  water	   Variable	   X	  μl	   X	  μl	  T4	  DNA	  ligase	  (3U/μl)	   1μl	   1μl	   -­‐	  Total	  volume	   10μl	   10μl	   10μl	  	  The	   following	   day,	   the	   ligation	   reactions	   were	   subsequently	   transformed	  into	   SURE	   chemically	   competent	   E.coli	   cells,	   for	   vector	   amplification	   and	  initial	  assessment	  of	  ligation	  success.	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 Transformation	  of	  Plasmid	  into	  Chemically	  Competent	  3.4.5
E.coli	  To	   determine	   if	   the	   target	   gene	   of	   interest	   or	   linkers	   has	   been	   integrated	  into	   the	   vector	   plasmid	   DNA,	   the	   expression	   plasmid	   constructs	   were	  transformed	  into	  competent	  E.	  coli	  cells.	  To	  transform	  the	  cells,	  200μl	  of	  the	  chemically	   competent	   E.coli	   cells	   were	   added	   into	   each	   eppendorf	   and	   a	  suitable	  volume	  of	   the	  plasmid	  of	   interest	  added	   (no	  more	   than	  10%	  total	  volume	  of	  cells),	  all	  this	  was	  carried	  out	  on	  ice.	  Cells	  were	  gently	  mixed	  and	  incubated	   on	   ice	   for	   15	  minutes.	   Heat	   shocking	   at	   42°C	   for	   1	  minute	  was	  used	   to	   enhance	   the	   bacterial	   cell	   wall	   permeability,	   allowing	   uptake	   of	  plasmid.	  After	  that,	  cells	  were	  immediately	  chilled	  on	  ice	  for	  an	  additional	  5	  minutes.	   Under	   sterile	   condition,	   800μl	   SOC	   media	   was	   added	   to	   each	  eppendorf	  of	  cells	  and	  incubated	  for	  a	  further	  40-­‐45	  minutes	  at	  37°C.	  After	  incubation,	   cells	  were	   centrifuged	   for	   5-­‐10	  minutes	   at	   1073	   x	   g	   using	   the	  bench	  top	  centrifuge	  at	  room	  temperature.	  	  The	  supernatant	  was	  discarded	  and	   cell	   pellet	   resuspended	   in	   100μl	   SOC	   media.	   Transformed	   cells	   were	  plated	   out	   on	   LB	   agar	   plates	   containing	   100μg/ml	   carbenicillin	   at	   two	  dilutions;	  10%	  (1	  tenth	  cells	  diluted	  in	  90μl	  SOC	  media)	  and	  90%	  (9/10	  of	  cells)	   to	   accommodate	   any	   potential	   overgrowth	   of	   colonies,	   and	   allow	  isolated	  colony	  selection.	  Plates	  were	  incubated	  overnight	  at	  37°C.	  Next	  day,	  colony	   counts	   were	   carried	   out	   for	   each	   experimental	   ligation	   and	   both	  controls	  to	  evaluate	  whether	  DNA	  ligations	  had	  been	  successful.	  
 Plasmid	  Preparation	  and	  Glycerol	  Stocks	  3.4.6Small-­‐scale	   copies	   of	   expression	   plasmid	   are	   generally	  made	   to	   propagate	  transformed	   cells	   from	   ligation	   reactions	   and	   for	   initial	   analyses	   of	  expression	  constructs	  for	  protein	  expression	  in	  mammalian	  cells.	  A	  number	  of	   colonies	   from	   the	   previously	   transformed	   competent	   E.	   coli	   cells	  containing	   the	   expression	   plasmid	   were	   selected	   and	   seeded	   into	   1ml	   LB	  broth	   containing	   1μl	   of	   100mg/ml	   carbenicillin.	   Colonies	   were	   then	  incubated	  during	  the	  day	  at	  37°C	  in	  orbital	  shaker	  (200rpm).	  Thereafter,	  a	  1/1000	  (5μl)	  dilution	  of	  each	  was	  seeded	  into	  5ml	  LB	  broth	  with	  100μg/ml	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stock	  carbenicillin	  and	   incubated	  overnight.	  On	  the	   following	  day,	  200μl	  of	  50%	   (v/v)	   glycerol	   (important	   for	   long-­‐term	   storage	   of	   bacteria,	   as	   it	  prevents	   the	   formation	  of	   ice	   crystals	   that	   can	  damage	   the	   cell	  wall)	  were	  added	   to	  800μl	  of	  each	  clone	  and	  stored	  at	   -­‐80°C.	  Up	   to	  5ml	  plasmid	  DNA	  from	   overnight	   cultures	   were	   purified	   using	   a	   Qiagen	   plasmid	   mini	  preparation	  kit	  as	  per	  the	  manufacturer’s	  procedure.	  The	  concentrations	  of	  purified	  plasmid	  were	  quantified	  using	   a	  Nanodrop	   spectrometer	  ND100V	  at	  a	  wavelength	  of	  260nm.	  
 Screening	  of	  Potential	  Clones	  from	  Ligations	  3.4.7For	  initial	  screening	  of	  the	  clones	  so	  as	  to	  identify	  potential	  positive	  clones	  with	   insert	   prior	   to	   sending	   for	   sequencing,	   plasmid	   samples	   from	   mini	  preps	  were	  double-­‐digested	  with	  the	  restriction	  enzymes	  that	  were	  used	  for	  the	   cloning.	   	   Plasmid	   digestion	   was	   confirmed	   using	   agarose	   gel	  electrophoresis	   as	   outlined	  before	   at	   section	  3.4.3.	   Positive	  plasmids	  were	  sent	  for	  DNA	  sequencing.	  	  
 Plasmid	  Sequence	  Analysis	  3.4.8All	  plasmid	  samples	  with	  an	  appropriate	  forward	  and	  reverse	  primers	  were	  sent	   to	   the	   Department	   of	   Core	   Genomic	   within	   the	   Sheffield	   University	  School	  of	  Medicine	   to	   confirm	   that	  DNA	  cloning	  had	  generated	  a	  vector	  of	  desired	  nucleotide	  sequence.	  The	  genomic	  sequence	  results	  were	  analyzed	  using	  SeqMan	  (DNASTAR	  Lasergene	  software).	  	  
 	  Cell	  Culture	  and	  Protein	  Expression	  3.5
 Growth	  and	  General	  Maintenance	  of	  CHO	  Flp-­‐In	  Cells	  3.5.1Mammalian	  CHO	  Flp-­‐In	  cells	  were	  used	  for	  protein	  expression	  of	  the	  tandem	  GCSF	   constructs,	   which	   are	   the	   subjects	   of	   our	   studies.	   From	   the	   liquid	  nitrogen	  stock	  of	  untransfected	  Chinese	  hamster	  ovary	  cells	  (CHO	  Flp-­‐In),	  a	  vial	   (at	   2-­‐3	   x	   106	   cells/ml)	   was	   removed,	   thawed	   and	   grown	   in	   growth	  media	   (Ham's/F12	   DMEM	  media	   containing	   10%	   Fetal	   Calf	   Serum	   (FCS),	  2mM	   L-­‐glutamine,	   and	   100µg/ml	   Streptomycin	   /	   Penicillin	   and	   100μg/ml	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Zeocin)	  and	  were	  grown	  in	  a	  5%	  CO2	  incubator	  at	  37°C.	  	  For	   passaging,	   the	   adherent	   cells	   were	   removed	   by	   the	   addition	   of	  trypsin/EDTA	   and	   incubated	   2-­‐3	   minutes.	   The	   resulting	   suspension	   was	  then	  diluted	  with	  complete	  medium	  transferred	  to	  a	  sterile	  30ml	  universal	  and	   centrifuged	   for	   5	   minutes	   at	   67	   x	   g	   to	   remove	   supernatant.	   The	   cell	  pellet	  was	  resuspended	  in	  the	  appropriate	  media.	  Cells	  were	  maintained	  at	  approximately	  80-­‐90%	  confluence	   in	   a	  T-­‐75	   flask.	  At	   this	  density	   the	   cells	  are	  routinely	  passaged	  at	  1	  in	  10	  dilution.	  	  
 Trypan	  Blue	  Exclusion	  Method	  3.5.2Trypan	  blue	  is	  used	  to	  stain	  cells	  to	  differentiate	  between	  live	  and	  dead	  cells	  during	   cell	   counting.	   The	   dead	   cells	   exclusively	   take	   up	   the	   blue	   dye	   and	  thus	   appear	   blue	   when	   visualized	   under	   a	   light	   microscope.	   This	  distinguishes	   them	   from	   the	   live	   cells,	   which	   appear	   bright.	   This	  characteristic	   of	   dead	   cells	   differentiation	   is	   particularly	   important	   when	  assessing	   the	  viability	  of	   the	   cells	   culture.	  Using	  heamocytometer	   (used	   to	  count	   cells	   number	   in	   a	   specific	   volume	   of	   fluid	   to	   give	   an	   approximate	  number	  of	  cells	  in	  the	  whole	  fluid),	  Trypan	  blue	  was	  applied	  at	  1:1	  dilution	  with	  media	   sample.	  The	   total	   number	  of	   cells	  was	   calculated	  per	  ml	  using	  the	  below	  equation:	  	  	  	  	  	  	  	  	  	  	  Total	  cell	  number	  per	  ml=	  total	  cell	  number	  x	  Dilution	  factor	  x	  104	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  No	  of	  squares	  	  	  
 Transient	  Expression	  of	  GCSF	  Tandems	  in	  CHO	  Flp-­‐In	  	  3.5.3All	  GCSF	  constructs	  (plasmids)	  were	  transiently	  transfected	  into	  CHO	  Flp-­‐In	  cells	   as	   an	   initial	   screen	   for	   protein	   expression	   prior	   to	   development	   of	   a	  stable	  cell	  line.	  CHO	   Flp-­‐In	   cells	   were	   grown	   in	   antibiotic	   free	   media	   (Ham's/F12	   DMEM	  media	   containing	   10%	   Fetal	   Calf	   Serum	   (FCS),	   2mM	   L-­‐glutamine,	   and	  100µg/ml	   Streptomycin	   /	   Penicillin).	   At	   approximately	   70%	   confluence,	  cells	   were	   removed	   from	   the	   plate	   by	   the	   addition	   of	   trypsin/EDTA	   and	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reseeded	  at	  a	  density	  of	  0.2	  x	  106	  cells/well	  into	  a	  24	  well	  plate	  on	  the	  day	  prior	  to	  transfection.	  Cells	  were	  allowed	  to	  grow	  overnight	  in	  antibiotic	  free	  media.	   The	   following	   day,	   media	   was	   replaced	   with	   500μl	   antibiotic	   free	  growth	  media.	  	  A	   transfection	   reaction	   mix	   was	   prepared	   using	   a	   Fugene-­‐6	   transfection	  reagent	   (transfection	   reagent	   designed	   to	   transfect	   plasmid	   DNA	   into	  multiple	   cell	   lines	   with	   low	   toxicity	   and	   high	   efficiency)	   to	   experimental	  DNA	  ratio	  of	  3:2,	  in	  a	  volume	  of	  100μl	  serum	  free	  growth	  media	  (Ham's/F12	  DMEM	  media	   containing	   2mM	  L-­‐glutamine,	   and	   100µg/ml	   Streptomycin	   /	  Penicillin).	  Prior	  to	  use,	  Fugene-­‐6	  was	  equilibrated	  to	  room	  temperature	  and	  vortexed.	  Then,	  6μl	  of	  Fugene-­‐6	  was	  added	  to	  the	  reaction	  mix,	  being	  careful	  to	   avoid	   contact	   with	   the	   plastic	   sides	   of	   eppendorf,	   and	   followed	   by	   the	  addition	   of	   4μg	   of	   plasmid.	   Transfection	   with	   a	   known	   plasmid	   that	  expresses	   well	   (pGCSFSecTag4A1)	   was	   used	   as	   a	   positive	   control.	   Non-­‐transfected	   cells	  were	   used	   as	   a	   negative	   control	   in	   each	   experiment.	   The	  transfection	   mixes	   were	   gently	   flicked	   to	   mix	   and	   incubated	   at	   room	  temperature	  for	  15	  minutes.	  Each	  transfection	  mix	  was	  pipetted	  drop-­‐wise	  into	  its	  corresponding	  well	  and	  gently	  rocked	  to	  ensure	  an	  even	  distribution.	  All	  plates	  were	  incubated	  at	  37°C	  with	  5%	  CO2	  for	  72	  hrs	  prior	  to	  harvesting	  the	   media.	   Finally,	   the	   media	   for	   each	   transfection	   (containing	   secreted	  product)	   was	   centrifuged	   and	   supernatant	   was	   transferred	   to	   a	   clean	  universal	   tube	   for	   protein	   expression	   analyses	   using	   any	   available	  convenient	  method	  (western	  blot	  or	  Elisa).	  	  
 Generation	  of	  Stable	  CHO	  Flp-­‐In	  Cell	  lines	  3.5.4The	   expression	   for	   GCSF	   tandems	   was	   enabled	   using	   the	   Invitrogen	   CHO	  Flp-­‐In	   system.	   The	   CHO	   Flp-­‐In	   system	   was	   chosen	   since	   it	   enabled	   rapid	  integration	   of	   a	   GOI	   into	   a	   specific	   site	   within	   the	   host	   genome	   for	   high	  expression.	  	  	  The	  CHO	  Flp-­‐In	  host	  cell	  line	  has	  a	  single	  Flp	  recombinase	  target	  (FRT)	  site	  located	   at	   a	   transcriptionally	   active	   genomic	   locus	   and	   is	   resistant	   to	   the	  antibiotic	  zeocin.	  The	  plasmid	  (A	  modified	  version	  of	  pSecTag-­‐V5/FRT-­‐Hist:	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see	  Appendix	  C)	  contains	  the	  gene	  of	  interest	  as	  well	  as	  an	  FRT	  site	  and	  has	  the	  hygromycin	  B	  resistance	  gene.	  	  Stable	   cells	  are	  generated	  by	  co-­‐transfection	  of	   the	  plasmid	  containing	   the	  gene	   of	   interest	   (GOI)	   and	   another	   plasmid,	   pOG44	   (a	   5.8	   kb	   Flp-­‐recombinase	   expression	   vector	   responsible	   for	   Flp-­‐recombinase	  expression)	  into	  the	  Flp-­‐In	  cell	  line.	  	  The	  expression	  of	  Flp	  recombinase	  results	  in	  the	  integration	  of	  the	  GOI	  into	  the	  genome	  via	  the	  FRT	  site.	  	  Stable	  cells	  are	  then	  selected	  using	  hygromycin	  B,	   thus	   the	  need	   for	   clonal	   selection	   is	   not	   necessary	   as	   integration	   of	   the	  DNA	  is	  directed.	  The	  process	  of	  culturing	  the	  Flp-­‐In	  cell	  line	  was	  conducted	  as	  per	  manufacture’s	  protocol	  using	  basic	  cell	  culture	  techniques.	  	  The	   day	   before	   transfection	   cells	   were	   removed	   from	   a	   T75	   flask	   by	   the	  addition	  of	  trypsin/EDTA	  and	  reseeded	  into	  6	  well	  plates	  at	  a	  concentration	  of	  0.25	  x	  106	  cells	  per	  well	  in	  a	  total	  volume	  of	  2ml.	  Cells	  were	  left	  overnight	  to	  achieve	  about	  60-­‐70%	  confluency.	  Transfections	   were	   carried	   out	   the	   next	   day.	   Briefly,	   a	   number	   of	   sterile	  eppendorf	   tubes	   each	   containing	   92.5μl	   serum	   free	   media	   (without	  antibiotics)	  were	  set	  up.	  To	  each	  tube,	  7.5µl	  of	  Fugene-­‐6	  was	  slowly	  dropped	  onto	  the	  surface	  of	  media	  and	  flicked	  to	  mix.	  In	  separate	  sterile	  eppendorfs,	  250ng	  of	  plasmid	  of	  interest	  was	  mixed	  with	  5μg	  of	  the	  pOG44	  plasmid	  and	  pipetted	   into	   the	   tube	  containing	  Fugene-­‐6	  mix	  and	  contents	  mixed	  gently	  by	   flicking.	   Tubes	   were	   incubated	   at	   room	   temperature	   for	   15	   minutes.	  Fugene-­‐6	   only	   was	   used	   as	   a	   negative	   control	   and	   a	   known	   expression	  plasmid	  (pGCSFSecTag4A1)	  was	  used	  as	  a	  positive	  control.	  All	   transfection	  mixes	   were	   carefully	   pipetted	   drop-­‐wise	   onto	   cells	   in	   each	   labelled	  individual	  well	  of	  a	  6	  well	  plate,	  and	   incubated	  at	  37	  °C,	  5%	  CO2	  for	  24-­‐48	  hrs.	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At	   24-­‐48	   hrs	   post-­‐transfection,	   the	   culture	   medium	   in	   each	   well	   was	  removed	   and	   replaced	   with	   2ml	   growth	   medium	   (Ham's/F12	   medium	  containing	  10%	  FCS,	  100µg/ml	  Streptomycin	  /100IU/ml	  Penicillin,	  2mM	  L-­‐glutamine)	   containing	   600μg/ml	   Hygromycin	   B	   antibiotic	   as	   selective	  reagent.	   Cells	   were	   then	   allowed	   to	   grow	   until	   desired	   confluency	   with	  media	  replacement	  every	  2	  days.	  Routine	  observations	  were	  made	  as	  to	  the	  cells	   appearance,	  with	   successfully	   transfected	   cells	   appearing	   fibroblastic	  and	   growing	   out	   in	   clumps,	   whereas,	   dead	   cells	   appeared	   spherical	   in	  solution.	   Cells	   were	   not	   allowed	   to	   get	   too	   confluent,	   as	   the	   antibiotics	  would	  become	  ineffective.	  	  When	  plates	  had	  a	  number	  of	  individual	  colonies	  growing	   out	   they	   were	   removed	   from	   the	   wells	   by	   the	   addition	   of	   0.5ml	  Trypsin-­‐EDTA	   (T/E)	   and	   centrifuged	   at	   67	   x	   g	   for	   5	   minutes	   The	  supernatant	  was	   discarded	   and	   cell	   pellet	   resuspended	   in	   5ml	   transfected	  growth	  media	  and	  grown	  in	  T-­‐25	  flasks	  until	  cells	  became	  nearly	  confluent	  with	  media	   change	   every	   2	   days.	   Once	   confluent	   cells	   were	   removed	   and	  transferred	  to	  T-­‐75	  flasks	  with	  the	  same	  growth	  media	  in	  a	  total	  volume	  of	  12-­‐15ml.	  Cells	  were	  considered	  stable	  when	  all	  control	  cells	  were	  dead	  and	  cells	  were	  dividing	  normally.	  This	  took	  normally	  2-­‐4	  weeks.	  	  
 Analysis	  of	  Crude	  Media	  from	  Transfected	  Cells	  Lines	  3.5.5For	   protein	   expression	   analysis	   of	   stable	   &	   transiently	   transfected	   cells	  lines,	   it	   was	   required	   to	   serum	   starve	   cells	   prior	   to	   analysis.	   	   T-­‐75	   flasks	  containing	   stable	   cells	   were	   grown	   until	   an	   appropriate	   confluency	   was	  reached.	  Thereafter,	  cells	  were	  serum-­‐starved:	  Media	  was	  removed	  from	  the	  T-­‐75	  flasks	  and	  replaced	  with	  12-­‐15ml	  serum	  free	  media	  and	  incubated	  for	  2-­‐3	  days	  at	  37	  °C,	  5%	  CO2.	  After	   incubation	  media	  was	  transferred	  to	  clean	  30ml	   universal	   tube	   and	   centrifuged	   to	   remove	   any	   cellular	   debris.	   The	  supernatant	  of	   each	   sample	  was	   then	   carefully	   removed	   to	   another	   sterile	  universal	   tube	   and	   stored	   at	   4°C	   until	   required	   for	   protein	   expression	  analyses	  using	  any	  available	  convenient	  method	  (western	  blot	  or	  Elisa).	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 Storage	  of	  Stable	  Cell	  Lines	  in	  Liquid	  Nitrogen	  3.5.6Stable	  cell	  lines	  were	  grown	  to	  confluency	  in	  T-­‐75	  flasks	  at	  which	  point	  cells	  were	   removed	   using	   an	   appropriate	   volume	   of	   trypsin/EDTA.	   Once	   cells	  were	  detached	  an	  appropriate	  volume	  of	  serum	  growth	  media	  was	  added	  to	  each	   flask	   to	   neutralise	   Trypsin/EDTA.	   	   The	   suspended	   cells	   for	   all	   flasks	  were	  then	  pooled	  together	  in	  a	  clean	  30ml	  universal	  tube	  and	  centrifuged	  at	  67	  x	  g	  for	  5	  minutes	  to	  pellet.	  The	  supernatant	  was	  discarded	  and	  cells	  were	  resuspended	   in	   a	   freezing	   mixture	   (foetal	   calf	   serum/DMSO	   mixture	   are	  ratio	  9/1)	   to	  make	  a	   final	   concentration	  between	  2-­‐4	   x	  106	   cells/ml.	  Once	  cells	  were	  resuspended,	   immediately	  1ml	  portions	  were	  aliquoted	  to	  clean	  cryogenic	  freezing	  vials	  labelled	  with	  construct	  name,	  cell	  line,	  date	  and	  cell	  number.	   Cryogenic	   vials	   were	   finally	   placed	   in	   a	   polystyrene	   freezer	   box	  surrounded	  with	  cotton	  wool	  and	  stored	  at	  -­‐80°C.	  This	  step	  is	  important	  to	  freeze	  cells	  gently	  and,	  prevent	  ice	  crystal	  formation	  within	  the	  stable	  cells.	  Later,	  cells	  were	  transferred	  to	  liquid	  nitrogen	  for	  long	  time	  storage.	  
 Adaptation	  of	  Stable	  CHO	  Cells	  to	  Hyclone	  Media	  3.5.7The	  stable	  cells	  taken	  from	  liquid	  nitrogen	  were	  thawed	  and	  grown	  in	  T75	  flask	   growth	  medium	   for	   1-­‐2	   days	   until	   an	   appropriate	   confluency.	   	   Cells	  were	   resuspended	   in	  Hyclone	   SMF4CHO	  Utility	  media	   (no	  Hygromycin	   B)	  for	  adaption	  and	  media	  was	  change	  every	  2-­‐3	  days.	  
 Expression	  of	  GCSF	  Tandems	  in	  Roller	  Bottle	  Culture	  	  3.5.8After	   growing	   to	   the	   maximum	   level	   in	   T75	   flask,	   stable	   cells	   were	  transferred	   to	   2	   x	   1	   litre	   roller	   bottles	   (maximum	   volume	   500ml)	   at	   a	  starting	   density	   of	   ~0.25x106/ml	   (each	   roller	   bottle	   contained	   about	  500ml).	   Cells	  were	   grown	  at	  37°C	  5%	  CO2	  with	  mixing	   (Cell	  Roll	   Cellspine	  Control	   Unit	  was	   used	   to	  mix	   the	   stable	   cells	   at	   4rpm)	   until	   viability	  was	  ~30%,	   with	   samples	   regularly	   taken	   every	   2	   or	   3	   days	   to	   assess	   protein	  expression	  and	  cell	  viability.	  Thereafter,	  the	  cells	  were	  centrifuged	  at	  14,981	  x	   g	   (JLA	   16.250)	   for	   30	  minutes	   at	   4°C	   to	   clear	   cellular	   debris	   and	   10mM	  final	   concentration	   of	   Benzamidine	   HCl	   (serine	   protease	   inhibitor)	   was	  
58	  
added	   to	   the	   1L	  media	   sample	   to	   prevent	   protein	   degradation.	   The	  media	  sample	  was	   then	   concentrated	   using	   a	   vivaflow	   concentrator	   (See	   section	  3.6)	  and	  stored	  at	  -­‐40°C	  until	  required.	  Samples	  were	  analysed	  by	  western	  blotting	  and	  Elisa.	  
 Vivaflow	  200	  Concentrator	  3.6Vivaflow	   200	   concentrator	   was	   used	   to	   concentrate	  media	   sample	   to	   10x	  less	   volume	   (i.e.	   from	  1L	   to	   100ml).	   This	  was	   important	   to	   save	   time	   and	  make	   the	   process	   of	   purification	   easier.	   The	   Vivaflow	   200	   concentration	  system	  comprised	  of	  a	  membrane	  module	  with	  10kDa	  molecular	  weight	  cut-­‐off,	  inlet	  and	  outlet	  tubes,	  and	  pump	  (Masterflex	  pump).	  Before	  starting	  the	  process,	  the	  tubes	  were	  cleaned	  with	  0.5M	  NaOH	  followed	  by	  washing	  with	  500ml	   of	   deionized	  water	  with	   the	   filtrate	   going	   to	   the	  waste.	   The	  media	  sample	  was	   then	   circulated	   through	   the	   system	   for	   approximately	   3-­‐4	   hrs	  (the	  media	  sample	  was	  placed	  on	  ice	  during	  concentration	  to	  avoid	  protein	  degradation),	   and	   the	   culture	   volume	   concentrated	   down	   to	   10	   times	   less	  volume	   within	   this	   period,	   followed	   by	   storage	   at	   -­‐40°C	   until	   ready	   for	  purification.	   After	   each	   concentration	   cycle,	   deionized	   water	   was	   flushed	  through	   the	   system	   with	   the	   filtrate	   going	   to	   the	   waste.	   The	   system	   was	  cleaned	   by	   recirculating	   250ml	   of	   0.5M	   NaOH	   through	   the	   system	   at	  100ml/min	   for	   30-­‐40	   minutes.	   Finally,	   the	   system	   was	   drained	   and	  recirculated	  with	  500ml	  deionized	  water	  for	  5-­‐10	  minutes	  with	  the	  filtrate	  going	  to	  the	  waste.	  For	  storage,	  the	  module	  was	  filled	  with	  20%	  ethanol	  and	  refrigerated	  at	  4°C.	  	  
 Protein	  Purification	  3.7
 Purification	  of	  GCSF	  Tandems	  Using	  IMAC	  3.7.1Tandem	  proteins	  were	  designed	  with	  a	  His-­‐Tag	  at	  the	  C-­‐terminus.	  The	  His-­‐tag	  in	  each	  tandem	  facilitates	  easy	  purification	  of	  the	  desired	  protein	  when	  passed	  over	  a	  metal	  chelate	  column.	  	  The	  high	  affinity	  of	  histidine	  for	  nickel	  ions	   allows	   the	   protein	   to	   bind	   to	   the	   Immobilized	   Metal	   Affinity	  Chromatography	   (IMAC)	   column	   while	   most	   of	   other	   proteins	   remain	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unbound.	   The	   column	   was	   washed	   with	   a	   solution	   of	   moderate	   ionic	  strength	   to	   dissociate	   proteins	   that	   may	   have	   bound	   to	   the	   column	   non-­‐specifically.	   The	   target	   protein	  with	   His-­‐tag	   is	   released	   from	   the	   IMAC	   by	  adding	   high	   concentrations	   of	   histidine	   analogues	   (e.g.	   imidazole)	   to	  compete	  with	  his-­‐tag	  for	  nickel	  binding.	  As	  a	  result,	  the	  eluted	  target	  protein	  with	  his-­‐tag	  could	  be	  separated	  from	  any	  protein	  contaminants	  (Block	  et	  al.,	  2009).	  The	  separated	  protein	   fraction	  undergoes	  dialysis	   in	  PBS	  at	  4°C	   for	  2hrs	  and	  then	  overnight	  (after	  PBS	  buffer	  change).	  The	  dialysed	  protein	  was	  stored	  at	  -­‐80°C.	  	  Step-­‐wise	  detail	  for	  the	  purification	  step	  is	  provided	  below.	  Before	  applying	  the	  media	  sample	  to	  the	  1	  ml	  IMAC	  column	  (GE	  Healthcare),	  all	   tubing	  was	  cleaned	  with	  0.2M	  NaOH	  and	   then	  rinsed	  with	  H2O	  prior	   to	  use.	   A	   fresh	   IMAC	   column	  was	   charged	  with	   4mg/ml	   Nickel	   chloride	   and	  equilibrated	  with	  equilibration	  buffer	   (20mM	  NaP3,	  pH	  7.4,	  0.5M	  NaCl	  and	  10%	  glycerol).	  Media	   sample	  was	  defrosted	   and	   centrifuged	   at	   30,910	   x	   g	  (JA-­‐25.5)	  for	  30	  minutes	  at	  4°C	  to	  clarify.	  Media	  sample	  was	  diluted	  1:1	  with	  40mM	   NaP3,	   pH	   7.4,	   1M	   NaCl,	   20%	   glycerol	   and	   20mM	   imidazole.	   Media	  sample	  was	   then	   filtered	  (using	  Millipore	  0.22um	  filters)	  and	   loaded	  on	   to	  the	   IMAC	   column	   at	   2ml/minute	   (sample	   contained	   10mM	   imidazole)	   at	  room	   temperature	   or	   sometimes	   4°C	   to	   avoid	   protein	   degradation.	   The	  unbound	  fraction	  (flow	  through)	  was	  collected	  and	  the	  column	  washed	  with	  10	   column	  volumes	   (CV’s)	   equilibration	  buffer	  with	   the	   addition	  of	   10mM	  imidazole,	  followed	  by	  10	  CV’s	  with	  the	  addition	  of	  10mM	  imidazole	  at	  2ml/	  minute.	  These	  two	  washes	  were	  used	  to	  remove	  contaminants.	  	  Different	   concentrations	   of	   imidazole	   were	   made	   up	   in	   20mM	   sodium	  acetate,	  0.5M	  NaCl,	  pH	  6.0,	  10%	  glycerol	  (pH	  6.0	  buffer)	  as	  shown	  in	  Table	  3.6	  were	   used	   to	   elute	   the	   bound	  protein	   (Target	   protein)	   from	   the	   IMAC	  column	  using	  a	  step	  elution	  method.	  1ml	   fractions	  were	  collected	  (3	  x	  1ml	  per	   concentration).	   The	   eluted	   proteins	   were	   analysed	   by	   SDS-­‐PAGE/Bradford	  assay	  and	   the	  relevant	   fractions	  were	  pooled	  and	  dialysed	  against	   at	   least	   1L	   PBS	   buffer	   at	   4°C	   for	   1,	   2	   hrs	   and	   overnight	   (A	   fresh	  change	   of	   PBS	   buffer	   was	   used	   per	   dialyse)	   to	   remove	   all	   salts	   and	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imidazole.	   At	   the	   end	   of	   each	   purification,	   the	   IMAC	   column	   was	   washed	  with	  0.2M	  NaOH	  followed	  by	  10	  CV’s	  of	  water	  and	  stored	  in	  20%	  ethanol.	  	  Table	  3-­‐6:	  	  Concentrations	  of	  imidazole	  
Imidazole	  concentration	  (mM)	   Imidazole	  (ml)	   pH	  6.0	  buffer	  (ml)	  20	   0.2	   4.8	  50	   0.5	   4.5	  100	   1	   4	  200	   2	   3	  350	   3.5	   1.5	  500	   5	   -­‐	  
  
 
 Purification	  of	  GCSF	  Using	  Cibacron	  Blue	  Sepharose	  	  3.7.2The	   stable	   cells	   of	   native	   GCSF	   (ligand	   only)	   were	   taken	   from	   liquid	  nitrogen,	  thawed	  and	  grown	  in	  T75	  flasks	  as	  described	  in	  section	  3.5.7	  and	  3.5.8	   and	   were	   thereafter	   transferred	   to	   4	   big	   roller	   bottles	   (maximum	  volume	   1	   liter)	   at	   a	   starting	   density	   of	   ~0.5x106/ml	   (each	   roller	   bottle	  contained	   about	   500ml).	   Cells	   were	   grown	   at	   37°C	   5%	   CO2	   until	   viability	  was	  ~30%,	  with	  samples	  regularly	  taken	  every	  2	  or	  3	  days	  to	  assess	  protein	  expression	  and	  cell	  viability.	  Because	  native	  GCSF	  has	  no	  His-­‐tag,	  a	  Cibacron	  Blue	  Sepharose	   (www.gelifesciences.com)	  column	  was	  used	   to	  purify.	  This	  dye	  ligand	  chromatography	  resembles	  native	  substrate	  which	  proteins	  have	  affinity	  for.	  When	  proteins	  pass	  through	  this	  column,	  the	  goal	  of	  this	  dye	  is	  to	   bind	   the	   target	   protein	   and	   expel	   all	   unbound	   proteins.	   The	   bound	  protein	   could	   then	  be	  eluted	  by	   changing	   the	  buffer	   composition,	   often	  by	  increasing	  the	  buffer	  pH.	  Media	  sample	  of	  recombinant	  human	  GCSF	  (rhGCSF)	  was	  placed	  on	  ice	  and	  precipitated	   with	   35%	   (w/v)	   (20.11g/100ml)	   ammonium	   sulphate	  (AmSO4).	   	  The	  solution	  was	  then	  incubated	  at	  4°C	  with	  mixing	  for	  1hr.	  The	  resulting	  suspension	  was	  centrifuged	  at	  43589	  x	  g,	  4°C	  for	  30	  minutes	  and	  the	   supernatant	  was	   kept	   to	   check	   if	   it	   contains	   rhGCSF	   (1st	  supernatant).	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The	  pellet	  was	  solubilized	  in	  10ml	  20mM	  TRIS	  buffer	  pH	  7.0.	  On	  ice,	  the	  pH	  of	   the	  media	  was	  dropped	   from	  7.0	   to	  5.0	  by	  adding	  10ml	  100mM	  sodium	  acetate	   buffer	   and	   incubating	   on	   ice	   at	   4°C	   for	   30	  minutes.	   The	   resulting	  suspension	   was	   centrifuged	   at	   43589	   x	   g,	   4°C	   for	   30	   minutes	   and	   the	  supernatant	  was	  kept	  (2nd	  supernatant).	  A	  1ml	  Blue	  Sepharose	  column	  (GE	  Healthcare),	  was	  first	  equilibrated	  with	  10	  column	  volumes	  (CV’s)	  of	  20mM	  sodium	   acetate,	   pH	   5.0	   and	   then	   supernatant	   was	   loaded	   onto	   the	   1ml	  column	   at	   room	   temperature	   and	   unbound	   fraction	   collected	   (Flow	  through).	  The	  column	  was	  washed	  with	  5	  CV’s	  sodium	  acetate	  buffer,	  pH	  5.0	  buffer	  followed	  by	  3	  ×	  5ml	  (3	  ×	  5	  CV’s)	  20mM	  Tris	  buffer	  pH	  7.0.	  The	  column	  was	   finally	   washed	  with	   5	   ×	   2	  ml	   20mM	   Tris,	   1mM	   EDTA	   at	   pH	   8.0	   (the	  target	   protein	  was	   observed	   to	   elute	   at	   a	   high	   concentration	   in	   this	   step).	  Eluted	  proteins	  were	  stored	  at	  -­‐80°C.	  Finally,	  the	  column	  was	  washed	  with	  5	  ×	  2ml	  of	  20mM	  Tris,	  1mM	  EDTA	  and	  1M	  NaCl,	  pH	  8.0	   to	  clean	  the	  column	  and	   stored	   at	   4°C.	   When	   required,	   samples	   were	   analysed	   by	   coomassie	  stain,	  western	  blotting	  and	  Elisa.	  
 Analysis	  of	  Protein	  3.8
 Bradford	  Protein	  Assay	  	  3.8.1The	   Bradford	   protein	   assay	   was	   routinely	   used	   to	   measure	   the	  concentration	  of	  our	  purified	   tandem	  proteins	  and	  rhGCSF	   in	  a	   solution.	  A	  10mg/ml	  solution	  of	  BSA	  was	  prepared	  in	  double	  distilled	  water	  and	  diluted	  to	   1mg/ml,	   then	   to	   100μg/ml	   by	   10-­‐fold	   dilution	   (i.e.	   1ml	   BSA	   +	   9ml	  ddH2O).	   The	   standards	   below	   were	   prepared	   from	   this	   100μg/ml	   (Table	  3.7).	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Table	  3-­‐7:	  Standard	  curve	  preparation	  
	  
Standards	   and	   Unknown	   samples	   were	   prepared	   in	   duplicate	   as	  
follows:	  0.8ml	   of	   each	   standard	   was	   pipetted	   into	   separate1.5ml	   eppendorf	   tubes	  and	   0.2ml	   dye	   reagent	   was	   then	   added,	   mixed	   gently	   and	   incubated	   for	  5mins	  at	  room	  temperature.	  Unknown	  samples	  were	  diluted	  appropriately	  into	   a	   final	   volume	   of	   0.8ml	   ddH2O.	   0.2ml	   dye	   reagent	   was	   then	   added,	  mixed	  gently	  and	   incubated	   for	  5mins.	  All	   standard	  and	  unknown	  samples	  were	   transferred	   into	   plastic	   disposable	   cuvettes	   before	   reading	   in	  spectrophotometer	  at	  595nm.	  	  
 Analysis	  of	  Proteins	  by	  SDS-­‐	  PAGE	  	  3.8.2




in	  assay	  (μg/ml)	  
Dilution	   	  
25	   20	   x4	   2ml	  100μg/ml	  +	  6ml	  ddH2O	  12.5	   10	   x2	   2.5ml	  25μg/ml	  +	  2.5ml	  ddH2O	  6.25	   5	   x2	   2.5ml	  12.5μg/ml	  +	  2.5ml	  ddH2O	  2.5	   2	   x2.5	   2ml	  6.25μg/ml	  +	  3ml	  ddH2O	  1.25	   1	   x2	   2ml	  2.5μg/ml	  +	  2ml	  ddH2O	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removed	  with	  a	  filter	  paper.	  A	  5%	  stacking	  gel	  was	  prepared	  for	  the	  second	  layer	   by	   combining	   830μl	   of	   30%	  Acrylamide	   (0.8%	   (w/v)	   bis-­‐acrylamide	  stock	  solution	  (37.5:1	  ratio)),	  3.45ml	  sterile	  MilliQ	  water,	  630μl	  of	  stacking	  buffer	  (0.5	  M	  Tris-­‐HCl,	  0.4%	  SDS	  (w/v),	  pH	  6.8),	  5μl	  of	  TEMED,	  50μl	  of	  10%	  APS	  and	  the	  mixture	  was	  poured	  onto	  the	  top	  of	  the	  resolving	  gel	  up	  to	  the	  top	  of	  the	  gel	  plate,	  and	  a	  1.0	  mm	  well	  comb	  was	  immediately	  inserted	  into	  the	   top	   of	   the	   stacking	   gel,	   avoiding	   air	   bubble	   formation.	   The	   gel	   was	  allowed	  to	  set	  at	  room	  temperature	  for	  15	  minutes.	  
 Preparation	  of	  Samples	  for	  SDS-­‐PAGE	  3.8.2.2Following	   quantification	   of	   the	   proteins,	   0.5ml	   eppendorf	   tubes	   were	  labeled	  and	  the	  final	  volume	  of	  each	  sample	  was	  added	  to	  equal	  volume	  of	  2x	   Laemmli	   sample	   buffer.	   Sometimes,	   dithiothreitol	   (DDT),	   a	   reducing	  agent	   was	   added	   to	   the	   mixture	   to	   a	   final	   concentration	   of	   25mM	   (to	  minimize	  dimerization	  of	   samples).	  The	  eppendorf	   tubes	  were	   centrifuged	  at	   11,337g	   for	   4	   seconds	   and	   incubated	   at	   95°C	   for	   5	   minutes	   using	   the	  Techne	  Dri-­‐Block	  BD-­‐2D.	  Samples	  were	  carefully	  pipetted	   into	  wells	  of	   the	  10%	  gel	  in	  1x	  running	  buffer	  (0.25	  M	  Tris	  HCl,	  1.92	  M	  Glycine	  and	  1%	  SDS	  (w/v),	   pH	   8.3).	   Samples	   were	   run	   against	   a	   standard	   molecular	   weight	  marker.	  The	  gel	  was	  initially	  run	  for	  30	  minutes	  using	  PS250-­‐2	  power	  pack	  at	  75v	  until	  samples	  had	  passed	  through	  the	  stacking	  gel	  and	  then	  turned	  up	  to	  100v	   for	  1	  hour.	   	  The	   separated	  proteins	  were	  visualized	  by	   coomassie	  staining	   (0.25%	  Bromophenol	  blue	  R-­‐25	   (w/v),	  50%	  methanol	   (v/v),	  10%	  acetic	  acid	  (v/v)),	  or	  transferred	  onto	  a	  PVDF	  membrane	  for	  further	  protein	  analyses	  by	  western	  blotting.	  	  
 Visualized	  Protein	  Gels	  with	  Coomassie	  Blue	  3.8.2.3Coomassie	   blue	   is	   a	   rapid	   and	   sensitive	   technique	   for	   the	   visualization	   of	  microgram	  quantities	  of	  protein	  using	   the	  principle	  of	  protein-­‐dye	  binding	  between	   dye	   sulfonic	   acid	   groups	   and	   positive	   protein	   amine	   groups	  through	   ionic	   interaction.	   SDS-­‐PAGE	   gel	   was	   incubated	   in	   the	   coomassie	  blue	   staining	   solution	   at	   room	   temperature	   with	   gentle	   shaking	   for	   30	  minutes	   on	   an	   orbital	   shaker.	   The	   stain	   was	   decanted	   and	   rinsed	   with	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deionized	   water.	   The	   gel	   was	   then	   destained	   (Destain	   solution:	   10%	  methanol	  (v/v)	  and	  5%	  acetic	  acid	  (v/v)).	  To	  aid	  the	  destaining	  process	  the	  solution	  was	   heated	   in	   a	  microwave	   oven	   for	   1	  minute	   at	   full	   power	   and	  gently	   mixed	   on	   an	   orbital	   shaker	   at	   room	   temperature	   until	   the	   desired	  background	  was	  achieved.	  	  
 Western	  Blotting	  3.8.3
 Transfer	  of	  Proteins	  to	  PVDF	  Membrane	  3.8.3.1The	   transfer	   of	   proteins	   separated	   by	   SDS-­‐PAGE	   onto	   polyvinylidene	  diflouride	   (PVDF)	   membrane	   allows	   specific	   protein	   analyses	   by	   western	  blotting.	   The	   separated	   proteins	   were	   routinely	   transferred	   from	   the	   gel	  onto	  PVDF	  membrane	  using	  a	  Mini-­‐Protean	  3	  blotting	  apparatus	  (Bio-­‐Rad).	  As	   PVDF	  membrane	   is	   hydrophobic,	   30	   seconds	   treatment	  with	  methanol	  was	   required	   in	   order	   to	   wet	   the	   membrane	   before	   equilibrating	   in	   the	  transfer	  buffer	   (Transfer	  buffer:	  2g	  glycine	  and	  5.8g	  Tris	  base	  dissolved	   in	  1000	  ml	  of	  MilliQ	  water).	  After	  that,	  2	  gauze	  pads,	  2	  filter	  papers,	  the	  PVDF	  membrane	  and	  the	  gel	  were	  assembled	  in	  the	  blotting	  apparatus	  as	  shown	  in	  Figure	  3.1.	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Figure	  3-­‐1:	  Design	  of	  transferring	  assembly	  The	   scheme	   displays	   the	   preparation	   of	   the	   variant	   coats	   in	   the	   transfer	  buffer.	   In	   the	   presence	   of	   high	   pH	  buffer,	   the	   protein	   transfer	   from	  anode	  towards	  cathode,	  thus	  the	  variant	  coats	  were	  prearranged	  to	  permit	  moving	  of	  proteins	  into	  the	  PVDF	  membrane.	  	  Gauze	  layer	  (a),	  filter	  papers	  (b),	  the	  gel	  comprising	  the	  separated	  proteins	  (c)	  and	  the	  PVDF	  membrane	  (d).	  	  Using	   the	   PS250-­‐2	   power	   pack,	   the	   system	   was	   run	   at	   100v	   for	   1hr.	  Following	   completion	   of	   transfer	   the	   PVDF	   membrane	   was	   blocked	  overnight	  at	  4°C	   in	  100	  ml	  of	  5%	  milk	  protein	  prepared	   in	  PBS-­‐Tween-­‐20	  (0.05%).	  
 Western	  Blotting	  Detection	  of	  GCSF	  	  3.8.3.2After	   transfer	   and	  blocking,	   the	  PVDF	  membrane	  was	  briefly	  washed	  with	  50	   ml	   PBS/Tween-­‐20	   (0.05%).	   The	   membrane	   was	   then	   incubated	   with	  primary	   rabbit	   anti-­‐human	   GCSF	   antibody	   at	   a	   dilution	   of	   1:5000	   (2μl	  antibody	   in	  10	  ml	  of	  5%	  blocking	  buffer)	  at	  room	  temperature	  on	  a	  Stuart	  Mini	  Orbital	  Shaker	  at	  115rpm	  for	  1.5	  hrs.	  The	  membrane	  was	  then	  washed	  with	   50	  ml	   of	   PBS/T	   for	   15	  minutes.	   The	  membrane	   was	   then	   incubated	  with	   secondary	   antibody	   (Goat	   anti-­‐Rabbit	   antibody	   linked	   to	   horseradish	  peroxidase	   (HRP)	  at	   a	  dilution	  of	  1:10000	   (1μl	   antibody	   into	  10	  ml	  of	  5%	  blocking	  buffer))	  on	  a	  Mini	  Orbital	  Shaker	  at	  115rpm	  for	  35	  minutes.	  After	  incubation,	   the	  membrane	  was	   rinsed	   three	   times	   in	  50	  ml	   of	   PBS/T	  on	   a	  Mini	   Orbital	   Shaker	   at	   65	   rpm	   for	   15	   minutes	   per	   wash.	   Visualization	   of	  GCSF	   constructs	   was	   carried	   out	   using	   BM	   chemiluminescence	   blotting	  
66	  
substrate	   solution	  according	   to	   the	  manufacturer’s	   instructions.	  Under	   red	  safety	   light	   in	   a	   dark	   room,	   a	   sensitive	   Fuji	   film	   was	   placed	   over	   the	  membrane	   inside	   a	   hyper	   cassette	   and	   exposed	   for	   approximately	   10	  seconds.	   The	   film	   was	   then	   transferred	   into	   developing	   solution	   (Kodak)	  until	  bands	  were	  detected.	  The	  film	  was	  placed	  into	  water	  to	  remove	  excess	  developing	   solution	   and	   then	   placed	   into	   fixing	   solution	   (Kodak)	   for	  approximately	   1	   minute.	   Different	   lengths	   of	   exposure	   were	   used	   to	  optimise	   the	   quality	   of	   the	   western	   blot.	   Molecular	   weights	   of	   the	   GCSF	  constructs	  were	  determined	  by	  comparison	  to	   loaded	  protein	  standards	  of	  known	  molecular	  weights.	  	  
 Enzyme	  Linked	  Immunosorbent	  Assay	  (Elisa)	  3.8.4Elisa	  is	  a	  sensitive	  and	  specific	  method	  for	  quantification	  of	  proteins.	  It	  was	  used	  in	  this	  project	  to	  measure	  GCSF	  tandem	  protein	  in	  crude	  and	  purified	  media,	  and	  also	  in	  rat	  serum	  (in	  vivo	  study).	  The	  method	  involves	  the	  use	  of	  a	   specific	   monoclonal	   antibody	   (mAb),	   used	   to	   coat	   a	   microtiter	   plate	  (Capture	  antibody).	  The	  Ab	  on	  the	  plate	  will	  capture	  the	  protein	  of	  interest	  following	   the	   addition	   of	   the	   sample.	   The	   addition	   of	   secondary	   mAb	  (Detection	   antibody)	   labelled	   with	   biotin,	   will	   also	   bind	   to	   the	   protein	   of	  interest.	   The	   biotin	   labelled	   antibody	   allows	   binding	   of	   a	   streptavidin-­‐conjugated	   enzyme.	   Washing	   was	   used	   between	   steps	   to	   remove	   any	  unbound	  proteins.	  A	  substrate	  is	  added	  to	  the	  reaction	  to	  produce	  a	  colour	  reaction	   that	   is	  directly	  proportional	   to	   the	   amount	  of	   bound	  protein.	  The	  concentration	  of	  bound	  protein	  is	  measured	  by	  comparison	  with	  a	  standard	  curve	  of	  known	  protein	  concentration.	  A	  standard	  curve	  ranging	  from	  0nM	  to	  5nM	  was	  generated	   from	   the	   rhGCSF	  working	   concentration	   (shaded	   in	  gray	   in	   Table	   3.8).	   Similar	   standard	   curves	   were	   generated	   for	   the	   GCSF	  tandems	  (test	  proteins	  and	  controls)	  from	  purified	  proteins	  by	  diluting	  each	  individual	  stock	  concentrations	  to	  a	  starting	  of	  5nM.	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Table	  3-­‐8:	  Preparation	  of	  GCSF	  standards	  
Sample	  (μl)	   LKC	  buffer	  (μl)	   [GCSF]	  nM	   Dilution	  Stock	  @	  16000nM	   -­‐	   16000	   -­‐	  5	  of	  16000nM	   495	   160	   100x	  25	  of	  160nM	   400	   10	   16x	  500	  of	  10nM	   500	   5	   2x	  500	  of	  5nM	   500	   2.5	   2x	  400	  of	  2.5nM	   600	   1	   2.5x	  500	  of	  1nM	   500	   0.5	   2x	  500	  of	  0.5nM	   500	   0.25	   2x	  500	  of	  0.25nM	   500	   0.125	   2x	  500	  of	  0.125nM	   500	   0.0625	   2x	  500	  of	  0.0625nM	   500	   0.03125	   2x	  500	  of	  0.03125M	   500	   0.0156	   2x	  500	  of	  0.156M	   500	   0.0078	   2x	  	  Details	  of	  the	  initial	  stock	  concentrations	  for	  all	  GCSF	  (tandems	  and	  native)	  used	  for	  the	  standard	  curve	  are	  tabulated	  below	  (Table	  3.9).	  
	  
Table	  3-­‐9:	  Initial	  stock	  concentrations	  of	  rhGCSF	  and	  GCSF	  tandem	  
proteins	  
Construct	   Concentration	  stock	  (nM)	  Commercial	  rhGCSF	   500	  Purified	  rhGCSF	   16000	  GCSF2NAT	   10,800	  GCSF2QAT	   1,0000	  GCSF4NAT	   15,000	  GCSF4QAT	   5,000	  GCSF8NAT	   15,000	  GCSF8QAT	   15,100	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For	   the	   ELISA	   assay:	   96-­‐well	  microtiter	   plates	  were	   coated	  with	   100μl	   of	  capture	  antibody	   (BVD13-­‐3A5)	  at	  1μg/ml	   in	   coating	  buffer	   (0.1M	  NaHCO3,	  pH	  9.2)	  and	  incubated	  at	  4°C	  overnight.	  	  The	   next	   day	   plates	   were	   washed	   3x	   with	   230μl	   PBS-­‐Tween-­‐20	   (0.05%),	  patted	  dry	  and	  blocked	  for	  1hr	  at	  room	  temperature	  with	  200μl	  3%	  (w/v)	  BSA	  in	  PBS-­‐Tween-­‐20.	  	  Control	   and	   unknown	   protein	   samples	   were	   prepared	   in	   LKC	   buffer	   as	  shown	  in	  Table	  3.6.	  (LKC:	  50ml	  of	  0.5M	  Tris,	  15ml	  of	  0.5M	  NaCl,	  50μl	  0.1%	  Tween-­‐20,	  0.25g	  bovine	  gamma	  globulin,	  0.25g	  NaN3	  &	  2.5g	  BSA	  and	  made	  up	  to	  with	  sterile	  water	  and	  stored	  at	  4°C).	  	  Plates	   were	   washed	   as	   previously	   described	   followed	   by	   the	   addition	   of	  100μl	  of	  either	  control	  or	  unknown	  protein	  samples	  to	  specified	  wells	  and	  incubated	  for	  2	  hrs	  at	  room	  temperature	  with	  mixing.	  	  Plates	  were	  washed	   again	   as	   previously	   described	   and	   100μl	   of	   detection	  antibody	   (BVD11-­‐37G10)	   at	   2μg/ml	   in	   LKC	   buffer	   was	   then	   added	   to	   all	  wells	  followed	  by	  incubation	  for	  2	  hrs	  at	  room	  temperature	  with	  mixing.	  Plates	  were	   again	  washed	   as	   described	   followed	   by	   the	   addition	   of	   100μl	  streptavidin-­‐HRP	   at	   1μg/ml	  made	   up	   in	   0.5%	  BSA/PBS-­‐T	   to	   all	   wells	   and	  incubated	   at	   room	   temperature	   for	   30	   minutes	   with	   mixing.	   Plates	   were	  finally	   washed	   6x	   with	   230μl	   PBS-­‐T	   before	   the	   addition	   of	   100μl	   TMB	  (3,3’5,5’-­‐tetramethylbenzide	   liquid	   substrate)	   to	   all	   wells.	   Once	   a	   good	  colour	  change	  was	  observed,	  100μl	  of	  5%	  sulphuric	  acid	  (H2SO4)	  was	  added	  to	   all	   wells	   to	   stop	   the	   reaction.	   The	   plates	   were	   read	   at	   450nm	   with	  background	  plate	  correction	  at	  630nm	  using	  a	  Biotech	  FLX800	  plate	  reader	  and	   Gen5	   software.	   Results	   were	   analysed	   using	   Microsoft	   Excel	   and	  GraphPad	  Prism	  6	  used	  for	  curve	  fit	  analysis.	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 AML-­‐193	  Proliferation	  Assay	  3.8.5The	  biological	  activities	  of	  rhGCSF	  and	  GCSF	  tandems	  were	  evaluated	  using	  an	  AML-­‐193	  cell-­‐based	  proliferation	  assay	  (Human	  acute	  myeloid	  leukemic	  cell	   line).	   GCSF	   stimulates	   the	   proliferation	   of	   the	   AML-­‐193	   cell	   line.	   The	  main	   objective	   of	   this	   method	   was	   to	   show	   that	   GCSF	   tandems	   could	  stimulate	   the	   proliferation	   of	   AML-­‐193	   cells	   in	   comparison	   to	   rhGCSF.	  	  Details	   of	   this	   assay	   method	   and	   associated	   cell	   culture	   development	   are	  provided	  below.	  
 Growth	  of	  the	  AML-­‐193	  Cell	  Line	  3.8.5.1Cells	  (ATCC,	  Batch	  No.	  3475266)	  were	  removed	  from	  liquid	  nitrogen	  storage	  and	  defrosted	  by	  placing	  into	  a	  37°C	  water	  bath	  for	  2	  minutes.	  The	  contents	  of	   the	  vial	  were	  then	  transferred	  to	  a	  T-­‐25	  flask	  containing	  4	  ml	  of	  culture	  medium	   (5%	   FBS,	   4mM	   L-­‐glutamine,	   100	   U/ml	   penicillin,	   100	   µg/ml	  streptomycin,	   5	  µg/ml	   transferrin,	   5	  µg/ml	   insulin	   and	  5	  ng/ml	  GM-­‐CSF	   in	  Iscove’s	   modified	   Dulbecco’s	   medium).	   The	   AML-­‐193	   cells	   were	   routinely	  cultured	  to	  a	  density	  of	  2	  x106	  cells/ml	  but	  not	  exceeding	  2.5	  x	  106	  cells/ml	  	  	  (5%	  CO2,	  37°C).	  Passages	  were	  performed	  2	   times	  a	  week	  and	  cell	  density	  and	  viability	  was	  assessed	  by	  trypan	  blue	  exclusion	  as	  previously	  described	  at	  section	  3.5.2.	  	  
 AML-­‐193	  Bioassay	  3.8.5.2After	  a	  minimum	  of	  two	  passages,	  the	  AML-­‐193	  cells	  were	  ready	  for	  use	  in	  the	  bioassay.	  The	  cells	  were	  prepared	  for	  the	  assay	  by	  washing	  3	  times	  with	  10ml	  PBS	  and	  the	  washed	  cells	  were	  recovered	  by	  centrifuging	  at	  168	  x	  g	  for	  5	  minutes.	  The	  final	  cell	  pellet	  was	  then	  reconstituted	  in	  the	  assay	  medium	  (5%	   FBS,	   4mM	   L-­‐glutamine,	   100	  U/ml	   penicillin,	   100	  µg/ml	   streptomycin,	  5	  µg/ml	   insulin,	   5	  µg/ml	   transferrin	   in	   Iscove’s	   modified	   Dulbecco’s	  medium)	  and	  cell	  density	  adjusted	  to	  0.5	  x	  106	  cells/ml.	  	  A	   commercial	   GCSF	  was	   used	   to	   generate	   a	   standard	   curve	   for	   the	   assay.	  0.2mg/ml	  rhGCSF	  (Biolegend)	  was	  reconstituted	  in	  PBS	  and	  1%	  (w/v)	  BSA	  to	   a	   concentration	   of	   10	   µg/ml	   (500nM	   stock),	   divided	   into	   10	  µl	   aliquots	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and	   stored	   at	   -­‐80°C.	   On	   each	   day	   of	   assay	   1	   vial	   was	   removed	   from	   the	  frozen	  stock	  and	  a	  standard	  curve	  ranging	  from	  0nM	  to	  5nM	  was	  generated	  as	   shown	   in	   Table	   3.10.	   Similar	   standard	   curves	   were	   generated	   for	   the	  GCSF	  tandems	  (test	  proteins	  and	  controls)	  from	  purified	  proteins	  by	  diluting	  each	  individual	  stock	  concentrations	  to	  a	  starting	  concentration	  of	  10nM.	  
Table	  3-­‐10:	  Preparation	  of	  GCSF	  standard	  curve	  
Sample	  (μl)	   Assay	  media	  (μl)	   [GCSF]	  nM	   Dilution	  
5ul	  of	  Stock	  @	  500nM	   495	   5	   100x	  220	  of	  5nM	   220	   2.5	   2x	  200	  of	  2.5nM	   300	   1	   2.5x	  250	  of	  1nM	   250	   0.5	   2x	  250	  of	  0.5nM	   250	   0.25	   2x	  250	  of	  0.25nM	   250	   0.125	   2x	  250	  of	  125nM	   250	   0.06	   2x	  250	  of	  0.06nM	   250	   0.03	   2x	  250	  of	  0.03nM	   250	   0.015	   2x	  250	  of	  0.015nM	   250	   0.008	   2x	  150	  of	  0.008nM	   300	   0.003	   3x	  150	  of	  0.003nM	   300	   0.0015	   3x	  150	  of	  0.015nM	   300	   0.0008	   3x	  	  50µl	  of	  each	  test	  protein	  was	  added	  to	  the	  wells	  of	  a	  96-­‐well	  microplate	  in	  triplicate.	   50µl	   of	   AML-­‐193	   cells	   at	   0.5	   x	   106	  cells/ml	  were	   then	   added	   to	  each	   well	   with	   gentle	   agitation	   to	   mix	   the	   contents	   (i.e.	   cells	   suspension,	  standard	  and	  samples).	  	  Control	  wells,	  which	  contained	  only	  assay	  medium	  and	   cells	   suspension	   (50µl	  +	  50µl),	   and	  blank	  wells,	  which	   contained	  only	  assay	  medium	  (100µl)	  were	  also	  set	  up.	  	  For	  3	  days,	  AML-­‐193	  cells	  were	  exposed	   to	   the	  different	  concentrations	  of	  test	   proteins	   in	   a	   CO2	   incubator	   (5%	   CO2,	   37°C)	   and	   then	   20µl	   of	   MTS	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(Celltiter	  96	  Aqueous	  One	  Solution	  from	  Promega)	  was	  added	  to	  each	  well.	  	  Readings	  were	   taken	   every	   40	  minutes	   at	   490nm	  using	   a	   Biotech	   FLX800	  plate	  reader	  for	  a	  total	  of	  2	  hrs.	  The	  results	  were	  displayed	  using	  Microsoft	  Excel	   and	   analysed	   with	   Gen5	   software.	   GraphPad	   Prism	   6	   was	   used	   for	  curve	  fit	  analysis.	  
 Short	  Term	  Stability	  of	  GCSF	  Tandem	  Molecules	  	  3.8.6The	  protein	  stability	  was	  assessed	  by	  testing	  purified	  samples	  at	  3	  different	  temperatures	  (4°C,	  RmT	  and	  -­‐80°C	  freeze	  thaw	  (F/T)	  cycles)	  over	  an	  8	  day	  period.	  	  Purified	  tandem	  proteins	  were	  taken	  from	  the	  -­‐80°C	  and	  diluted	  to	  0.8	  mg/ml	  with	   filter	   sterile	   PBS	   and	   kept	   on	   ice.	   All	  manipulations	  were	  carried	  out	  under	  sterile	  conditions.	  Aliquots	  of	  protein	  at	  0.8	  mg/ml	  were	  placed	  at	  RmT,	  4°C	  or	  -­‐80°C	  in	  sterile	  1.5	  ml	  eppendorf	  tubes.	  	  Samples	  were	  taken	  on	  days	  0,	  1,	  4	  and	  8	  (samples	  taken	  on	  day	  zero,	  represent	  untreated	  sample	   controls)	   and	   immediately	   diluted	   with	   an	   equal	   volume	   of	   SDS-­‐PAGE	   buffer	   to	   0.4	   mg/ml	   (Laemmlli	   buffer)	   and	   heated	   at	   95°C	   for	   5	  minutes	  to	  denature.	  Samples	  were	  analysed	  by	  10%	  SDS-­‐PAGE	  and	  protein	  bands	  visualised	  by	  coomassie	  staining	  (A	  total	  of	  7.5µg	  protein	  was	  loaded	  per	   lane)	   and	   western	   blotting	   (a	   total	   of	   100ng	   protein	   was	   loaded	   per	  lane).	  
 Experimental	  Procedure	  for	  In	  vivo	  Study	  3.9The	   aim	   of	   this	   protocol	   was	   to	   determine	   the	   pharmacokinetic	   (PK)	   and	  pharmacodynamics	   (PD)	   properties	   of	   rhGCSF	   and	   GCSF	   tandems	  (GCSF2NAT,	   4NAT,	   8NAT	   &	   8QAT)	   in	   Sprague	   Dawley	   rats	   following	  intravenous	  injection	  and	  look	  at	  the	  effects	  of	  these	  constructs	  on	  the	  WBCs	  and	  neutrophils	  population.	  Pre-­‐Dose	   (-­‐24	  hr)	   samples	  of	  300-­‐400µl	  of	  blood	   sample	  were	   taken	   from	  each	   rat	   before	   injection	  with	   test	   protein.	   These	   served	   as	   control	   blood	  samples.	   Next	   day,	   groups	   of	   six	   male	   rats	   were	   administered	   a	   single	  intravenous	  dose	  of	   rhGCSF,	  GCSF	   tandem,	  or	   vehicle	   (PBS	  only)	   at	   250µg	  per	  /kg	  protein.	  At	  the	  following	  time	  points	  of	  0.5,	  1,	  2,	  4,	  8,	  12,	  24,	  48	  &	  72	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hrs	  post=injection,	  ~300-­‐400µl	  of	  blood	  samples	  were	  collected	   from	  each	  rat	   from	   the	   tail	   vein	   under	   anaesthesia	   using	   isoflurane.	   Blood	   samples	  were	   centrifuged	   (for	   serum	   preparation),	   labelled	   and	   stored	   at	   -­‐80°C.	  Counts	  of	  blood	  cells	  (CBCs)	  were	  performed	  on	  selected	  samples	  (-­‐24,	  12,	  24,	  48	  and	  72	  hrs)	  using	  an	  automated	  coulter	  counter.	  Blood	  smears	  were	  fixed	   and	   stained	   by	   a	   routine	   laboratory	   method	   (H&E	   or	   Giemsa).	  Thereafter,	   all	   samples	   for	   analysis	   were	   transferred	   to	   the	   University	   of	  Sheffield	   for	   data	   confirmation	   and	   further	   analyses.	   Elisa	   was	   used	   to	  measure	  the	  concentration	  of	  proteins	  in	  each	  serum	  sample	  at	  0.5,	  1,	  2,	  4,	  8,	  12,	  24,	  48,	  72	  hrs	  post-­‐dose.	  	  
 Ethics	  3.9.1All	  animal	  experiments	  were	  approved	  by	  the	  local	  ethical	  committee	  of	  the	  University	  of	  Isfahan.	  
 	  Statistical	  Analysis	  	  3.10
In	  vitro	  analyses	  of	  all	  purified	  GCSF	  tandems	  were	  performed	  on	  GraphPad	  Prism	  6	  using	  a	  Mann-­‐Whitney	  test	  (a	  non-­‐parametric	  test	  that	  is	  often	  used	  to	  compare	  two	  groups	  that	  come	  from	  the	  same	  population).	  The	  statistical	  comparison	  of	  the	  tandem	  proteins	   in	  rat	  plasma	  for	  the	  pharmacokinetics	  study	   data	   were	   analysed	   using	   the	   non-­‐compartmental	   method	   of	   data	  analysis.	  This	   involved	  the	  use	  of	  Winnonlin	  6.3	  PK	  program	  developed	  by	  Phoenix	   Certara.	   Significance	   between	   terminal	   half-­‐life	   data	   of	   GCSF	  tandems	   was	   performed	   with	   GraphPad	   Prism	   6	   using	   one-­‐way	   ANOVA	  (used	   to	   determine	   any	   significant	   differences	   between	   three	   or	   more	  groups	   of	   sample	   data).	   The	   pharmacodynamics	   studies	   of	   the	   GCSF	  tandems	  at	  selected	  sampling	  time	  points	  (-­‐24,	  12,	  24,	  48	  and	  72	  hrs)	  were	  analysed	  with	  GraphPad	  Prism	  6	  using	  multiple	  T-­‐test.	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 Results	  1:	  Cloning	  and	  Expression	  of	  GCSF	  Tandems	  	  4.








 Introduction	  4.2In	   medicine,	   any	   protein	   used	   for	   therapeutic	   purposes	   is	   not	   only	   a	  sequence	  of	   amino	  acids	  determined	  by	  a	  particular	  gene,	  but	   still	   require	  editing,	   altering	   of	   amino	   acids	   or	   addition	   of	   sugars.	   These	  modifications	  following	   the	   preliminary	   translation	   of	   the	   protein	   are	   called	   post-­‐translational	  processes	   (Li	  and	  d'Anjou,	  2009).	   	  Glycosylation	  refers	   to	   the	  post-­‐translational	   process	   that	   covalently	   linking	   oligosaccharide	   to	  polypeptides.	  It	  is	  one	  of	  the	  most	  common	  protein	  modifications	  and	  more	  than	   50%	   of	   proteins	   are	   glycosylated	   in	   the	   body,	   which	   are	   mainly	  secreted	  or	  part	  of	  cell	  membrane	  components	  (Sola	  et	  al.,	  2007).	  Normally,	  the	   attachment	   reaction	   of	   glycans	   to	   a	   protein	   begins	   in	   the	   endoplasmic	  reticulum	   (ER)	   and	   is	   completed	   in	   the	   Golgi	   apparatus.	   The	   two	   major	  forms	   are	   O-­‐linked	   glycosylation	   and	   N-­‐linked	   glycosylation	   (Saint-­‐Jore-­‐Dupas	  et	  al.,	  2007).	  	  	  N-­‐linked	  glycosylation	  is	  attached	  to	  the	  amide	  nitrogen	  of	  asparagine	  (Asn)	  residues	   within	   the	   common	   consensus	   sequence	   Asn-­‐X-­‐Ser/Thr	   where	   X	  can	  be	  any	  amino	  acid	  except	  proline	  (Pro)	  (Kornfeld	  and	  Kornfeld,	  1985).	  	  No	   particular	   consensus	   sequences	   are	   recognized	   for	   O-­‐linked	  glycosylation.	   Thus,	   N-­‐linked	   glycosylation	   is	   preferentially	   used	   in	   many	  technologies	  of	  protein	  modification	  (Spiro,	  2002).	  Asterion	   have	   designed	   different	   strategies	   of	   protein	   fusion	   technologies	  with	  a	  view	  to	  generating	  longer	  acting	  therapies.	  One	  such	  strategy	  is	  based	  upon	   tandem	  proteins	   linked	   a	   via	   flexible	   linker	   (Gly4Ser)n	   that	   has	   been	  designed	  to	  contain	  N-­‐linked	  glycosylation	  motifs	   (glycosylation	  consensus	  sequences).	   It	   has	   been	   hypothesized	   that	   inserted	   glycosylation	   motifs	  within	   the	   linker	   region	   rather	   than	   the	   ligand	   would	   be	   recognized	   by	  mammalian	   cells	   for	   glycosylation.	   This	   would	   result	   in	   an	   increased	  molecular	   weight	   without	   interfering	   with	   the	   biological	   activity	   of	   the	  ligand.	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The	   Linker	   region	   was	   designed	   to	   incorporate	   2,	   4	   and	   8	   glycosylation	  motifs	   (Asn-­‐Ala-­‐Thr	   (NAT))	   and	   their	   respective	   controls	   in	   which	  Glutamine	  (or	  Q)	  replaces	  N	  in	  NAT	  sequence	  motif	  to	  produce	  QAT	  which	  would	  not	  be	  recognized	  by	  mammalian	  cells	   for	  glycosylation.	  Up	  to	  eight	  glycosylation	   sites	   were	   introduced	   to	   assess	   whether	   more	   efficient	  glycosylation	   could	   increase	   the	  molecular	  weight	   and	   subsequently	   delay	  renal	  clearance.	  	  The	   table	   below	   summarizes	   all	   GCSF	   tandem	   structures	   and	   their	  respective	   controls	   (Table	   4.1).	   A	   full	   description	   of	   the	   amino	   acid	  sequences	  of	  these	  tandems	  can	  be	  seen	  in	  Appendix	  A.2.	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Table	   4-­‐1:	   The	   structure	   of	   GCSF	   tandems	   with	   modified	   flexible	  
linkers	  (Gly4Ser)n	  The	   glycosylation	   consensus	   sequences	   are	   highlighted	   in	   red	   (NAT:	   Asn-­‐Ala-­‐Thr).	   The	   control	   non-­‐glycosylation	   consensus	   sequences	   are	  highlighted	   in	   blue	   (QAT:	   Gln-­‐Ala-­‐Thr).	   The	   linkers	   are	   built	   around	   a	  flexible	   glycine-­‐serine	   (Gly4Ser)n	   sequence	   (these	   linkers	   were	   gene	  synthesised	   by	   Eurofins	   MWG).	   Each	   tandem	   contains	   a	   C-­‐terminal	   6	   x	  Histidine	  tag	  (Used	  to	  aid	  purification	  using	  IMAC).	  	  




Summary	  of	  sequence	  
pSecTagGCSF2NAT_Hist	   2	  x	  NAT	   147bp	   GCSF-­‐G4S-­‐	  G2NAT-­‐	  G4S-­‐G4S-­‐G4S-­‐G4S-­‐G2NAT-­‐G4S-­‐GS-­‐GCSFx6H	  
pSecTagGCSF2QAT_Hist	   2	  x	  QAT	   147bp	   GCSF-­‐G4S-­‐	  G2QAT-­‐	  G4S-­‐G4S-­‐G4S-­‐G4S-­‐G2QAT-­‐G4S-­‐GS-­‐GCSFx6H	  
pSecTagGCSF4NAT_Hist	   4	  x	  NAT	   147bp	   GCSF-­‐G4S-­‐	  G2NAT-­‐	  G4S-­‐G2-­‐NAT-­‐G4S-­‐G2-­‐	  NAT-­‐G4S-­‐G2NAT-­‐G4S-­‐GS-­‐GCSFx6H	  
pSecTagGCSF4QAT_Hist	   4	  x	  QAT	   147bp	   GCSF-­‐G4S-­‐	  G2QAT-­‐	  G4S-­‐G2-­‐QAT-­‐G4S-­‐G2-­‐QAT-­‐G4S-­‐G2QAT-­‐G4S-­‐GS-­‐GCSFx6H	  
pSecTagGCSF8NAT_Hist	   8	  x	  NAT	   282bp	   GCSF-­‐G4S-­‐	  G2-­‐NAT-­‐	  G4S-­‐G2-­‐NAT-­‐G4S-­‐G2-­‐	  NAT-­‐G4S-­‐G2NAT-­‐	  G4S-­‐	  G2-­‐NAT-­‐	  G4S-­‐G2-­‐NAT-­‐G4S-­‐G2-­‐	  NAT-­‐G4S-­‐G2NAT-­‐G4S-­‐GS-­‐GCSFx6H	  









 Aim	  and	  Hypotheses	  4.2.1As	   mentioned	   previously,	   proteins	   have	   been	   directly	   modified	   by	  increasing	   the	   glycosylation	   on	   the	   proteins	   (Elliott	   et	   al.,	   2003),	   and	   this	  could	   potentially	   affect	   protein	   bioactivity	   and	   increase	   immunogenicity.	  	  Previously	   a	   tandem	   of	   two	   GH	   molecules	   joined	   by	   a	   flexible	   (Gly4Ser)n	  peptide	  linker	  containing	  variable	  numbers	  of	  glycosylation	  motifs	  from	  2	  to	  8	  was	  created.	  	  This	  method	  avoided	  altering	  or	  modifying	  the	  protein	  itself	  directly.	   	   These	   molecules	   were	   shown	   to	   be	   glycosylated	   with	   increased	  MW	  and	  were	  biologically	  active.	   In	   this	  chapter,	   the	  aim	   is	   to	  replace	   two	  GH	   ligands	   in	  a	   tandem	  with	   two	  GCSF	   ligands.	  The	   initial	   stage	  will	  be	   to	  construct	   a	   tandem	  molecule	   containing	   two	   GCSF	   ligands	   using	   PCR	   and	  then	   ligate	   in	   relevant	   linker	   regions.	   	   As	   GCSF	   is	   known	   to	   bind	   to	   its	  receptor	   at	   2:2	   stoichiometry,	   we	   hypothesized	   that	   the	   resulting	   tandem	  GCSF	   molecule	   will	   be	   available	   to	   bind	   to	   the	   two	   GCSF-­‐receptors	   and	  induce	  downstream	  signal	  transduction.	  
 Objectives	  4.2.21-­‐ Construct	   a	   tandem	  molecule	   containing	   two	   ligands	   of	   GCSF	   using	  PCR.	  2-­‐ Insert	  variable	  linkers	  between	  a	  tandem	  GCSF	  molecule	  that	  contain	  increasing	   numbers	   of	   glycosylation	   motifs	   and	   control	   non-­‐glycosylation	  motifs.	  3-­‐ Express	  and	  analyse	  GCSF	  tandems	  from	  a	  mammalian	  cell	  line.	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 Construction	  of	  GCSF	  Tandems	  	  4.3To	   initially	   construct	   the	  GSCF	   tandem	  a	   template	   plasmid	  was	  used.	   This	  plasmid	   contained	   a	   tandem	   GH	  molecule	   linked	   via	   a	   glycosylated	   linker	  containing	  2	  x	  NAT	  motifs	  and	  was	  available	   in	   the	  Ross	  group	   laboratory.	  The	   method	   employed	   will	   be	   to	   replace	   each	   GH	   molecule	   with	   a	   GCSF	  molecule	  and	  thus	  produce	  a	  GCSF	  tandem	  containing	  2	  x	  NAT	  motifs	  with	  a	  GCSF	  secretion	  signal.	  Once	  constructed,	  it	  will	  be	  a	  simple	  matter	  to	  replace	  the	   linker	   region	   in	   the	   GCSF	   tandem	   using	   the	   restriction	   enzymes	  XhoI/BamH1	  with	   other	   suitable	   linkers	   containing	   either	   NAT	   or	   control	  QAT	   motifs	   (Figure	   4.1).	   A	   full	   protein	   sequence	   of	   GH,	   GCSF	   and	   linker	  region	  constructs	  in	  Appendix	  B.	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Figure	   4-­‐1:	   The	   diagram	   summarizes	   the	   process	   of	   producing	   GCSF	  
tandems	  containing	  variable	  linkers	  
	  [A]	   Both	   GCSF-­‐L1	   and	   L2	   (highlighted	   in	   green)	   containing	   restriction	  enzyme	  sites	  (highlighted	  in	  yellow)	  were	  PCRed	  from	  pGCSFSecTag4A1.	  [B]	  Both	   GH	   molecules	   (highlighted	   in	   green)	   are	   removed	   from	  pSecTagGH2NAT	  plasmid	  and	   replaced	  with	   the	  GCSF	   (GCSF	  L1	  &	  L2).	   [C]	  The	   original	   (Gly4Ser)n	   linker	   (highlighted	   in	   orange)	   is	   replaced	   with	  variable	  glycosylated	  and	  non-­‐glycosylated	   linkers.	  The	  plasmid	  contains	  a	  CMV	   promoter	   region	   (highlighted	   in	   white),	   GCSF	   signal	   sequence	  (highlighted	   in	   blue),	   6x	   Hist	   tag	   (highlighted	   in	   pink)	   and	   a	   stop	   codon	  (highlighted	   in	   pink).	   A	   full	   diagram	   of	   the	   plasmid	   used	   in	   this	   study	   is	  provided	  in	  Appendix	  C.	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 Construction	  of	  pSecTag	  GCSF-­‐L1_Hist	  4.3.1The	   first	   full-­‐length	   nucleotide	   sequence	   of	   GCSF	   with	   signal	   sequence	  (GCSF-­‐L1)	   was	   PCRed	   from	   the	   template	   plasmid	   pSecTagGCSF4A1	   (See	  Table	   4.2	   and	   Figure	   4.1.A	   for	   description)	   using	   a	   forward	   primer	   (GCSF	  Nhe1)	   and	   reverse	  primer	   (GCSF	  XhoI	  Rev)	   (See	   full	   nucleotide	   sequences	  for	   both	   primers	   in	   Appendix	   A.1)	   and	   digested	  with	   restriction	   enzymes	  NheI/XhoI.	   This	   produced	   a	   full-­‐length	   GCSF	   molecule,	   GCSF-­‐L1	   (612bp)	  containing	  the	  signal	  sequence	  of	  GCSF	  with	  a	  5	  prime	  NheI	  site	  along	  with	  a	  3	  prime	  XhoI	  restriction	  site	  (Figure	  4.2).	  	  	  
Table	  4-­‐2:	  	  Description	  of	  the	  two	  plasmids	  that	  were	  used	  to	  produce	  
psecTagGCSF2NAT_Hist	  
Construct	  name	   N-­‐terminal	  
domain	  
Linker	   C-­‐terminal	  
domain	  
Expression	  
vector	  GCSF4A1	   GCSF	   (Gly4Ser)x6	   GCSF-­‐R	   pSecTag	  GH2NAT_Hist	   GH	   (Gly4Ser)n	  with	  2	  glycosylated	  motifs	   GH	   pSecTag	  
 
 The	   pSecTagGH2NAT_Hist	   was	   digested	   with	   double	   restriction	   enzymes	  Nhe1/Xho1	   to	   remove	   GH	   Ligand	   1	   (GH-­‐L1).	   Single	   enzyme	   digests	   were	  used	  to	  confirm	  enzyme	  activity	  (Figure	  4.3).	  Thereafter	   GCSF-­‐L1	  was	   ligated	   into	   pSecTagGH2NAT_Hist	   to	   produce	   the	  plasmid	  pSecTagGCSF2NAT_Hist-­‐L1	  (This	  contains	  GCSF-­‐L1	  and	  GH-­‐L2	  with	  a	  linker	  region	  containing	  2	  x	  NAT	  glycosylation	  sites).	  The	  ligation	  reaction	  was	  performed	  as	  described	  at	  section	  3.4.4.	  	  To	   confirm	   the	   construction	   of	   pSecTagGCSF2NAT_Hist-­‐L1,	   plasmid	   mini	  preparations	  were	  digested	  using	  Nhe1/Xho1	  to	  generate	  a	  GCSF-­‐L1	  0.6kb	  insert	  (Figure	  4.4).	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Figure	  4-­‐2:	  	  PCR	  of	  GCSF-­‐L1	  PCR	   of	   GCSF-­‐L1	   (DNA)	   using	   forward	   primer	   (GCSF	   Nhe1)	   and	   reverse	  primer	   (GCSF	   XhoI	   Rev)	   run	   on	   1%	   agarose	   gel	   alongside	   1kb	   ladder	   as	  standard.	  	  	  The	   presence	   of	   GCSF-­‐L1	   at	   (~0.6kb)	  which	   is	   the	   expected	   size	   indicates	  that	  PCR	  has	  been	  successful.	  	  	  	  
Lane	  1:	  PCR	  GCSF-­‐L1	  (~0.6kb).	  	  
Lane	  M:	  1kb	  DNA	  Ladder:	  Molecular	  weight	  marker:	   Bands	   starting	   at	   the	   bottom	   (0.5,	  1.0,	  1.5,	  2.0,	  3.0,	  4.0,	  5.0,	  6.0,	  8.0,	  10.0	  Kb).	  	  
Lane	  2:	  Negative	  control	  (primers	  only).	  




Figure	  4-­‐3:	  Double	  digest	  of	  pSecTagGH2NAT_Hist	  Double	   digest	   of	   pGH2NAT_Hist	   using	   NheI	   and	   XhoI	   separated	   on	   1%	  agarose	  gel	  electrophoresis.	  	  The	  presence	  of	  an	  insert	  at	  ~0.6kb	  in	  lane	  1	  indicates	  a	  successful	  double	  digest.	   	  A	  single	  band	   is	  observed	   in	  both	   lanes	  2	  and	  3,	  which	  shows	   that	  plasmids	   used	   in	   the	   digestion	   reaction	   were	   cut	   by	   the	   individual	  restriction	   enzyme.	   	   The	   double	   digested	   plasmid	   runs	   at	   a	   slightly	   lower	  molecular	  weight	  compared	  to	  the	  single	  digested	  plasmids,	  which	  is	  due	  to	  the	  excision	  of	  the	  GH-­‐L1	  from	  the	  starting	  plasmid	  pSecTagGH2NAT_Hist.	  GCSF-­‐L1	  was	  then	  ligated	  into	  pSecTagGH2NAT_Hist	  to	  produce	  the	  plasmid	  pSecTagGCSF2NAT_Hist-­‐L1.	  This	  contains	  GCSF-­‐L1	  and	  GH-­‐L2	  with	  a	  linker	  region	  containing	  2	  x	  NAT	  glycosylation	  sites.	  For	  potential	  plasmid	  clones	  were	  generated	  from	  the	  ligation	  plate	  colonies	  and	  were	  analysed	  by	  both	  double	  digestion	  with	  NheI/XhoI	  (see	  Figure	  4.4)	  and	  DNA	  sequencing.	  	  	  
Lane	   1:	   The	   upper	   band	   represents	   the	  pSecTagGH2NAT_Hist	  (cut	  plasmid),	  lower	  band	  (~0.6kb)	  represents	  GH-­‐L1	  insert	  as	  a	  result	  of	  a	   successful	   double	   digest	   by	   both	   restriction	  enzymes. 
  
Lane	  2:	  NheI	  digest	  of	  pSecTagGH2NAT_Hist. 
  
Lane	  3:	  XhoI	  digest	  of	  pSecTagGH2NAT_Hist.	   
  
Lane	  M:	  1kb	  Ladder:	  Molecular	  weight	  marker:	  Bands	   starting	  at	   the	   bottom	   (0.5,	  1.0,	   1.5,	  2.0,	  3.0,	  4.0,	  5.0,	  6.0,	  8.0,	  10.0	  Kb). 
1	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  	  	  	  	  	  	  	  	  	  	  	  3	  	  	  	  	  	  	  	  	  
M	   




Figure	   4-­‐4:	   Double	   digest	   of	   pSecTagGCSF2NAT_Hist-­‐L1	   potential	  





Lane	   1,	   2	   &	   3:	   The	  upper	   band	   represents	  the	  cut	  plasmid	  and	  the	  small	  fragment	  band	  represents	   the	  GCSF-­‐L1	   (~0.6kb)	   as	   a	   result	  of	   a	   successful	   double	   digests	   by	   both	  NheI/XhoI	  restriction	  enzymes.	  
 
Lane	  4:	  Unsuccessful	  digest.	  
 
Lane	   M:	   1kb	   Ladder:	   Molecular	   weight	  marker:	   Bands	   starting	   at	   the	   bottom	   (0.5,	  1.0,	  1.5,	  2.0,	  3.0,	  4.0,	  5.0,	  6.0,	  8.0,	  10.0	  Kb).	   
 	  
1	  	  	  	  	  	  	  	  	  	  2	  	  	  	  	  	  	  	  	  	  3	  	  	  	  	  	  	  	  4	  	  	  	  	  	  	  M	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 Construction	  of	  pSecTagGCSF-­‐L2_Hist	  	  4.3.2The	  second	   full-­‐length	  nucleotide	  sequence	  of	  GCSF-­‐L2	  was	  PCRed	  using	  a	  forward	   primer	   (GCSF	   BamH1)	   and	   reverse	   primer	   (GCSF	   Age1	   Rev)	  (Appendix	   A.1)	   from	   the	   template	   plasmid	   pSecTagGCSF4A1	   and	   digested	  with	  BamHI/AgeI.	  This	  produced	  a	  full	  length	  GCSF	  molecule	  containing	  a	  5	  prime	  BamHI	   site	   along	  with	   a	   3	   prime	  AgeI	   site	   (present	   in	   plasmid	   just	  prior	   to	   the	   Hist	   tag)	   (Figure	   4.5.).	   	   The	   PCR	   fragment	  was	   then	   digested	  with	  BamH1/Age1	  and	  gel	  isolated.	  	  pSecTagGCSF2NAT_Hist-­‐L1	   was	   then	   digested	   with	   restriction	   enzymes	  BamHI/AgeI	  to	  remove	  GH-­‐L2	  and	  the	  digested	  plasmid	  gel	  isolated.	  Single	  enzyme	   digests	   were	   used	   to	   confirm	   enzyme	   activity	   (Figure	   4.6).	  Thereafter	  GCSF-­‐L2	  was	  ligated	  into	  pSecTagGCSF2NAT_Hist-­‐L1	  to	  form	  the	  new	  plasmid,	  pSecTagGCSF2NAT_Hist.	  This	  contains	  a	  GCSF	  tandem	  with	  a	  linker	  region	  containing	  2	  x	  NAT	  glycosylation	  sites	  (refer	  to	  Figure	  4.1.B).	  To	  confirm	  the	  authenticity	  of	  the	  new	  construct,	  plasmid	  mini	  preparations	  were	   digested	   using	   BamHI/AgeI	   to	   visualise	   the	   GCSF-­‐L2	   insert	   (Figure	  4.7).	  	  During	  sequencing,	  it	  was	  difficult	  to	  read	  the	  whole	  gene	  for	  tandem	  GCSF	  (i.e.	  GCSFL1-­‐linker-­‐GCSF-­‐L2)	  using	  CMVF	  due	  to	  the	  presence	  of	  GCSF-­‐L1	  in	  the	   same	   plasmid.	   Therefore	   we	   decided	   to	   follow	   the	   protocol	   below	   to	  remove	  GCSF-­‐L2	   using	  BamHI/AgeI	   (Figure	   4.8)	   and	   ligate	   to	   the	   plasmid	  pSecTag_link	  to	  form	  pSecTag_link_GCSF-­‐L2	  (Figure	  4.9).	  Using	  this	  method	  the	  GCSF_L2	  insert	  was	  successfully	  sequenced	  using	  CMVF.	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Figure	  4-­‐5:	  Generation	  of	  PCR	  fragment	  GCSF-­‐L2	  Generation	   of	   PCR	   fragment	   using	   a	   forward	   primer	   (GCSF	   BmaH1)	   and	  reverse	  primer	  (GCSF	  Age1	  Rev)	  separated	  on	  a	  1%	  agarose	  gel.	  	  The	  result	   in	   lane	  1	  shows	  that	  GCSF-­‐L2	  is	  at	   the	  expected	  size	  of	  ~	  0.6kb,	  indicating	  a	  successful	  PCR.	  	  	  	  	  	  	  	  	  
1	  	  	  	  	  	  	  	  	  	  M	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2 Lane	  1:	  PCR	  of	  GCSF-­‐L2	  (~0.6kb). 	   
Lane	   M:	   1kb	   DNA	   Ladder:	   Molecular	  weight	   marker:	   Bands	   starting	   at	   the	  bottom	  (0.5,	  1.0,	  1.5,	  2.0,	  3.0,	  4.0,	  5.0,	  6.0,	  8.0,	  10.0	  Kb). 	   
Lane	  2:	  Negative	  control	  (primers	  only). 
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Lane	   1:	   The	   upper	   band	   represents	   the	  pSecTagGCSF2NAT_Hist_L1	   (cut	  plasmid)	   lower	  band	  (~0.6kb)	  represents	  GH-­‐L2	  insert	  (~0.6kb)	  as	  a	  result	  of	  a	  successful	  double	  digest.	  	  	  
Lane2:	  BamHI	  digest	  of	  pSecTagGCSF2NAT_Hist_L1.	  	  
	  
Lane3:	  AgeI	  digest	  of	  pSecTagGCSF2NAT_Hist_L1.	  Age1.	  	  	  
Lane	  M:	  1kb	  Ladder.	  Molecular	  weight	  marker:	  Bands	  starting	  at	   the	   bottom	  (0.5,	   1.0,	  1.5,	   2.0,	   3.0,	  4.0,	   5.0,	  6.0,	  8.0,	  10.0Kb).	  
1	  	  	  	  	  	  	  	  	  	  	  	  	  2	  	  	  	  	  	  	  	  	  	  	  3	  	  	  	  	  	  	  	  	  	  	  	  M	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Figure	  4-­‐7:	  Double	  digest	  of	  pSecTagGCSF2NAT_Hist	  potential	  clones	  Double	   digest	   of	   pSecTagGCSF2NAT_Hist	   using	   BamHI/AgeI	   separated	   on	  1%	  agarose	  gel	  electrophoresis.	  
	  The	  presence	  of	   an	   insert	   at	  ~0.6kb	   in	   lanes	  2,	  3	   and	  4	   indicates a positive 
ligation.	  Unsuccessful	  digest	  observed	  at	  lane	  1	  probably	  due	  to	  missing	  one	  or	  both	  BamHI/AgeI	  restriction	  enzymes	  or that this clone has no insert.	  The	  three	  positive	  clones	  take	  forward	  for	  sequencing.	  	  	  	  	  	  
Lane	  1:	  Unsuccessful	  digest.	  	  
Lane	  2,	  3	  &	  4:	  The	  upper	  band	  represents	  the	  pSecTagGCSF2NAT_Hist	   cut	   plasmid	   and	   the	  below	   small	   fragment	   band	   represents	   the	  GCSF-­‐L2	   (~0.6kb)	   as	   a	   results	   of	   a	   successful	  double	  digests	  by	  both	  BamHI/AgeI	  restriction	  enzymes.	  	  	  Lane	   M:	   1kb	   Ladder:	   Molecular	   weight	  marker:	  Bands	   starting	  at	   the	  bottom	  (0.5,	  1.0,	  1.5,	  2.0,	  3.0,	  4.0,	  5.0,	  6.0,	  8.0,	  10.0	  Kb).	  	  
1	  	  	  	  	  	  	  	  	  	  2	  	  	  	  	  	  	  	  	  3	  	  	  	  	  	  4	  	  	  	  	  	  M 
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Figure	  4-­‐8:	  Removal	  of	  GCSF	  L2	  from	  pGCSFsecTagGCSF2NAT_Hist	  	  Double	   digest	   of	   pSecTagGCSF2NAT_Hist	   using	   BamHI/AgeI	   separated	   on	  1%	  agarose	  gel	  electrophoresis.	  	  The	  presence	  of	  the	  below	  small	  fragment	  band	  (~0.6kb)	  at	  lane	  1	  indicates	  a	  successful	  double	  digest	  by	  both	  restriction	  enzymes	  for	  the	  second	  GCSF-­‐L2.	  A	  single	  band	  is	  observed	  in	  both	  2	  and	  3	  lanes,	  which	  shows	  the	  plasmid	  used	  in	  the	  digestion	  reaction	  was	  cut	  by	  the	  individual	  restriction	  enzyme.	  Also	  the	  double	  digested	  fragment	  runs	  at	  a	  slightly	  lower	  molecular	  weight	  compared	  to	  the	  single	  digestion	  fragments,	  which	  is	  due	  to	  excision	  of	  the	  GCSF-­‐L2	  fragment	  from	  the	  pSecTagGCSF2NAT_Hist.	  The	  GCSF	  L2	  fragment	  was	  gel	  isolated	  and	  ligated	  to	  pSecTag_link	  (Figure	  4.9).	  	  
Lane	   1:	   The	   upper	   band	   represents	   the	  pSecTagGCSF2NAT_Hist	   cut	   plasmid	   and	   the	   small	  fragment	   represents	   the	   second	   GCSF-­‐L2	   (~0.6kb)	  as	   a	   result	   of	   a	   successful	   double	   digests	   by	   both	  BamHI/AgeI	  restriction	  enzymes.	  	  	  
Lane2:	  BamHI	  digest	  of	  pSecTagGCSF2NAT_Hist.	  	  	  
Lane3:	  AgeI	  digest	  of	  pSecTagGCSF2NAT_Hist.	  	  	  
Lane	   M:	   1kb	   Ladder.	   Molecular	   weight	   marker:	  Bands	   starting	  at	   the	  bottom	  (0.5,	  1.0,	  1.5,	  2.0,	  3.0,	  4.0,	  5.0,	  6.0,	  8.0,	  10.0Kb).	  
1	  	  	  	  	  	  	  	  	  	  	  	  	  2	  	  	  	  	  	  	  	  	  	  	  3	  	  	  	  	  	  	  	  	  	  	  	  M 
89	  
	  
Figure	  4-­‐9:	  Double	  digest	  of	  pSecTag_link_GCSF-­‐L2	  potential	  clones	  Double	  digest	  of	  pSecTag_link_GCSF-­‐L2	  using	  BamHI/AgeI	  separated	  on	  1%	  agarose	  gel	  electrophoresis.	  	  









Lane	   1,	   2,	   3	   &	   4:	   The	   upper	   band	  represents	   the	   pSecTag_link_GCSF-­‐L2	   cut	  plasmid	   and	   lower	   band	   represents	   the	  GCSF-­‐L2	   (~0.6kb)	   as	   a	   result	   of	   a	  successful	   double	   digests	   by	   both	  BamH1/Age1	  restriction	  enzymes.	  	  	  
Lane	   M:	   1kb	   Ladder:	   Molecular	   weight	  marker:	  Bands	  starting	  at	  the	  bottom	  (0.5,	  1.0,	  1.5,	  2.0,	  3.0,	  4.0,	  5.0,	  6.0,	  8.0,	  10.0	  Kb).	  
	  	  	   
	  1	  	  	  	  	  	  	  	  	  	  2	  	  	  	  	  	  	  	  	  3	  	  	  	  	  	  	  	  4	  	  	  	  	  	  	  	  	  M	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 Generating	  GCSF	  Tandems	  with	  Variable	  Linkers	  4.4Successful	   construction	   of	   pSecTasgGCSF2NAT_Hist	   produced	   a	   vector	  containing	  a	  flexible	  linker	  with	  two	  glycosylation	  motifs	  between	  two	  GCSF	  ligands	  and	  read	  through	  to	  the	  X6	  Hist	  purification	  tag	  present	  within	  this	  plasmid.	  As	   a	   result,	   this	   tandem	  could	  be	  used	   as	   a	   template	   for	   creating	  multiple	   GCSF	   constructs	   containing	   variable	   glycosylated	   and	   non-­‐glycosylated	  linkers	  (refer	  to	  Table	  4.1).	  A	  full	  description	  of	  the	  amino	  acid	  sequences	  of	  these	  tandems	  can	  be	  found	  in	  Appendix	  B.	  The	  2NAT	  linker	  fragment	  was	  digested	  from	  pSecTagGCSF2NAT_Hist	  using	  Xho1/	   BamH1	   restriction	   enzymes	   and	   replaced	   with	   other	   linkers	  containing	  glycosylation	  and	  non-­‐glycosylation	  motifs	   (2QAT,	  4NAT,	  4QAT,	  8NAT	  and	  8QAT)	   (See	  Figure	  4.3.C).	  The	   linkers	  were	   already	  available	   as	  BamHI/XhoI	  digested	  fragments.	  The	   ligation	   of	   each	   linker	   was	   sequenced	   using	   CMVF	   and/or	   BGHRev	  primers	   to	   confirm	   the	   successful	   ligation	   (A	   full	   description	   of	   the	   amino	  acid	   sequences	   of	   all	   linkers	   can	   be	   found	   in	   Appendix	   B.3)	   and	   double	  digestion	   with	   XhoI	   and	   BamHI.	   pSecTagGCSF4NAT_Hist	   &	  pSecTagGCSF8QAT_Hist	   are	   shown	   as	   examples	   of	   the	   restriction	   digests.	  Single	  enzyme	  digests	  were	  used	  to	  confirm	  enzyme	  activity	  (Figure	  4.10	  &	  4.11).	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Figure	   4-­‐10:	   Double	   digest	   potentially	   positive	   clone	   of	  	  	  	  	  	  	  	  	  	  	  	  
pSecTagGCSF4NAT_Hist.	  1%	  agarose	  gel	  electrophoresis	  analysis	  of	  double	  digest	  potentially	  positive	  clone	  of	  GCSF4NAT_Hist	  using	  XhoI/BamHI	  as	  a	  double	  digest	  for	  the	  linker	  (4NAT).	  
 
	  
Figure	   4-­‐11:	   Double	   digest	   potentially	   positive	   clone	   of	   pSecTag	  
GCSF8QAT_Hist	  1%	  agarose	  gel	  electrophoresis	  analysis	  of	  double	  digest	  potentially	  positive	  clone	   of	   pSecTagGCSF8QAT_Hist	   using	   XhoI/BamHI	   as	   a	   double	   digest	   for	  the	  linker	  (8QAT).	  
Lane	   1:	   Double	   Xho1/BamH1	   digests	   of	  pSecTagGCSF4NAT_Hist	  to	  produce	  the	  linker	  4NAT.	  The	  presence	   of	   fragment	   at	   282bp	   indicates	   successful	  cloning.	  	  
Lane	  2:	  Undigested	  pSecTagGCSF4NAT	  _Hist.	  
Lane	  3:	  	  XhoI	  digest	  of	  pSecTagGCSF4NAT_Hist.	  	  
Lane	  4:	  	  BamHI	  digest	  of	  pSecTagGCSF4NAT_Hist.	  	  
Lane	  M:	   1kb	  Ladder:	  Molecular	  weight	  marker:	   Bands	  starting	  at	  the	  bottom	  (0.5,	  1.0,	  1.5,	  2.0,	  3.0,	  4.0,	  5.0,	  6.0,	  8.0,	  10.0	  Kb).	  
	  1	  	  	  	  	  	  	  2	  	  	  	  	  	  	  3	  	  	  	  	  	  	  	  4	  	  	  	  	  	  	  	  M	  	  	  
	  	  	  1	  	  	  	  	  	  	  	  2	  	  	  	  	  	  	  3	  	  	  	  	  	  4	  	  	  	  M1	  	  	  M2	   Lane	   1:	   Double	   XhoI/BamHI	   digests	   of	  pSecTagGCSF8QAT_Hist	  to	  produce	  the	  linker	  8QAT.	  The	  presence	   of	   fragment	   at	   282bp	   indicates	   successful	  cloning.	  	  
Lane	  2:	  Undigested	  pSecTagGCSF8QAT	  _Hist.	  
Lane	  3:	  XhoI	  digest	  of	  pSecTagGCSF8QAT_Hist	  	  
Lane	  4:	  BamHI	  digest	  of	  pSecTagGCSF8QAT_Hist	  	  
Lane	   M1:	   100bp	   ladder:	   Molecular	   weight	   marker:	  Bands	   starting	   at	   the	  bottom	  (100,	   200,	  300,	  400,	  500,	  600,	  700,	  800,	  900,	  1000,	  1200,	  1517	  bp).	  
Lane	  M2:	  1kb	  Ladder:	  Molecular	  weight	  marker:	  Bands	  starting	  at	  the	  bottom	  (0.5,	  1.0,	  1.5,	  2.0,	  3.0,	  4.0,	  5.0,	  6.0,	  8.0,	  10.0	  Kb).	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In	  conclusion,	  the	  presence	  of	  a	  fragment	  at	  282bp	  in	  lane	  1	  for	  both	  figures	  as	  resulted	  of	  double	  digest	  using	  Xho1/BamH1	  indicates	  successful	  cloning	  for	  both	  linker	  4NAT	  and	  8QAT.	  A	  supercoiled	  band	  is	  observed	  in	  lane	  2	  for	  both	   figures	   as	   a	   resulted	   of	   undigested	   plasmid.	   Also,	   a	   single	   band	   is	  observed	   in	   both	   3	   and	   4	   lanes	   for	   both	   figures,	   which	   shows	   that	   the	  plasmid	  used	  in	  this	  digestion	  reaction	  was	  cut	  by	  the	  individual	  restriction	  enzyme.	  	  
 Expression	  and	  Analysis	  of	  GCSF	  Tandems	  4.5After	   the	   successful	   construction	   of	   GCSF2NAT_Hist,	   GCSF2QAT_Hist,	  GCSF4NAT_Hist,	   GCSF4QAT_Hist,	   GCSF8NAT_Hist	   and	   GCSF8QAT_Hist,	   all	  plasmids	  were	  transiently	  and	  stably	  transfected	  into	  CHO	  Flp-­‐In	  cells,	  and	  serum	   free	   media	   harvested	   for	   analysis	   (refer	   to	   section	   3.5).	   Media	  samples	  were	  analysed	  using	  Elisa	  and	  western	  blotting	  to	  detect	  expression	  and	  an	  increase	  in	  molecular	  weight	  of	  proteins	  due	  to	  glycosylation.	  
 Transient	  Transfection	  of	  CHO	  Flp-­‐In	  Cells	  4.5.1As	  an	   initial	  assessment	  of	  protein	  expression,	  all	  plasmid	  constructs	  were	  transiently	   transfected	   into	   CHO	   Flp-­‐In	   cells	   and	   serum	   free	   media	  harvested	  and	  analysed	  via	  Elisa	  and	  western	  blot.	  
 Analysis	  of	  Expression	  by	  Elisa	  4.5.1.1To	   verify	   whether	   or	   not	   protein	   tandems	   were	   successfully	   expressed,	  media	   of	   protein	   samples	   were	   analysed	   via	   Elisa	   using	   the	   procedure	  described	  in	  section	  3.8.4.	  The	  results	  of	  Elisa	  are	  given	  in	  Table	  4.3.	  	   	  
93	  
Table	   4-­‐3:	   GCSF	   sandwich	   Elisa	   analysis	   of	   transiently	   expressed	  
tandem	  proteins.	  GCSF	  was	  used	  as	  standard	  
Protein	   μg/ml	   nM	   SEM	   %CV	  Negative	  control	   0.07	   0.0	   0.0	   2.80	  GCSF2QAT_Hist	   2.35	   51.77	   0.02	   3.89	  GCSF2NAT_Hist	   1.82	   40.19	   0.01	   2.09	  GCSF4QAT_Hist	   0.94	   20.72	   0.01	   1.95	  GCSF4NAT_Hist	   2.07	   45.81	   0.01	   3.09	  GCSF8QAT_Hist	   3.00	   61.88	   0.03	   6.28	  GCSF8NAT_Hist	   5.64	   116.20	   0.02	   2.81	  	  It	   can	   be	   seen	   in	   the	   table	   above	   that	   the	   Elisa	   has	   detected	   all	   tandem	  proteins,	   which	   indicates	   a	   successful	   transient	   expression.	   However,	   the	  purpose	   of	   this	   method	   is	   to	   detect	   expression	   only,	   as	   true	   level	   of	  expression	  is	  likely	  to	  be	  inaccurate	  since	  the	  GCSF	  standard	  curve	  is	  based	  upon	   monomeric	   GCSF,	   not	   specific	   tandem	   molecules	   (more	   details	   in	  discussion	  part).	  	  A	  maximum	  expression	  of	  5.64μg/ml	  for	  GCSF8NAT_Hist	  is	  observed	  and	  a	  minimum	  of	   0.94μg/ml	   for	   GCSF4QAT_Hist.	  %CV	   of	   less	   than	   10%	   can	   be	  seen	   for	   all	   protein	   samples	   which	   is	   considered	   an	   acceptable	   degree	   of	  variability	   between	   samples	   (between	   replicate	   values)	   in	   many	  commercially	  used	  Elisa’s.	  	  
 Analysis	  of	  Expression	  by	  Western	  Blotting	  4.5.1.2To	   assess	   whether	   protein	   tandems	   have	   undergone	   successful	  glycosylation,	   10μl	   of	   each	   media	   sample	   was	   diluted	   equally	   with	   2	   x	  Laemmli	  buffer	   and	   separated	  on	  a	  10%	  SDS-­‐PAGE	  gel.	  The	   samples	  were	  then	   transferred	   to	   PVDF	   membrane	   and	   western	   blotted	   as	   outlined	   in	  methods	   (Section	   3.8.3).	   The	   results	   of	   the	   western	   blot	   are	   presented	   in	  Figure	  4.12.	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Figure	   4-­‐12:	   Western	   blot	   of	   media	   samples	   from	   transiently	  
transfected	  CHO	  Flp-­‐In	  cells	  	  Lane	  1*;	  GCSF2QAT_Hist	  (2	  x	  QAT).	  Lane	  2*;	  GCSF2NAT_Hist	  (2	  x	  NAT).	  Lane	  3;	   GCSF4QAT_Hist	   (4	   x	   QAT).	   Lane	   4;	   GCSF4NAT_Hist	   (4	   x	   NAT).	   Lane	   5;	  GCSF8QAT_Hist	  (8	  x	  QAT).	  Lane	  6;	  GCSF8NAT_Hist	  (8	  x	  NAT).	  Western	  blot	  shows	   a	   definite	   increase	   in	   molecular	   weight	   for	   glycosylated	   molecules	  (GCSF2NAT_Hist,	   GCSF5NAT_Hist,	   and	   GCSF8NAT_Hist)	   compared	   to	   non-­‐glycosylated	   controls	   (GCSF2QAT_Hist,	   GCSF4QAT_Hist,	   GCSF8QAT_Hist).	  *Lane	  1	  and	  2	  were	  taken	  from	  another	  gels	  as	  didn’t	  run	  correctly	  with	  the	  above	  gel.	  	  
 As	  can	  be	  observed	  in	  Figure	  4.12	  western	  blotting	  successfully	  detected	  all	  GCSF	   tandems.	   A	   very	   clear	   shift	   can	   be	   seen	   in	   molecular	   weight	   for	  glycosylated	   molecules	   (GCSF2NAT_Hist,	   GCSF5NAT_Hist,	   and	  GCSF8NAT_Hist)	   compared	   to	   non-­‐glycosylated	   controls	   (GCSF2QAT_Hist,	  GCSF4QAT_Hist,	  GCSF8QAT_Hist).	  Glycosylated	  molecules	  show	  an	  increase	  in	  molecular	  weight,	  which	  is	  consistent	  with	  their	  linkers’	  being	  successful	  glycosylated.	  	  	  	  	  	  	  In	  addition,	  it	  can	  also	  be	  seen	  that	  there	  is	  a	  slight	  difference	  in	  molecular	  weight	   between	   GCSF8QAT_Hist	   compared	   to	   GCSF4QAT_Hist	   and	  GCSF2QAT,	  this	  is	  due	  to	  the	  difference	  in	  linker	  length.	  GCSF8QATHist	  has	  a	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linker	   length	   of	   282bp	   =	   94	   amino	   acids	   compared	   to	   147bp	   =49	   amino	  acids	  for	  both	  GCSF4QAT_Hist	  and	  GCSF2QAT_Hist.	  	  
 Stable	  Cell	  Line	  Development	  in	  CHO	  Flp-­‐In	  Cell	  Lines	  4.5.2Since	   all	   tandems	   were	   shown	   to	   be	   expressed	   and	   intact	   from	   transient	  transfections,	  all	  GCSF	  tandems	  were	  taken	  forward	  to	  make	  stable	  cell	  lines	  in	  CHO	  FIp-­‐In	  cells	  as	  described	  in	  section	  3.5.4.	  Non-­‐transfected	  cells	  were	  used	  as	  a	  negative	  control.	  	  	  
 Analysis	  of	  GCSF	  Tandems	  by	  Elisa	  4.5.2.1Stable	  cells	  were	  incubated	  in	  serum	  free	  media	  for	  2-­‐3	  days	  then	  harvested	  and	  analysed	  (See	  section	  3.5.5).	  Elisa	  data	  is	  shown	  in	  Table	  4.4.	  	  	  	  
Table	  4-­‐4:	  Results	  of	  GCSF	  sandwich	  Elisa	  for	  stably	  expressed	  GCSF	  
tandems	  
Construct	   μg/ml	   nM	   SEM	   %CV	  GCSF2QAT	   2.82	   62.04	   0.038	   8.11	  GCSF2NAT	   3.97	   87.81	   0.021	   3.46	  GCSF4QAT	   4.67	   102.95	   0.047	   6.98	  GCSF4NAT	   3.13	   69.20	   0.018	   3.48	  GCSF8QAT	   7.69	   158.62	   0.032	   3.29	  GCSF8NAT	   3.89	   80.14	   0.047	   8.01	  	  From	   the	   above	   data,	   all	   protein	   samples	   have	   been	   detected.	   It	   can	   be	  shown	   that	   GCSF8QAT_Hist	   is	   the	   most	   highly	   expressed	   protein	   at	  7.69μg/ml	   and	   GCSF2QAT_Hist	   being	   the	   lower	   expressed	   at	   2.82μg/ml.	  %CV	  is	  below	  10%	  for	  all	  protein	  samples,	  which	  indicates	  good	  consistency	  between	  triplicates.	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 Analysis	  of	  GCSF	  Tandems	  by	  Western	  Blotting	  	  4.5.2.210μl	  of	  each	  serum	   free	  media	   sample	  was	  equally	  diluted	   in	  2	  x	  Laemmli	  buffer	   and	   separated	   on	   a	   10%	   SDS-­‐PAGE	   gel.	   The	   samples	   were	   then	  transferred	   to	   PVDF	   membrane	   and	   analysed	   by	   western	   blotting.	   The	  results	  are	  shown	  in	  Figure	  4.13.	  	  
	  
 
Figure	  4-­‐13:	  Western	  blot	   of	   stable	   CHO	  Flp-­‐In	   cell	  media	   expressing	  
GCSF	  tandems	  Lane	  1;	  GCSF2QAT_Hist	  (2	  x	  QAT).	  Lane	  2;	  GCSF2NAT_Hist	  (2	  x	  NAT).	  Lane	  3;	   GCSF4QAT_Hist	   (4	   x	   QAT).	   Lane	   4;	   GCSF4NAT_Hist	   (4	   x	   NAT).	   Lane	   5;	  GCSF8QAT_Hist	  (8	  x	  QAT).	  Lane	  6;	  GCSF8NAT_Hist	  (8	  x	  NAT).	  Western	  bot	  shows	   an	   increase	   in	   molecular	   weight	   for	   glycosylated	   molecules	  (GCSF2NAT_Hist,	   GCSF4NAT_Hist,	   and	   GCSF8NAT_Hist)	   compared	   to	   non-­‐glycosylated	  controls	  (GCSF2QAT_Hist,	  GCSF4QAT_Hist,	  GCSF8QAT_Hist).	  	  	  Western	   blotting	   successfully	   detected	   all	   GCSF	   tandems.	   All	   glycosylated	  and	  non-­‐glycosylated	  GCSF	  tandems	  are	  running	  at	  approximately	  the	  same	  molecular	  weights	  that	  were	  observed	  previously	  in	  transient	  transfections.	  This	   suggests	   the	   separation	   by	   SDS-­‐PAGE	  has	   run	   appropriately	   and	   that	  samples	  have	  successful	  glycosylation	  at	  the	  consensus	  sequence	  within	  the	  linker	  region.	  Glycosylated	  constructs	  exhibited	  increased	  molecular	  weight	  over	  non-­‐glycosylated	  molecules	  and	  rhGCSF	  (Table	  4.5).	  
97	  
Table	  4-­‐5:	  Determined	  and	  observed	  MW’s	  of	  expressed	  GCSF	  tandems	  	  	  
Construct	   Determined	  MW	  
(kDa)*	  
Observed	  MW	  (kDa)	  
(approximation)	  
rhGCSF	   18.8	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  _	  
GCSF2QAT_Hist	   45.4	   ~	  45	  
GCSF2NAT_Hist	   45.2	   ~	  52	  
GCSF4QAT_Hist	   45.4	   ~	  45	  
GCSF4NAT_Hist	   45.2	   ~	  60	  
GCSF8QAT_Hist	   48.5	   ~	  49	  
GCSF8NAT_Hist	   48.5	   ~	  70	  	  *MW’s	   calculated	   using	   DNASTAR	   Lasergene	   version	   8	   and	   the	   observed	  MW	  estimated	  using	  western	  blot	  analysis	  (see	  Figure	  4-­‐13).	  
	  
 In	  vitro	  Biological	  Activity	  of	  Crude	  Media	  4.6Biological	   activity	   of	   GCSF	   tandems	  was	  measured	   using	   the	   human	   acute	  myeloid	   leukemic	   cell	   line	   (AML-­‐193	   cell	   line),	   which	   proliferates	   in	  response	  to	  GCSF.	  To	  determine	  if	  the	  expressed	  GCSF	  tandem	  proteins	  are	  biologically	  active,	  stable	  clone	  crude	  media	  was	  tested	  for	  bioactivity	  using	  the	  AML	  193	  proliferation	  assay	  as	  described	  in	  section	  3.8.5.	  As	  expected,	  all	  crude	  media	  obtained	  from	  stable	  cell	  lines	  are	  biologically	  active	  above	  that	   of	   the	   negative	   control,	   growth	   hormone	   (GH).	   The	   assay	   appears	   to	  reach	   absorbance	   saturation	   of	   around	   0.25	   for	   the	   rhGCSF	   and	   all	   GCSF	  tandems	  (Figure	  4.14.A	  &	  B).	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Figure	  4-­‐14:	  In	  vitro	  biological	  activity	  for	  rhGCSF	  and	  GCSF	  tandems	  






 Discussion	  4.7In	  this	  chapter,	  the	  cloning,	  sequencing	  and	  expression	  of	  two	  GCSF	  ligands	  linked	   by	   a	   variably	   glycosylated	   and	   non-­‐glycosylated	   linkers	   were	  examined.	  	  The	   data	   obtained	   has	   shown	   that	   it	   is	   possible	   to	   incorporate	   2,	   4	   and	   8	  NAT	   (Asn-­‐Ala-­‐Thr)	   or	   QAT	   (Glu-­‐Ala-­‐Thr)	   motifs	   	   	   between	   tandem	   GCSF	  ligands.	   The	   NAT	   linker	   containing	   tandems	   have	   been	   successfully	  glycosylated	   as	   shown	   by	   an	   increase	   in	   the	   molecular	   weight	   of	   the	  constructs	   upon	   expression	   in	  mammalian	   CHO	   Flp-­‐In	  cells	   as	   verified	   by	  western	  blotting.	  CHO	  Flp-­‐In	  cell	   lines	  were	  used	  to	  express	  all	  GCSF	  constructs	  as	  these	  cell	  lines	   have	   been	   widely	   used	   to	   express	   recombinant	   proteins.	   	   The	   main	  reason	  for	  their	  use	  is	  the	  possession	  of	  glycosylation	  mechanism	  similar	  to	  those	   in	   humans.	   The	   cells	   are	   efficient	   and	   easy	   to	   culture	   and	   relatively	  express	   high	   level	   of	   proteins	   (Damiani	   et	   al.,	   2009).	   Additionally,	   these	  mammalian	   cell	   lines	   are	   preferred	   due	   to	   their	   ability	   to	   correctly	   fold	  proteins	  during	  biosynthesis	  (Wurm,	  2004).	  	  Ordinarily,	  CHO	  cell	  lines	  were	  not	  capable	  of	  both	  sialyation	  types	  observed	  in	  human	  body	  (alpha	  2,3	  and	  2,6-­‐glycosidic	   linkages	   are	   participate	   in	   glycan	   structure)	   as	   it	   lacks	   the	  enzyme	   alpha	   2,6-­‐	   sialyltransferase	   and	   this	   could	   cause	   immunological	  response	   and	   thus	   influence	   the	   therapeutic	   application	   of	   the	   GCSF	  constructs.	   However,	   CHO	   cells	   that	   are	   capable	   of	   sialylation	   have	   been	  genetically	  engineered	  by	   insertion	  of	   alpha	  2,6-­‐sialylation	  expressing	   into	  the	  DNA	   sequence	   of	   the	   cells	   (Damiani	   2009).	   Furthermore,	   the	   CHO	   cell	  line	   is	   the	   industry	   standard	   for	   recombinant	   therapeutic	   proteins	  production	   and	   many	   protein	   drugs	   are	   manufactured	   in	   this	   system	  (mostly	  antibodies)	  without	  problems.	  	  	  The	  Elisa	   has	   detected	   all	   tandem	  proteins,	   indicating	   successful	   transient	  and	  stable	  expression.	  However,	   the	  purpose	  of	   this	  method	  was	   to	  detect	  expression	   only	   as	   quantifiable	   levels	   of	   expression	   are	   likely	   to	   be	  inaccurate.	   This	  may	   be	   due	   to	   overestimating	   of	   Elisa	   since	   the	   standard	  
100	  
curve	  is	  based	  upon	  monomeric	  GCSF	  and	  therefore	  is	  not	  ideal	  to	  measure	  these	  tandems.	  Purified	  GCSF	  tandem	  was	  not	  obtainable	  at	  the	  same	  time	  of	  carrying	  out	  these	  experiments	  and	  thus	  the	  monomeric	  GCSF	  was	  the	  best	  alternative.	  As	  a	  result,	  the	  number	  of	  GCSF	  molecules	  per	  mole	  of	  tandem	  is	  double	   the	   number	   of	   rhGCSF	   molecules.	   Besides,	   although	   our	   GCSF	  tandems	  are	  not	  directly	  glycosylated,	   it	   is	  difficult	   to	  understand	  how	  the	  influence	   of	   protein	   conformation	   and	   glycosylation	   of	   these	   tandem	  proteins	   affects	   the	   binding	   of	   antibody	   and	   thus	   influence	   Elisa	   results.	  Byrne	  et	  al.,	  (2007)	  indicated	  that	  glycosylation	  could	  completely	  eradicate	  the	   polypeptide	   recognition	   site	   of	   antibody.	   In	   contrast,	   analysis	   of	   these	  tandems	   using	   western	   blotting	  may	   provide	   a	   truer	   visual	   of	   expression	  since	   proteins	   are	   in	   their	   denatured	   form	   and	   this	   may	   expose	   their	  recognition	  sites	  for	  the	  antibody	  more.	  Protein	  denaturation	  as	  a	  result	  of	  sample	   heating	   may	   also	   reduce	   the	   possible	   steric	   hindrance	   caused	   by	  glycosylation	  to	  antibody	  recognition	  sites.	  It	  is	  important	  to	  consider	  these	  factors	   since	   it	   is	   difficult	   to	   determine	   whether	   or	   not	   equivalent	  concentrations	  of	   protein	   sample	  have	  been	   tested	   in	   the	  GCSF	  bioactivity	  assay.	  	  Previously	   we	   stated	   that,	   western	   blotting	   showed	   an	   increase	   in	   the	  molecular	  weight	  of	  glycosylated	  tandems	  (GCSF2NAT_Hist,	  GCSF4NAT_Hist	  and	  GCSF8NAT_Hist).	  The	  only	  different	   in	  these	  tandems	  compared	  to	  the	  non-­‐glycosylated	   control	   is	   the	   presence	   of	   N-­‐linked	   glycosylation	   motifs	  with	  in	  the	  linker,	  supporting	  successful	  glycosylation.	  	  The	   key	   behind	   successful	   N-­‐linked	   glycosylation	   is	   the	   selection	   of	   a	  consensus	   sequence	   (As	   mentioned	   previously,	   the	   common	   consensus	  sequence	   for	   N-­‐linked	   glycosylation	   is	   Asn-­‐X-­‐Ser/Thr	  where	   X	   can	   be	   any	  amino	  acid	  except	  proline	  (Kornfeld	  and	  Kornfeld,	  1985).	  Thus,	  efficiency	  of	  glycosylation	   is	   likely	   to	   be	   determined	   by	   the	   amino	   acid	   (Thr)	   that	  occupies	   the	   third	   position.	   It	   has	   been	   shown	   that	   glycosylation	   is	   more	  efficient	   when	   Threonine	   is	   occupying	   the	   third	   position	   as	   opposed	   to	  Serine,	  with	   efficiency	   shown	   to	   be	   twice	   as	   high	   and	   in	   other	   cases	   even	  forty	  fold	  (Kasturi	  et	  al.,	  1995,	  Picard	  et	  al.,	  1995).	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The	   crude	  media	   of	   each	   tandem	  GCSF	   stable	   clones	  was	   tested	   using	   the	  AML	   193	   proliferation	   assay.	   At	   this	   stage,	   this	   assay	   would	   give	   a	  preliminary	   indication	   whether	   GCSF	   tandems	   could	   maintain	   biological	  activity	   since	   their	   biological	   activity	   showed	   similar	   data	   to	   rhGCSF.	  Whether	   the	   glycosylations	   affect	   the	   biological	   activity	   is	   difficult	   to	  interpret	   since	   quantification	   was	   completed	   using	   monomeric	   GCSF	   and	  not	   the	   specific	   tandems:	   there	   could	   well	   be	   differences	   in	   detection	  between	  the	  tandems	  perhaps	  due	  to	  steric	  hindrance	  by	  glycosylations.	  It	  has	  been	   reported	   that	   the	   insertion	  of	   a	  Histidine	  purification	   tag	   in	   to	  recombinant	   proteins	   may	   potentially	   dislocate	   the	   three-­‐dimensional	  structure	  of	  the	  polypeptide	  protein	  (Block	  et	  al.,	  2009),	  this	  may	  eventually	  impact	  upon	   receptor	  binding	   and	  negatively	   affect	   protein	  bioactivity.	  All	  tandems	  were	  Hist	  tagged	  and	  the	  initial	  data	  of	  AML193	  assay	  from	  crude	  media	   showed	   that	   it	   is	   possible	   to	   introduce	   another	   GCSF	   and	   X6His	  purification	  tag	  into	  the	  C-­‐terminus	  of	  a	  GCSF	  (to	  create	  a	  tandem	  GCSF)	  and	  still	  maintain	  biological	  activity.	  Pure	  proteins	  would	  give	  better	  indication	  as	   to	   whether	   a	   X6His	   purification	   tag	   or	   glycosylation	   could	   negatively	  affect	   protein	   bioactivity.	   	   For	   further	   analysis	   and	   characterisation,	   GCSF	  tandem	  proteins	  were	  purified	  using	  IMAC.	  This	  will	  be	  discussed	  in	  the	  next	  chapter.	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 Results	  2:	  Large-­‐scale	  Production	  and	  Analysis	  of	  5.
GCSF	  Tandems	  
 Summary	  5.1The	   previous	   chapter	   showed	   that	   it	   is	   possible	   to	   clone,	   sequence	   and	  express	   two	   GCSF	   ligands	   linked	   by	   variable	   glycosylated	   and	   non-­‐glycosylated	  linkers.	  Therefore,	  for	  further	  PK/PD	  analysis,	  it	  was	  necessary	  to	  purify	  these	  GCSF	  tandem	  proteins	  using	  Nickel	  IMAC.	  This	  chapter	  shows	  that	   IMAC	   is	   an	   appropriate	   method	   for	   purifying	   GCSF	   tandems	   with	  histidine	  tags.	  IMAC	  permits	  a	  fast	  and	  easy	  way	  for	  purification	  due	  to	  the	  strong	  affinity	  of	  a	  nickel-­‐complex	  (Ni2+-­‐NTA)	  for	  the	  histidine	  tag	  present	  in	  the	   GCSF	   tandems.	   	   All	   GCSF	   tandems	   produced	   high	   levels	   of	   protein	  (between	  1	   to	   4mg	  per	   litre	   as	   assessed	  by	  Bradford	   assay)	   from	  a	   stable	  CHO	   cell	   line	   and	  were	   considered	   to	   be	   90-­‐95%	   pure	   as	   judged	   by	   SDS-­‐PAGE.	   Molecular	   weights	   and	   the	   integrity	   of	   each	   GCSF	   tandem	   were	  confirmed	   by	   SDS-­‐PAGE	   and	   western	   blotting.	   Purified	   protein	   was	   then	  passed	  over	  for	  PK/PD	  studies.	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 Introduction	  	  5.2For	  decades,	  cloning	  and	  the	  following	  recombinant	  expression	  of	  protein	  is	  commonly	   used	   in	   molecular	   biology.	   As	   purification	   of	   recombinant	  proteins	   is	   frequently	   a	   challenging	   step,	   a	   short	   affinity	   epitope	   tag	   was	  designed	   to	   aid	   purification	   process.	   Usually,	   these	   short	   amino	   acid	  sequences	  are	  added	  either	  to	  the	  N	  or	  C	  terminal	  ends	  of	  a	  protein.	  Then,	  these	   amino	   acid	   sequences	   can	   expose	   epitopes	   for	   specific	   binding	  partners	   like	   antibodies.	   The	   X6	   His	   tag	   (HHHHHH)	   is	   one	   of	   the	   most	  commonly	   used	   protein	   tags	   that	   permits	   a	   fast	   and	   easy	   way	   for	  purification	   that	   is	   based	   on	   the	   strong	   affinity	   of	   histidine	   for	   divalent	  cations	   (such	   as	   Zn,	   Cu,	   Co	   and	   Ni).	   The	   electron	   donor	   groups	   on	   the	  imidazole	   ring	   of	   histidine	   form	   coordination	   bonds	  with	   the	   immobilized	  metal	  ion	  matrices	  under	  native	  conditions	  in	  high	  or	  low	  salt	  buffers.	  In	  our	  purification	  system,	  immobilized	  nickel-­‐complex	  Ni2+-­‐NTA	  beads	  were	  used.	  In	   the	   Immobilized	   Metal	   Affinity	   Chromatography	   (IMAC)	   purification	  system,	  the	  bound	  protein	  is	  eluted	  off	  the	  column	  using	  imidazole,	  which	  is	  a	  histidine	  analogue,	   as	   it	   competes	  with	  his-­‐tagged	  protein	   for	  binding	   to	  the	   divalent-­‐metal	   ions	  matrix.	   	   As	   a	   result,	   the	   eluted	   target	   protein	   can	  simply	   be	   separated	   from	   unwanted	   contaminated	   proteins	   in	   the	   elution	  mixture	  (Block	  et	  al.,	  2009,	  Kreisig	  et	  al.,	  2014).	  
 Aim	  and	  Hypothesis	  5.2.1Following	   the	   successful	   cloning	  and	  expression	  of	   the	   tandem	  proteins	   in	  the	  previous	  chapter,	  it	  was	  necessary	  to	  purify	  these	  tandem	  proteins	  from	  mammalian	  cell	  lines	  (CHO	  FIp-­‐In	  cells)	  stably	  expressing	  each	  tandem.	  The	  tandem	   GCSF	   expressing	   cells	   were	   grown	   in	   roller	   bottles	   and	   target	  protein	  harvested	  from	  the	  media	  as	  a	  secreted	  product,	  purified	  and	  passed	  over	  for	   in	  vivo	  PK/PD	  analysis.	  In	  order	  to	  facilitate	  the	  purification	  of	  the	  target	   proteins,	   the	   expression	   constructs	   were	   tagged	   at	   the	   C-­‐terminal	  with	   a	   6-­‐Histidine.	   As	  Nickel	   IMAC	   column	   is	   known	   to	   have	   high	   binding	  affinity	   for	   histidine,	   we	   hypothesized	   that	   the	   histidine	   tag	   in	   our	   GCSF	  tandems	  will	  bind	  to	  nickel	  column	  and	  facilitate	  the	  purification.	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 Results	  5.3
 Cell	  Growth	  and	  Productivity	  5.3.1Hyclone	  SMF4CHO	  Utility	  media	  adapted	  stable	  CHO	  Flp-­‐In	  cell	   lines	  of	  all	  GCSF	   tandems	  were	   thawed	   from	   liquid	   nitrogen	   stocks.	   After	   a	   period	   of	  growth	   and	   expansion,	   cells	   were	   transferred	   to	   two	   non-­‐vented	   roller	  bottles	  containing	  Hyclone	  SFM4CHO	  Utility	  media	  and	  grown	  at	  37°C	  with	  gentle	  agitation	  in	  a	  CO2-­‐free	  incubator	  at	  37°C,	  for	  protein	  production	  (each	  roller	   bottle	   contained	   approximately	   500ml	   of	   culture	   volume).	   Starting	  with	  a	  density	  of	  ~0.25	  x	  106	  cells/ml,	   the	   cells	  were	  grown	  until	   viability	  declined	   below	   30%	   (took	   approximately	   10	   -­‐	   11	   days)	   as	   previously	  described	   in	   section	   3.5.8.	   100µl	   of	  media	   samples	   were	   routinely	   taken	  every	  2	  or	  3	  days	   and	  analysed	   for	   total	   cell	   number	   and	  viability	  using	   a	  trypan	   blue	   exclusion	   (see	   section	   3.5.2).	   	   Elisa	   was	   also	   used	   to	   analyse	  protein	  productivity	  as	  described	  in	  section	  3.8.4.	  There	   were	   cell	   growth	   and	   maximal	   viable	   cell	   population	   differences	  observed	   for	   the	   GCSF	   tandems	   during	   the	   expression	   studies.	   While	   all	  GCSF	   tandem	   cells	   had	   approximately	   a	   similar	   %	   of	   viable	   cells	   (Figure	  5.1b),	  they	  however	  had	  varied	  peak	  viable	  cells	  number,	  ranging	  from	  1.25	  to	   1.9	   million	   cells	   per	   ml	   (1.25-­‐1.9	   x	   106/ml)	   with	   GCSF2NAT	   and	  GCSF4NAT	  having	  the	  least	  and	  highest	  peak	  cells	  densities,	  respectively.	  A	  steady	  exponential	  growth	  was	  observed	  for	  the	  GCSF2QAT	  and	  GCSF4NAT	  up	  to	  a	  maximal	  viable	  cell	  density	  at	  day	  4	  (viable	  densities	  of	  1.7	  x	  106/ml	  &	  1.14	  x	  106/ml	  respectively).	  This	  is	  in	  contrast	  to	  other	  cell	  lines	  in	  which	  maximal	   viable	   cell	   densities	   were	   reached	   on	   day	   7	   for	   2NAT	   (1.24	   x	  106/ml),	  GCSF8NAT	  (1.68	  x	  106/ml)	  and	  GCSF8QAT	  (1.34	  x	  106/ml),	  and	  at	  day	  9	   for	  GCSF4QAT	  (1.62	  x	  106/ml)	   (Figure	  5.1a).	  The	  GCSF8NAT	  culture	  produces	   product	   at	   an	   earlier	   time	   point	   than	   other	   cultures,	   peaking	   on	  day	   7	   but	   losses	   viability	   at	   an	   earlier	   stage.	   Most	   of	   the	   tandem	   GCSF	  cultures	   retained	   a	   high	   viability	   up	   to	   at	   least	   day	   7	   (day	   6	   for	   8NAT	  culture)	   with	   viabilities	   at	   ~60%	   (Figure	   5.1b).	   Consequently,	   8NAT-­‐expressing	  cells	  were	  harvested	  for	  protein	  production	  on	  day	  7	  of	  growth,	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as	   the	   %viability	   declined	   rapidly	   beyond	   this	   period,	   whereas	   all	   other	  GCSF	  tandems	  were	  grown	  up	  to	  day	  9	  before	  culture	  media	  were	  harvested.	  Beyond	  day	  9	  there	  was	  a	  significant	  loss	  of	  cell	  viability	  (Figure	  5.1b;	  4QAT	  and	   4NAT	   expressing	   cells).	   This	   was	   expected	   as	   nutrient	   depletion	   and	  host	  cell	  metabolic	  waste	  would	   impact	  cell	  proliferation.	  Therefore,	  at	   the	  time	  of	  harvest,	  majority	  of	  the	  tandem	  GCSF	  expressing	  cells	  were	  at	  least	  60%	  viable.	  Harvesting	   the	  culture	  media	  at	   this	   stage	  helped	  prevent	  any	  potential	  protein	  degradation.	  	  Interestingly,	  protein	  production	  was	  detectable	  as	  early	  as	  day	  2	  of	  culture	  growth	   with	   a	   consistent	   increase	   in	   protein	   productivity	   as	   the	   cells	  number	   increases	   (Figure	   5.1c).	   There	  was	   a	   dramatic	   increase	   in	   protein	  productivity	   for	  most	  GCSF	   tandems	  up	   to	  at	   least	  day	  7	  with	  productivity	  peaking	   at	   >50mg/L	   except	   2QAT	   and	  8QAT	  which	  maintain	   a	   steady	   low	  level	   of	   expression	   showing	   a	   maximal	   peak	   expression	   of	   10mg/L	   &	  17mg/L	   respectively.	   The	   significant	   difference	   in	   protein	   productivity	   for	  most	  of	  the	  GCSF	  tandems	  expressing	  cells	  was	  observed	  to	  occur	  between	  day	   4	   and	   day	   9,	   during	   which	   2NAT	   and	   4NAT	   protein	   yield	   rose	   from	  approximately	   20mg/L	   on	   day	   7	   to	   about	   55mg/L	   and	   50mg/L	   on	   day	   9	  respectively,	  and	  30mg/L	  on	  day	  4	  to	  50mg/L	  on	  day	  7	  for	  8NAT.	  While	  the	  underlying	  reason	  for	  the	  sudden	  enhanced	  productivity	  was	  unclear,	  it	  was	  inferred	  that	  the	  expressing	  cells	  might	  have	  become	  better	  adapted	  to	  the	  conditions	  of	  growth.	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Figure	  5-­‐1:	  GCSF	  tandems	  expressing	  cells	  growth	  and	  productivity	  The	   figure	   shows	   the	   total	   viable	   cells	   (a)	   and	  %	   viability	   of	   the	   tandem	  expressing	   cells	   (b)	   for	   all	   glycosylated	   tandem	   proteins	   (GCSF2NAT,	  GCSF4NAT	   &	   GCSF8NAT)	   together	   with	   their	   respective	   controls,	   non-­‐glycosylated	  tandem	  proteins	  (GCSF2QAT,	  GCSF4QAT	  &	  GCSF8QAT),	  as	  well	  as	  the	  productivity	  of	  the	  cells	  within	  a	  9-­‐day	  growth	  period	  (c).	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Figure	  5-­‐2:	  Western	  blot	  analysis	  of	  roller	  bottle	  media	  samples	  Stable	  CHO	  Flp-­‐In	  cells	  expressing	   the	  GCSF	  tandems	  were	  grown	   in	  roller	  bottle	  cultures	  and	  samples	  taken	  every	  2	  days	  up	  to	  a	  total	  of	  11	  days.	  	  10µl	  of	   samples	   from	   culture	   medium	   for	   each	   tandem	   GCSF	   construct	   were	  analysed	  by	  western	  blotting.	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 Purification	  of	  GCSF	  Tandems	  Using	  IMAC	  5.3.2The	  culture	  media	   for	  each	  GCSF	   tandem	  was	   taken	   from	  roller	  bottle	  and	  spun	  down	  to	  pellet	   the	  cell	  debris	  by	  centrifugation	  (18000	  g,	   JLA-­‐16.250	  Fixed-­‐Angle	   Rotor	   for	   30	   minutes	   at	   4°C).	   10mM	   final	   concentration	   of	  Benzamidine	   HCl	   (serine	   protease	   inhibitor)	   was	   added	   to	   the	   1L	   culture	  media	   to	   prevent	   protein	  degradation.	  Using	   a	  Vivaflow	  200	   concentrator,	  media	  samples	  were	  concentrated	  about	  10-­‐fold	  i.e.	  100ml.	  The	  sample	  was	  diluted	  1:1	  with	  equilibration	  buffer	  prior	  to	  IMAC	  as	  previously	  described	  at	  section	  3.7.1.	  	  	  
 Purification	  of	  GCSF2NAT	  5.3.2.1Culture	  media	  collected	  from	  GCSF2NAT	  expressing	  cells	  was	  concentrated	  and	  purified	  on	  a	  Nickel	  IMAC	  column.	  Western	  blotting	  results	  showed	  that	  the	   majority	   of	   GCSF2NAT	   protein	   bound	   to	   the	   IMAC	   column	   with	  negligible	  amounts	  observed	  in	  the	  flow	  through	  (Figure	  5.3.A).	  High	  purity	  protein	   (>90%	   pure)	   was	   eluted	   using	   imidazole	   containing	   buffers	   with	  concentrations	   ranging	   between	   200mM	   and	   350mM	   (shown	   in	   bold	  typeface,	   elutions	   6,7,8	   &	   9	   in	   figure	   5.3.A).	   Elutions	   using	   imidazole	  concentrations	  below	  or	  above	  this	  range	  (100mM	  or	  500mM	  respectively)	  were	   observed	   to	   be	   of	   low	  purity	  when	   analysed	  by	   SDS-­‐PAGE	   and	  were	  thus	   excluded	   from	   the	   study.	   High	   purity	   elutions	   were	   collected	   and	  pooled	   together	   for	  dialysis.	  Dialysis	  was	  performed	   to	   remove	  any	  excess	  imidazole	  or	  other	  salts	  (Figure	  5.3.B).	  	  Pre	  and	  post	  dialysed	  proteins	  were	  measured	   by	   Bradford	   assay	   (Table	   5.1)	   and	   analysed	   by	   10%	   SDS	   PAGE	  followed	   by	   western	   blot	   analysis	   to	   confirm	   the	   purification	   and	   size	   of	  GCSF2NAT.	   Coomassie	   stained	   10%	   SDS	   -­‐PAGE	   showed	   that	   the	   post-­‐dialysis	   GCSF2NAT	   protein	   was	   stable	   with	   minimal	   protein	   degradation	  (visible	  as	  contaminated	  bands	  at	  20-­‐25kda).	  These	  lower	  molecular	  weight	  (LMW)	   bands	  may	   have	   resulted	   from	   handling	   or	   partial	   cleavage	   of	   the	  tandem	   GCSF2NAT	   linker	   (the	   observed	   molecule	   at	   this	   low	   molecular	  weight	   was	   predicted	   to	   be	   an	   equivalent	   of	   a	   GCSF	   ligand	   and	   non-­‐glycosylated	  linker).	  Analysis	  of	  pellet	  samples	  post	  dialysis	  does	  show	  the	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Figure	  5-­‐3:	  purification	  development	  of	  IMAC	  for	  GCSF2NAT	  10μl	   of	   protein	   samples	   from	   each	   stage	   of	   the	   GCSF2NAT	   purification	  process	   were	   separated	   on	   a	   10%	   SDS-­‐PAGE	   and	   stained	  with	   coomassie	  blue	   for	  visualization	   (A,	   left	   figure),	  while	  100ng	  of	   the	   same	  sample	  was	  analysed	  by	  western	  blotting	  (A,	  right	   figure)	  (UL=Unfiltered	   load,	  L=Load,	  FL=Flow	   through,	   W=Wash	   pH	   7.4	   &	   6.0,	   M=	   Markers,	   5-­‐10=	   Elutions)	  Thereafter,	  active	  elution	  fractions	  were	  pooled,	  dialysed	  and	  analysed	  on	  a	  10%	   SDS-­‐PAGE	   gel	   by	   coomassie	   staining	   (B,	   left	   figure)	   and	   western	  blotting	  (B,	  right	  figure)	  (1=	  Pre-­‐Dialysis,	  2=	  Post-­‐Dialysis	  and	  Post-­‐Dialysis	  pellet).	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Total	  Protein	  	  	  	  	  	  	  	  	  
(mg)	  
%Recovery	  
Unfiltered	  load	   -­‐	   220	   680.46	   149.70	   -­‐	  Load	   -­‐	   220	   790.48	   173.90	   100	  Unbound	   -­‐	   220	   655.83	   144.28	   83	  Wash	  pH	  7.4	   -­‐	   1	   69.62	   0.07	   0.04	  E5	   200	   1	   839.74	   0.84	   0.48	  
E6	   200	   1	   539.24	   0.54	   0.3	  
E7	   350	   1	   1031.86	   1.03	   0.59	  
E8	   350	   1	   1333.99	   1.33	   0.76	  







 Purification	  of	  GCSF2QAT	  5.3.2.2Culture	  media	  collected	  from	  GCSF2QAT	  expressing	  cells	  was	  concentrated	  and	  purified	  on	  a	  Nickel	  IMAC	  column.	  Western	  blotting	  results	  showed	  that	  the	  majority	  of	  GCSF2QAT	  protein	  in	  the	  media	  was	  bound	  to	  the	  IMAC	  with	  negligible	  amounts	  observed	  in	  the	  flow	  through	  (Figure	  5.4.A).	  High	  purity	  protein	   (>90%	   pure)	   was	   eluted	   using	   imidazole	   containing	   buffers	   with	  concentrations	   ranging	   between	   200mM	   and	   350mM	   (shown	   in	   bold	  typeface	   7,8,9	   &	   10	   in	   figure	   5.4.A).	   Elutions	   using	   with	   imidazole	  concentrations	  below	  or	  above	  this	  range	  (100mM	  or	  500mM	  respectively)	  were	   observed	   to	   be	   of	   low	  purity	  when	   analysed	  by	   SDS-­‐PAGE	   and	  were	  thus	   excluded	   from	   the	   study.	   High	   purity	   elutions	   were	   collected	   from	  IMAC	  purification	  and	  pooled	  together	  for	  dialysis.	  Dialysis	  was	  performed	  to	   remove	  any	  excess	   imidazole	  or	  other	   salts	   (Figure	  5.4.B).	  Pre	  and	  post	  dialysed	   protein	   were	   then	   measured	   by	   Bradford	   assay	   (Table	   5.2)	   and	  analysed	  by	  10%	  SDS	  PAGE	  followed	  by	  western	  blot	  analysis	  to	  confirm	  the	  purification	  and	  size	  of	  GCSF2QAT.	  Coomassie	  stained	  10%	  SDS	  -­‐PAGE	  post-­‐dialysis	   protein	   analyses	   showed	   that	   the	   GCSF2QAT	   protein	   was	   highly	  stable	   with	   very	   minimal	   protein	   degradation	   (visible	   as	   contaminated	  bands	  at	  20-­‐25kda).	  These	  LMW	  bands	  may	  have	  resulted	  from	  handling	  or	  partial	  cleavage	  of	  the	  tandem	  GCSF2QAT	  linker.	  The	  observed	  molecule	  at	  this	   LMW	   was	   predicted	   to	   be	   equivalent	   to	   GCSF	   ligand	   and	   non-­‐glycosylated	   linker	   since	   similar	   bands	   corresponding	   to	   these	   were	  observed	   on	   western	   blot	   at	   elution	   8.	   Analysis	   of	   pellet	   samples	   post	  dialysis	  showed	  the	  presence	  of	  a	  protein	  band	  at	  ~40kDa	  of	  low	  intensity,	  however	  this	  was	  not	  detected	  by	  western	  blotting.	  Western	   blotting	   also	   did	   not	   pick	   up	   the	   LMW	   bands	   of	   pre	   and	   post	  dialysed	  samples	  present	  post	  coomassie	  staining.	   	  However,	   it	  did	  pick	  up	  the	  LMW	  band	  in	  elution	  8	  and	  this	  might	  confirm	  that	  LMW	  bands	  are	  not	  missing	   the	  antigenic	  site	  or	  are	  below	  detection	   limit	  of	  antibody,	  but	   the	  blots	   might	   not	   have	   been	   exposed	   long	   enough	   to	   see	   the	   contaminant	  bands.	  Nevertheless,	  the	  LMW	  proteins	  were	  of	  significantly	  lower	  intensity	  when	   compared	   to	   the	   intact	   molecule,	   suggesting	   an	   appreciably	   high	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purity	   yield	   during	   purification.	   	   A	   total	   of	   1.81mg	   of	   GCSF2QAT	   was	  recovered	  of	  >90%	  purity	  from	  1	  litre	  a	  media.	  	  
	  
Figure	  5-­‐4:	  Purification	  development	  of	  IMAC	  for	  GCSF2QAT	  10μl	   of	   protein	   samples	   from	   each	   stage	   of	   the	   GCSF2QAT	   purification	  process	   were	   separated	   on	   a	   10%	   SDS-­‐PAGE	   and	   stained	  with	   coomassie	  blue	   for	   visualization	   (A,	   left	   figure),	   while	   100ng	   of	   same	   samples	   were	  analysed	   by	   Western	   blot.	   (A,	   right	   figure)	   (UL=Unfiltered	   load,	   L=Load,	  FL=Flow	   through,	   W=Wash	   pH7.4	   &	   6.0,	   M=Markers,	   5-­‐11=	   Elutions).	  Thereafter,	  active	  elution	  fractions	  were	  pooled,	  dialysed	  and	  analysed	  on	  a	  10%	   SDS-­‐PAGE	   gel	   by	   coomassie	   staining	   (B,	   left	   figure)	   and	   western	  blotting	  (B,	  right	  figure)	  (1=	  Pre-­‐Dialysis,	  2=	  Post-­‐Dialysis	  and	  Post-­‐Dialysis	  pellet).	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Table	  5-­‐2:	  Protein	  concentrations	  of	  GCSF2QAT	  during	  the	  purification	  
process	  The	   table	   features	   the	   concentrations	   of	   GCSF2NAT	   at	   each	   stage	   of	   the	  purification	  process	  in	  the	  IMAC	  column.	  The	  elutions	  in	  bold	  typeface	  (7,	  8,	  









Total	  Protein	  	  	  	  	  	  	  	  	  
(mg)	  
%Recovery	  
Unfiltered	  load	   -­‐	   230	   503.12	   115.72	   -­‐	  Load	   -­‐	   230	   448.93	   103.25	   100	  Unbound	   -­‐	   230	   440.72	   101.37	   98	  Wash	  pH	  7.4	   -­‐	   1	   153.37	   0.15	   0.15	  Wash	  pH	  6.0	   	   1	   26.93	   0.03	   0.03	  E1	   50	   1	   150.08	   0.15	   0.15	  E2	   100	   1	   486.70	   0.49	   0.5	  E3	   100	   1	   260.10	   0.26	   0.25	  E4	   100	   1	   376.68	   0.38	   0.37	  E5	   200	   1	   567.16	   0.57	   0.55	  E6	   200	   1	   386.54	   0.39	   0.38	  
E7	   200	   1	   600.00	   0.60	   0.58	  
E8	   350	   1	   987.52	   0.99	   0.96	  
E9	   350	   1	   737.93	   0.74	   0.72	  




 Purification	  of	  GCSF4NAT	  5.3.2.3Culture	  media	  collected	  from	  GCSF4NAT	  expressing	  cells	  were	  concentrated	  and	  purified	  on	  a	  Nickel	  IMAC	  column.	  	  Western	  blot	  results	  showed	  that	  the	  majority	   of	   GCSF4NAT	   released	   from	   CHO	   cells	   were	   bound	   to	   the	   IMAC	  column	  with	  negligible	  amounts	  observed	  in	  the	  flow	  through	  (Figure	  5.5.A).	  High	  purity	  protein	  (~95%	  pure)	  was	  eluted	  using	  imidazole	  elution	  buffers	  with	   concentrations	   ranging	  between	  200mM	  and	  350mM	   (shown	   in	  bold	  typeface	   5,6,7,8	   &	   9	   in	   figure	   5.5.A).	   Elutions	   using	   with	   imidazole	  concentrations	   below	   or	   above	   this	   range	   (e.g.	   100mM	   and	   500mM)	  analysed	  were	  considered	  to	  be	  of	   low	  purity	  when	  analysed	  by	  SDS-­‐PAGE	  and	  were	  thus	  excluded	  from	  the	  study.	  High	  purity	  elutions	  were	  collected	  from	   IMAC	   and	   pooled	   together	   for	   dialysis.	   Dialysis	   was	   performed	   to	  remove	   any	   excess	   imidazole	   or	   other	   salts	   (Figure	   5.5.B).	   Pre	   and	   post	  dialysed	   proteins	   were	   measured	   by	   Bradford	   assay	   (Table	   5.3)	   and	  analysed	  by	  10%	  SDS	  PAGE	  followed	  by	  western	  blot	  analysis	  to	  confirm	  the	  integrity	  of	  purified	  GCSF4NAT	  protein	  and	  size.	  	  In	   addition,	   A	   few	   other	   LMW	  bands	   observed	   by	   10%	   SDS-­‐PAGE	   (A,	   left	  figure)	  were	  confirmed	  to	  be	  contaminants	  since	  no	  bands	  corresponding	  to	  these	  were	  observed	  after	  dialysis	  (B,	  left	  figure).	  Western	  blotting	  also	  did	  not	   pick	   up	   the	   LMW	   bands	   of	   elutions	   samples	   present	   post	   coomassie	  staining.	   	   Nevertheless,	   the	   LMW	   proteins	   were	   of	   significantly	   lower	  intensity	  when	  compared	  to	  the	  intact	  molecule,	  suggesting	  an	  appreciably	  high	   purity	   yield	   during	   purification	   A	   total	   of	   4.11mg	   of	   GCSF4NAT	  was	  recovered	  of	  >95%	  purity	  from	  1	  litre	  a	  media.	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Figure	  5-­‐5:	  Purification	  analysis	  of	  IMAC	  for	  GCSF4NAT	  10μl	   of	   protein	   samples	   from	   each	   stage	   of	   the	   GCSF2NAT	   purification	  process	  were	   separated	   on	   a	   10%	   SDS-­‐PAGE	   and	   stained	  with	   Coomassie	  blue	   for	   visualization	   (A,	   left	   figure),	   while	   100ng	   of	   same	   samples	   were	  analysed	   by	   Western	   blot.	   (A,	   right	   figure)	   (UL=Unfiltered	   load,	   L=Load,	  FL=Flow	   through,	   W=Wash	   pH7.4	   &	   6.0,	   M=Markers,	   4-­‐10=	   Elutions).	  Thereafter,	  active	  elution	  fractions	  were	  pooled,	  dialysed	  and	  analysed	  on	  a	  10%	   SDS-­‐PAGE	   gel	   by	   coomassie	   staining	   (B,	   left	   figure)	   and	   western	  blotting	  (B,	  right	  figure)	  (1=	  Pre-­‐Dialysis,	  2=	  Post-­‐Dialysis	  and	  Post-­‐Dialysis	  pellet).	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Table	  5-­‐3:	  Protein	  concentrations	  of	  GCSF4NAT	  during	  the	  purification	  
process	  The	   table	   features	   the	   concentrations	   of	   GCSF4NAT	   at	   each	   stage	   of	   the	  purification	   process	   in	   the	   IMAC	   column.	   The	   elutions	   in	   bold	   typeface	  









Total	  Protein	  	  	  	  	  	  	  	  	  
(mg)	  
Recovery	  
Unfiltered	  load	   -­‐	   228	   411.17	   93.75	   -­‐	  Load	   -­‐	   228	   452.22	   103.11	   100	  Unbound	   -­‐	   228	   381.61	   87.01	   84	  Wash	  pH	  7.4	   -­‐	   1	   72.91	   0.07	   0.07	  Wash	  pH	  6.0	   	   1	   22.00	   0.02	   0.02	  E1	   100	   1	   146.80	   0.15	   0.15	  E2	   100	   1	   360.26	   0.36	   0.35	  E3	   100	   1	   205.91	   0.21	   0.2	  E4	   200	   1	   629.56	   0.63	   0.61	  
E5	   200	   1	   616.42	   0.62	   0.6	  
E6	   200	   1	   856.16	   0.86	   0.83	  
E7	   350	   1	   565.52	   0.57	   0.55	  
E8	   350	   1	   1337.27	   1.34	   1.3	  E9	   350	   1	   1141.87	   1.14	   1.1	  E10	   500	   1	   595.07	   0.60	   0.58	  Pre-­‐Dialysis	   -­‐	   6	   902.13	   5.41	   5.2	  Post-­‐Dialysis	   -­‐	   6	   685.46	   4.11	   4	  Pellet	   -­‐	   0.1	   549.10	   0.05	   0.05	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 Purification	  of	  GCSF4QAT	  5.3.2.4Culture	  media	  collected	  from	  GCSF4QAT	  expressing	  cells	  were	  concentrated	  and	  purified	  on	  Nickel	   IMAC	  column.	  Western	  blotting	  results	  showed	  that	  the	   majority	   of	   GCSF4QAT	   protein	   bound	   to	   the	   IMAC	   column	   with	  negligible	  amounts	  observed	  in	  the	  flow	  through	  (Figure	  5.6.A).	  High	  purity	  protein	   (>90%	   pure)	   was	   eluted	   using	   imidazole	   elution	   buffers	   with	  concentrations	   ranging	   between	   200mM	   and	   350mM	   (shown	   in	   bold	  typeface	   9,10,11	   &	   12	   in	   figure	   5.6.A).	   Eluting	   using	   with	   imidazole	  concentrations	  below	  or	  above	  this	  range	  (100mM	  or	  500mM	  respectively)	  were	   observed	   to	   be	   of	   low	  purity	  when	   analysed	  by	   SDS-­‐PAGE	   and	  were	  thus	   excluded	   from	   the	   study.	   High	   purity	   elutions	   collected	   from	   IMAC	  purification	   were	   pooled	   together	   for	   dialysis.	   Dialysis	   was	   performed	   to	  remove	   any	   excess	   imidazole	   or	   other	   salts	   (Figure	   5.6.B).	   Pre	   and	   post	  dialysed	   proteins	   were	   measured	   by	   Bradford	   assay	   (Table	   5.4)	   and	  analysed	  by	  10%	  SDS	  PAGE	  followed	  by	  western	  blot	  analysis	  to	  confirm	  the	  purification	  and	  size	  of	  GCSF4QAT.	  	  Western	   blotting	   showed	   that	   the	   post-­‐dialysis	   GCSF2NAT	   protein	   was	  stable	   with	   very	   minimal	   protein	   degradation	   (visible	   as	   contaminated	  bands	  at	  20-­‐25kda).	  These	  LMW	  bands	  may	  have	  resulted	  from	  handling	  or	  partial	  cleavage	  of	  the	  tandem	  GCSF4QAT	  linker	  (the	  observed	  molecule	  at	  this	   low	   molecular	   weight	   was	   predicted	   to	   be	   an	   equivalent	   of	   a	   GCSF	  ligand	   and	  non-­‐glycosylated	   linker).	  Nevertheless,	   the	  LMW	  proteins	  were	  of	   significantly	   lower	   intensity	   when	   compared	   to	   the	   intact	   molecule,	  suggesting	   an	   appreciably	   high	  purity	   yield	   during	  purification.	   	   A	   total	   of	  1.11mg	  of	  GCSF4QAT	  was	  recovered	  of	  >90%	  purity	  from	  1	  litre	  a	  media.	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  Figure	  5-­‐6:	  Purification	  analysis	  of	  IMAC	  for	  GCSF4QAT	  10μl	   of	   protein	   samples	   from	   each	   stage	   of	   the	   GCSF4QAT	   purification	  process	  were	   separated	   on	   a	   10%	   SDS-­‐PAGE	   and	   stained	  with	   Coomassie	  blue	   for	   visualization	   (A,	   left	   figure),	   while	   100ng	   of	   same	   samples	   were	  analysed	   by	   Western	   blot.	   (A,	   right	   figure)	   (UL=Unfiltered	   load,	   L=Load,	  FL=Flow	  through,	  W=Wash	  pH7.4,	  M=Markers,	  1-­‐14=	  Elutions).	  Thereafter,	  active	  elution	  fractions	  were	  pooled,	  dialysed	  and	  analysed	  on	  a	  10%	  SDS-­‐PAGE	  gel	  by	  coomassie	  staining	  (B,	  left	  figure)	  and	  western	  blotting	  (B,	  right	  figure)	  (1=	  Pre-­‐Dialysis	  and	  2=	  Post-­‐Dialysis).	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Table	  5-­‐4:	  Concentrations	  of	  GCSF4QAT	  during	  the	  purification	  process	  The	   table	   features	   the	   concentrations	   of	   GCSF4QAT	   at	   each	   stage	   of	   the	  purification	  process	   in	   the	   IMAC	  column.	  The	  elutions	   in	  bold	   typeface	  (9,	  









Total	  Protein	  	  	  	  	  	  	  	  	  
(mg)	  
Recovery	  
Unfiltered	  load	   -­‐	   217	   1472.6	   319.55	   -­‐	  Load	   -­‐	   217	   700.82	   152.08	   100	  Unbound	   -­‐	   217	   638.42	   138.54	   91	  Wash	  pH	  7.4	   -­‐	   1	   247.62	   0.25	   0.16	  E1	   50	   1	   0.00	   0.00	   0	  E2	   50	   1	   0.00	   0.00	   0	  E3	   50	   1	   0.00	   0.00	   0	  E4	   100	   1	   0.00	   0.00	   0	  E5	   100	   1	   0.00	   0.00	   0	  E6	   100	   1	   208.21	   0.21	   0.14	  E7	   200	   1	   188.51	   0.19	   0.13	  E8	   200	   1	   165.52	   0.17	   0.11	  
E9	   200	   1	   667.98	   0.67	   0.44	  
E10	   350	   1	   671.26	   0.67	   0.44	  
E11	   350	   1	   444.66	   0.44	   0.29	  
E12	   350	   1	   214.78	   0.21	   0.14	  E13	   500	   1	   0.00	   0.00	   0	  Pre-­‐Dialysis	   -­‐	   5	   366.83	   1.83	   1.2	  Post-­‐Dialysis	   -­‐	   5	   222.33	   1.11	   0.7	  Pellet	   -­‐	   0.1	   41.71	   0.00	   0	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 Purification	  of	  GCSF8NAT	  5.3.2.5Analyses	   of	   GCSF8NAT	   protein	   pre-­‐	   and	   post-­‐	   purification	   by	   western	  blotting	  showed	  that	  the	  GCSF8NAT	  protein	  in	  the	  culture	  medium	  (secreted	  by	   CHO	   cells)	  was	   able	   to	   bind	   to	   the	   IMAC	   column.	  However,	   the	   results	  equally	   showed	   protein	   degradation	   for	   this	   particular	   tandem	   protein	   in	  both	  the	  crude	  culture	  media	  sample	  (Figure	  5.7.A)	  and	  the	  purified	  elution	  samples	   (Figure	   5.7.B).	   For	   the	   culture	   media	   samples,	   the	   western	   blot	  results	   (Figure	   5.7.A)	   showed	   consistent	   increase	   in	   expressed	   GCSF8NAT	  protein	   by	   CHO	   cells	   in	   the	   culture	   media	   during	   the	   9	   days	   incubation	  period,	   running	   at	   the	   right	  molecular	  weight	   of	  ~70kDa.	  However,	   below	  the	   target	   protein	   bands,	   another	   band	   running	   at	   a	   LMW	   (~37kDa)	   was	  also	  observed.	  The	  degradation	  increased	  during	  purification	  (seen	  as	  triplet	  bands	  running	  at	  ~15-­‐25kDa	  and	  another	  band	  at	  ~37kDa),	  suggesting	  that	  the	   tandem	   GCSF8NAT	   is	   not	   as	   stable	   as	   other	   tandems.	   Therefore,	   a	  number	   of	   measures	   were	   put	   in	   place	   to	   improve	   the	   stability	   of	   the	  protein.	  	  
	  
Figure	   5-­‐7:	   Western	   blot	   analysis	   of	   roller	   bottle	   media	   samples	   for	  
GCSF8NAT	  
(A)	  Results	  of	  western	  blot	  shows	  increasing	  protein	  expression	  from	  day	  0	  to	   day	   9	   for	  GCSF8NAT.	   (B)	  Western	   blot	   analysis	   showing	   IMAC	   elutions	  and	   dialysed	   samples	   for	   GCSF8NAT	   (M=Markers,	   1-­‐4=	   Elutions,	   5=	   Pre-­‐Dialysis,	  6=	  Post-­‐Dialysis	  &	  7=	  Post-­‐Dialyses	  Pellet).	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To	   improve	   the	   stability	  of	  GCSF8NAT,	   the	   incubation	   temperature	   for	   the	  stable	  cell	  growth	  and	  the	  culture	  volume	  were	  optimised.	  The	  CHO	  cells	  of	  GCSF8NAT	  were	  grown	   in	  2	   litres	  not	  1	   litre	  of	  Hyclone	  media	  at	  31°C	  (as	  against	  previous	  37°C).	  The	  cells	  were	  seeded	  at	  0.25x106/ml,	  and	  allowed	  to	   grow	   for	   7	   days	   or	   until	   viability	   reached	   70%	   (rather	   than	   9	   days	   or	  allowing	   the	   variability	   to	   decline	   just	   below	   70%,	   respectively).	  Western	  blotting	   analyses	   of	   the	   protein	   samples	   in	   the	   culture	  media	   (Figure	   5.8)	  showed	  a	  consistent	  increase	  in	  GCSF8NAT	  protein	  expression	  during	  the	  7	  days	   of	   cell	   growth	   (bands	   running	   at	   ~50-­‐70kDa)	   with	   no	   other	   visible	  bands	  observed,	  which	   is	  an	   indication	  that	  this	  adjustments	  enhanced	  the	  stability	  of	  GCSF8NAT.	  
	   	  
Figure	  5-­‐8:	  Western	  blot	  analysis	  of	  roller	  bottle	  media	  samples	  for	  
GCSF8NAT	  10μl	   samples	   taken	   at	   2-­‐3	   days	   intervals	   from	   GCSF8NAT	   culture	   media	  grown	   for	   7	   days	   were	   separated	   by	   SDS-­‐PAGE	   and	   analysed	   by	   western	  blotting.	   The	   western	   blot	   results	   shows	   a	   consistent	   increase	   in	   protein	  expression	  from	  day	  0	  to	  day	  7	  for	  GCSF8NAT.	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Figure	  5-­‐9:	  Purification	  analysis	  of	  IMAC	  samples	  for	  GCSF8NAT	  10μl	   of	   protein	   samples	   from	   each	   stage	   of	   the	   GCSF8NAT	   purification	  process	   were	   separated	   on	   a	   10%	   SDS-­‐PAGE	   and	   stained	  with	   coomassie	  blue	   for	   visualization	   (A,	   left	   figure),	   while	   100ng	   of	   same	   samples	   were	  analysed	   by	   western	   blot.	   (A,	   right	   figure)	   (UL=Unfiltered	   load,	   L=Load,	  FL=Flow	   through,	   W=Wash	   pH7.4,	   6.0	   M=Markers,	   1-­‐11=	   Elutions).	  Thereafter,	  active	  elution	  fractions	  were	  pooled,	  dialysed	  and	  analysed	  on	  a	  10%	  SDS-­‐PAGE	  gel	  by	  coomasie	  staining	  (B,	  left	  figure)	  and	  western	  blotting	  (B,	   right	   figure)	   (1=	   Pre-­‐Dialysis	   and	   2=	   Post-­‐Dialysis	   &	   3=	   Post-­‐Dialysis	  pellet).	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Table	  5-­‐5:	  Concentrations	  of	  GCSF8NAT	  during	  the	  purification	  process	  The	   table	   features	   the	   concentrations	   of	   GCSF4NAT	   at	   each	   stage	   of	   the	  purification	  process	  in	  the	  IMAC	  column.	  The	  elutions	  in	  bold	  typeface	  (4,	  5,	  









Total	  Protein	  	  	  	  	  	  	  	  	  
(mg)	  
Recovery	  
Unfiltered	  load	   -­‐	   220	   3787.74	   833.30	   -­‐	  Load	   -­‐	   220	   2162.52	   475.75	   100	  Unbound	   -­‐	   220	   2074.96	   456.49	   96	  Wash	  pH	  7.4	   -­‐	   1	   3952.36	   3.95	   0.83	  Wash	  pH	  6.0	   	   1	   22.42	   0.02	   0.004	  E3	   200	   1	   1129.25	   1.13	   0.24	  
E4	   200	   1	   814.01	   0.81	   0.17	  
E5	   200	   1	   1560.07	   1.56	   0.33	  
E6	   350	   1	   1528.55	   1.53	   0.32	  
E7	   350	   1	   589.84	   0.59	   0.33	  E8	   350	   1	   635.38	   0.64	   0.13	  Pre-­‐Dialysis	   -­‐	   4	   802.80	   3.21	   0.67	  Post-­‐Dialysis	   -­‐	   4	   727.50	   2.91	   0.61	  Pellet	   -­‐	   0.1	   601.40	   0.06	   0.01	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 Purification	  of	  GCSF8QAT	  5.3.2.6Crude	  culture	  medium	  from	  stable	  CHO	  cells	  expressing	  tandem	  GCSF8QAT	  proteins	   were	   passed	   over	   an	   IMAC	   column.	   Western	   blotting	   results	  showed	   that	   the	   majority	   of	   the	   tandem	   protein	   was	   bound	   to	   the	   IMAC	  column	  and	  only	  very	  little	  was	  observed	  in	  the	  flow	  through	  (Figure	  5.10.A	  Wrong).	  High	  purity	  protein	  was	  eluted	  between	  an	  imidazole	  concentration	  of	  200nM	  and	  350nM	  (shown	  in	  bold	  typeface	  5,	  6,	  7	  &	  8	  in	  figure	  5.10.A).	  Other	  elutions	  below	  or	  above	  this	  range	  (100nM	  and	  500nM	  respectively)	  were	   observed	   to	   be	   of	   low	   purity	  when	   analysed	   by	   SDS-­‐PAGE	   and	   thus	  excluded	   from	   the	   study.	   High	   purity	   elutions	   were	   collected	   and	   pooled	  together	   for	   dialysis	   so	   as	   to	   remove	   any	   excess	   imidazole	   or	   other	   salts	  (Figure	   5.10.B).	   Pre	   and	   post	   dialysed	   protein	   samples	  were	  measured	   by	  Bradford	   assay	   (Table	   5.6)	   and	   analysed	   by	   10%	   SDS	   PAGE	   followed	   by	  western	  blot	  analysis	  to	  confirm	  the	  purification	  and	  size	  of	  GCSF8QAT.	  	  Coomassie	   stained	   10%	   SDS	   –PAGE	   showed	   the	   post-­‐dialysis	   GCSF8QAT	  protein	  was	   stable	   as	   no	  degradation	  or	   other	   visible	   contaminated	  bands	  were	   observed	   by	   western	   blot.	   However,	   a	   very	   minimal	   amount	   of	  contaminated	  bands	  (presumed	  to	  be	  degraded	  tandem	  GCSF8QAT	  protein)	  are	   observed	   on	   the	   coomassie	   stained	   gel,	   which	   are	   insignificant	   when	  compared	  to	  the	  amount	  of	  pure	  protein	  running	  at	  the	  predicted	  molecular	  weight.	  A	  total	  of	  2.93mg	  of	  GCSF8QAT	  was	  recovered	  of	  >95%	  purity	  from	  1	  litre	  a	  media.	  	  	  	  Also,	   dimer	   formation	  was	   observed	   pre	   and	   post	   dialysis	  which	   could	   be	  seen	  as	  bands	  running	  at	  twice	  the	  predicted	  molecular	  weight	  of	  GCSF8QAT	  in	  the	  western	  blotting	  image	  (Figure	  5.10.B,	  right	  picture).	  




Figure	  5-­‐10:	  Purification	  development	  of	  IMAC	  for	  GCSF8QAT	  10μl	   of	   protein	   samples	   from	   each	   stage	   of	   the	   GCSF8QAT	   purification	  process	   were	   separated	   on	   a	   10%	   SDS-­‐PAGE	   and	   stained	  with	   coomassie	  blue	   for	   visualization	   (A,	   left	   figure),	   while	   100ng	   of	   same	   samples	   were	  analysed	   by	   Western	   blot.	   (A,	   right	   figure)	   (UL=Unfiltered	   load,	   L=Load,	  FL=Flow	   through,	   W=Wash	   pH7.4	   &	   6.0,	   M=Markers,	   1-­‐11=	   Elutions).	  Thereafter,	  active	  elution	  fractions	  were	  pooled,	  dialysed	  and	  analysed	  on	  a	  10%	  SDSPAGE	  gel	  by	  coomassie	  staining	  (B,	  left	  figure)	  and	  western	  blotting	  (B,	  right	  figure)	  (1=	  Pre-­‐Dialysis	  and	  2=	  Post-­‐Dialysis	  &	  3=	  Post-­‐D-­‐Pellet).	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Table	  5-­‐6:	  Protein	  concentrations	  of	  GCSF8QAT	  during	  the	  purification	  









Total	  Protein	  	  	  	  	  	  	  	  	  
(mg)	  
Recovery	  
Unfiltered	  load	   -­‐	   230	   1406.90	   323.59	   -­‐	  Load	   -­‐	   230	   1144.17	   263.16	   100	  Unbound	   -­‐	   230	   779.64	   179.32	   68	  Wash	  pH	  7.4	   -­‐	   1	   204.93	   0.20	   0.08	  E1	   50	   1	   116.26	   0.12	   0.05	  E2	   50	   1	   418.39	   0.42	   0.16	  E3	   200	   1	   707.39	   0.71	   0.27	  E4	   200	   1	   592.45	   0.59	   0.22	  
E5	   200	   1	   1232.84	   1.23	   0.5	  
E6	   350	   1	   1594.09	   1.59	   0.6	  
E7	   350	   1	   1091.63	   1.09	   0.4	  
E8	   350	   1	   1265.68	   1.27	   0.5	  E9	   500	   1	   648.28	   0.65	   0.24	  Pre-­‐Dialysis	   -­‐	   4	   990.80	   3.96	   1.5	  Post-­‐Dialysis	   -­‐	   4	   732.75	   2.93	   1.1	  Pellet	   -­‐	   0.1	   56.49	   0.01	   0.004	  	  	   	  
130	  
 Summary	  of	  GCSF	  Protein	  Tandems	  Purification	  5.3.2.7It	  was	  possible	  to	  purify	  GCSF	  tandems	  linked	  by	  a	  flexible	  linker	  (Gly4Ser)n	  from	   a	  mammalian	   cell	   line	   (CHO	  Flp-­‐In	   cells).	   	   The	   glycosylated	   tandems	  showed	  an	   increase	   in	  molecular	  weight	  above	   that	  of	   their	  controls	   (non-­‐glycosylated	   tandems)	   as	   assessed	   by	   SDS-­‐PAGE	   and	   western	   blotting	  (Figure	  5.11).	  
	  
Figure	  5-­‐11:	  Purified	  GCSF	  tandems	  analysed	  by	  coomassie	  blue	  and	  
western	  blot	  
	  In	   addition,	   both	   coomassie	   blue	   and	   western	   blotting	   analyses	   showed	   a	  large	   smeared	   band	   for	   each	   individual	   glycosylated	   GCSF	   tandem	   when	  compared	   to	   the	   corresponding	   non-­‐glycosylated	   tandem	   control,	   which	  could	  be	  attributed	  to	  a	   large	  heterogeneous	  protein	  population.	  The	  reason	  for	   the	   observed	   increasing	   degree	   of	   population	   heterogeneity	   across	   the	  tandem	  GCSF	  proteins	  will	  be	  discussed	  later.	  	   	  
(A)	   Purified	   GCSF	   tandem	  molecules	   analysed	   by	   coomassie	  blue.	   Lane	   1;	   GCSF2QAT,	   Lane	   2;	  GCSF2NAT,	   Lane	   3;	   GCSF4QAT,	  Lane	   4;	   GCSF4NAT,	   Lane	   5;	  GCSF8QAT,	   Lane	   6;	   GCSF8NAT,	  Lane	   M;	   1kb	   marker.	   A	   total	   of	  7.5µg	  protein	  was	  loaded	  per	  lane	  
(B)	   Purified	   GCSF	   tandem	  molecules	   analysed	   by	   western	  blot.	   	   Lane	   1;	   GCSF	   2QAT,	   Lane	   2;	  GCSF2NAT,	   Lane	   3;	   GCSF	   4QAT,	  Lane	   4;	   GCSF4NAT,	   Lane	   5;	   GCSF	  8QAT,	  Lane	  6;	  GCSF8NAT.	  A	  total	  of	  100ng	  protein	  was	  loaded	  per	  lane	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 Discussion	  5.4The	   expression	   studies	   of	   the	   GCSF	   tandems	   containing	   a	   C-­‐terminal	  histidine	   tag	   showed	   that	   the	   target	   genes	   could	   be	   stably	   expressed	   in	   a	  CHO	   cell	   line.	   However,	   glycosylated	   tandems	   showed	   high	   level	   of	  expression	   compared	   to	   non-­‐glycosylated	   tandems	   (i.e.	   both	   2QAT	   and	  8QAT	  showed	   the	   lowest	   level	  of	  expression	  during	  culture	  growth).	  Since	  there	   is	  no	  difference	  between	  glycosylated	  and	  non-­‐glycosylated	   tandems	  except	  for	  the	  linker,	  it	  seems	  that	  the	  presence	  of	  NAT	  motifs	  is	  enhancing	  DNA	   transcription	   more	   than	   QAT	   motifs,	   which	   in	   turn	   increased	   the	  productivity	  of	  protein.	  	  The	   purification	   data	   indicated	   that	   IMAC	  was	   an	   appropriate	  method	   for	  purifying	  the	  GCSF	  tandems.	  All	  GCSF	  tandems	  were	  easily	  eluted	  from	  the	  IMAC	   by	   adding	   a	   high	   concentration	   of	   imidazole	   (an	   analogue	   of	  Histidine).	   IMAC	   permits	   a	   fast	   and	   easy	   way	   for	   purification	   due	   to	   the	  strong	  affinity	  of	  a	  nickel-­‐complex	  Ni2+-­‐NTA	  to	  the	  histidine	  sequences	  of	  the	  GCSF	  tandems.	  Consequently,	  all	  constructs	  produced	  sufficient	  quantities	  of	  pure	   protein	   (between	   1	   to	   4mg	   per	   litre	   as	   assessed	   by	  Bradford	   assay),	  which	  was	   sufficient	   for	   the	  PK/PD	   studies,	   and	  was	   considered	   to	  be	  90-­‐95%	  pure	  as	  assessed	  by	  SDS-­‐PAGE	  followed	  by	  western	  blotting	  to	  confirm	  the	  molecular	  weight	  and	  integrity	  of	  each	  construct.	  Some	  contaminating	  bands	  were	  observed	  for	  all	  GCSF	  tandems	  during	  the	  purification	  process	  as	  evidenced	  by	  coomassie	  staining.	  While	  these	  bands	  appeared	  to	  be	  degraded	  products,	  the	  amount	  of	  degradation	  observed	  was	  negligible	   when	   compared	   to	   the	   stable	   non-­‐degraded	   proteins.	  Interestingly,	   most	   of	   the	   contaminated	   or	   degraded	   GCSF	   tandems	   were	  separated	   from	   the	   stable	   and	   pure	   proteins	   by	   dialysis	   through	   a	  semipermeable	   membrane	   with	   10kDa	   molecular	   weight	   cut-­‐off	   (e.g.	   a	  cellulose	   membrane	   with	   pores).	   Dialysis	   technique	   is	   an	   important	   step	  after	   purification	   for	   removing	   any	   excess	   imidazole,	   salts	   or	   other	   small	  molecules.	   Molecules	   that	   have	   sizes	   bigger	   than	   the	   cellulose	   membrane	  pores	  were	   retained	   inside	   the	  dialysis	  bag,	  while	  other	   smaller	  molecules	  or	   salts	   diffuse	   through	   the	   pores	   into	   the	   dialyses	   buffer	   Post-­‐dialysis	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analysis	  by	  coomassie	  staining	  or	  western	  blotting	  showed	  all	  GCSF	  tandems	  to	  be	  of	  the	  correct	  molecular	  weight	  with	  no	  degradation	  as	  there	  were	  no	  visible	   contaminants	   or	   degraded	   bands	   observed,	   suggesting	   that	   the	  dialysis	  was	  efficient	  for	  removing	  the	  contaminants	  for	  most	  of	  the	  purified	  samples.	  	  However,	  for	  the	  majority	  of	  tandem	  molecules	  expression	  and	  purification	  was	   completed	   without	   difficulty,	   however	   for	   one	   tandem	   in	   particular	  (GCSF8NAT)	   we	   experienced	   difficulties	   with	   the	   stability	   during	   the	  expression	   and	   purification.	   It	  was	   difficult	   to	   determine	  what	   caused	   the	  degradation,	   as	   other	   tandems	  were	   stable	   when	   purified	   using	   the	   same	  purification	   method.	   To	   investigate	   the	   reason	   for	   GCSF8NAT	   instability,	  samples	  were	   taken	  during	  cell	  growth	   in	  roller	  bottles	  before,	  during	  and	  after	   the	   purification.	   The	   protein	   samples	   were	   analysed	   by	   western	  blotting,	  and	  the	  results	  revealed	  that	  the	  degradation	  occurred	  during	  both	  protein	  expression	  and	  purification	  processes.	  Consequently,	  the	  conditions	  for	   expressions	   and	  purifications	  were	  modified	  with	   a	   view	   to	   improving	  the	  stability	  of	  GCSF8NAT	  during	  the	  entire	  protein	  production	  processes.	  	  Firstly	  the	  incubation	  time	  was	  reduced	  from	  9	  days	  to	  7	  days	  so	  that	  cells	  could	   be	   harvested	   at	   a	   higher	   viability	   (60%	   or	   higher)	   as	   it	  was	   earlier	  noticed	   that	   growing	   CHO	   cells	   for	   longer	   time	   points	   led	   to	   increased	  protein	  degradation,	  probably	  due	  to	  increased	  protease	  activity	  associated	  with	  the	  increased	  cell	  death.	  	  The	  temperature	  at	  which	  growth	  and	  expression	  was	  also	  reduced	  to	  31°C	  from	  37°C.	  These	  adjustments	  made	  to	  the	  conditions	  of	  protein	  expression	  were	   necessary,	   as	   it	   has	   been	   shown	   that	   while	   longer	   linkers	   were	  preferable	   for	   the	   preservation	   of	   the	   independent	   folding	   and	   biological	  activities	   of	   two	   proteins,	   they	   could	   also	   be	   easily	   cleaved	   by	   proteases,	  because	   the	   structures	   and	   the	   adjacent	   regions	   of	   these	   linkers	   are	  more	  loosely	  connected	  (Liu	  et	  al.,	  2005).	  	  A	  similar	  pattern	  was	  observed	  with	  the	  GCSF8NAT,	  which	  has	  a	  long	  linker	  similar	   to	   GCSF8QAT	   (non-­‐glycosylated	   control).	   In	   the	   initial	   expression	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studies	   under	   the	   same	   conditions,	   GCSF8NAT	   protein	   was	   degraded	  whereas	   GCSF8QAT	   was	   not.	   Another	   contributory	   factor	   to	   GCSF8NAT	  degradation	   could	   be	   associated	   with	   the	   presence	   of	   8	   N-­‐linked	  glycosylation	   sites,	  which	   restricts	   intramolecular	   interaction	   between	   the	  two	  GCSF	  ligands	  and	  thus	  leaving	  the	  linker	  exposed	  to	  proteolytic	  attack.	  However,	   During	   protein	   expression,	   there	   is	   a	   probability	   that	   the	   GCSF	  molecules	  in	  GCSF8QAT	  (non-­‐glycosylated	  control)	  for	  instance	  would	  bind	  to	   each	   other	   due	   to	   the	   formation	   of	   intra-­‐molecular	   disulphide	   bond	  resulting	   from	   the	   interaction	   of	   free	   cysteine	   residues	   (Cys17)	   that	  were	  present	  on	  the	  individual	  GCSF	  molecule	  (which	  was	  observed	  to	  be	  the	  case	  as	  dimer	  formation	  was	  earlier	  observed	  for	  the	  tandem	  GCSF8QAT	  but	  not	  in	   GCSF8NAT)	   Consequently,	   the	   binding	   of	   the	   GCSF	   molecules	   in	  GCSF8QAT	  would	  protect	  the	  linker,	  to	  an	  extent,	  from	  proteolytic	  cleavage.	  	  The	  beneficiary	  effect	  of	  decreasing	   culture	   temperature	  was	   seen	  on	  EPO	  production	   in	   CHO	   cell	   line.	   Consequently,	   a	   2.5-­‐fold	   increase	   in	   the	  maximum	   concentration	   of	   EPO	   was	   achieved	   by	   decreasing	   temperature	  from	   37°C	   to	   33°C	   (Yoon	   et	   al.,	   2003).	   Lowering	   the	   culture	   temperature	  increase	  protein	   expression	  by	   slowing	  down	  protein	   translation	  and	   thus	  facilitates	  correct	  folding	  of	  protein.	  Lowering	   the	   temperature	   during	   culture	   of	   GCSF8NAT	   equally	   enhanced	  the	  protein	  production	  when	  compared	  to	  other	  tandem	  GCSF	  proteins.	  This	  is	  evidenced	  by	  a	  49mg/L	  productivity	  with	  GCSF8NAT	  at	  day	  7	  during	  cell	  growth	  in	  roller	  bottles	  compared	  to	  21mg/L,	  19.3mg/L,	  8.1mg/L,	  34.5mg/L	  and	  16.3mg/L	  yield	  with	  GCSF4NAT,	  GCSF2NAT,	  GCSF2QAT,	  GCSF4QAT	  and	  GCSF8QAT	  respectively.	  Also,	  the	  adjustments	  made	  to	  the	  conditions	  of	  expression	  cells	  growth	  for	  the	   tandem	   GCSF8NAT	   was	   further	   justified	   by	   the	   abrogation	   of	   GCSF	  protein	   degradation	   that	   were	   earlier	   observed	   during	   initial	   protein	  expression	   and	   purification.	   To	   prevent	   potential	   protein	   degradation	  during	   the	   purification	   process,	   especially	   for	   GCSF8NAT,	   all	   the	   tandems	  GCSF	  purifications	  were	  purified	  at	  4°C.	   	  The	  western	  blotting	  was	  used	  to	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confirm	  the	  stability	  since	  degraded	  proteins	  were	  not	  easily	  visible	   in	   the	  gel	   with	   coomassie	   staining	   (~5-­‐10μg	   purified	   protein),	   whereas	   western	  blot	  offers	  a	  better	  detection	  with	  ~0.1μg	  of	  protein	  load.	  	  Tandem	  proteins	  analysed	  by	  SDS-­‐PAGE	  and	  western	  blotting	  also	  revealed	  an	   obvious	   increase	   in	   the	   population	   heterogeneity	   in	   glycosylated	  tandems	  that	  was	  not	  apparent	   in	  the	  non-­‐glycosylated	  tandem	  controls.	  A	  possible	  reason	  for	  the	  observed	  high	  heterogeneity	  of	  the	  population	  could	  be	  due	  to	  both	  macro-­‐	  (glycosylation	  site	  occupancy)	  and	  micro-­‐	  (structure	  of	  glycosylation	  relating	  length,	  composition	  and	  branching	  pattern),	  which	  is	   frequently	   present	   in	   the	   final	   population	   of	   recombinantly	   expressed	  glycosylated	   proteins	   (Sola	   and	   Griebenow,	   2009	   and	   Sinclair	   and	   Elliott,	  2005).	  In	   conclusion	   the	   glycosylated	   GCSF	   tandems	   and	   their	   respective	   non-­‐glycosylated	  controls	  were	  successfully	  purified	  by	  IMAC	  and	  the	  purity	  was	  90-­‐95%	   as	   assessed	   by	   SDS-­‐PAGE	   and	   western	   blotting.	   However,	   before	  being	   passed	   over	   for	   the	   future	   PK/PD	   in	   vivo	   study	   it	   was	   required	   to	  measure	  their	  biological	  activity.	  This	  will	  be	  discussed	  in	  the	  next	  chapter.	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 Results	  3:	  In	  vitro	  Bioactivity	  Evaluation	  and	  6.
Temperature	  Stability	  of	  GCSF	  Tandems	  
 Summary	  6.1Purification	   of	   glycosylated	   and	   non-­‐glycosylated	   GCSF	   tandem	  molecules	  was	   achievable,	   as	   evidenced	   by	   the	   previous	   chapter.	   The	   purified	  glycosylated	   tandem	   molecules	   also	   showed	   increased	   molecular	   weight	  above	   that	   of	   controls	  when	   analysed	   by	   SDS-­‐PAGE	   and	  western	   blotting.	  However,	  before	  analysing	  the	  pharmacokinetics	  and	  pharmacodynamics	  of	  these	  tandem	  molecules,	  it	  is	  imperative	  to	  analyse	  their	  in	  vitro	  bioactivity	  and	  stability.	  In	  this	  study,	  the	  in	  vitro	  bioactivity	  of	  the	  GCSF	  tandems	  was	  tested	  using	  an	  AML-­‐193	  proliferation	  assay.	  These	  cells	  have	  been	  shown	  to	   proliferate	   in	   response	   to	   GCSF	   treatment.	   The	   short-­‐term	   stability	   of	  GCSF	   tandems	   was	   investigated	   by	   two	   different	   ways.	   First	   by	   testing	  samples	   from	   the	   stability	   experiment	   in	   the	  AML-­‐193	  assay	  at	  37°C	   for	  3	  days.	   Second	   by	   testing	   purified	   samples	   from	   stock	   at	   3	   different	  temperatures	   (4°C,	   room	   temperature	   (RmT)	  and	   -­‐80°C	   freeze	   thaw	   (F/T)	  cycles)	   over	   an	   8	   day	   period.	   The	   results	   indicated	   significant	   increased	  bioactivity	  for	  GCSF	  tandems	  compared	  with	  rhGCSF	  (EC50	  for	  tandems	  were	  about	   3-­‐fold	   lower	   than	   that	   for	   rhGCSF).	   All	   GCSF	   tandems	   showed	   good	  stability	   with	   no	   visible	   signs	   of	   degradation	   under	   all	   conditions	   studied	  (4°C,	   RmT	   and	   -­‐80°C	   freeze	   thaw)	   over	   an	   8	   days	   period	   and	   also	   after	  incubation	  with	  AML-­‐193	  cells	  at	  37°C	  for	  3	  days.	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 Introduction	  6.2Acute	   myeloid	   leukemia	   (AML)	   is	   a	   disorder	   of	   the	   myeloid	   lineage	  characterized	   by	   the	   quick	   growth	   of	   abnormal	  white	   blood	   cells	  (WBCs)	  that	   accumulate	   in	   the	   bone	   marrow	  and	   result	   of	   exhibiting	   a	   new	  morphological	   and	   immunophenotypic	   features	   to	   the	   myeloid	   lineage	  (Vardiman	  et	  al.,	  2009).	  	  AML-­‐193	  is	  one	  of	  8	  cell	  lines	  that	  were	  established	  from	  50	  patients	  with	  childhood	  acute	  leukemia	  (Lange	  et	  al.,	  1987,	  Valtieri	  et	   al.,	   1991).	  From	   those	  eight	   cell	   lines,	  AML-­‐193	  was	  derived	   from	  a	  13-­‐year-­‐old	  female	  with	  acute	  myeloid	  leukemia,	  which	  was	  then	  the	  only	  cell	  line	   that	   required	   conditioned	   media	   to	   grow	   and	   proliferate.	   In	   vitro,	  cytokines	   such	   as	   GM-­‐CSF	   and	   GCSF	   have	   been	   identified	   to	   support	   the	  growth	   and	   proliferation	   of	   hematopoietic	   stem	   cells.	   Interestingly,	   these	  cytokines	  have	  also	  been	  shown	  to	  support	  the	  growth	  and	  proliferation	  of	  AML-­‐193	   cells	   (Favreau	   and	   Sathyanarayana,	   2012).	   Based	   on	   these	  findings,	   we	   hypothesized	   that	   AML-­‐193	   cell	   line	   would	   proliferate	   in	  response	  to	  GCSF	  tandem	  proteins	  in	  a	  manner	  comparable	  to	  the	  available	  rhGCSF.	   Therefore	   the	   proliferation	   bioassay	   was	   used	   to	   test	   the	  hypothesis.	  	  The	  basic	  proliferation	  bioassay	  is	  a	  colorimetric	  method	  routinely	  used	  to	  determine	  the	  number	  of	  viable	  AML-­‐193	  cells.	  As	  earlier	  mentioned,	  AML-­‐193	   growth	   is	   stimulated	   in	   the	   presence	   of	   an	   active	   GCSF	   protein.	   A	  commercially	   available	   MTS	   reagent	   which	   contains	   a	   tetrazolium	  compound	   and	   an	   electron	   coupling	   reagent	   is	   used	   to	   estimate	   the	  proliferation	   of	   cells.	   Generally,	   metabolically	   active	   cells	   produce	  dehydrogenase	   enzymes	   that	   produce	   NADPH	   into	   the	   medium	   as	   a	   by-­‐product.	  The	  produced	  NADPH	  reduces	   the	  MTS	   tetrazolium	  compound	   in	  the	   medium	   to	   give	   a	   yellow	   coloration	   (formazan	   product	   is	   soluble	   in	  tissue	   culture	   media),	   which	   can	   be	   read	   photometrically	   at	   490nm	  (Berridge	  and	  Tan,	  1993).	  The	  MTS	  compound	  is	  hydrolyzed	  by	  the	  NADPH	  producing	  cells	   into	  a	  yellow	  coloured	  product.	  The	   intensity	  of	   the	  colour	  produced	  is	  directly	  proportional	  to	  the	  concentration	  of	  the	  active	  enzymes	  present	   in	   the	  medium,	  which	   in	   turn	   is	  dependent	  on	   the	  number	  of	  cells	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present	   (Cory	  et	  al.,	   1991).	  Therefore	   cell	   growth	   is	  directly	   related	   to	   the	  level	  of	  NADPH	  in	  the	  media	  and	  hence	  the	  activity	  of	  GCSF.	  In	   the	   modified	   proliferation	   assay	   used	   in	   this	   study,	   the	   AML-­‐193	   cells	  were	   seeded	   in	   96	   well	   plates	   to	   the	   rhGCSF,	   GCSF	   tandems	   and	   their	  controls	   separately	  and	  grown	   for	  3	  days.	  MTS	  reagent	  was	   then	  added	   to	  estimate	  the	  proliferation	  of	  AML-­‐193	  cells	  that	  respond	  to	  the	  presence	  of	  GCSF	  in	  the	  medium.	  	  Readings	  were	  taken	  at	  490nm	  every	  40	  minutes	  for	  2	  hrs	  using	  a	  96	  well	  plate	  reader.	  	  
 Aim	  and	  Hypothesis	  	  6.2.1It	  is	  essential	  that	  the	  biological	  activity	  of	  a	  protein	  be	  retained	  following	  its	  purification.	   Maintaining	   the	   activity	   of	   the	   target	   protein	   is	   especially	  important	  for	  the	  future	  pharmacokinetic	  (PK)	  in	  vivo	  study.	  	  Also,	  proteins	  are	   best	   known	   to	   perform	   their	   biological	   functions	   when	   in	   the	   right	  conformation.	  Hence,	  it	  is	  essential	  to	  investigate	  the	  biological	  activities	  of	  the	   GCSF	   tandems,	   at	   different	   temperature	   conditions	   to	   determine	   the	  stability	  of	   the	  molecules.	  Therefore,	   the	  aim	  of	   this	   chapter	   is	   to	  measure	  the	  biological	  activity	  of	  the	  glycosylated	  GCSF	  tandems	  using	  AML-­‐193	  cell	  line,	   and	   to	   determine	   the	   short-­‐term	   stability	   of	   these	   constructs	   under	  different	   temperatures.	   The	   stability	   was	   assessed	   at	   3	   different	  temperatures	   (4°C,	   RmT	   and	   -­‐80°C	   freeze	   thaw	   (F/T)	   cycles)	   over	   8	   days	  period.	   Also,	   samples	   of	   GCSF	   tandems	   were	   taken	   after	   incubation	   with	  AML-­‐193	  cells	  at	  37°C	   for	  3	  days	  and	  tested	  for	  stability.	  We	  hypothesized	  that	  our	  GCSF	   tandems	  will	  be	  biologically	  active	  and	  stable	   similar	   to	   the	  rhGCSF	  post-­‐purification.	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 Results	  6.3
 In	  vitro	  Bioactivity	  Evaluation	  6.3.1The	   biological	   activity	   of	   GCSF	   tandems	  was	   evaluated	   using	   an	   AML-­‐193	  cell-­‐based	   proliferation	   assay.	   AML-­‐193	   cells	   were	   removed	   from	   liquid	  nitrogen	  storage	  and	  prepared	  as	  described	  in	  Section	  3.8.5.1.	  50µl	  of	  serial	  dilutions	   of	   rhGCSF	   and	   GCSF	   tandem	   proteins	   were	   added	   into	   the	  appropriate	  well	  of	  a	  96-­‐well	  microplate.	  50µl	  of	  AML-­‐193	  cell	  suspension	  at	  a	   density	   of	   5x105	   cells/ml	  was	   then	   added	   to	   the	   same	  plate	   and	   shaken	  gently	   to	   allow	   mixing	   of	   cell	   suspension	   with	   samples.	   	   Control	   wells	  contained	  	  assay	  medium	  and	  AML-­‐193	  cells	  	  (50µl	  +	  50µl)	  and	  blank	  wells	  contained	   only	   assay	   medium	   (100µl)	   as	   previously	   described	   (Section	  3.8.5.2).	  	  	  Cells	   were	   exposed	   to	   different	   concentrations	   of	   test	   proteins	   in	   CO2	  incubator	   (5%	  CO2,	   37°C)	   and	   then	  20µl	   of	  MTS	   (Celltiter	   96	   aqueous	  one	  solution	   cell	  proliferation	  assay	   from	  Promega)	  was	  added	   to	   each	  well	   to	  give	  a	  colour	  change	  that	  determines	  the	  number	  of	  viable	  cells	  in	  the	  assay.	  	  Readings	   were	   taken	   every	   40	   minutes	   for	   2	   hrs	   of	   incubation	   (5%	   CO2,	  37°C).	  The	  plates	  were	   finally	  read	  at	  490nm	  using	  a	  BioTek	  FLX800	  plate	  reader	   and	   Gen5	   software	   as	   previously	   described	   (Section	   3.8.5.2).	   The	  results	   from	  different	   concentrations	  of	   test	  protein	  were	   subtracted	   from	  control	  wells	  (AML-­‐193	  cells	  only)	  obtained	  at	  490nm.	  Each	  experiment	  was	  repeated	  at	  least	  in	  triplicate.	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 In	  vitro	  Biological	  Activity	  of	  GCSF2NAT	  and	  Its	  Control	  6.3.1.1The	   results	   indicate	   that	   rhGCSF,	   purified	   GCSF2NAT	   and	   GCSF2QAT	  tandems	   can	   stimulate	   the	   proliferation	   of	   the	   AML-­‐193	   cell	   line.	   Both	  purified	   GCSF2NAT	   and	   GCSF2QAT	   tandems	   show	   a	   significant	   biological	  activity	   with	   both	   standard	   curves	   shifted	   to	   the	   left	   in	   comparison	   to	  rhGCSF.	  Besides	   this,	  both	   tandems	  show	  a	  greater	  maximal	  stimulation	  of	  AML193	  cells	  compared	  to	  rhGCSF	  (Figure	  6.1.A).	  Based	  on	  the	   findings	  of	  sigmoidal	  dose	   response	   curves	   (GraphPad	  Prism),	   the	  values	  of	  EC50	   (the	  concentration	   which	   causes	   50%	   of	   maximal	   response)	   for	   each	   protein	  were	  calculated	  (Figure	  6.1.B).	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Figure	  6-­‐1:	  Proliferation	  of	  AML-­‐193	  cells	  in	  the	  presence	  of	  tandems	  
and	  rhGCSF	  
(A)	   AML-­‐193	   cells	   were	   stimulated	   with	   GCSF2NAT,	   GCSF2QAT	   tandems	  and	  rhGCSF.	  The	  absorbance	  values,	  which	  are	   indicative	  of	   the	  number	  of	  live	   cells	   present,	   were	   plotted	   against	   the	   natural	   logarithm	   of	   the	   GCSF	  concentrations	   (rhGCSF	   and	   GCSF	   tandems).	   Sigmoidal	   dose-­‐response	   fit	  (for	   variable	   slope)	   was	   used	   for	   the	   data	   analyses.	   (B)	   EC50	   values	  calculated	   for	   GCSF2NAT,	   GCSF2QAT	   tandem	   &	   rhGCSF	   using	   GraphPad	  Prism	   software.	   Significance	   between	   EC50	   values	   of	   GCSF	   tandems	   and	  rhGCSF	   was	   performed	   with	   Graphpad	   prism	   using	   Mann-­‐Whitney	   test.	  Results	   are	   given	   as	   standard	  mean	   of	   error	   (SEM)	   for	   triplicate	   wells	   in	  graph	  A	  and	  triplicate	  EC50	  in	  graph	  B.	  (*	  =	  p	  value	  of	  <0.05)	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 In	  vitro	  Biological	  Activity	  of	  GCSF4NAT	  and	  Its	  Control	  6.3.1.2The	   results	   below	   show	   that	   rhGCSF,	   GCSF4NAT	   and	   GCSF4QAT	   can	  stimulate	   the	   proliferation	   of	   the	   AML-­‐193	   cell	   line.	   Both	   tandems	   show	  significant	  increased	  bioactivity	  with	  both	  standard	  curves	  shifted	  to	  the	  left	  in	  comparison	  to	  rhGCSF	  (Figure	  6.2.A).	  	  	  Based	  on	  the	  findings	  of	  sigmoidal	  dose	  response	  curves	  (GraphPad	  Prism),	   the	  values	  of	  EC50	  were	  shown	  in	  the	  Figure	  6.2.B.	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Figure	  6-­‐2:	  Proliferation	  of	  AML-­‐193	  cells	  in	  the	  presence	  of	  tandems	  
and	  rhGCSF	  
(A)	   AML-­‐193	   cells	   were	   stimulated	   with	   GCSF4NAT,	   GCSF4QAT	   tandems	  and	   rhGCSF.	   (B)	   Shows	   EC50	   values	   calculated	   for	   GCSF4NAT,	   GCSF4QAT	  tandem	   &	   rhGCSF	  Graph	   using	   Pad	   Prism	   software.	   Significance	   between	  EC50	   values	   of	   GCSF	   tandems	   and	   rhGCSF	   was	   performed	   with	   GraphPad	  Prism	  using	  Mann-­‐Whitney	  test.	  Results	  are	  given	  as	  SEM	  for	  triplicate	  wells	  in	  graph	  A	  and	  triplicate	  EC50	  in	  graph	  B.	  (*	  =	  p	  value	  of	  <0.05)	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 In	  vitro	  Biological	  Activity	  of	  GCSF8NAT	  and	  Its	  Control	  6.3.1.3The	  bioactivity	  results	   for	  GCSF8NAT	  &	  GCSF8QAT	  show	  similar	  results	   to	  previous	   tandem	   proteins	   and	   together	   with	   rhGCSF	   can	   stimulate	   the	  proliferation	   of	   the	   AML-­‐193	   cell	   line.	   Both	   tandems	   show	   significant	  increased	  biological	  activity	  with	  both	  standard	  curves	  shifted	  to	  the	  left	  in	  comparison	  to	  rhGCSF.	  Both	  tandems	  also	  show	  a	  greater	  maximal	   level	  of	  activity	  than	  rhGCSF	  (Figure	  6.3.A).	  Based	  on	  the	  findings	  of	  sigmoidal	  dose	  response	   curves	   (GraphPad	   Prism),	   the	   values	   of	   EC50	   were	   calculated	  (Figure	  6.3.B).	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Figure	  6-­‐3:	  Proliferation	  of	  AML-­‐193	  cells	  in	  the	  presence	  of	  tandems	  
and	  rhGCSF	  
(A)	   AML-­‐193	   cells	   were	   stimulated	   with	   GCSF8NAT,	   GCSF8QAT	   tandems	  and	   rhGCSF.	   (B)	   Shows	   EC50	   values	   calculated	   for	   GCSF4NAT,	   GCSF4QAT	  tandem	   &	   rhGCSF	   using	   GraphPad	   Prism	   software.	   Significance	   between	  EC50	   values	   of	   GCSF	   tandems	   and	   rhGCSF	   was	   performed	   with	   GraphPad	  Prism	  using	  Mann-­‐Whitney	  test.	  Results	  are	  given	  as	  SEM	  for	  triplicate	  wells	  in	  graph	  A	  and	  triplicate	  EC50	  in	  graph	  B.	  (*	  =	  p	  value	  of	  <0.05)	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 Short	  Term	  Stability	  of	  GCSF	  Tandem	  Molecules	  	  6.3.2The	   protein	   stability	  was	   assessed	   by	   two	   different	  ways.	   First	   by	   testing	  samples	   from	   the	   stability	   experiment	   in	   the	   AML-­‐193	   assay.	   Second	   by	  testing	  purified	  samples	  from	  stock	  at	  3	  different	  temperatures	  (4°C,	   room	  temperature	  (RmT)	  and	  -­‐80°C	  freeze	  thaw	  (F/T)	  cycles)	  over	  8	  days	  period.	  	  
 Protein	  Samples	  from	  the	  Stability	  Experiment	  in	  the	  6.3.2.1
AML-­‐193	  Assay	  	  During	  the	  AML-­‐193	  stability	  experiment,	  5μg	  of	  each	  tandem	  protein	  were	  incubated	   with	   AML-­‐193	   cells	   at	   37°C	   for	   3	   days.	   Protein	   samples	   were	  taken	  and	  analysed	  by	  10%	  SDS-­‐PAGE	  gel	  and	  protein	  bands	  visualised	  by	  western	  blotting	  (Figure	  6.4).	  This	  step	  is	   important	  to	  determine	  whether	  GCSF	  protein	  tandems	  are	  degraded	  or	  not	  during	  incubation.	  	  
	  
Figure	  6-­‐4:	  Stability	  of	  GCSF	  tandems	  after	  incubation	  with	  AML-­‐193	  
cells	  Western	  blot	  with	   anti	  GCSF	  antibodies	   show	  no	  visible	  degradation	   in	   all	  GCSF	  tandems	  (Lane	  1;	  GCSF2QAT,	  Lane	  2;	  GCSF2NAT,	  Lane	  3;	  GCSF4QAT,	  Lane	  4;	  GCSF4NAT,	  Lane	  6;	  GCSF8QAT,	  Lane	  7;	  GCSF8NAT).	  A	  total	  of	  100ng	  protein	  was	  loaded	  per	  lane.	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Figure	  6-­‐6:	  Temperature	  stability	  of	  GCSF2QAT	  Coomassie	  blue	  and	  western	  blot	  with	  anti	  GCSF	  antibodies	  show	  GCSF2QAT	  under	   different	   temperatures	   stability	   conditions.	   In	   each	   gel	   the	   lanes	  contain	  samples	  taken	  at	  D0,	  D1,	  D4	  and	  D8	  stored	  at	  RmT,	  4°C,	  and	  -­‐80°C	  thawed/refrozen	  in	  each	  day.	  No	  visible	  degradation	  in	  protein	  tandems	  in	  any	  sample	  under	  all	  conditions	  studied	  (4°C,	  RmT	  and	  -­‐80°C	   freeze	  thaw)	  over	  the	  8	  days	  period.	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Figure	  6-­‐10:	  Temperature	  stability	  of	  GCSF8QAT	  Coomassie	  blue	  and	  western	  blot	  with	  anti	  GCSF	  antibodies	  show	  GCSF8QAT	  under	   different	   temperatures	   stability	   conditions.	   In	   each	   gel	   the	   lanes	  contain	  samples	  taken	  at	  D0,	  D1,	  D4	  and	  D8	  stored	  at	  RmT,	  4°C,	  and	  -­‐80°C	  thawed/refrozen	  in	  each	  day.	  No	  visible	  degradation	  in	  protein	  tandems	  in	  any	  sample	  under	  all	  conditions	  studied	  (4°C,	  RmT	  and	  -­‐80°C	   freeze	  thaw)	  over	  the	  8	  days	  period. 
 In	   summary,	   all	   samples	   of	   protein	   tandems	   show	   no	   visible	   degradation	  under	   all	   conditions	   studied	   (4°C,	   RmT	  and	   -­‐80°C	   freeze	   thaw)	  over	   the	  8	  days	  period,	  which	   implies	   the	  high	   short	   term	   stability	   of	   these	   tandems.	  However,	   GCSF4QAT	   shows	   around	   20%	   dimer	   formation	   upon	   analysing	  by	  SDS-­‐PAGE	  and	  western	  blot.	  The	  probable	  reason	  for	  dimer	  formation	  in	  one	  of	  the	  constructs	  (GCSF4QAT)	  will	  be	  discussed	  in	  the	  final	  discussion.	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 Discussion 6.4In	   this	   chapter,	   to	   determine	   the	   suitability	   of	   the	   purified	   glycosylated	  tandem	  proteins	  and	  their	  respective	  non-­‐glycosylated	  controls	  for	  the	  PK	  in	  
vivo	   studies;	   it	   was	   imperative	   to	   assess	   their	   biological	   activities.	   While	  active	  proteins	  are	  essential	  for	  use	  in	  the	  PK	  studies,	  it	  is	  equally	  important	  that	   the	  proteins	  be	   stable	   over	   the	   course	  of	   administration	   in	   an	   animal	  model	  and	  post-­‐administration	  analyses	  of	   the	  protein	  samples.	  Therefore,	  AML-­‐193	   cell	   line	   was	   used	   to	   measure	   the	   bioactivity	   of	   these	   tandem	  proteins	  due	   to	   the	   ability	   of	   rhGCSF	   to	  proliferate	   this	   type	  of	   cell	   line	   in	  
vitro.	   	   Furthermore,	   stability	   of	   these	   tandem	   proteins	   was	   also	   analysed	  using	   different	   temperatures	   (RmT,	   4°C	   and	   -­‐80°C	   F/T)	   and	   also	   after	  incubation	  with	  AML-­‐193	  cells	  at	  37°C	  for	  3	  days.	  	  The	   biological	   activity	   results	   show	   that	   AML-­‐193	   proliferation	   assay	   is	   a	  valid	  quantitative	   in	  vitro	  model	   for	  measuring	   the	  activity	  of	   glycosylated	  GCSF	   tandems	   and	   their	   respective	   non-­‐glycosylated	   controls.	   Also,	   the	  results	   indicate	   that	   these	   tandem	   proteins	   exhibit	   agonistic	   action	   by	  stimulating	  the	  proliferation	  of	  AML-­‐193	  cells.	   Initial	  bioassay	  experiments	  showed	  that	  the	  best	   level	  of	  absorbance	  achievable,	  upon	  the	  induction	  of	  the	   cells	   to	   MTS	   reagent	   at	   37°C	   for	   2	   hrs	   is	   around	   0.25	   at	   490nm.	  	  Extending	   the	   time	   of	   induction	   beyond	   2	   hrs	   resulted	   in	   no	   significant	  increase	  in	  the	  colour	  change.	  It	  is	  apparent	  from	  the	  results	  that	  the	  tandem	  proteins	  exhibited	  significant	   increased	  biological	  activity	  compared	   to	   the	  rhGCSF	  (EC50	  for	  tandems	  were	  about	  3-­‐fold	  lower	  than	  that	  for	  rhGCSF).	  	  The	   observed	   increase	   in	   biological	   activity	   could	   be	   attributed	   to	   two	  factors;	  the	  design	  of	  the	  tandem	  molecule	  (two	  GCSF	  ligands	  linked	  with	  a	  flexible	  linker)	  and	  also	  the	  linker	  length.	  	  Normally,	  two	  GCSF	  ligands	  bind	  two	  GCSF	  receptors	  forming	  a	  homodimer	  (Larsen	  et	  al.,	  1990).	  The	  binding	  of	   the	  GCSF	   ligand	   to	   the	   receptor	   occurs	   at	   a	   2:2	   ligand:receptor	   subunit	  stoichiometry,	   forming	   a	   cross-­‐over	   configuration	   between	   the	   receptor	  subunits.	  This	  structural	  configuration	  enables	  the	  trans-­‐phosphorylation	  of	  the	  receptors	  and	  initiates	  downstream	  signal	  transduction.	  However,	  a	  lag	  in	  the	  availability	  or	  binding	  of	  a	  second	  GCSF	  ligand	  to	  the	  receptor	  would	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result	   in	   delayed	   activation	   of	   the	   signaling	   pathway.	   This	   potential	   delay	  may	  be	  absent	   in	   the	   tandem	  molecule,	   as	   there	  are	   two	  covalently	   linked	  GCSF	   molecules	   in	   tandem	   that	   are	   readily	   available	   for	   binding	   to	   the	  receptors.	  	  The	   observed	   potency	   of	   the	   tandem	   molecules	   is	   consistent	   with	   other	  published	  research	  studies	  where	  two	  ligands	  linked	  in	  tandem	  resulted	  in	  a	  novel	  molecule	  with	  higher	  bioactivity	  than	  the	  wild	  type.	  The	  binding	  of	  the	  EPO	   ligand	   to	   the	   receptor	   occurs	   at	   a	   2:2	   ligand:receptor	   subunit	  stoichiometry	  similar	   to	   that	   in	  GCSF.	  Sytkowski	  et	  al.,	   (1999)	  generated	  a	  fusion	   of	   two	   hematopoietic	   growth	   factor	   erythropoietin	   (Epo)	   linked	   in	  tandem	  using	  a	  17-­‐amino	  acid	  flexible	  peptide	  linker.	  The	  specific	  biological	  activity	   of	   the	   Epo	   tandem	   at	   1,007	   IU/μg	   was	   found	   to	   be	   significantly	  greater	   than	  that	  of	   the	  native	  Epo	  protein	  at	  352	  IU/μg.	  Furthermore,	   the	  comparative	   studies	   of	   the	   pharmacokinetics	   of	   the	   Epo	   tandem	   and	   the	  native	  Epo	  proteins	  in	  mice	  showed	  the	  tandem	  molecule	  to	  be	  more	  potent,	  causing	   a	   significant	   increase	   in	   red	   blood	   cell	   production	   within	   7	   days	  whereas	   the	   conventional	   recombinant	   Epo	   control	   had	   no	   obvious	  stimulating	  effect	  (Sytkowski	  et	  al.,	  1999).	  	  Furthermore,	   compared	   to	   the	   fusion	   constructs	   in	   the	   aforementioned	  research	  studies,	  in	  our	  GCSF	  tandem	  the	  linker	  length	  is	  a	  significant	  factor	  for	  consideration	   in	   the	  design	  of	  a	   fusion	  expression	  construct,	  as	  studies	  have	   shown	   that	   inappropriately	   short	   linkers	   could	   result	   in	   loss	   of	  biological	  activities	  or	  potency	  in	  tandem	  fusion	  molecules.	  Research	  by	  Qui	  et	  al.,	  (1998),	  showed	  the	  bioactivity	  of	  a	  tandem	  Epo	  fusion	  construct	  with	  a	  shorter	  linker	  sequence	  (glycine	  (G)	  3-­‐7	  peptide	  was	  compared	  with	  the	  Epo	  tandem	   with	   a	   longer	   linker	   sequence	   17-­‐amino	   acid	   (A-­‐[G-­‐G-­‐G-­‐G-­‐S]3-­‐T) .The	   results	   revealed	   that,	  while	   both	   tandem	  molecules	  were	   biologically	  active	   the	   Epo	   tandem	   with	   the	   shorter	   linker	   showed	   no	   increase	   in	  bioactivity	   over	   the	   native	   Epo	   whereas	   the	   Epo	   tandem	   with	   the	   longer	  linker	   was	   significantly	   more	   biologically	   active	   (Qiu	   et	   al.,	   1998).	   This	  suggests	   that,	   tandem	  fusion	   ligands	  with	   linker	   length	   long	  enough	  would	  facilitate	   simultaneous	   binding	   of	   the	   ligands	   to	   the	   receptors,	   which	   in	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effect	  induces	  the	  homodimerization	  and	  activation	  of	  the	  receptors,	  which	  in	  turn	  initiate	  the	  downstream	  signal	  transduction.	   	  Whereas,	   in	  a	  tandem	  fusion	   molecule	   with	   short	   linker	   sequence,	   the	   two	   ligands	   linker	   could	  potentially	   restrict	   the	   binding	   of	   one	   of	   the	   two	   ligands	   to	   the	   receptor,	  which	   inadvertently	  would	   exhibit	   similar	   activity	   to	   a	   ‘free’	   ligand	  bound	  receptor.	   In	   the	   design	   of	   our	   three	   glycosylated	   GCSF	   tandems	   and	   their	  controls,	   linker	   lengths	   used	   were	   long	   enough	   and,	   all	   the	   tandem	  molecules	   had	   similar	   biologically	   activity.	   	   This	   suggests	   that	   the	   linker	  lengths	  between	   the	   tandem	  GCSF	   ligands	   in	   the	   six	  expression	  constructs	  investigated	   (49	   amino	   acids	   for	   GCSF2NAT/2QAT,	   GCSF4NAT/4QAT	   and	  94-­‐amino	  acids	  for	  GCSF8NAT/8QAT)	  were	  long	  enough	  to	  allow	  both	  GCSF	  ligands	   in	   the	   tandem	   molecule	   to	   bind	   both	   receptors.	   This	   equally	  contributed	   to	   the	  higher	  biological	   activities	  observed	   in	   these	  constructs	  compared	  to	  the	  rhGCSF.	  The	  data	  also	  indicate	  that	  the	  biological	  activity	  of	  glycosylated	  tandems	  is	  very	   similar	   to	   their	   non-­‐glycosylated	   controls.	   For	   instance,	   the	   tandem	  molecule	  with	   2	   glycosylation	   sites	   showed	   similar	   results	   to	   the	   4	   and	   8	  glycosylation	   sites.	   	   It	   is	   apparent	   from	   the	   result	   that	   increasing	   the	   N-­‐linked	  glycosylation	  sites	  has	  no	  noticeable	  negative	   impact	  on	   the	   in	  vitro	  biological	  activity	  of	  GCSF.	  	  The	  GCSF	  tandems	  also	  showed	  a	  high	  degree	  of	  stability	  in	  vitro	  during	  the	  temperature	  stability	  test.	  The	  results	  (SDS-­‐PAGE	  and	  western	  blot)	  showed	  no	  visible	  degradation	   in	   the	  analysed	   tandem	  proteins	   samples,	  under	  all	  conditions	  studied	  (4°C,	  RmT	  and	  -­‐80°C	  freeze	  thaw),	  over	  the	  8	  days	  period	  and	   also	   after	   incubation	   with	   AML-­‐193	   cells	   at	   37°C	   for	   3	   days.	   This	  suggests	   that	   the	   tandem	  molecules	  achieve	   the	  right	  conformation	  during	  protein	  synthesis	  in	  CHO	  cells.	  	  The	   glycosylated	   tandem	   molecules	   are	   devoid	   of	   dimerisation,	   whereas,	  non-­‐glycosylated	   tandems	   showed	   some	   dimer	   formation	   that	   was	   more	  obvious	   in	   GCSF4QAT	   (a	   control	   for	   GCSF4NAT	   tandem	   molecule).	  	  GCSF4QAT	   was	   estimated	   to	   contain	   approximately	   20%	   dimer	   when	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analysed	   by	   Coomassie	   blue	   and	   western	   blotting	   (Refer	   to	   Figure	   6.8).	  However,	   all	   the	   controls	   showed	   similar	   biological	   activity	   in	   the	  proliferation	  bioassay.	  This	  indicated	  that	  the	  presence	  of	  a	  dimer	  does	  not	  affect	  the	  overall	  bioactivity	  of	  the	  GCSF4QAT	  control	  molecule.	  	  Routinely,	   proteins	   are	   stored	   as	   frozen	   solutions	   at	   -­‐80°C	   and	   this	   may	  preserve	  the	  stability	  of	  proteins	  for	  longer	  periods	  of	  time.	  However,	  it	  was	  observed	   that	   long	   time	   freezing	   at	   -­‐80°C	   may	   be	   the	   cause	   of	   dimer	  formation	   as	   found	   in	   GCSF4QAT,	   which	   was	   stored	   at	   -­‐80°C	   for	   about	   a	  year.	   Prior	   to	   freezing	   (i.e.	   during	   expression	   and	   purification)	   no	  dimerisation	   was	   observed	   in	   the	   GCSF4QAT	   just	   like	   the	   other	   test	  molecules.	  	  Two	   factors	   may	   have	   contributed	   to	   the	   observed	   dimerisation	   of	  GCSF4QAT	  after	  longer	  storage	  at	  -­‐80°C.	  First,	  the	  dimer	  formation	  could	  be	  attributed	   to	   the	   presence	   of	   free	   cysteine	   residue	   (Cys17)	   in	   the	   GCSF	  structure	  coupled	  with	  the	  absence	  of	  glycosylation	  in	  the	  molecule.	  Native	  GCSF	   contains	   five	   cysteine	   residues,	   two	   internal	   disulfide	   bonds	   at	  positions	  Cys36–	  Cys42	  and	  Cys64–	  Cys74	  leaving	  one	  free	  cysteine	  residue	  at	   position	   Cys17	   with	   a	   free	   sulfhydryl	   group.	   It	   is	   possible	   that	   during	  longer	  storage	  in	  -­‐80°C,	  the	  free	  cysteine	  (Cys17)	  of	  one	  GCSF	  tandem	  may	  form	   inter-­‐molecular	   disulfide	   bonds	   with	   another	   GCSF	   tandem,	   which	  results	  in	  the	  formation	  of	  GCSF	  tandem	  dimer.	  This	  view	  is	  supported	  by	  a	  recent	   study	  where	   the	   Cys17	   in	   the	   GCSF	  molecule	  was	   substituted	  with	  Ala17	   (alanine	   instead	   of	   cysteine	   in	   wild-­‐type	   GCSF)	   using	   direct	  mutagenesis	  and	  recombinant	  DNA	  technology.	  The	  resulting	  GCSF	  mutant	  exhibited	  enhanced	  in	  vitro	  stability	  and	  higher	  activity	  in	  vivo	  than	  the	  wild-­‐type	  GCSF,	   perhaps	   through	   the	   elimination	  of	  dimerisation	   caused	  by	   the	  formation	  of	  intermolecular	  disulfide	  bonds	  (Jiang	  et	  al.,	  2011).	  While	  other	  GCSF	   tandems	   also	   contain	   GCSF	   units	   with	   free	   cysteine	   (Cys17),	   the	  glycosylation	   of	   the	   polypeptide	   chains	   may	   have	   induced	   unique	  conformational	   changes	   that	   prevent	   intermolecular	   disulphide	   bond	  formation	  with	  another	  tandem	  or	  with	  GCSF	  in	  the	  same	  tandem.	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Another	   possible	   reason	   of	   dimerisation	   is	   the	   incorporation	   of	   glutamine	  (Q)	   into	   the	   linker	   of	   the	   non-­‐glycosylated	   control	   GCSF	   tandem	   (i.e.	  GCSF4QAT)	  compared	  to	  asparagine	  (N)	  in	  the	  glycosylated	  GCSF	  tandems.	  It	   has	   been	   shown	   that	   incorporation	   of	   a	   poly-­‐glutamine	   into	   a	   protein	  resulted	  in	  the	  formation	  of	  dimers.	  The	  glutamine	  repeats	  in	  proteins	  form	  hydrogen	  bonds	  as	  a	  polar	   zipper	   (two	  paired	  antiparallel	  β-­‐sheet	   strands	  held	   together	   by	   hydrogen	   bonds	   between	   their	   amide	   groups)	   (Perutz,	  1995,	  Hoffner	  and	  Djian,	  2005).	  However,	  since	  the	  control	  tandem	  molecule	  has	   a	   single	   point	   mutation	   that	   allows	   for	   glutamine	   incorporation,	   the	  involvement	  of	  the	  incorporated	  glutamine	  in	  the	  dimer	  formation	  is	  rather	  ambiguous.	  Perhaps,	  analysing	  the	  control	  tandem	  protein	  on	  a	  reduced	  gel	  (i.e.	  containing	  DTT)	  would	  elucidate	  the	  type	  of	  bond	  that	  is	  present	  in	  the	  dimers,	   whether	   the	   dimers	   were	   covalently	   linked	   or	   not	   through	  disulphide	  bridges.	  	  Moreover,	  the	  control	  tandem	  has	  no	  N-­‐glycosylation	  sites	  at	  the	  linker	  and	  therefore	   would	   show	   less	   steric	   hindrance	   towards	   the	   formation	   of	   a	  dimer	   when	   compared	   to	   other	   glycosylated	   tandems.	   A	   number	   of	  published	   research	   studies	   have	   highlighted	   that	   glycosylated	   molecules	  have	   molecular	   characteristics	   that	   significantly	   affect	   the	   function	   of	   the	  molecule.	  For	  instance,	  it	  was	  recently	  reported	  that	  N-­‐linked	  glycosylation	  modulates	   dimerisation	   of	   human	   protein	   disulfide	   isomerase	   (PDIA2)	  (important	  enzyme	   for	   the	  correct	  maturation	  and	   folding	  of	  proteins	   that	  reside	   or	   transit	   into	   the	   endoplasmic	   reticulum	   (ER)).	   	   This	   protein	   was	  shown	   to	   be	   glycosylated	   at	   the	   asparagine	   residues	   of	   three	   N-­‐linked	  glycosylation	  sites	  (N127,	  N284	  and	  N516).	  The	  finding	  was	  that	  mutation	  at	  N284	   led	   to	   an	   increase	   in	   the	   dimer	   formation	   of	   PDIA2	   (Walker	   et	   al.,	  2013).	   This	   suggests	   that,	   the	   site	   directed	   mutagenesis	   abrogated	   the	  glycosylation	  characteristics	  in	  the	  mutant	  molecule.	  Glycosylation	   in	   the	   tandem	   molecules	   possibly	   creates	   steric	   hindrance.	  The	   presence	   of	   charge	   repulsion	   among	   molecules	   due	   to	   the	   negative	  charge	   and	   a	   huge	   relative	   volume	   occupied	   by	   sialic	   acid	   as	   described	  previously	  in	  the	  introduction	  chapter.	  However,	  the	  biological	  activity	  data	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of	   non-­‐glycosylated	   GCSF	   tandems	   were	   comparable	   to	   that	   observed	   for	  glycosylated	  GCSF	  tandems,	  indicating	  that	  dimerisation	  did	  not	  affect	  the	  in	  
vitro	  biological	  activity.	  	  In	   conclusion,	   The	   GCSF	   tandems	   demonstrated	   better	   biological	   activity	  compared	   to	   the	   rhGCSF	   and	   showed	   high	   stability	   at	   4C,	   RmT,	   37°C	   and	  multiple	  F/T	  cycles	  at	  -­‐80°C.	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 Results	  4:	  Pharmacokinetic	  &	  Pharmacodynamic	  7.
Analysis	  of	  rhGCSF	  and	  GCSF	  Tandems	  in	  a	  Rat	  
Model	  
 Summary	  7.1Glycoproteins	   represent	   a	   major	   value	   for	   the	   next	   marketed	   and	   clinical	  generation	  of	  therapeutic	  proteins.	  A	  full	  understanding	  of	  the	  function	  and	  nature	  of	   the	  glycosylation	  and	   its	   influence	  on	  pharmacology	  properties	   is	  crucial	   in	   finding	   and	   developing	   efficient	   and	   safe	   glycoprotein	  biopharmaceuticals.	   In	   the	   previous	   chapter,	   glycosylated	   GCSF	   tandems	  together	   with	   non-­‐glycosylated	   controls	   have	   shown	   better	   bioactivity	  compared	   to	   rhGCSF	   and	   high	   stability.	   In	   vivo	   pharmacokinetic	   and	  pharmacodynamics	   properties	   of	   these	   GCSF	   tandem	   proteins	   were	  measured	   in	   normal	   Sprague	  Dawley	   strain	   rats	  with	   full	   ethical	   approval.	  GCSF2NAT,	  GCSF4NAT	  and	  GCSF8NAT,	  containing	  2,	  4	  &	  8	  glycosylation	  sites	  respectively,	  displayed	  a	  reduced	  rate	  of	  clearance	  compared	  to	  both	  rhGCSF	  and	   non-­‐glycosylated	   GCSF	   tandem	   controls.	   Although	   the	   half-­‐life	   of	  GCSF8NAT	   exhibited	   no	   further	   enhancement	   beyond	   that	   of	   GCSF4NAT,	  pharmacodynamics	   (PD)	   displayed	   a	   significant	   increase	   in	   the	   number	   of	  circulating	   neutrophils	   at	   48	   hrs	   in	   rats	   compared	   to	   12	   hrs	   reported	   for	  GCSF4NAT	   and	   GCSF2NAT,	   leading	   us	   to	   hypothesize	   that	   GCSF8NAT	   is	   a	  more	  efficient	  stimulator	  of	  neutrophils.	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 Introduction	  7.2Pharmacokinetics	   (PK)	   is	   described	   as	   the	   study	   that	   evaluates	   the	   time	  course	  of	  drug	  absorption,	  distribution,	  metabolism	  and	  excretion	   in	   living	  organisms	  such	  as	  rats.	  It	  is	  sometimes	  described	  as	  what	  the	  body	  does	  to	  a	  drug.	  In	  contrast,	  pharmacodynamics	  (PD)	  is	  described	  as	  what	  a	  drug	  does	  to	   the	   body,	   for	   example,	   in	   our	   case	   what	   GCSF	   does	   to	   neutrophil	  population	   in	   the	  organism.	  Protein	  drugs’	  PK/PD	  are	   typically	  affected	  by	  fast	   elimination	   in	   intravenous	   administration	   from	   the	   human	   body,	   via	  proteolytic,	   renal,	   hepatic,	   and	   receptor	   mediated	   clearance	   mechanisms	  (Tang	  et	  al.,	  2004,	  Mahmood	  and	  Green,	  2005).	  Thus,	  PK/PD	  data	   that	  are	  produced	  from	  relevant	  species	  like	  mouse	  or	  rat	  support	  the	  prediction	  of	  PK/PD	   in	  humans	  and	  may	  help	   to	  generate	   safe	  and	  effective	   therapeutic	  applications	  for	  current	  therapies.	  	  In	  humans,	  GCSF	  has	  a	  short	  serum	  in	  vivo	  half-­‐life	  of	  1.79	  hrs	  (Tanaka	  et	  al.,	  1991).	   Consequently,	   individual	   patients	   with	   neutropenia	   require	   daily	  injections	   to	   increase	   neutrophils	   in	   the	   blood	   circulation,	   which	   leads	   to	  poor	  patient	  compliance.	  However,	  the	  current	  product	  on	  the	  market	  that	  is	  a	  long-­‐acting	  form	  of	  GCSF	  called	  PEG-­‐rhGCSF	  (with	  terminal	  half-­‐life	  of	  7.05	  hrs)	   which	   is	   administered	   once	   per	   chemotherapy	   cycle	   to	   enhance	   the	  number	   of	   neutrophils	   (Tanaka	   et	   al.,	   1991).	   It	   has	   been	   reported	   that	  modifications	   of	   GCSF	   by	   covalently	   attaching	   a	   chemical,	   polyethylene	  glycol	   (PEG),	  can	  change	  the	  PK	  and	  PD	  properties	  of	  GCSF	  to	  significantly	  increase	   the	   time	   the	  modified	   native	  GCSF	   remains	   effective	   in	   the	   blood	  circulation	   (Delgado	   et	   al.,	   1992).	   Results	   from	   receptor	   binding,	   in	   vitro	  proliferation	   and	   neutrophil	   function	   studies	   show	   that	   PEG-­‐rhGCSF	   and	  native	  GCSF	  have	  a	  similar	  mechanism	  of	  action	   in	   the	  circulation	  (Lord	  et	  al.,	   2001).	   	   In	   rat	  models,	   rhGCSF	   is	  mainly	   eliminated	  by	   the	   renal	   route;	  therefore,	   the	   presence	   of	   PEG	   moiety	   increases	   the	   molecular	   weight	   of	  GCSF	  and	  reduces	  its	  renal	  clearance	  by	  glomerular	  filtration	  (Jain	  and	  Jain,	  2008).	  	  Efforts	   have	   been	   made	   to	   improve	   the	   pharmacokinetic	   behaviour	   of	  therapeutic	   proteins	   by	   the	   addition	   of	   natural	   carbohydrates.	   In	   the	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previous	   chapter,	   the	   addition	   of	   natural	   carbohydrates	   (via	   N-­‐linked	  glycosylations)	   to	   the	   GCSF	   tandem	   has	   improved	   the	   bioactivity	   and	  stability.	   It	   has	   also	   been	   reported	   that	   hyperglycosylation	   can	   regulate	  activity	   and	   the	  pharmacokinetic	  profile	   of	  GCSF	   (using	   the	  mutant	  hGCSF	  (Phe140Asn))	   leading	   to	   prolonged	   GCSF	   in	   the	   circulation	   and	   a	   more	  effective	   molecule	   than	   native	   GCSF	   in	   stimulating	   differentiation	   and	  proliferation	  of	  hematopoietic	  cells	  (Chung	  et	  al.,	  2011).	  	  Hyperglycosylation	  closely	  resembles	  PEGylation	  but	  has	  an	  added	  advantage	  over	  PEGyaltion.	  For	   instance,	   hyperglycosylation	   involves	   the	   biodegradable	   nature	   of	  carbohydrates,	  while	  in	  contrast	  the	  whole	  PEG	  molecule	  is	  often	  processed	  for	   excretion	   in	   the	   human	   body	   without	   undergoing	   an	   initial	  biodegradation	  which	   could	   be	   toxic	   to	   the	   body	   (Patel	   et	   al.,	   2014).	   This	  possible	  toxicity	  of	  PEGylation	  was	  supported	  by	  the	  detection	  of	  PEG	  only	  in	  bile	   (Caliceti	  and	  Veronese,	  2003).	  Beside	   these	  advantages,	   this	  project	  used	   hyperglycosylation	   (N-­‐linked	   glycosylated	   linker)	   to	   increase	   the	  molecular	  weight	   of	  GCSF	   and	  may	   also	  protect	   it	   from	  proteolysis	   due	   to	  the	   presence	   of	   terminal	   sialic	   acid	   that	   shields	   the	   underlying	   galactose	  peptides	  from	  protease	  recognition	  and	  cleavage	  within	  the	  circulation	  (Sola	  and	  Griebenow,	  2009).	  	  This	  is	  supported	  by	  a	  study	  carried	  out	  by	  Raju	  and	  Scallon	  (2007)	  who	  demonstrated	  that	  removal	  of	  terminal	  sugars	  from	  Fc	  antibody	  fragments	  resulted	  in	  increased	  sensitivity	  to	  papain.	  	  In	  this	  chapter,	  the	  construction	  of	  novel	  recombinant	  GCSF	  tandems	  results	  in	   molecules	   with	   reduced	   clearance	   while	   retaining	   bioactivity.	   It	   also	  alleviates	  potential	  problems	  with	  direct	  glycosylation	  of	   the	   ligand,	  which	  may	  reduce	  bioactivity	  and	  potentially	  introduce	  immunogenic	  sites.	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 Aim	  and	  Hypothesis	  7.3
In	   vivo	   strength	   of	   therapeutic	   proteins	   is	   often	   strongly	   associated	   with	  residence	   time	   of	   blood	   circulating.	   This	   is	   a	   function	   of	   the	   drug’s	   PK	  behaviour	   including,	   serum	   half-­‐life,	   clearance	   rate	   and	   the	  minimum	   and	  maximum	   concentrations.	   In	   the	   previous	   chapter,	   glycosylated	   GCSF	  tandems	   and	   their	   respective	   controls	   have	   shown	   better	   bioactivity	   in	  comparison	   to	   rhGCSF	   and	   high	   stability.	   	   Thus,	   the	   aim	   of	   the	   current	  chapter	   is	   to	  determine	   the	  pharmacokinetic	  properties	  of	   rhGCSF	  &	  GCSF	  tandems	  in	  normal	  adult	  Sprague	  Dawley	  strain	  rats	  following	  intravenous	  injections	  and	  the	  effects	  of	  these	  GCSF	  tandems	  on	  white	  blood	  cell	  (WBCs)	  and	   neutrophil	   populations.	   We	   hypothesised	   that	   our	   glycosylated	   GCSF	  tandems	   will	   have	   longer	   circulating	   half-­‐lives	   and	   more	   potent	   (i.e.	  mobilizing	  more	  neutrophils)	  compared	  to	  the	  rhGCSF.	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 Results	  7.4
 Preliminary	  Test	  for	  the	  Effect	  of	  Rat’s	  Serum	  on	  Elisa	  7.4.1




Figure	  7-­‐1:	  Effect	  of	  rat	  serum	  on	  the	  sensitivity	  of	  Elisa	  assay	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 Preliminary	  Pharmacokinetic	  Analysis	  in	  Normal	  7.4.2
Sprague	  Dawley	  Rats	  
 	  Elisa	  Results	  7.4.2.1The	   pharmacokinetic	   performance	   of	   glycosylated	   GSCF	   tandem	  (GCSF2NAT,	  4NAT,	  8NAT	  &	  8QAT)	  was	  evaluated	  in	  Sprague	  Dawley	  rats	  to	  assess	  the	  longevity	  of	  exposure	  in	  comparison	  to	  rhGCSF.	  250μg/kg	  (75μg	  per	   rat)	   of	   rhGCSF,	   GCSF2NAT,	   GCSF4NAT,	   GCSF8NAT,	   GCSF8QAT	   and	  vehicle	   (PBS	   only)	   were	   given	   by	   intravenous	   injection	   (IV).	   0.3	   to	   0.4ml	  blood	  sample	  were	  taken	  at	  specified	  time	  points	  (-­‐24	  pre-­‐injection,	  0.5,	  1,	  2,	  4,	   8,	   12,	   24	   &	   48,	   72	   hrs)	   and	   centrifuged	   for	   serum	   preparation	   as	  previously	  described	  in	  section	  3.9.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  GCSF	  Elisa	  was	  used	  to	  measure	  the	  concentration	  of	  proteins	  in	  each	  serum	  GCSF	  tandems	  samples	  and	  rhGCSF	  at	  -­‐24,	  0.5,	  1,	  2,	  4,	  8,	  12,	  24,	  48,	  72	  hrs	  post-­‐dose.	   The	   data	   analyses	   of	   these	   samples	   suggested	   that	   the	  pharmacokinetic	   profiles	   for	   GCSF	   tandems	   (GCSF2NAT,	   4NAT,	   8NAT	   &	  8QAT)	   following	   intravenous	  dosing	  at	  250μg/kg	  displayed	  a	  reduced	  rate	  of	   clearance	   compared	   to	   the	   published	   rhGCSF	   (Figures	   7.2	   –	   7.7).	  However,	   the	   rhGCSF	   molecule	   in	   this	   study	   appeared	   to	   be	   mistakenly	  injected	  subcutaneously	  as	  against	  intravenous	  injection	  of	  other	  test	  GCSF	  tandems.	  This	  however	  was	  not	  confirmed	  by	  the	  contractor	  (more	  details	  provided	  in	  the	  sections	  below).	  For	  this	  reason,	   the	  rhGCSF	  samples	  were	  excluded	   from	  further	  data	  analyses,	   so	  as	   to	  avoid	   inconsistencies	   in	  data	  analyses.	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Figure	  7-­‐2:	  Elisa	  analysis	  of	  rhGCSF	  pharmacokinetics	  in	  normal	  rat	  
(A)	   Six	   rats	   were	   injected	   with	   250μg/kg	   of	   native	   purified	   recombinant	  GCSF	   protein	   intravenously.	   Serum	   samples	  were	   taken	   24	   hrs	   before	   the	  injection	  and	  0.5,	  1,	  2,	  4,	  8,	  12,	  24,	  48,	  72	  hrs	  post	   injection.	   	  The	  samples	  were	  analysed	  by	  ELISA	  to	  determine	  the	  concentration	  (nM)	  of	  rhGCSF	  in	  the	   serum	   and	   clearance	   rate.	   The	   results	   for	   each	   rat	   at	   each	   individual	  sampling	  time	  points	  are	  tabulated.	  Missing	  samples	  shaded	  in	  grey.	  (B)	  The	  concentrations	  of	  rhGCSF	  were	  plotted	  against	  the	  time	  of	  sampling	  for	  each	  individual	  rat.	  	  	   	  
! Rat$
Time$(hr)$ 1$ 2$ 3$ 4$ 5$ 6$
324$ 0! 3.1! !! 0! 0! 2.6!
0.5$ 1.9! 2.3! 21.7! 2.5! 0.6! 23.8!
1$ 4.6! 3.6! 4! 25.4! 8.1! 7.1!
2$ 23.8! !! 4.1! 45.8! 5! 24.1!
4$ 0.7! 5.2! 1.8! 11.3! 5.1! 8.3!
8$ 9.2! 2.6! 5.9! 4.5! 3.1! !!
12$ 1.4! !! !! 1.4! 1.9! 1.2!
24$ 0! 0! 0! 0! !! 0!
48$ 0! 0! 0! 0! 0! 5!
72$ 0! 0! 0! 0! 0! 0!




















 Pharmacokinetic	  Analysis	  of	  GCSF2NAT	  in	  Normal	  Rats	  7.4.2.1.2All	   rats	   in	   this	   group	   exhibited	   similar	   patterns	   of	   protein	   clearance	  with	  similar	  an	  early	  peak	  concentration	  of	  0.5	  hrs,	  which	  suggests	  that	  the	  rats	  were	  successfully	  injected	  intravenously.	  Rat	  6	  serum	  samples	  and	  a	  few	  of	  other	   serum	   samples	  were	  missing	   (shaded	   boxes	   in	   grey),	   as	   these	  were	  not	  received	  from	  the	  contractor	  who	  did	  the	  IV	  injection	  and	  sampling.	  Two	  samples	  were	   labelled	  with	   similar	   information	   (shaded	  boxes	   in	   red)	  and	  were	  therefore	  omitted	  from	  the	  study	  (Figure	  7.3).	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Figure	  7-­‐3:	  Elisa	  analysis	  of	  GCSF2NAT	  pharmacokinetics	  in	  normal	  rat	  
(A)	   Six	   rats	   were	   injected	   with	   250μg/kg	   of	   purified	   GCSF2NAT	  intravenously.	   Serum	   samples	  were	   taken	   24	   hrs	   before	   the	   injection	   and	  0.5,	  1,	  2,	  4,	  8,	  12,	  24,	  48,	  72	  hrs	  post	  injection.	   	  The	  samples	  were	  analysed	  by	  an	  Elisa	  to	  determine	  the	  concentration	  (nM)	  of	  GCSF2NAT	  in	  the	  serum	  and	   clearance.	   The	   results	   for	   each	   rat	   at	   each	   individual	   sampling	   time	  point	   were	   tabulated.	   Missing	   samples	   shaded	   in	   grey.	   Omitted	   samples	  shaded	  in	  red.	   (B)	  The	  concentration	  of	  GCSF2NAT	  was	  plotted	  against	  the	  time	  of	  sampling,	  for	  each	  individual	  rat.	  	   	  
!! Rat$
Time$(hr)$ 1$ 2$ 3$ 4$ 5$ 6$
324$ 2! 2.8! 0! 0.7! 0! !!
0.5$ 90.7! 42.1! 20.5! 49! 40! !!
1$ 45.5! 31.3! 15.1! !! 11.9! !!
4$ !! 12.4! 10! 5.8! 9.2! !!
8$ 12.7! 4.6! 7.1! 6.9! 8.2! !!
12$ 8.5! 6.8! 6.2! 5.7! 2.4! !!
24$ 3.9! 1.6! 2! 1.6! 0! !!
48$ 8.4! 0! 0! 1.9! 0! !!
72$ 0! 0! 0! 0! 0! !!

















 Pharmacokinetic	  Analysis	  of	  GCSF4NAT	  in	  Normal	  Rats	  7.4.2.1.3Analysis	  of	  the	  pattern	  of	  clearance	  between	  the	  rats	  shows	  that	  rats	  were	  successfully	   injected	   intravenously.	   Rat	   6	   serum	   samples	   and	   a	   few	  of	   the	  other	   samples	   were	   missing	   (shaded	   boxes	   in	   grey),	   as	   these	   were	   not	  received	  from	  the	  contractor	  who	  did	  the	  IV	  injection	  and	  sampling	  (Figure	  7.4).	  
   
 
 
Figure	  7-­‐4:	  Elisa	  analysis	  of	  GCSF4NAT	  pharmacokinetics	  in	  normal	  rat 
(A)	   Six	   rats	   were	   injected	   with	   250μg/kg	   of	   purified	   GCSF4NAT	  intravenously.	   Serum	   samples	  were	   taken	   24	   hrs	   before	   the	   injection	   and	  0.5,	  1,	  2,	  4,	  8,	  12,	  24,	  48,	  72	  hrs	  post	  injection.	   	  The	  samples	  were	  analysed	  by	  Elisa	  to	  determine	  the	  concentration	  (nM)	  of	  GCSF4NAT	  in	  the	  serum	  and	  clearance.	  Missing	   samples	   shaded	   in	   grey	   (B).	  The	   results	   for	   each	   rat	   at	  each	   individual	   sampling	   time	   point	  were	   tabulated.	   The	   concentration	   of	  GCSF4NAT	  was	  plotted	  against	  the	  time	  of	  sampling,	  for	  each	  individual	  rat.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
!! Rat$
Time$(hr)$ 1$ 2$ 3$ 4$ 5$ 6$
324$ !! 0! 0! 3.3! 25.8! !!
0.5$ 81.6! 63.1! !! 4.7! 61.6! !!
1$ 53! 19.3! 8.9! 14.6! 75.9! !!
2$ 36.7! 14.6! !! 21.2! 40.5! !!
4$ 20.6! 14.5! 7.8! 11.6! 35.6! !!
8$ 12.3! !! 11! 14.5! 45.7! !!
12$ !! 4.5! 8.2! 8.2! 29.8! !!
24$ 5.8! 1.7! 1.9! 12! 13.3! !!
48$ 0! 1.7! 0! 1.9! 7.8! !!
72$ 1.4! 1.8! 0! 0.7! 22.8! !!



















 Pharmacokinetics	  Analysis	  of	  GCSF8NAT	  in	  Normal	  Rats	  7.4.2.1.4	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Analysis	  of	  the	  pattern	  of	  clearance	  between	  the	  rats	  shows	  that	  rats	  were	  successfully	  injected	  intravenously.	  Rat	  6	  serum	  samples	  and	  a	  few	  of	  other	  serum	   samples	   were	   missing	   (shaded	   boxes	   in	   grey),	   as	   these	   were	   not	  received	   from	   the	   contractor	   who	   did	   the	   IV	   injection	   and	   sampling.	   In	  addition,	  Rat	  1	  showed	  a	  very	  high	  protein	  concentration	  in	  all	  time	  points	  (shaded	  boxes	   in	  red)	  compared	  to	  other	  rats.	  Rat	  1	  was	  repeated	  but	  still	  give	  a	  very	  high	  value.	  Therefore,	   it	  was	  decided	   to	  omit	   from	   the	   current	  study	   after	   discussions	   with	   Phoenix	   Certara	   (half-­‐life	   =	   270.7	   hrs	   as	  analysed	   by	  Winnonlin	   PK	   program	  provided	   by	   Phoenix	   Certara)	   (Figure	  7.5).	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Figure	  7-­‐5:	  Elisa	  analysis	  of	  GCSF8NAT	  pharmacokinetics	  in	  normal	  rat	  
(A)	   Six	   rats	   were	   injected	   with	   250μg/kg	   of	   purified	   GCSF8NAT	  intravenously.	   Serum	   samples	  were	   taken	   24	   hrs	   before	   the	   injection	   and	  0.5,	  1,	  2,	  4,	  8,	  12,	  24,	  48,	  72	  hrs	  post	  injection.	   	  The	  samples	  were	  analysed	  by	  Elisa	  to	  determine	  the	  concentration	  (nM)	  of	  GCSF8NAT	  in	  the	  serum	  and	  clearance.	   The	   results	   for	   each	   rat	   at	   each	   individual	   sampling	   time	   point	  were	  tabulated.	  Missing	  samples	  shaded	  in	  grey.	  Omitted	  samples	  shaded	  in	  red.	   (B)	   The	   concentration	   of	   GCSF8NAT	  was	   plotted	   against	   the	   time	   of	  sampling,	  for	  each	  individual	  rat.	  	  	   	  
!! Rat$ Rat$repeated$
Time$(hr)$ 1$ 2$ 3$ 4$ 5$ 6$ 1$
524$ 22.6! 0! 2.1! 5.7! 0! !! 8.4!
0.5$ !! 86! 17.7! 51.3! 31.4! !! !!
1$ 170.1! 19.9! 11.1! 37.6! 18.1! !! 144.8!
2$ !! 17.5! 8.5! 37.3! 35.5! !! !!
4$ 16.4! 14.8! 7.7! 27.6! 18.6! !! 9.9!
8$ !! 13.1! 11.3! 19.2! 12.1! !! !!
12$ 17.2! 4.5! 5.2! 13! 5.1! !! 15.8!
24$ 9.1! 4.3! 1.3! 1.1! 3.1! !! 20.7!
48$ !! 0.1! 0! 0! 0! !! !!
72$ 21.8! 1.3! 0! 0! 0! !! 16.8!
A$
B$

















 Pharmacokinetic	  Analysis	  of	  GCSF8QAT	  in	  Normal	  Rats	  	  7.4.2.1.5Analysis	  of	  the	  pattern	  of	  clearance	  between	  the	  rats	  shows	  that	  rats	  were	  successfully	   injected	   intravenously.	   A	   few	   of	   the	   serum	   samples	   were	  missing	   (shaded	   boxes	   in	   grey),	   as	   these	   were	   not	   received	   from	   the	  contractor	  who	  did	  the	  IV	  injection	  and	  sampling.	  Additionally,	  Rat	  5	  and	  6	  showed	   a	   very	   low	   protein	   concentration	   in	   all	   time	   points	   compared	   to	  other	   rats.	   	   Both	   rats	  were	   repeated	  but	   they	   still	   give	   a	   very	   low	  protein	  concentration	  (shaded	  boxes	  in	  red),	  therefore,	  rat	  5	  &	  6	  were	  omitted	  from	  this	  study	  (Figure	  7.6).	  	  
	  
Figure	  7-­‐6:	  Elisa	  analysis	  of	  GCSF8QAT	  pharmacokinetics	  in	  normal	  rat.	  
(A)	   Six	   rats	   were	   injected	   with	   250μg/kg	   of	   purified	   GCSF8QAT	  intravenously.	   Serum	   samples	  were	   taken	   24	   hrs	   before	   the	   injection	   and	  0.5,	  1,	  2,	  4,	  8,	  12,	  24,	  48,	  72	  hrs	  post	  injection.	   	  The	  samples	  were	  analysed	  by	  Elisa	  to	  determine	  the	  concentration	  (nM)	  of	  GCSF8QAT	  in	  the	  serum	  and	  clearance.	   The	   results	   for	   each	   rat	   at	   each	   individual	   sampling	   time	   point	  were	  tabulated.	  Missing	  samples	  shaded	  in	  grey.	  Omitted	  samples	  shaded	  in	  red.	   (B)	   The	   concentration	   of	   GCSF8QAT	   was	   plotted	   against	   the	   time	   of	  sampling,	  for	  each	  individual	  rat.	  	  
!! Rat$ Rat$repeated$
Time$(hr)$ 1$ 2$ 3$ 4$ 5$ 6$ 5$ 6$
524$ !! 0! 0! 0! 0! #0.2! 0! #0.2!
0.5$ 66! !! 74! 9.4! 2.3! 0.6! 4.1! 4.7!
1$ 48.1! !! 46.2! !! 0.8! 0.1! 0.8! 0.1!
2$ 16.6! 9.6! 11.9! 10.5! 2.7! 1.3! 0.2! 4.1!
4$ 7.7! 9.5! !! 11.1! 7.7! #0.5! 0.65! #0.5!
8$ 5.6! 7.4! 10.4! 8.3! 3.3! #1.3! 0.794! #1.3!
12$ 0! 2.7! 3.9! 2.5! 2.7! !! 0! !!
24$ 0.4! 1.6! 1.1! 1! 0.5! #1.9! 0.5! #1.9!
48$ 0! 0! 0! 0! 0! #2! 0! #2!
72$ 0! 0! 0! 0.8! 0! #1.2! 0! #1.2!
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Figure	  7-­‐7:	  Elisa	  analysis	  of	  GCSF	  tandems	  in	  normal	  rat	  models	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (A)	  250μg/kg	  of	  GCSF2NAT,	  GCSF4NAT,	  GCSF8NAT,	  and	  GCSF8QAT	  proteins	  were	   given	   intravenously	   to	   Sprague	   Dawley	   rats.	   Serum	   samples	   were	  taken	  at	  specified	  time	  points	  (-­‐24,	  0.5,	  1,	  2,	  4,	  8,	  12,	  24	  &	  48,	  72	  hrs).	  The	  results	   of	   the	   mean	   concentrations	   for	   each	   tandem	   at	   each	   individual	  sampling	  time	  point	  in	  normal	  rats	  were	  tabulated.	  (B)	  The	  average	  protein	  concentrations	   of	   each	   GCSF	   tandem	   were	   plotted	   against	   the	   time	   of	  sampling,	   for	   each	   individual	   rat.	   Data	   are	   given	   as	   standard	   error	   of	   the	  mean	   (SEM)	   for	   at	   least	   four	   rats	   per	   group.	   Significance	   between	   Elisa	  results	  of	  GCSF	  tandems	  was	  performed	  with	  GraphPad	  Prism	  using	  Nonlin	  fit	  test.	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From	  the	  Elisa	  data	  of	  GCSF	  tandems,	  it	  can	  be	  seen	  that	  for	  IV	  the	  maximum	  serum	  concentration	  was	  reached	  at	  the	  earliest	  sampling	  time-­‐point	  of	  0.5-­‐	  hr	  for	  all	  samples.	  However,	  the	  rate	  of	  decline	  thereafter	  was	  much	  slower	  for	  GCSF	   tandems	   (GCSF2NAT,	  4NAT,	  8NAT	  &	  8QAT).	   Interestingly,	   all	   the	  GCSF	   tandems	   displayed	   a	   reduced	   rate	   of	   clearance	   compared	   to	   the	  published	  rhGCSF	  when	  the	  half-­‐life	  was	  calculated	  using	  Winnonlin	  6.3	  PK	  program	  developed	  by	  Phoenix	  Certara	   (more	  details	  about	  half-­‐life	   in	   the	  next	  section).	  	  	  
 Terminal	  Half-­‐life	  Analyses	  of	  GCSF	  Tandems	  by	  the	  Non-­‐7.4.2.2
Compartmental	  Method	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Comparative	  analyses	  of	   the	  Elisa	  data	   for	   the	  glycosylated	  GCSF	   tandems	  (GCSF2NAT,	   4NAT	   and	   8NAT)	   and	   their	   non-­‐glycosylated	   control	  (GCSF8QAT)	   suggested	   that	   all	   the	   GCSF	   tandem	   molecules	   have	   similar	  clearance	  with	  GCSF4NAT	  exhibiting	  a	  slightly	  higher	  serum	  concentration	  at	  24	  hrs	  of	   injection.	  However,	  the	  increase	  was	  not	  significantly	  different	  from	  other	  GCSF	  tandems.	  In	  order	  to	  determine	  in	  vivo	  terminal	  half-­‐life	  of	  the	   GCSF	   tandems	   and	   control,	   the	   pharmacokinetic	   data	   were	   analysed	  using	  the	  non-­‐compartmental	  method	  of	  data	  analysis.	  This	  involved	  the	  use	  of	  Winnonlin	   6.3	   PK	   program	  developed	   by	   Phoenix	   Certara	   to	   determine	  the	  terminal	  half-­‐life	  of	  the	  tandem	  GCSF	  proteins	  in	  each	  individual	  rat	  used	  in	   this	   study.	   The	   results	   obtained	   from	   the	   analyses	   are	   shown	   below	  (Table	  7.1	  and	  Figure	  7.8).	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Table	  7-­‐1:	  Tandem	  GCSF	  proteins	  terminal	  half-­‐life	  analyses	  by	  non-­‐
compartmental	  method	  for	  each	  rat	  The	  terminal	  half-­‐life	  of	  the	  tandem	  GCSF	  molecules	  were	  determined	  using	  a	  Winnonlin	  6.3	  PK	  program	  developed	  by	  Phoenix	  Certara.	  The	  results	  of	  the	  groups	  of	  rats	  used	   for	  each	   individual	   tandem	  molecule	  analyses	  (B1-­‐B5:	  2NAT,	  C1-­‐C4:	  4NAT,	  D2-­‐D5:	  8NAT,	  E1-­‐E4:	  8QAT).	  Cmax:	  concentration	  maximum	  (nM);	  Tmax:	  time	  maximum	  (hr);	  AUC0-­‐24:	  Area	  Under	  the	  Curve	  during	   24	   hrs;	   No	   points:	   Terminal	   half-­‐life	   points	   (at	   least	   3	   points);	  Lambda	  z:	  Slope	  of	  the	  drop;	  Half-­‐life	  (hr);	  the	  time	  required	  for	  the	  protein	  concentration	  to	  fall	  to	  half	  its	  initial	  amount.	  	  
	  	   	  
Construct) Rat) Cmax)(nM)) Tmax)(hr)) AUC0624) No)points) Lambda)z) Half)life)(hr))!! B1! 90.7! 0.5! 377.2! 3! 0.07! 9.66!!! B2! 49! 0.5! 202.6! 3! 0.09! 7.32!!GCSF2NAT! B3! 40! 0.5! 125! 4! 0.13! 5.14!!! B4! 42.1! 0.5! 201.6! 5! 0.11! 6.05!!! B5! 20.5! 0.5! 161.7! 5! 0.08! 8.26!
!GCSF4NAT! C1! 81.6! 0.5! 366.8! 3! 0.06! 11.81!C2! 63.1! 0.5! 195.6! 5! 0.11! 6.56!C3! 21.2! 2! 154.3! 3! 0.04! 15.99!C4! 75.9! 1! 756.3! 3! 0.075! 9.26!
!GCSF8NAT! D2! 86! 0.5! 242.8! 6! 0.07! 9.69!D3! 17.7! 0.5! 147.6! 3! 0.13! 5.31!D4! 51.3! 0.5! 380! 3! 0.18! 3.75!D5! 35.5! 2! 246.1! 4! 0.09! 7.85!
!GCSF8QAT! E1! 66! 0.5! 141.9! 3! 0.15! 4.54!E2! 9.6! 2! 108.5! 4! 0.09! 7.62!E3! 74! 0.5! 203.1! 4! 0.12! 6.01!E4! 11.1! 4! 120.3! 3! 0.12! 5.81!
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Figure	  7-­‐8:	  Tandem	  GCSF	  proteins	  terminal	  half-­‐life	  analyses	  by	  non-­‐
compartmental	  method	  for	  each	  rats’	  group	  
(A)	   The	   terminal	  half-­‐life	  of	   the	   tandem	  GCSF	  molecules	  were	  determined	  using	   a	   Winnonlin	   6.3	   PK	   program	   developed	   by	   Phoenix	   Certara.	   The	  results	   of	   the	   average	   for	   each	   treatment	   group	   together	   with	   published	  GCSF	  were	   tabulated.	   (B)	   The	  average	   terminal	  half-­‐life	   for	   each	  molecule	  was	  graphically	  represented.	  Data	  are	  given	  as	  standard	  error	  of	   the	  mean	  (SEM)	  for	  at	  least	  four	  rats	  per	  group.	  Significance	  between	  terminal	  half-­‐life	  data	  of	  GCSF	  tandems	  was	  performed	  with	  GraphPad	  Prism	  using	  One-­‐Way	  ANOVA.	  	  	   	  
































Figure	   7-­‐9:	   Percentage	   change	   in	   blood	   neutrophils	   following	  
intravenous	  administration	  of	  GCSF	  tandems	  
(A)	  GCSF2NAT	  and	  controls	  (GCSF8QAT,	  rhGCSF	  &	  vehicle),	  (B)	  GCSF4NAT	  and	   controls	   (GCSF8QAT,	   rhGCSF	   &	   vehicle),	   (C)	   GCSF8NAT	   and	   controls	  (GCSF8QAT,	  rhGCSF	  &	  vehicle),	  (D)	  GCSF2NAT,	  GCSF4NAT	  and	  GCSF8NAT	  	  &	   (E)	   showing	   total	   WBC	   counts	   following	   intravenous	   administration	   of	  GCSF	   tandems	   (GCSF2NAT,	   4NAT,	   8NAT	   &	   8QAT),	   rhGCSF	   and	   vehicle	   to	  normal	  rats.	  Data	  are	  given	  as	  standard	  error	  of	  the	  mean	  (SEM)	  for	  at	  least	  four	  rats	  per	  group.	  The	  pharmacodynamics	  studies	  of	  the	  GCSF	  tandems	  at	  these	   selected	   sampling	   time	   points	   (-­‐24,	   12,	   24,	   48	   and	   72	   hrs)	   were	  analysed	   with	   GraphPad	   Prism	   using	   multiple	   T-­‐test.	   	   Stars	   indicate	  neutrophil	  values	   that	  are	  significantly	  different	  between	  rats	   treated	  with	  GCSF	  tandems,	  rhGCSF	  and	  vehicle	  (*	  =	  p	  value	  of	  <0.05).	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 Discussion	  	  7.5In	   the	   previous	   chapter,	   the	   GCSF	   tandem	  molecules	   demonstrated	   better	  biological	  activity	  compared	  to	  the	  rhGCSF	  and	  showed	  high	  stability	  at	  4°C,	  RmT,	  37°C	  and	  multiple	  F/T	  cycles.	  Hence,	  these	  molecules	  were	  tested	  for	  the	  pharmacokinetics	   and	  pharmacodynamics	   (PK/PD)	  properties	   in	   an	   in	  
vivo	   study.	   The	   pharmacokinetic	   performance	   of	   selected	   constructs	  (GCSF2NAT,	   4NAT,	   8NAT	   and	   its	   control	   GCSF8QAT)	   was	   evaluated	   in	  normal	   adult	   Sprague	   Dawley	   rats.	   Serum	   samples	   were	   quantified	   using	  Elisa	  technique	  to	  assess	  the	  delay	  in	  renal	  clearance	  (half-­‐life)	  compared	  to	  the	  reported	  rhGCSF.	  This	  chapter	  equally	  evaluated	  the	  pharmacodynamics	  (PD)	   by	  measuring	   the	   effect	   of	   these	  GCSF	   tandems	   on	   the	   population	   of	  WBCs	  and	  neutrophils	  since	  GCSF	  is	  routinely	  used	  clinically	  to	  increase	  the	  number	  of	  neutrophils.	  In	   the	  PK	  analysis	   the	  detection	  of	  maximum	  protein	   levels	   at	   the	   earliest	  sampling	  time-­‐point	  of	  0.5	  hr,	  and	  decline	  thereafter	  for	  the	  rest	  of	  the	  time	  points,	   verified	   the	   successful	   IV	   injection	   of	   rats	   in	   all	   samples	   except	  rhGCSF.	   The	   results	   for	   rhGCSF	   were	   omitted	   from	   this	   study	   due	   to	  problems	   with	   the	  mode	   of	   injection.	   The	   rats	   should	   have	   been	   injected	  intravenously	   through	   the	   neck	   vein,	   but	   rats	   showed	   potential	  subcutaneous	  clearance	  for	  some	  of	  the	  time	  points	  when	  analysed	  by	  Elisa.	  The	   affected	   sample	   time	   points	  were	   at	   1	   and	   2	   hrs,	  which	   showed	   high	  protein	   levels	   compared	   to	   samples	   taken	   at	   time	   point	   0.5	   hr.	   It	   was	  presumed	  that	  the	  contractor	  might	  have	  missed	  the	  neck	  vein	  during	  the	  IV	  injection	  and	  injected	  the	  rats’	  muscle	  instead	  of	  the	  vein.	  Out	  of	  the	  5	  rats	  used	   for	   the	   in	   vivo	   PK/PD	   studies	   of	   rhGCSF,	   only	   1	   rat	   appeared	   to	   be	  injected	   intravenously.	   To	   annul	   any	   potential	   inconsistencies	   and	  misinterpretation	   of	   data,	   and	   erroneous	   data	   analyses,	   eliminating	   the	  rhGCSF	   control	   data	   from	   the	   in	   vivo	   study	   was	   considered	   appropriate.	  	  Consequently,	  the	  half-­‐life	  of	  the	  GCSF	  tandems	  proteins	  were	  compared	  to	  the	  published	  rhGCSF	  due	  to	  time	  limitation	  of	  this	  project.	  	  	  The	   pharmacokinetic	   profiles	   for	   all	   GCSF	   tandems	   following	   intravenous	  dosing	  at	  250μg/kg	  showed	  an	  approximately	  3	  fold	  longer	  circulating	  half-­‐
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life	   compared	   to	   that	   reported	   for	   the	   rhGCSF	   (Tanaka	   et	   al.,	   1991).	  Additionally,	   the	   results	   also	   showed	   that	  GCSF4NAT	  had	   a	   slower	   rate	   of	  clearance	   (10.74	   hrs)	   at	   24	   hrs	   post	   injection	   compared	   to	   other	   GCSF	  tandems	   (GCSF2NAT=7.38;	   GCSF8NAT=6.74;	   GCSF8QAT=5.87).	   However,	  this	   increase	  was	  only	  marginal,	   and	  not	   significantly	  different	   from	  other	  GCSF	  tandems.	  Interestingly,	  the	  GCSF8NAT	  with	  more	  glycosylation	  sites	  (8	  sites)	  had	  a	   slightly	   lower	   clearance	   rate	   compared	   to	   the	  other	   two	  GCSF	  tandems	  with	   lower	   numbers	   of	   glycosylation	   sites	   (4	   sites	   in	   GCSF4NAT	  and	   2	   sites	   in	   GCSF2NAT).	   This	   implies	   that	   there	   was	   a	   maximum	  glycosylation	  level	  in	  the	  GCSF	  tandems	  beyond	  which	  further	  glycosylation	  provided	   no	   additional	   benefit	   towards	   prolongation	   of	   the	   half-­‐life	   as	  observed	  in	  GCSF8NAT.	  	  The	  GCSF8QAT	  tandem	  has	  a	  similar	  clearance	  rate	  to	  all	  other	  glycosylated	  tandems,	   implying	   that	   the	   linker	   glycosylations	   are	   not	   required	   for	   the	  improved	   clearance	   of	   these	  molecules.	   It	   therefore	   appears	   that	   it	   is	   the	  increase	   in	  Mw	  of	   the	   tandem	  by	  virtue	  of	   containing	   two	  GCSF	  molecules	  that	  is	  responsible	  for	  the	  observed	  delayed	  clearance.	  Both	  GCSF	  molecules	  also	   have	   the	   potential	   to	   be	   O-­‐link	   glycosylated	   which	   would	   also	  contribute	  to	  the	  increased	  Mw	  seen	  over	  that	  of	  native	  GCSF	  and	  therefore	  may	   contribute	   further	   to	   the	   delayed	   clearance.	   Study	  by	  Marinaro	   et	   al.,	  (2000)	   showed	   that	   the	   removal	   of	   O-­‐linked	   glycosylated	   from	   human	  IGFBP-­‐6	  (Insulin-­‐like	  growth	  factor	  binding	  proteins-­‐6	  act	  as	  inhibitor	  of	  IGF	  actions)	   decrease	   the	   circulating	   half-­‐life	   by	   2.3	   fold	   compared	   to	  glycosylated-­‐IGFBP-­‐6	  (Marinaro	  et	  al.,	  2000).	  	  	  This	   theory	   is	   supported	   by	   a	   study	   that	   was	   performed	   on	   recombinant	  human	   Follicle-­‐Stimulating	   Hormone	   (rhFSH)	   containing	   different	   N-­‐glycosylated	  linker	  inserts	  between	  the	  α-­‐	  and	  β-­‐	  chains	  in	  the	  same	  rhFSH	  ligand.	   In	   this	   study,	   the	   terminal	   half-­‐life	   of	   three	   rhFSH	  molecules	   with	  increasing	  N-­‐linked	  glycosylations:	  rhFSH-­‐N1	  (1	  glycosylation	  site),	  rhFSH-­‐N2	   (2	   glycosylation	   sites)	   and	   rhFSH-­‐N4	   (4	   glycosylation	   sites)	   and	   one	  rhFSH	  with	  no	  N-­‐linked	  glycosylation	  but	  only	  has	  the	  linker	  insert	  (rhFSH-­‐N0),	  were	  assessed	  after	  intravenous	  injection	  into	  Sprague	  Dawley	  rats. In	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the	   same	   study,	   two	   other	   molecules	   with	   O-­‐linked	   glycosylation	   were	  equally	   tested,	   in	   vivo,	   to	   determine	   the	   half-­‐life.	   These	   are	   rhFSH-­‐CTP	  (comprising	  of	  a	  unique	  carboxy-­‐terminal	  peptide	  (CTP)	  that	  contains	  4	  O-­‐	  linked	  glycosylation	  sites	  inserts	  as	  a	  linker	  between	  the	  α-­‐	  and	  β-­‐	  chains	  in	  the	  same	  rhFSH	  ligand)	  and	  rhFSH-­‐O1	  (1	  O-­‐linked	  glycosylation	  site	  inserts	  as	  a	  linker	  between	  the	  α-­‐	  and	  β-­‐	  chains	  in	  the	  same	  rhFSH	  ligand).	  The	  half-­‐lives	  of	  the	  O-­‐linked	  glycosylated	  rhFSH	  molecules	  when	  compared	  to	  those	  of	   the	  N-­‐linked	  showed	   that	  hyperglycosylation	  of	  either	  O-­‐	  or	  N-­‐linked	  of	  the	  rhFSH	  ligand	  increased	  the	  half-­‐life	  of	  rhFSH.	  However,	  the	  increase	  was	  not	  linearly	  related	  to	  the	  carbohydrate	  sizes	  and	  numbers,	  as	  the	  rhFSH-­‐2N,	  rhFSH-­‐4N	   and	   rhFSH-­‐CTP	   (4	  O-­‐linked	   glycosylation)	   had	   similar	   half-­‐lives	  which	   were	   2	   fold	   longer	   compared	   to	   rhFSH,	   rhFSH-­‐N0	   and	   rhFSH-­‐O1	  (Klein	  et	  al.,	  2002,	  Weenen	  et	  al.,	  2004).	  	  Furthermore,	  another	   independent	  study	  also	  described	  an	   increase	   in	   the	  half-­‐life	   of	   rhFSH	  by	   introducing	   two	  N-­‐linked	   glycosylation	   sites	   at	   the	  N	  terminus	  of	  the	  α-­‐subunit	  (Perlman	  et	  al.,	  2003),	  which	  is	  different	  from	  the	  linker	  with	   glycosylation	   sites	   in	   the	   earlier	  mentioned	   studies	   on	   rhFSH.	  This	  suggests	  that	  the	  increase	  in	  the	  number	  of	  glycosylation	  sites	  in	  rhFSH,	  irrespective	   of	   the	   location	   or	   the	   type	   was	   responsible	   for	   the	   observed	  increase	  in	  terminal	  half-­‐life	  of	  rhFSH	  in	  these	  studies.	  	  The	  importance	  of	  hyperglycosylation	  to	  a	  longer	  terminal	  half-­‐life	  is	  further	  highlighted	   in	   another	   study	   carried	   out	   to	   investigate	   the	   effects	   of	  introducing	  different	  number	  of	  N-­‐linked	  glycosylation	  sites	  on	  the	  half-­‐life	  of	   a	   small	   bispecific	   single-­‐chain	   diabody	   (scDb	   CEACD3)	   (Used	   for	   the	  retargeting	  of	   cytotoxic	  T	   cells	   to	  CEA-­‐expressing	   tumor	   cells).	   Stock	  et	   al.	  introduced	  3,	  6,	  or	  9	  N-­‐glycosylation	  sites	  in	  the	  flanking	  linker	  of	  the	  scDb	  molecule	   and	   a	   C-­‐terminal	   extension.	   Interestingly,	   the	   results	   showed	   a	  prolonged	  circulating	  half-­‐life	  for	  all	  three	  scDb	  constructs	  compared	  to	  the	  unmodified	   scDb.	   However,	   the	   addition	   of	   3	   N-­‐glycosylation	   sites	   is	  adequate	   to	  prolong	  circulation	   time	  and	  not	   significantly	  different	   from	  6	  or	  9	  N-­‐linked	  glycosylation	  (Stork	  et	  al.,	  2008).	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These	  studies	  revealed	  that	  the	  addition	  of	  a	  few	  N	  or	  O-­‐glycans	  either	  in	  a	  linker	   or	   covalently	   bound	   to	   a	   protein	   improved	   the	   pharmacokinetic	  properties	  of	   the	  protein,	   thus	  producing	   a	  novel	  protein	  with	  moderately	  prolonged	   terminal	   half-­‐life.	   However,	   there	   is	   a	   maximum	   benefit	   of	  glycosylation	  regarding	  the	  half-­‐life,	  and	  additional	  glycosylation	  sites	  might	  not	  extend	  circulation	  time.	  	  This	  view	  is	  consistent	  with	  our	  findings	  in	  the	  PK	   studies,	   where	   all	   the	   proteins	   showed	   similar	   terminal	   half-­‐life	  irrespective	  of	  the	  numbers	  of	  glycosylation	  sites	  in	  the	  linker.	  	  The	  potency	  of	  each	  GCSF	  tandem	  was	  evaluated	   in	  vivo	  using	  white	  blood	  cell	   (WBC)	   and	   neutrophil	   counts.	   WBC	   counts	   showed	   no	   statistical	  difference	   in	   number	   following	   injection	   with	   either	   vehicle	   (PBS	   only),	  rhGCSF,	  GCSF2NAT	  and	  GCSF4NAT.	  However,	  WBC	  levels	  peaked	  at	  24	  hrs	  post-­‐injection	   for	   GCSF8NAT	   and	   its	   respective	   control	   GCSF8QAT	   before	  returning	   to	   baseline	   values	   at	   72	   hrs.	   However,	   this	   effect	   was	   not	  significantly	  different	  from	  that	  observed	  in	  the	  rhGCSF	  and	  vehicle	  controls.	  	  	  In	   contrast,	   all	   rats	   injected	   with	   GCSF	   tandems	   and	   rhGCSF	   showed	   an	  increase	   in	   the	  percentage	  of	   circulating	  neutrophils	  particularly	  at	  12	  hrs	  post	  injection	  for	  GCSF2NAT	  and	  GCSF4NAT	  compared	  to	  controls	  (Vehicle,	  rhGCSF	  &	  GCSF8QAT).	  This	  observed	  increase	  in	  the	  number	  of	  neutrophils	  at	   12	   hrs	   is	   consistent	   with	   that	   reported	   by	   Ulich	   et	   al.	   (1988).	   In	   their	  studies	   in	   mice,	   they	   observed	   that	   a	   single	   injection	   of	   GCSF	   induced	   a	  temporary	   neutropenia	   in	   the	   mice.	   However,	   the	   number	   of	   circulating	  neutrophils	  was	  found	  to	  increase	  significantly	  by	  5-­‐fold	  within	  30	  minutes	  and	   peaked	   at	   12	   hrs	   post-­‐injection.	   While	   there	   was	   an	   increase	   in	   the	  number	  of	  circulating	  neutrophils,	  the	  number	  of	  mature	  neutrophils	  in	  the	  bone	  marrow	  became	  significantly	  reduced	  (Ulich	  et	  al.,	  1988).	  	  The	   percentage	   of	   neutrophils	   in	   human	   blood	   circulation	   is	   around	   60-­‐65%,	  which	  is	  different	  from	  rats	  and	  mice.	  The	  percentage	  of	  neutrophils	  in	  normal	  rats	  is	  between	  22-­‐44.9%	  (Sharma,	  2013)	  and	  that	  of	  normal	  mice	  is	  between	   10-­‐40%	   of	   total	   cell	   counts	   in	   the	   peripheral	   blood	  (www.ahc.umn.edu/rar/refvalues).	   In	  the	   in	  vivo	  studies,	   the	  percentage	  of	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neutrophils	   at	   12	   hrs	   for	   GCSF2NAT,	   GCSF4NAT	   and	   GCSF8NAT	   was	  between	   60-­‐70%	   in	   normal	   rats	   compared	   to	   rhGCSF,	   GCSF8QAT	   and	  vehicle	   (~45%).	   The	   presence	   of	   high	   percentage	   of	   neutrophils,	   but	   very	  low	  percentage	  of	  other	  cells	  such	  as	  lymphocytes	  (normal	  range;	  56-­‐78%),	  monocytes,	   eosinophils	   or	   basophils,	   indicates	   that	   GCSF	   is	   selective	   for	  neutrophils.	  This	  observation	  is	  consistent	  with	  the	  report	  that	  the	  presence	  of	   mature	   and	   immature	   (or	   band)	   neutrophils	   in	   circulation,	   but	   not	  lymphocytes	   or	   eosinophils,	   was	   a	   result	   of	   GCSF	   induced	   stimulation	   of	  neutrophils	  from	  the	  bone	  marrow	  into	  the	  blood	  (Semerad	  et	  al.,	  2002).	  	  In	   the	   current	   study,	   a	   higher	   increase	   in	   the	   percentage	   of	   circulating	  neutrophils	  at	  12	  hrs	  post	   injection	  was	  observed	   for	  both	  GCSF2NAT	  and	  GCSF4NAT	   and	   48	   hrs	   post	   injection	   for	   GCSF8NAT	   compared	   to	   controls	  (Vehicle,	   rhGCSF	   &	   GCSF8QAT).	   This	   confirms	   the	   positive	   role	   of	  glycosylation	   in	   improving	   the	   pharmacodynamics	   of	   our	   GCSF	   tandems.	  Although	   the	   half-­‐life	   of	   GCSF8NAT	   exhibited	   no	   further	   enhancement	  beyond	  either	  the	  GCSF2NAT,	  GCSF4NAT	  or	  its	  control	  GCSF8QAT,	  the	  high	  percentage	   of	   neutrophils	   in	  GCSF8NAT	   compared	   to	   other	   tandems	   leads	  us	   to	   hypothesize	   that	   GCSF8NAT	   is	   a	   more	   efficient	   stimulator	   of	  neutrophils	   as	   it	   has	   a	   longer	   duration	   of	   action	   evidenced	   by	   high	  circulating	   neutrophil	   levels	   at	   48	   hrs.	   This	   could	   be	   due	   to	   a	   compound	  effect	  of	  being	  larger	  in	  size,	  more	  glycosylations	  (more	  terminal	  sialisation)	  or	   the	   presence	   of	   up	   to	   eight	   glycosylations	   sites	   could	   impede	   the	  interaction	   of	   these	   GCSF	   molecules	   (impede	   dimer	   formation)	   making	   it	  more	  active	  in	  the	  circulation.	  	  	  The	  number	  of	  N-­‐linked	  glycosylation	  sites	  within	  GCSF8NAT	  tandem	  linker	  increased	   its	   size	   to	   ~70kDa,	   which	   is	   bigger	   than	   both	   GCSF4NAT	  (~55kDa)	  and	  GCSF2NAT	  (~40kDa).	  We	  can	  hypothesis	  that	  GCSF4NAT	  and	  2NAT	  are	  cleared	  more	  efficiently	  via	  filtration	  by	  the	  kidney,	  the	  increased	  size	  of	  GCSF8NAT	  delays	   its	  clearance	  by	   filtration,	  as	  kidney	   is	  reportedly	  known	  to	  filter	  molecules	  smaller	  than	  the	  human	  serum	  albumin	  (67kDa)	  (Dennis	  et	  al.,	  2002).	  	  Also	  terminal	  sialisation	  of	  GCSF8NAT	  tandem	  would	  also	  prevent	  clearance	  via	  filtration	  in	  the	  kidney	  due	  to	  over-­‐expression	  of	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a	   negatively	   charged	   barrier	   alongside	   the	   glomerular	   filtration	   barrier,	  preventing	   the	   passage	   of	   glycoproteins	   through	   charge	   repulsion	   (Varki,	  2008).	  	  Furthermore,	  the	  non-­‐glycosylated	  GCSF	  tandem	  controls	  were	  observed	  to	  form	   dimers	   in	   vitro,	   which	   could	   be	   attributed	   to	   the	   formation	   of	  intermolecular	   or	   intramolecular	   disulphide	   bonds	   resulting	   from	   the	  interaction	  of	  the	  free	  cysteine	  residues	  (Cys17)	  present	  on	  individual	  GCSF	  molecules.	  Dimers	  are	  unable	  to	  induce	  signal	  transduction,	  which	  leads	  to	  less	   stimulation	   of	   neutrophils.	   Dimer	   formation	   is	   potentially	   easier	   in	  control	  tandems	  due	  to	  less	  steric	  hindrance	  from	  glycosylation	  whereas	  in	  8NAT	  (and	  other	  glycosylated	  tandems)	  the	  presence	  of	  glycosylation	  within	  the	  linker	  could	  be	  inhibitory	  to	  the	  formation	  of	  dimers.	  For	  instance,	  2NAT	  and	   4NAT	   stimulated	   more	   neutrophils	   than	   8QAT	   at	   12	   hrs	   but	   8NAT	  stimulated	   more	   neutrophils	   than	   8QAT	   at	   48	   hrs	   after	   intravenous	  injection.	  The	  presence	  of	  up	   to	  eight	  glycosylation	   sites	   could	   impede	   the	  interaction	  of	  these	  GCSF	  molecules	  better	  than	  Both	  GCSF2NAT	  and	  4NAT	  (less	   glycosylation	   motifs).	   This	   was	   evidenced	   by	   stability	   results	   in	   the	  previous	  chapter,	  showed	  a	  slight	  dimer	  formation	  for	  both	  2NAT	  and	  4NAT,	  whereas,	   GCSF8NAT	   showed	   no	   dimer	   formation	   at	   all	   (please	   refer	   to	  Figure	   6.5,	   6.7	   and	   6.8).	   This	   may	   also	   be	   a	   contributing	   factor	   to	   the	  observed	   increase	   in	   neutrophil	   counts	  with	   these	   proteins	   and	   therefore	  increase	  clearance	  via	  the	  neutrophils-­‐mediated	  pathway.	  One	   of	   the	   main	   ways	   in	   which	   GCSF	   is	   cleared	   is	   via	   the	   neutrophil	  mediated	  pathway.	  It	  is	  this	  pathway	  that	  we	  hypothesise	  is	  the	  main	  route	  of	   clearance	   of	   our	   glycosylated	   GCSF	   tandems.	   This	   effect	   has	   been	   seen	  with	   Pegfilgratim,	   which	   was	   developed	   to	   improve	   PK	   and	   PD	   of	   GCSF	  molecules	   (i.e.	   decreased	   clearance	   via	   kidneys	   therefore	   increased	  clearance	  via	  neutrophils).	   For	  example,	   concentrations	  of	  Pegfilgrastim	   in	  patient	   serums	   following	   administration,	   remain	   high	   during	   neutropenia,	  but	   reduced	   when	   the	   numbers	   of	   neutrophils	   increase	   (Curran	   and	   Goa,	  2002).	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While	   these	   observations	   were	   different	   from	   our	   initial	   expectations	  regarding	   the	   terminal	   half-­‐life	   of	   the	   GCSF	   tandems	   in	   circulation,	   as	  we	  hypothesized	  that	  increasing	  the	  glycosylation	  sites	  would	  increase	  the	  size	  and	  thus	  delay	  the	  clearance,	  our	  studies	  showed	  that	  the	  pharmacokinetic	  and	   pharmacodynamics	   properties	   of	   a	   therapeutic	   protein	   could	   be	  divergent.	   These	   observations	   are	   similar	   to	   the	   findings	   in	   an	   FSH	   study	  where	  the	  terminal	  half-­‐life	  of	  different	  analogues	  of	  FSH	  with	  two	  (rhFSH-­‐N2)	   and	   four	   (rhFSH-­‐N4)	   glycosylation	   sites	   were	   found	   to	   have	   similar	  circulating	   half-­‐lives	   but	   rhFSH-­‐N4	  was	  more	   potent	   in	   the	   stimulation	   of	  inhibin	  A	  and	  follicles	  than	  the	  rhFSH-­‐N2	  due	  to	  the	  addition	  of	  large,	  highly	  branched	  carbohydrates	  (Weenen	  et	  al.,	  2004).	  	  Therefore,	  our	  studies	  of	  the	  tandem	  proteins	  revealed	  that	  all	  glycosylated	  tandem	   GCSF	   proteins	   are	   more	   potent	   than	   rhGCSF	   (containing	  intramolecular	   O-­‐linked	   glycosylation)	   and	   GCSF8QAT	   (containing	   linker	  and	   O-­‐linked	   glycosylation).	   However,	   despite	   a	   negligible	   difference	   in	  circulating	   half-­‐lives	   of	   the	   tandem	   GCSF	   proteins,	   GCSF8NAT	   is	   the	   only	  tandem	  with	  a	  significant	  potency	  over	  rhGCSF	  and	  GCSF8QAT,	  being	  a	  more	  potent	  stimulator	  of	  neutrophils.	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 General	  Discussion	  8.GCSF	  is	  a	  hormone	  produced	  by	  different	  tissues	  to	  stimulate	  the	  production	  of	  neutrophils	  from	  the	  bone	  marrow	  into	  the	  blood	  circulation.	  The	  rhGCSF	  has	  been	   shown	   to	   stimulate	  neutrophils	   for	   the	   treatment	  of	  neutropenic	  patients,	   and	   in	   stem	   cell	   mobilization	   in	   the	   circumstance	   of	   BM	  transplantation.	  The	  commercial	  products	  of	  rhGCSF	  fall	  under	  the	  category	  of	   either	   short	   acting	   half-­‐life,	   such	   as,	   Filgrastim	   (NEUPOGEN®)	   and	  Lenograstim	   (Granocyte®)	   where	   in	   the	   pharmacokinetic	   properties	   and	  structural	  homology	  of	   the	  protein	  are	  similar	   to	   the	  human	  GCSF,	  or	   long	  acting	   half-­‐life	   such	   as,	   Pegfilgrastim	   (Neulasta),	   where	   in	   chemical	  alteration	   with	   PEGylation	   has	   been	   applied	   to	   prolong	   the	  pharmacokinetics	  by	  reduced	  renal	  clearance.	  Since	  there	  is	  a	  need	  for	  less	  frequent	   (daily)	   dosing,	   the	   use	   of	   short-­‐acting	   GCSF	   products	   have	   been	  limited	   and	   shifted	   towards	   the	   use	   of	   the	   long-­‐acting	   products	   (e.g.	  Neulasta).	  The	   fast	   growing	  market	   size	  will	   increase	   demand	   for	   generating	   similar	  long-­‐acting	   rhGCSF.	   	   Therefore,	   it	   is	   essential	   to	   produce	   new	   GCSF	  compounds	   with	   improved	   properties	   over	   other	   products.	   Asterion	   is	  employing	  its	  proprietary	  protein	  fusion	  technology	  (ProFuseTM)	  to	  produce	  a	  new	  form	  of	   long-­‐acting	  GCSF	  molecule	   that	  retains	   the	  pharmacokinetic	  and	  efficiency	  of	  Neulasta,	  but	  with	  a	  more	  competitive	  manufacturing	  and	  cost-­‐of-­‐goods	  benefits	  over	  Neulasta.	  A	  previous	  study	  by	  Asterion	  has	  shown	  that	  the	  use	  of	  glycosylated-­‐linkers	  between	   two	   GH	   ligands	   to	   create	   protein-­‐tandems	   resulted	   in	   their	  glycosylation	   and	   an	   increased	   MW	  whilst	   maintaining	   biological	   activity.	  This	  technology	  can	  be	  easily	  applied	  to	  other	  molecules	  such	  as,	  GCSF.	  The	   data	   obtained	   in	   this	   study	   have	   shown	   that	   it	   is	   possible	   to	   clone,	  express	  and	  purify	  tandem	  GCSF	  molecules	  containing	  variably	  glycosylated	  linker	   regions	   from	  a	   CHO	   cell	   line.	   The	  purified	  GCSF	   tandems	   are	   stable	  with	   no	   degradation.	   The	   apparent	   stability	   could	   be	   attributed	   to	   the	  incorporated	   Gly4Ser	   flexible	   linker.	   This	   had	   been	   demonstrated	   in	  
188	  
recombinant	  single-­‐chain	  Fv	  antibody	  production	  where	  the	  use	  of	  Gly4Ser	  linker	   offered	   the	   advantages	   of	   stability	   and	   lack	   of	   immunogenicity	  (Huston	   et	   al.,	   1993).	   Our	   data	   (western	   blots)	   suggest	   that	   these	  glycosylation	   consensus	   sequences	   (motifs)	   are	   glycosylated	   upon	  expression	   in	   CHO	   Flp-­‐In	   cells	   (mammalian	   cell	   lines)	   as	   the	   MW	   of	  glycosylated	   tandem	   proteins	   are	   higher	   than	   their	   corresponding	   non-­‐glycosylated	   controls.	   The	   MW	   of	   the	   non-­‐glycosylated	   tandem	   GCSF	  controls	   2QAT,	   4QAT,	   and	   8QAT	   were	   45kDa,	   45kDa	   and	   49kDa	  respectively,	   whereas	   that	   of	   their	   corresponding	   glycosylated	   GCSF	  tandems	   (2NAT,	  4NAT,	   and	  8NAT)	  were	  approximately	  52kDa,	  60kDa	  and	  70kDa.	  	  A	  study	  by	  Mann	  and	  Jensen	  (2003)	  highlighted	  that	  each	  unit	  of	  N-­‐linked	  glycosylation	   contribute	  a	  minimum	  of	   approximately	  800Da	   to	   the	  construct	  mass.	  This	  is	  consistent	  with	  our	  observation	  of	  increased	  MWs	  in	  the	   glycosylated	   tandems	   (~7kDa,	   15kDa	   and	   ~21kDa)	   compared	   to	   the	  non-­‐glycosylated	  controls.	  However,	  the	  increased	  MW	  observed	  was	  higher	  than	  what	  was	  expected	  using	  Mann	  and	  Jensen’s	  prediction,	  which	  could	  be	  attributed	   to	   the	   unique	   design	   of	   our	   tandems	   to	   contain	   flexible	   linker.	  Each	  of	  our	  glycosylated	  GCSF	  tandem	  contains	  2,	  4	  or	  8	  glycosylation	  motifs	  within	   the	   flexible	   linker	   contribute	   to	   the	   increase	   in	  MW.	   Increasing	   the	  linker	   length	   to	   accommodate	   more	   glycosylation	   sites	   (motifs)	   further	  increases	   the	   MW	   of	   the	   molecule.	   Also,	   glycosylation	   within	   the	   flexible	  linker	   region	   increases	   the	   apparent	   weight	   of	   the	   tandems	   not	   just	   by	  weight	   but	   also	   by	   hydrodynamic	   volume,	  which	  may	  have	   contributed	   to	  the	   difference	   in	   MWs	   between	   our	   study	   and	   Mann	   and	   Jensens’.	   In	  contrast,	   the	   non-­‐glycosylated	   controls	   used	   in	   this	   work	   have	   shown	   an	  expected	  MW	   similar	   to	   those	   determined	   by	  DNASTAR	   laser	   gene	   (Table	  3.2)	  and	  they	  were	  therefore	  suitable	  controls	  in	  this	  perspective	  of	  proof	  of	  concept	  testing.	  	  All	  GCSF	  tandems	  studied	  showed	  similar	   in	  vitro	  biological	  activities	   in	  an	  AML-­‐193	   proliferation	   assay.	   This	   suggests	   that	   the	   use	   of	  hyperglycosylated	   linker	   technology	   is	   applicable	   for	   GCSF	   and	   other	  proteins	  since	  conjugation	  is	  not	  impeding	  or	  shielding	  residues	  within	  the	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peptide	   that	   are	   necessary	   for	   activity.	   However	   in	   vivo,	   although	   all	  tandems	  showed	  similar	  terminal	  half-­‐lives	  (range:	  5.87	  –	  10.74	  hrs)	  which	  were	   not	   significantly	   different,	   studies	   looking	   at	   neutrophil	  mobilization	  highlighted	   striking	   differences	   between	   these	   tandems.	   For	   instance,	   a	  higher	   increase	   in	   the	   percentage	   of	   circulating	   neutrophils	  was	   observed	  for	  both	  GCSF2NAT	  and	  GCSF4NAT	  at	  12	  hrs	  post	  injection	  and	  upto	  48	  hrs	  post	   injection	   for	  GCSF8NAT	  compared	   to	  controls	   (rhGCSF	  &	  GCSF8QAT).	  While	   this	   confirms	   the	   positive	   role	   of	   glycosylation	   in	   improving	   the	  pharmacodynamic	  of	  our	  GCSF	  tandems	  it	  equally	  showed	  GCSF8NAT	  as	  the	  most	  efficient	  stimulator	  of	  neutrophils	  as	  it	  has	  a	  longer	  duration	  of	  action	  evidenced	  by	  high	  circulating	  neutrophil	  levels	  at	  48	  hrs.	  This	  could	  be	  due	  to	   a	   compound	   effect	   of	   its	   larger	   in	   size,	   more	   glycosylations	   (more	  terminal	   sialylation)	   which	   limits	   its	   clearance	   by	   kidney	   filtration	   or	   the	  presence	   of	   8NAT	   sites	   in	   the	   linker	  which	   impedes	   the	   interaction	   of	   the	  GCSF	  molecules	   (dimer	   formation)	   in	   the	   tandem	  making	   it	  more	  active	   in	  circulation.	  	  Improving	  the	  circulating	  half-­‐life	  and	  neutrophils	  mobilization	  has	  been	  the	  mainstay	  of	  the	  new	  generation	  of	  GCSF.	  GCSF	  is	  cleared	  from	  circulation	  via	  kidney	   filtration	   or	   the	   neutrophil	   mediated	   pathway.	   Enhancing	   the	  clearance	   via	   neutrophil	   mediated	   pathway	   increases	   the	   number	   of	  neutrophils	   in	   circulation,	   a	   characteristic	   that	   is	   beneficial	   for	   treating	  patients	   with	   neutropenia.	   The	   only	   commercially	   available	   longer	   acting	  GCSF,	   Pegfilgratim,	   was	   developed	   to	   improve	   the	   PK	   and	   PD	   of	   GCSF	  molecule	   by	   PEGylation	   (i.e.	   decreased	   clearance	   via	   kidneys	   therefore	  increased	   clearance	   via	   neutrophils).	   Similarly,	   our	   glycosylated	   GCSF	  tandems	   were	   designed	   to	   be	   cleared	   through	   this	   pathway.	   We	  hypothesized	   that	   increasing	   the	   glycosylation	   sites	   in	   our	   GCSF	   tandems	  would	  increase	  the	  size	  and	  thus	  delay	  the	  clearance.	  However,	  our	  tandems	  circulating	  half-­‐lives	   (5.87	  –	  10.74	  hrs)	  are	  not	   significantly	  different	   from	  that	   of	   Pegfilgratim	   (7.05	   hrs)	   even	   though	   the	   molecular	   weights	   of	   our	  tandems	  (~45kDa-­‐70kDa)	  are	  more	  than	  Pegfilgratim	  (38.8kDa).	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Despite	   no	   apparent	   significant	   improvement	   in	   circulating	   half-­‐life	   over	  Pegfilgrastim,	   our	   GCSF	   tandem	   molecules	   provide	   some	   physiological	  advantages.	   For	   instance,	   while	   PEGylation	   of	   GCSF	   in	   Pegfilgrastim	   has	  been	   shown	   to	  be	  non-­‐biodegradable	   and	   toxic	   (Patel	   et	   al.,	   2014;	   Caliceti	  and	  Veronese,	  2003),	  and	   induce	  vacuole	   formation	   in	  renal	   tubes	   thereby	  affecting	   the	   tissue	  distribution	   (Zhang	  et	   al.,	   2014).	   In	   contrast,	   our	  GCSF	  tandems	  are	  in	  a	  naturally	  occurring	  structure	  being	  hyperglycosylated,	  and	  therefore	  can	  undergo	  degradation	  within	  the	  human	  body	  with	  no	  potential	  toxicity	  of	  PEGylation	  was	  supported	  by	  the	  detection	  of	  PEG	  in	  bile	  (Caliceti	  and	   Veronese,	   2003).	   Additionally,	   the	   cost	   of	   production	   of	   Pegfilgrastim	  (involves	  post-­‐expression	  and	  post-­‐purification	  chemical	  modification	  of	  the	  starting	  molecule	  rhGCSF)	  outweighs	   that	  of	  our	  GCSF	   tandems,	  which	  are	  easily	  expressed	  and	  purified	  using	  simple	  methods.	  
 Future	  Work	  8.1To	  have	  a	  comprehensive	  overview	  of	  our	  tandems,	  a	  few	  more	  studies	  are	  required	   which	   were	   not	   covered	   during	   the	   course	   of	   this	   study.	   	   For	  instance,	   in	   this	   study,	   we	   observed	   high	   variations	   in	   the	   percentage	   of	  neutrophils	   in	   the	   normal	   rats	   used	   for	   the	   in	   vivo	   studies,	   as	   the	   normal	  range	  of	  neutrophils	  is	  22-­‐44%.	  This	  constituted	  a	  challenge	  in	  the	  analysis	  of	   the	   in	   vivo	   studies,	   as	   the	   variations	   in	   the	   neutrophil	   counts	   made	   it	  difficult	   to	   determine	   the	   exact	   percentage	   of	   neutrophils	   in	   the	   rats,	  especially	   since	   rat’s	   neutrophils	   can	   increase	   even	  with	   stress	   during	   the	  injection	   or	   due	   to	   infection	   (Semerad	   et	   al.,	   2002).	   This	   observation	  was	  seen	  in	  rats	  injected	  with	  vehicle	  (PBS	  only)	  that	  exhibited	  high	  neutrophils	  similar	   to	   the	   test	   rats	   (please	   refer	   to	   Figure	   7.9).	   Consequently,	  neutropenic	  rats	  are	  recommended	  for	  use	  in	  the	  future	  study,	  as	  we	  need	  a	  base	  line	  for	  the	  evaluation	  of	  the	  number	  or	  percentage	  of	  neutrophils.	  Also,	  it	  was	  not	  conclusive	  if	  all	  the	  sites	  of	  glycosylation	  were	  occupied	  by	  glycan	   moieties	   during	   protein	   expression.	   Therefore,	   the	   level	   of	  glycosylation	   in	   the	   tandems	   could	   have	   been	   confirmed	   by	   Mass	  spectrometry	   (MS)	   analysis	   of	   the	   glycopeptides	   fragments	   following	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treatment	   of	   glycosylated	   tandems	   with	   the	   PGNaseF	   digestive	   enzyme	  (Gervais	  et	  al.,	  2003).	  Also,	  the	  effect	  of	  O-­‐linked	  glycosylation	  on	  clearance	  could	   have	   been	   determined,	   as	   all	   our	   GCSF	   tandems	   (N-­‐linked	  glycosylated)	  and	  their	  respective	  non-­‐glycosylated	  controls	  showed	  similar	  circulating	   half-­‐life.	   Additionally,	   looking	   at	   the	   structure	   of	   the	   tandems	  may	   give	   insight	   as	   to	  whether	   proteins	   are	  monomer,	   dimer,	   and	   of	   any	  inter	  or	  intramolecular	  associations.	  A	  number	  of	  analytical	  methods	  could	  be	   used	   to	   assess	   these	   structural	   characteristics	   such	   as	   Analytical	  Ultracentrifugation	   (monomer/dimer	   formation),	   Size	   Exclusion	  Chromatography	  (monomer/Dimer),	  Dynamic	  Light	  Scattering,	  and	  Small	  X-­‐Ray	  Scattering.	  
 Future	  Work	  to	  Improve	  GCSF	  Tandems	  	  8.1.1Our	   study	   showed	   that	   tandem	   GCSF	   molecules	   with	   a	   variable	   N-­‐linked	  glycosylated	   flexible	   linker	   have	   a	   therapeutic	   potential	   of	   stimulating	  neutrophils	   in	   neutropenic	   patients.	   However,	   improving	   the	   circulating	  half-­‐life	   of	   our	   tandems	   over	   the	   commercially	   available	   long-­‐acting	   GCSF	  (Pegfilgrastim)	  would	  provide	  novel	  longer	  acting	  GCSF	  products.	  This	  could	  be	   achieved	   by	   introducing	   two	  modifications:	   removing	   the	   free	   cysteine	  residue	   in	   GCSF	   molecule,	   and	   pH	   switching	   between	   cell-­‐surface	   and	  endosome.	  The	  native	  GCSF	  contains	  five	  cysteine	  residues,	  two	  internal	  disulfide	  bonds	  at	   positions	   Cys36–	   Cys42	   and	   Cys64–	   Cys74	   leaving	   one	   free	   cysteine	  residue	  at	  position	  Cys17	  with	  a	  free	  sulfhydryl	  group.	  The	  free	  Cys17	  of	  one	  GCSF	  tandem	  may	  form	  inter-­‐molecular	  disulfide	  bonds	  with	  another	  GCSF	  tandem,	  which	  results	   in	  the	  formation	  of	  a	  GCSF	  tandem	  dimer,	  which	  we	  have	  seen	  in	  non-­‐glycosylated	  GCSF	  tandems.	  However,	  it	  has	  been	  reported	  that	   the	   substitution	   of	   Cys17	  with	   alanine	   (alanine	   instead	   of	   cysteine	   in	  wild-­‐type	   GCSF)	   resulted	   in	   enhanced	   stability	   in	   vitro	   and	   higher	  bioavailability	  in	  vivo	  than	  wild-­‐type	  GCSF,	  possibly	  through	  the	  elimination	  of	  dimerisation	  caused	  by	  the	  formation	  of	   inter-­‐molecular	  disulfide	  bonds	  (Jiang	  et	  al.,	  2011).	  Therefore,	  substituting	  the	  Cys17	  with	  alanine	  for	  both	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GCSF	   ligands	   in	   our	   tandem	   could	   prevent	   dimer	   formation	   and	   thus	  increase	  their	  bioavailability.	  	  GCSF	   binds	   its	   receptor	   with	   a	   high	   affinity	   and	   this	   results	   in	   its	   rapid	  depletion	   via	   receptor-­‐mediated	   endocytosis	   by	   circulating	   neutrophils	  expressing	   GCSF-­‐R,	   thus	   diminishing	   its	   therapeutic	   efficiency	   at	   a	  pharmacokinetic	   level.	   It	   has	   been	   demonstrated	   that	   substituting	   ligand	  residues	   at	   the	   binding	   site	   of	   GCSF	   with	   histidine	   switches	   protonation	  states	   between	   cell-­‐surface	   and	   endosomal	   pH.	   Therefore,	   decreasing	   the	  physiological	   pH	   from	   ∼7	   at	   the	   cell	   surface	   to	   5	   or	   6	   in	   endosomes	   by	  selectively	  mutating	   amino	   acids	   at	   the	   GCSF	   binding	   site	  will	   deteriorate	  interactions	   at	   endosomal	   pH	   whilst	   maintaining	   the	   electrostatic	  interactions	  at	  extracellular	  pH,	  and	  consequently	   increase	  endocytic	  GCSF	  recycling	  (Sarkar	  et	  al.,	  2002).	  Six	  ligand	  residues	  located	  at	  the	  binding	  site	  of	  GCSF	  (Glu20,	  Gln21,	  Asp110,	  Asp113,	  Thr117,	  and	  Gln120)	  are	  potential	  targets	  for	  the	  site-­‐directed	  mutagenesis	  with	  6	  histidine	  residues	  using	  two	  different	   single-­‐histidine	   mutants	   (neutral	   and	   protonated	   histidine).	   The	  suggested	  mutation	   is	   based	   on	   the	   principle	   that	   neutral	   histidine	  might	  retain	  relatively	  tight	  binding	  on	  the	  cell	  surface	  while	  protonated	  histidine	  might	   lead	   to	   a	   weaker	   binding	   in	   endosomal	   partitions.	   Therefore,	  substituting	  the	  amino	  acids	  of	  each	  GCSF	  ligand	  binding	  site	  in	  our	  tandems	  with	   histidine	   would	   reduce	   its	   receptor	   binding	   affinity	   in	   intracellular	  endosomal	  partitions	  and	  resultantly	  leads	  to	  an	  increased	  recycling	  of	  GCSF	  ligand	   from	   the	   intracellular	   cell	   to	   the	   extracellular	  medium	   and	   thereby	  extend	   the	   circulating	   half-­‐life	   of	   our	   GCSF	   tandems.	   This	   ultimately	  facilitates	   the	   endocytic	   GCSF	   ligand	   recycling	   and	   longer	   half-­‐life	   in	  extracellular	  circulation.	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 Conclusion	  9.The	  results	  obtained	  from	  this	  project	  exhibited	  that	  it	   is	  possible	  to	  clone,	  express	   and	   purify	   GCSF	   tandems.	   It	   also	   appeared	   that	   the	   use	   of	  glycosylated	  motifs	  (NAT)	  within	  a	  flexible	  linker	  between	  two	  GCSF	  ligands	  to	  generate	  protein-­‐tandems	  results	  in	  molecules	  with	  increased	  molecular	  weight	   according	   to	   the	   number	   of	   glycosylation	   sites.	   Tandems	   of	   GCSF	  have	   increased	   in	   vitro	  bioactivity	   compared	   to	  monomeric	   GCSF	   but	   this	  was	   independent	  of	   glycosylation	  and	  glycosylation	  did	  not	   inhibit	   in	  vitro	  bioactivity.	  Tandems	  with	  and	  without	  glycosylation	  had	  three-­‐fold	  greater	  half-­‐lives	   than	   rhGCSF	   but	   this	   was	   not	   determined	   by	   the	   number	   of	  glycosylation	   sites.	   There	   was	   evidence	   that	   GCSF8NAT	   was	   biologically	  active	   in	   vivo.	   	   The	   results	   confirm	   the	   hypothesis	   that	   it	   is	   possible	   to	  predictably	   increase	   the	   molecular	   weight	   of	   GCSF	   tandems	   and	   retain	  biological	   activity	   but	   this	   was	   not	   associated	   with	   a	   predictable	  prolongation	  of	  the	  serum	  half-­‐life.	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Appendix	  A	  
Appendix	  A.1.	  Nucleotide	  Sequences	  of	  Primers	  
Primer	   Nucleotide	  Sequence	  GCSF	  Nhe1	  	   5’-­‐AAATTTGGATCCGCTAGCCACCATGGCTGGACC-­‐3’	  GCSF	   Xho1	  Rev	   5’-­‐ATTCTCGAGGGGCTGGGCAAGGTGGCGTA-­‐3’	  GCSF	  BamH1	   5’-­‐AGGAGGGGATCCACCCCCCTGGG-­‐3’	  GCSF	   Age1	  Rev	   5’-­‐AAGAAGACCGGTTCCACCGGTTCCACCTCCACCGGGCTGGGCAAGGTGGCG-­‐3’	  CMVFor	   5’-­‐TATTACCATGGTGATGCGGTTTTGG-­‐3’	  BGHRev	   5’-­‐TAGAAGGCACAGTCGAGG-­‐3’	  GHseq2Rev	   5’-­‐AAGGCCAGCTGGTGCAGACG-­‐3’	  
	  
Appendix	  A.2.	  Restriction	  Endonucleases	  Cut	  Sites	  	  
Enzyme	   Restriction	  site	  Nhe1	   5’	  G/CTAGC	  3’	  3’	  CGATC/G	  5’	  Xho1	   5’	  G/TCGAG	  3’	  3’	  GAGCT/G	  5’	  BamH1	   5’	  G/GATCC	  3’	  3’	  CCTAA/G	  5’	  Age1	   5’	  A/CCGGT	  3’	  3’	  TGGCC/A	  5’	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Appendix	  B	  
Appendix	  B.1.	  Nucleotide	  and	  Amino	  Acid	  Sequences	  of	  GH	  Tandem	  
Nucleotide	  sequence	  GCTAGCcaccAtggctacaggctcccggacgtccctgctcctggcttttggcctgctctgcctgccctggct
tcaagagggcagtgccTTCCCAACCATTCCCTTATCCAGGCTTTTTGACAACGCTATGCTCCGCGCCCATCGTCTGCACCAGCTGGCCTTTGACACCTACCAGGAGTTTGAAGAAGCCTATATCCCAAAGGAACAGAAGTATTCATTCCTGCAGAACCCCCAGACCTCCCTCTGTTTCTCAGAGTCTATTCCGACACCCTCCAACAGGGAGGAAACACAACAGAAATCCAACCTAGAGCTGCTCCGCATCTCCCTGCTGCTCATCCAGTCGTGGCTGGAGCCCGTGCAGTTCCTCAGGAGTGTCTTCGCCAACAGCCTGGTGTACGGCGCCTCTGACAGCAACGTCTATGACCTCCTAAAGGACCTAGAGGAACGCATCCAAACGCTGATGGGGAGGCTGGAAGATGGCAGCCCCCGGACTGGGCAGATCTTCAAGCAGACCTACAGCAAGTTCGACACAAACTCACACAACGATGACGCACTACTCAAGAACTACGGGCTGCTCTACTGCTTCAGGAAGGACATGGACAAGGTCGAGACATTCCTGCGCATCGTGCAGTGCCGCTCTGTGGAGGGCAGCTGTGGCTTCLinker:variableTTCCCAACCATTCCCTTATCCAGGCTTTTTGACAACGCTATGCTCCGCGCCCATCGTCTGCACCAGCTGGCCTTTGACACCTACCAGGAGTTTGAAGAAGCCTATATCCCAAAGGAACAGAAGTATTCATTCCTGCAGAACCCCCAGACCTCCCTCTGTTTCTCAGAGTCTATTCCGACACCCTCCAACAGGGAGGAAACACAACAGAAATCCAACCTAGAGCTGCTCCGCATCTCCCTGCTGCTCATCCAGTCGTGGCTGGAGCCCGTGCAGTTCCTCAGGAGTGTCTTCGCCAACAGCCTGGTGTACGGCGCCTCTGACAGCAACGTCTATGACCTCCTAAAGGACCTAGAGGAAGGCATCCAAACGCTGATGGGGAGGCTGGAAGATGGCAGCCCCCGGACTGGGCAGATCTTCAAGCAGACCTACAGCAAGTTCGACACAAACTCACACAACGATGACGCACTACTCAAGAACTACGGGCTGCTCTACTGCTTCAGGAAGGACATGGACAAGGTCGAGACATTCCTGCGCATCGTGCAGTGCCGCTCTGTGGAGGGCAGCTGTGGCTTC(ggtgga	  ggtgga)	  ACCGGT-­‐catcatcaccatcaccat*	  
Amino	  acid	  Sequence:	  
matgsrtsIIIafgIIcIpwIqegsaFPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGFLinker:variableFPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGFGGGGTGHHHHHH*	  The	  GH	  tandem	  with	  a	  4x	  glycine	  sequence	  highlighted	  in	  purple	  was	  ligated	  into	  the	  vector	  pGHSecTag	  between	  Nhe1	  restriction	  site	  highlighted	  in	  blue	  and	  Age1	  restriction	  site	  highlighted	  in	  pink.	  The	  GH	  tandem	  containing	  GH	  signal	   sequence	   is	  highlighted	   in	  bold	   lower	   case.	  The	   linker	  between	   two	  GH	  molecules	   is	  highlighted	  in	  red.	   	  A	  Hist	   tag	   is	  highlighted	  in	  green.	  This	  molecule	  will	  be	  used	  as	  the	  template	  to	  replace	  with	  GCSF.	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Appendix	  B.2.	  Nucleotide	  and	  Amino	  Acid	  Sequences	  of	  GCSF	  Tandem	  
Nucleotide	  sequence	  GCTAGCcaccatggctggacctgccacccagagccccatgaagctgatggccctgcagctgctgctgtgg
cacagtgcactctggacagtgcaggaagccACCCCCCTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCAGCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATCTCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCCTCCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCCCAGCCCLinker:variableACCCCCCTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCAGCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATCTCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCCTCCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCCCAGCCC(ggtgga	  ggtgga)	  ACCGGT-­‐catcatcaccatcaccat*	  
Amino	  acid	  Sequence:	  
MAGPATQSPMKLMALQLLLWHSALWTVQEATPLGPASSLPQSFLLKCLEQVRKIQGDGAALQEKLCATYKLCHPEELVLLGHSLGIPWAPLSSCPSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQQMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLAQPlinker:variableTPLGPASSLPQSFLLKCLEQVRKIQGDGAALQEKLCATYKLCHPEELVLLGHSLGIPWAPLSSCPSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQQMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLAQPGGGGTGHHHHHH*	  
	   The	   GCSF	   tandem	   with	   a	   4x	   glycine	   sequence	   highlighted	   in	   purple	   was	  ligated	  into	  the	  vector	  pGHSecTag	  between	  Nhe1	  restriction	  site	  highlighted	  in	   blue	   and	   Age1	   restriction	   site	   highlighted	   in	   pink.	   The	   GCSF	   tandem	  containing	   GCSF	   signal	   sequence	   is	   highlighted	   in	   bold	   lower	   case.	   The	  linker	   between	   two	   GCSF	   molecules	   is	   highlighted	   in	   red.	   	   A	   Hist	   tag	   is	  highlighted	  in	  green.	  This	  molecule	  will	  be	  used	  as	  the	  template	  to	  ligate	  in	  different	  linker	  constructions.	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Appendix	  B.3.	  Nucleotide	  and	  Amino	  Acid	  Sequences	  of	  Linker	  Regions	  
Linker	   Nucleotide	  sequence	   Amino	  acid	  sequence	  GCSF2NAT	   CTCGAGGGTGGTGGAGGTAGTGGAGGAAACGCTACAGGAGGTGGCGGGTCTGGTGGGGGGGGCTCTGGAGGTGGAGGGTCAGGCGGGGGAGGATCAGGGGGAGGCGGTTCCGGGGGCAACGCAACCGGGGGCGGAGGCTCCGGATCC	  
LEGGGGSGGNATGGGGSGGGGSGGGGSGGGGSGGGGSGGNATGGGGSGS	  	  GCSF2QAT	   CTCGAGGGTGGTGGAGGTAGTGGAGGACAGGCTACAGGAGGTGGCGGGTCTGGTGGGGGGGGCTCTGGAGGTGGAGGGTCAGGCGGGGGAGGATCAGGGGGAGGCGGTTCCGGGGGCCAGGCAACCGGGGGCGGAGGCTCCGGATCC	  
LEGGGGSGGQATGGGGSGGGGSGGGGSGGGGSGGGGSGGQATGGGGSGS	  	  GCSF4NAT	   CTCGAGGGTGGAGGAGGTTCTGGAGGTAATGCTACTGGAGGTGGTGGCAGCGGAGGCAACGCAACAGGGGGTGGCGGATCTGGAGGAAACGCAACCGGTGGAGGGGGATCTGGTGGGAACGCTACCGGCGGAGGGGGCTCTGGATCC	  
LEGGGGSGGNATGGGGSGGNATGGGGSGGNATGGGGSGGNATGGGGSGS	  	  GCSF4QAT	   CTCGAGGGCGGCGGTGGGTCCGGTGGCCAGGCTACCGGAGGAGGCGGGAGTGGAGGCCAAGCCACAGGTGGCGGAGGGTCTGGCGGTCAGGCAACTGGCGGAGGAGGGTCAGGGGGGCAGGCCACGGGAGGTGGCGGGAGCGGATCC	  
LEGGGGSGGQATGGGGSGGQATGGGGSGGQATGGGGSGGQATGGGGSGS	  	  	  GCSF8NAT	   CTCGAGGGCGGCGGAGGGAGTGGCGGTAACGCTACGGGAGGAGGAGGCTCTGGCGGCAATGCAACCGGCGGTGGCGGGAGTGGCGGGAATGCCACAGGTGGGGGGGGTTCAGGCGGGAATGCTACTGGCGGCGGCGGTTCCGGAGGCGGAGGGTCTGGTGGGAACGCAACCGGTGGTGGTGGAAGCGGAGGGAATGCTACCGGTGGCGGAGGAAGCGGTGGTAACGCCACTGGAGGCGGCGGGTCCGGAGGCAACGCCACAGGGGGTGGAGGGTCAGGATCC	  
LEGGGGSGGNATGGGGSGGNATGGGGSGGNATGGGGSGGNATGGGGSGGGGSGGNATGGGGSGGNATGGGGSGGNATGGGGSGGNATGGGGSGS	  	  	  GCSF8QAT	   CTCGAGGGCGGCGGAGGGAGTGGCGGTCAAGCTACGGGAGGAGGAGGCTCTGGCGGCCAGGCAACCGGCGGTGGCGGGAGTGGCGGGCAAGCCACAGGTGGGGGGGGTTCAGGCGGGCAGGCTACTGGCGGCGGCGGTTCCGGAGGCGGAGGGTCTGGTGGGCAAGCAACAGGTGGTGGTGGAAGCGGAGGGCAGGCTACTGGTGGCGGAGGAAGCGGTGGTCAAGCCACTGGAGGCGGCGGGTCCGGAGGCCAGGCCACAGGGGGTGGAGGGTCAGGATCC	  
LEGGGGSGGQATGGGGSGGQATGGGGSGGQATGGGGSGGQATGGGGSGGGGSGGQATGGGGSGGQATGGGGSGGQATGGGGSGGQATGGGGSGS	  	  
The	  table	  above	  represents	  the	  linker	  regions	  that	  were	  ligated	  between	  two	  GCSF	  molecules	  using	  Xho1	  restriction	  site	  highlighted	   in	  pink	  and	  BamH1	  highlighted	   in	   green.	   Glycosylation	   motifs	   highlighted	   in	   red	   NAT	  (AsnAlaThr)	   are	   amino	   acids	   in	   which	   N	   is	   recognized	   by	   cells	   for	  glycosylation.	  While,	  non-­‐glycosylation	  motifs	  (Controls)	  highlighted	  in	  blue	  QAT	  (GlnAlaThr)	  are	  amino	  acids	   in	  which	  Q	   is	  not	  recognized	  by	  cells	   for	  glycosylation.	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Appendix	  C.	  pSecTag_Link-­‐Hist	  Modulating	  Vector:	  
	  	  	  	  
	   	   	  	   	  
Nhe1	   GCSF	  signal	  
sequence	  







4x glycine/ 6x Hist/stop codon 
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